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Abstract 
 
Background: Colorectal cancer is the result of dysregulation within classic regulatory 
pathways in epithelial stem-cell(s): the precursors giving rise to all other intestinal 
lineages. The resulting cancer stem-cell (CSC) generates tumours utilising its innate 
properties, e.g. self-renewal and lineage plasticity. CSCs appear to persist within a 
tumour as a distinct subtype responsible for local recurrence/metastasis. Therefore, 
therapies targeting colorectal CSCs may lead to improved cancer-specific outcome 
measures. The PROM-1/CD/AC133 cell surface marker has been associated with 
colorectal CSCs and its expression is reported as an independent negative prognostic 
marker. Therefore, this thesis sought to investigate the role of PROM-1/CD/AC133 in 
colorectal cancer. 
 
Methods: Tissue-culture, RT-qPCR, IHC, Western blotting, siRNA, PCR-array and 
FACS analyses were used to quantify and profile mRNA/protein expression patterns. 
 
Results: PROM-1/CD/AC133 was widely expressed in patient-matched colorectal 
tumour, adjacent normal epithelium, vascular invasion, lymph node metastases with 
significantly decreased expression in liver metastases. Furthermore, PROM-
1/CD/AC133 expression was not found to enrich colorectal cancer cell line 
populations for additional stem cell phenotypes (expression of ABCB1/ABCG2/BMI-
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1/CD44/LGR5/MSI-1). The data confirm the presence of alternative splice variants of 
PROM-1, and show that transcripts specifying PDZ binding predominate in colorectal 
cancer cell lines.  Concomitantly, siPROM-1 was shown to modulate the expression 
of several key transcripts in colorectal tumourigenesis as well as regulate signal 
transduction pathways including the central cancer, colorectal cancer, NF-kB and p53 
signalling cascades. 
 
Conclusions: PROM-1/CD/AC133 does not identify rare colorectal cancer cells 
responsible for tumourigenesis. However, it is associated with the regulation of 
signalling networks associated with cell growth, differentiation and apoptosis 
suggesting a potential role for this marker in colorectal tumourigenesis. The 
identification of specific target genes and signalling pathways in this thesis provides a 
springboard for further investigations into the functional role of this marker in 
colorectal cancer, with the potential for better treatments for this disease. 
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FITC - fluorescein isothiocyanate  
GNRH - gonadotropin-releasing hormone 
H2O2 - hydrogen-peroxide solution 
LM - liver metastasis  
LN - lymph node 
LOH - loss of herterozygosity 
LV - leucovorin  
M - metastasis 
MACS - microsatellite and chmosomal stability  
MAPK - mitogen-activated protein kinases 
MIN - microsatellite instability  
miRNA - micro RNA 
MMP - matrix metalloproteinase  
MMR - DNA mismatch repair system 
mRNA - messenger RNA 
MSI - microsatellite instability  
MSI-H - microsatellite instability high 
MSI-L - microsatellite instability low 
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MSS - microsatellite stability  
MT-PCR - multiplexed tandem polymerase chain reaction  
MTOR - mammalian target of rapamycin 
N - node 
PBS - phosphate buffer saline 
PCR - polymerase chain reaction 
PI3K - phosphatidylinositol 3-kinase  
qPCR - quatitative polymerase chain reaction  
R0 - complete removal of the tumour 
R1 - microscopic residual disease 
R2 - macroscopic residual disease 
RIN - RNA Integrity Number  
RNA - ribonucleic acid 
RNAi - RNA interference  
RT-PCR - real time polymerase chain reaction 
RT-qPCR - real time quantitative polymerase chain reaction 
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEMF - subepithelial myofibroblast  
siPROM-1 - PROM-1 ‘knock-down’ 
siRNA - RNA silencing 
SNP - single nucleotide polymorphisms  
snRNA - small nuclear ribonucleic acid 
T- tumour 
TAP - transit amplifying cell population 
TE - tris-EDTA  
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TGF-β - transforming growth factor β 
TIMP - tissue inhibitor of metalloproteinase  
Tm - melt temperature  
TNM - rumour node metastasis 
VGEF - vascular endothelial growth factor  
VI - adjacent normal  
φ - azimuth vector 
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1.1 COLORECTAL CANCER: CLINICAL OVERVIEW, REVIEW OF 
AVAILABLE DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE 
MOLECULAR BIOLOGICAL MARKERS & POSSIBLE FUTURE 
CLINICAL ROLE FOR CANCER STEM CELL BIOMARKERS. 
 
1.1.1  INTRODUCTION 
 
Complete surgical excision of a primary tumour continues to be the only cure for 
colorectal cancer (CRC), the second most commonly diagnosed malignancy in the 
developed world (De Hertogh and Geboes, 2010). Optimal patient management 
remains critically dependent on accurate information on the extent of tumour spread 
(Nelson, 2001). There are several prognostic scoring systems that aim to identify 
suitable candidates for surgery alone, stratify patients for clinical trials assessing 
(neo)-adjuvant therapy, predict risk of tumour recurrence and enable appropriate post 
treatment surveillance. However, the clinical response of CRC to chemotherapy 
regimens varies considerably between CRC patients, even when diagnosed with the 
same histological stage and grade of tumour. One reason is that prognostic scoring 
systems are inconsistent, with no prognostic factor common to all scoring systems 
(Gregoire et al., 2010; Figure 1.1). 
 
1 Introduction 
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Figure 1.1 – Conventional and molecular staging modalities. A. Conventional staging involves 
histological analysis of the resected tumour, surrounding tissues and draining lymphatic and vascular 
systems. B. Molecular staging might involve additional analysis of the primary tumour, blood or faeces 
and detection of metastasis-associated protein or peptides, genetic or epigenetic alterations and/or 
mRNA or miRNA signatures (Murphy et al., 2007). 
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Local extent of disease and metastasis to regional lymph nodes (LNs) constitute the 
basis of histopathological “TNM” staging, which takes into account the level of 
penetration of the primary tumour through the bowel wall (T), the degree of LN 
involvement (N) and the absence or presence of distant metastasis (M). In particular, 
the histologic detection of colorectal tumour cells in draining LNs is a poor prognostic 
factor as it is the primary indicator of systemic disease spread (Siegel, 1996). The 
American Joint Committee on Cancer (AJCC) has condensed the TNM system into 
four stages, ranging from stage I defined as early cancer through to advanced 
metastatic stage IV disease (Figure 1.2). TNM staging has been augmented by the 
residual tumour (R) classification, which describes the presence or absence of 
demonstrable residual tumour after surgery and distinguishes between potentially 
curative resections and primarily palliative surgical interventions: R0, complete 
removal of the tumour; R1, microscopic residual disease; or R2, macroscopic residual 
disease. Other important pathological findings that convey poor prognosis include 
lymphovascular or perineural tumour invasion, tumour differentiation, nuclear 
polarity, tubule configuration, lymphocytic infiltration, tumour budding, tumour 
obstructing the colonic / rectal lumen or perforation of the tumour (Jass et al., 2008). 
Stratification of TNM groups based on the presence or absence of preoperative 
elevated serum levels of carcinoembryonic antigen (CEA) has also been reported to 
convey poor clinical prognosis (Quirke and Morris, 2007). 
 
However, the considerable heterogeneity within each tumour stage results in 
inaccurate prognostication for individual patients, which is further compounded by 
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Figure 1.2 – Composite figure demonstrating the relationship between the modern TNM and AJCC 
colorectal cancer staging systems, and the largely historical Duke’s and Astler-Coller classifications 
(Based on the AJCC Cancer Staging Manual, 7th edition). Prefixes to these staging systems denote 
whether they are based upon clinical or pathological staging and the presence or absence of neo-
adjuvant therapy, as explained by the footnote contained within the figure above. 
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variability in the extent of LN harvest during surgery (Hohenberger et al., 2009) and 
LN detection during histopathological assessment (Pusztaszeri et al., 2009). This 
combination of factors results in clinical understaging of approximately one third of 
AJCC stage II patients (transmural bowel wall invasion and negative LNs), i.e. they 
experience an unexpected treatment failure and die (Ratto, 1998). This implies that a 
subgroup of patients with presumed CRC harbour a minimal, but clinically significant 
burden of occult disease that is undetectable utilising current techniques.  
 
Chemotherapy is currently used as an adjunct to surgery to improve disease free five- 
year survival rates in AJCC stage III and certain ‘high risk’ patients with stage II 
CRC, defined by validated pathologic prognostic markers described above (Jass et al., 
2008); by comparison, preoperative neo-adjuvant chemoradiotherapy is utilised to 
decrease local recurrence rates for a select group of patients with rectal cancer (Popek 
and Tsikitis, 2011). Unfortunately, traditional chemotherapeutic agents often display 
notable side effects that may render the patient intolerant to treatment. The majority of 
“average risk” AJCC stage II patients do not have adverse prognostic features and the 
benefit of adjuvant chemotherapy remains unproven in this setting (Dotan and Cohen, 
2011). However, it has become clear that AJCC stage II CRC encompasses a 
pathological spectrum with vastly different five-year disease free survival rates. Thus, 
an evolving and improved understanding of AJCC stage II CRC biology has begun to 
identify molecular markers that may improve risk assessment and treatment choices 
for these patients. One such parameter discussed later in this chapter is microsatellite 
instability (MIN), which serves as a marker for the DNA mismatch repair (MMR) 
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system function and is a useful tool for risk stratification, since patients with MIN 
tumours have increased overall survival. Furthermore, increased knowledge of the 
pharmacology of 5-fluorouracil (5-FU) (Gnoni et al., 2011), identification of its oral 
precursors, capecitabine / tegafur and modulators of their activity such as leucovorin, 
the discovery of new and potent cytotoxic drugs such as oxaliplatin / irinotecan, and 
the development of biological agents, including cetuximab / panitumumab / 
bevacizumab, has broadened the array of therapeutic options available for CRC, 
although the utility of these agents in AJCC stage II disease also remains unclear 
(Gravalos et al., 2009).  
 
Metastasis, a complex process that has only begun to be understood in recent years 
(Stein and Schlag, 2007; Royston and Jackson, 2009), is the leading cause of CRC-
related death. Clinicopathologic factors are inadequate to determine disease prognosis 
for CRC patients, with more than one third of patients dying from progressive 
systemic disease. Spread typically develops via lymphatic vessel or capillary network 
intravasation to nearby LN and distant organs, respectively; or direct invasion of 
adjacent structures or trans-coelomic spread within the abdominal cavity after the 
tumour has penetrated through the intestinal wall. The most common sites of distant 
metastasis are the liver, lungs, and brain. Despite a widespread understanding of the 
natural history of this disease there remains a need to identify additional, validated 
clinical and biological markers of CRC prognosis and treatment response. However, 
the search for such markers has been hampered by the numerous genomic aberrations 
associated with CRC metastasis (Aragane, 2001). 
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Improved understanding of the principal biological pathways associated with 
colorectal carcinogenesis has led to the development of new therapeutic agents that 
target specific molecular pathways involved in tumour cell proliferation, with the 
prospect of a high degree of biochemical specificity. Combined with the stratification 
of CRCs according to specific molecular alterations, this will increasingly guide 
treatment decisions utilising the latest generation of combination drug therapies 
(Pritchard and Grady, 2011). Nonetheless, from preclinical models and patient trials it 
is unclear whether combination strategies actually influence their proposed targets to 
induce growth inhibition (Kummar et al., 2010). In addition, targeted therapy agents 
are not effective in all patients (Asghar et al., 2010) and frequently have a much 
broader specificity than initially intended, resulting in systemic toxicity and 
unexpected side effects (De Hertogh and Geboes, 2010). This lack of specificity 
makes accurate, preoperative prediction of an individual patient’s responsiveness to 
chemotherapy challenging. Nevertheless, the identification of more sensitive and 
accurate molecular techniques can help, for example, with the use of anti-epidermal 
growth factor receptor (EGFR) therapies in the presence of KRAS mutations 
(Molinari et al., 2011). However, current treatment decisions are predominantly based 
upon clinicopathological stage at diagnosis (Schee et al., 2010) with chemotherapeutic 
agents administered arbitrarily. As a consequence, this often results in an ineffective 
therapy, delays the administration of a potentially useful drug, leads to toxicity, the 
development of resistant CRC subclones and unnecessary cost.  
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Whilst in the future therapies will be selected for an individual patient by assessment 
of their tumour and host response for tissue biomarkers predictive of disease free five-
year survival (Figure 1.1), their current identification using genomic, methylomic, 
transcriptomic, proteomic and metabolomics tools faces major technical, logistical 
and biological challenges (Bustin and Dorudi, 2004; Bustin and Mueller, 2005; Bustin 
and Mueller, 2006; Murphy et al., 2007; Hamilton, 2008). Furthermore, the increasing 
complexity of contemporary theories of tumourigenesis, which will be discussed later 
in this chapter, also increases the challenge of identifying where therapy is both 
appropriate and beneficial (Prenen et al., 2009). Hence the keen interest in the 
identification of biomarkers for early detection (diagnostic markers), risk stratification 
or prognosis (prognostic markers) and the prediction of treatment responses 
(predictive markers). Unfortunately, available biomarkers frequently reach the market 
place before they have been validated, and their adoption is often hindered by 
conflicting clinical evidence (Kelley et al., 2011). 
 
1.2 OVERVIEW OF CRC SCREENING AND SURGICAL TREATMENT 
 
Screening improves survival of patients with CRC (Pawa et al., 2011), but there is no 
international consensus on optimal screening technique, while an additional 
significant drawback is the rather limited patient compliance with present screening 
procedures (Nielsen et al., 2011). Nevertheless, many western health care systems 
have standardised population based screening for asymptomatic individuals over 60 
years of age at a national level, generally utilising enzymatic or immunological faecal 
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occult blood test systems as biomarkers to identify those who require endoscopic 
assessment of the colon and rectum (Booth, 2007).  
 
Surgery performed with curative intent aims to fully excise the colorectal tumour 
while achieving microscopically negative (R0) resection margins with >1 mm 
clearance of normal surrounding tissue. In practice, this is the most clinically relevant 
prognostic factor, since five-year disease free survival rates following R0 resection 
are around 64% vs. 17% after a microscopically positive margin (R1) with <1 mm 
clearance of normal tissue (Pawlik and Vauthey, 2008). Consequently, a great deal of 
attention has focused upon standardisation of surgical technique to facilitate R0 
resection for both colonic (Hohenberger et al., 2009) and rectal cancer (Heald and 
Ryall, 1986) patients. 
 
At the time of diagnosis around 20% of patients have a resectable primary tumour as 
well as resectable liver metastases without known extra-hepatic disease (Pozzo et al., 
2004). For these patients combined synchronous or delayed colorectal and hepatic 
resectional surgery has been described (Vauthey et al., 2005; Pathak et al., 2011) after 
which patients may be also treated with adjuvant chemotherapy, in order to try and 
eradicate the micrometastatic disease that is frequently present in this patient group 
(Nordlinger et al., 2008). An additional 15 – 25% of patients will present with other 
patterns of metastatic disease, and a further 20 – 25% will develop metastases during 
post-treatment follow up (Van Cutsem et al., 2010). These patients may be given 
(neo)-adjuvant chemotherapy to reduce primary tumour size and / or reduce the 
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burden of metastatic disease prior to consideration of surgery (Alberts et al., 2005; 
Gruenberger et al., 2008; Gruenberger et al., 2010). Since 30 – 50% of patients with 
metastases have hepatic disease only, this approach increases the likelihood of an 
improvement in clinical outcome measures, or even cure following resection, leading 
to five-year disease free survival rates of 25 – 71% (Cunningham et al., 2010). Recent 
studies also suggest highly selected patients with extra-hepatic disease may be 
considered for curative metastectomy with reported five-year disease free survival 
rates of approximately 50% (Hornbech et al., 2011). However, despite these advances 
overall clinical outcome measures remain poor for patients with widespread disease 
and the management for systemic metastatic disease at diagnosis is frequently 
palliative. 
 
1.3 CRC MOLECULAR SUBTYPES 
 
The detailed molecular analysis of CRC has significantly changed our understanding 
of colorectal tumourigenesis (Roukos et al., 2007). The early model of tumour 
progression from adenoma to carcinoma through the stepwise accumulation of genetic 
events to several key genes and genetic loci (Fearon and Vogelstein, 1990) has been 
replaced by the realisation that CRC is a morphologically and molecularly 
heterogeneous disease (Murphy et al., 2007; Ross, 2011). CRCs acquire an average of 
80 somatic mutations during their evolution from a benign to a metastatic state, of 
which an average of 14 are in cancer-associated genes (Sjoblom et al., 2006; Wood et 
al., 2007). Whilst the mutated genes in different CRCs overlap to only a minor extent, 
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they cluster within a small number of intracellular pathways (Yi et al., 2011), 
allowing their grouping into specific tumour phenotypes based on their molecular 
profiles (Figure 1.3). The development of CRC is believed to proceed over a five to 
ten-year time span, which provides an opportunity to detect adenomatous or 
cancerous lesions at an early stage. However, researchers are yet to fully focus on 
markers identifying adenomas that are likely to progress to CRC, since only a 
minority of adenomatous lesions ultimately become invasive (Ahlquist, 2010), and to-
date no molecular tests have been developed that can distinguish such premalignant 
lesions (Young and Bosch, 2011). In contrast with other carcinomas, reduced 
proliferation may be a biological feature characterising the majority of aggressive 
CRCs (Anjomshoaa et al., 2008), which has important implications for our 
understanding of the biology of CRC progression and for the selection of putative 
novel therapy options (Pritchard and Grady, 2011). 
 
There are at least four molecular subtypes of CRC, currently defined by the presence 
of chromosome instability (CIN), microsatellite instability (MIN or MSI) and 
epigenetic instability (Fearon, 2011; Figure 1.3). 
 
• The majority of sporadic CRC (up to 85%) display chromosomal instability 
(CIN), characterised by the presence of large structural or numerical 
alterations of the chromosomes in cancer cells (Lengauer et al., 1997). This 
phenotype is thought to arise through defects in a number of processes, 
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including aberrant expression or mutation of mitotic checkpoint genes, 
microtubule spindle defects, and telomere dysfunction. 
• A second group has a diploid karyotype but demonstrates a microsatellite 
instability (MIN) phenotype (Boland et al., 1998). In sporadic CRC this 
phenotype is caused by a loss of function through gene silencing, of DNA 
mismatch repair (MMR) genes, in particular, MLH1 (Kane et al., 1997). It is 
also associated with gain of function mutations in oncogenes such as BRAF 
(Nagasaka et al., 2004), tumour suppressor genes such as PTEN (Zhou et al., 
2002) and is often referred to as a mutator phenotype (Lothe et al., 1995). 
Although MIN tumours are associated with a better prognosis (Popat et al., 
2005; Walther et al., 2009), the predictive value of MIN is unclear, as reports 
of it being predictive of response to adjuvant 5-FU therapy in AJCC stage III 
MIN CRCs (Elsaleh et al., 2001; Elsaleh and Iacopetta, 2001) are contradicted 
by other studies (Ribic et al., 2003; Benatti et al., 2005; Jover et al., 2009). 
This uncertainty may be caused by the use of a single marker, such as MIN, 
that cannot account alone for the complexity of the mechanisms underlying 5-
FU cytotoxicity, with additional genome stability markers required 
(Guastadisegni et al., 2010).  
• A third group harbours apparently stable, near-diploid chromosomes and 
stable microsatellites (MACS) (Tang et al., 2004), is characterised by an 
earlier onset (Chan et al., 2001), distinct clinicopathological and molecular 
characteristics (Xie et al., 2007; Cai et al., 2008) and significantly worse 
prognosis (Banerjea et al., 2009). 
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Figure 1.3 – Colorectal tumourigenesis as a multi-pathway disease. The significant heterogeneity of 
colorectal cancer is reflected in the different molecular features of epigenetic (indicated by superscript 
text - me) and genetic (indicated by asterisk - *) alterations among these pathways, supporting data that 
demonstrate these different molecular subgroups are distinct clinical entities with associated 
implications for (neo)-adjuvant therapy selection. 
 
 
 
 
 
  PhD Thesis 2012 – Chapter 1 
 
 
_____________________________________________________________________ 
 
36 
 
 
 
• Epigenomic instability comprises either global hypomethylation (Yamada et 
al., 2005) or the CpG island methylator phenotype (CIMP) (Weisenberger et 
al., 2006; Figure 1.4). Hypomethylation is associated with CIN (Matsuzaki et 
al., 2005; Rodriguez et al., 2006) although the interaction of various types of 
genomic and epigenomic instability is not clear. CIMP is mainly associated 
with microsatellite instability in sporadic MIN patients who do not harbour 
any germline mutation in the MMR genes (Weisenberger et al., 2006). Patients 
showing this phenotype are defined as CIMP-high (CIMP-H) (Barault et al., 
2008; Ogino et al., 2009) or CIMP-1 (Shen et al., 2007). In contrast, tumours 
with a hypermethylated phenotype, (with or without KRAS mutation), but a 
comparatively low level of methylation are classified as CIMP-low (Ogino 
and Goel, 2008) or CIMP-2 (Shen et al., 2007). Heavy methylation is strongly 
associated with the BRAFV600E mutation, which identifies almost two thirds 
of CIMP CRC. For MIN CRCs, the BRAFV600E mutation is invariably 
associated with hMLH1 methylation (Nagasaka et al., 2004), and its presence, 
like increasing levels of CIMP, might worsen the prognosis of MSI CRC 
(Barault et al., 2008). This is of significance, as patients with CIMP-positive 
CRCs do not benefit from adjuvant 5-FU chemotherapy (Jover et al., 2011). 
 
The consequences of each type of instability at the genetic level remain poorly 
understood and the prognostic burden of CIMP is intertwined within the context of 
genomic instability in which it occurs. Although it is reasonable to use CIN and MIN 
status in clinical trials to stratify patients, the relative contributions of CIN, MIN and  
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Figure 1.4 – Molecular classification of CRC according to their MSI and CIMP status. Groups 1 - 6 
are derived from descriptions published previously (Jass, 2007; Ogino and Goel, 2008). The 
differences between MSI-L, MSS, CIMP-L and CIMP-0, respectively are subtle. Since groups 4, 5, and 
6 share similar clinical, pathological and molecular features, they may be combined into a single 
subtype, MSI-L/MSS CIMP-L/0 (Ogino and Goel, 2008). 
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CIMP to the outcome of patients with CRC need to be further investigated to better 
understand the effects and interactions of each variable (Ward et al., 2003).  
 
Around 85% of microsatellite stable CRC are characterised by allelic imbalance (AI) 
and chromosome 18q allelic loss was one of the first molecular markers associated 
with poor prognosis in CRC patients with AJCC stage II (Jen et al., 1994; Martinez-
Lopez et al., 1998; Ogunbiyi et al., 1998; Al-Mulla et al., 2006) and AJCC stage III 
disease (Jernvall et al., 1999; Watanabe et al., 2001). Furthermore, allelic loss at 
D18S61 and D18S851 has been associated with poorer response to chemotherapy 
(Barratt et al., 2002) and at D18S851 with liver metastasis (Tanaka et al., 2006). 
Interestingly, tumours expressing low levels of the SMAD4 protein or mRNA are 
associated with liver metastasis (Tanaka et al., 2006) and with significantly shortened 
five-year disease-free survival rates (Alhopuro et al., 2005). Nevertheless, in line with 
many molecular analyses, additional work has resulted in a far more complex picture 
that defies easy interpretation. Many reports show no difference in five-year survival 
rates between patients with and without 18q AI (Arango et al., 2005, Popat et al., 
2007; Bertagnolli et al., 2011; Pilozzi et al., 2011) and no association of loss of 
D18S851 and LN-positivity (Ghadimi et al., 2003). Remarkably, there is even a report 
that loss of heterozygosity (LOH) at D18S61 predicts a more favourable outcome, 
especially in AJCC stage II CRC (Pilozzi et al., 2011).  
 
There are numerous possible explanations for these discordant findings. There is 
extensive genetic heterogeneity within the tumour itself, particularly for 18q LOH 
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(Losi et al., 2005) in advanced CRCs, giving rise to several topographically distinct 
genotypic sub clones within the tumour (Baisse et al., 2001). Hence analysis of one or 
two biopsies may not result in an accurate assessment of the metastatic potential of 
the whole tumour. Other explanations include differences in the scoring of AI, use of 
different genetic markers that result in the analysis of AI in different regions on 
chromosome 18q, stage-specific effects of 18q, loss of 18q LOH significance in 
multivariate models as well as questions about what actually is being measured by 
18q AI (Tejpar et al., 2010). 
 
1.4 OTHER GENETIC MARKERS ASSOCIATED WITH CRC 
TUMOURIGENESIS 
 
CRC development is driven by several key pathways, in particular the wnt, 
transforming growth factor β (TGF-β), epidermal growth factor receptor (EGFR) 
signalling and phosphatidylinositol 3-kinase (PI3K) pathways, as well as by mutations 
in several tumour suppressor genes (Fearon, 2011). Although up to 70% of sporadic 
colorectal cancers acquire mutations in the adenomatous polyposis coli (APC) gene at 
the earliest stages of neoplasia, and activating mutations in the β-catenin (CTNNB1) 
gene have been observed, there is currently no clinical use for APC or CTNNB1 
mutations for treatment selection, prognosis or early cancer detection (Pritchard and 
Grady, 2011). Similarly, whilst SMAD4 expression levels may predict response to 5-
FU (Boulay et al., 2002; Alhopuro et al., 2005), none of the genetic markers 
associated with the TGF-β pathway have a definite clinical role. 
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This is in contrast to EGFR signalling mediators such as KRAS and BRAF, which are 
mutated in 40% and 15% of CRC, respectively. KRAS codons 12 or 13 mutations are 
relatively early events and result in constitutive signalling (McCormick, 1995) as well 
as driving epigenetic deregulation of the transcriptome (Schafer and Sers, 2011). 
BRAF is a direct downstream effector of KRAS and most mutations are a single base 
change resulting in the substitution of glutamic acid for valine at codon 600 (Siena et 
al., 2009). KRAS and BRAF mutations are mutually exclusive (Chan et al., 2003; 
Fransen et al., 2004), and as discussed earlier are more frequent in MSI-H and CIMP 
tumours. BRAF mutant CRCs may constitute a discrete disease subset characterized 
by a distinct pattern of metastatic spread (Tran et al., 2001). There is also evidence 
that up-regulation of the EGFR ligands epiregulin and amphiregulin is associated with 
an anti-EGFR drug response (Jacobs et al., 2009). 
 
Around 40% of CRCs harbour mutations in PI3K pathway genes, with the most 
frequent ones found in the p110a catalytic subunit of PIK3CA (Samuels, 2004) and 
the tumour suppressor PTEN (Danielsen et al., 2008). Mutations in PIK3CA (Kato et 
al., 2007) and absence of PTEN expression (Li et al., 2009) have been associated with 
a shorter survival, possibly in association with KRAS wild-type status (Ogino et al., 
2009). However, phosphorylated AKT expression has been associated with good 
prognosis (Baba et al., 2011) and overall survival of patients receiving adjuvant 
chemotherapy and / or radiotherapy is significantly longer in CRC with amplification 
of the PIK3CA gene (Jehan et al., 2009). Mutations in PIK3CA are associated with 
CIMP-H (Whitehall et al., 2001), but do not to predict liver metastasis development 
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(Bruuin et al., 2011) and are not consistent between primary tumour and associated 
metastasis (Laszlo, 2010). Hence, despite some promise, currently there is not 
sufficient evidence from clinical studies to support the use of PI3K pathway mutations 
as predictive or prognostic biomarkers (Pritchard and Grady, 2011). 
 
O6-methylguanine-DNA methyltransferase (MGMT) specifies a DNA repair protein 
that is often methylated during CRC development (Hibi et al., 2009). The resulting 
loss of mutagenesis policing is associated with an increase in point mutations in 
KRAS (Vogel et al., 2009) and has been implicated in the establishment of ‘field 
change’, the replacement of the normal epithelial cell population with a histologically 
non-dysplastic one that harbours genetic or epigenetic alterations (Vogel et al., 2009; 
Svrcek et al., 2010). 
 
However, despite its role in establishing aberrations in CRC, neither MGMT promoter 
methylation nor MGMT loss serves as a prognostic biomarker in CRC (Shima et al., 
2011). 
 
1.5 BIOMARKERS 
 
As previously stated most adjuvant treatments appear to benefit only a small portion 
of patients; hence, it is essential to select the right treatment for the right patient. 
Personalised medicine in clinical practice promises accurate prediction of an 
individual’s predisposition towards a disease, or optimised detection and management 
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of a patient’s disease in the context of individual genetic and environmental profiles. 
Clearly, its realisation depends on the identification of safe, effective and clinically 
relevant biomarkers for identifying and stratifying patients (La Thangue and Kerr, 
2011).  
 
Biomarkers are defined as biological substances, characteristics, or images that 
provide an indication of the biological state of an organism (Biomarkers Definitions 
Working Group, 2001). Hence this simple term hides significant complexity and can 
refer to physiological indicators such as blood pressure, molecular markers such as 
expression signatures or radiological biomarkers, such as those derived from 
computerised tomography or magnetic resonance imaging. As a measure of biological 
function, a biomarker can help reveal a mechanism or biological pathway, detect a 
disease or predict the future course of health or disease. If biomarkers are to be used 
properly, there needs to be an understanding of their sensitivity and specificity, how 
and in what contexts to use them, how to interpret them in those various contexts, and 
how to properly validate them (Olson et al., 2009).  
 
While cancer biomarkers have evolved from biochemical assays measuring proteins, 
hormones and enzymes after the onset of disease, powerful molecular assays targeting 
nucleic acids have potential utility in early screening or diagnosis as well as for more 
accurate classification, prognosis, risk stratification, treatment efficacy prediction and 
monitoring. In CRC a wide variety of biomarkers have been reported within the 
tumour itself, as well as in blood and faeces. In addition, a range of new biomarkers, 
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termed companion diagnostics, have been described that are designed to reflect the 
sensitivity and / or resistance of CRC to existing therapies and so aid clinicians in 
selecting therapies for patients (Cross, 2008). Predictors have been developed to 
stratify the risk of relapse for intermediate stage CRC after completion of surgical 
resection (Ross et al., 2010), while gene expression profiles of normal colorectal 
mucosa, colorectal adenomas and different stages of CRC have identified 
discriminative expression signatures that mark the tumour progression sequence 
(George and Kopetz, 2011). This provides a reservoir of candidate markers for the 
early diagnosis of high-risk colorectal adenomas, as well as potential therapeutic 
targets for CRC (Tang et al., 2010). Finally, a number of biomarkers have been 
proposed as specific predictors of chemotherapy and radiotherapy response and, in 
some instances, drug toxicity (Ross, 2011).  
 
Since predictive biomarkers forecast the differential effects of treatment on clinical 
outcome, they are the key to individualised (neo)-adjuvant treatment. For example, 
current staging stratagems have difficulty with the prospective identification of 
patients with LN-negative tumours who might benefit from adjuvant therapy; hence 
identification of molecular staging biomarkers has been an area of research priority 
(Bustin and Dorudi, 1998; Bustin and Dorudi, 2004; Bustin and Mueller, 2005; Bustin 
and Mueller, 2006; Bustin, 2006; Murphy et al., 2007; Bustin, 2008; Murphy and 
Bustin, 2009). KRAS, a negative predictive biomarker for response to treatment with 
EGFR antagonists, represents the first biomarker integrated into clinical practice for 
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CRC and helps identify patients with metastatic CRC who may or may not be 
candidates for anti-EGFR therapy (Lievre et al., 2006). 
 
Approximately 95% of cases of CRC would benefit from curative surgery if 
diagnosed at an early stage of disease. Consequently, early detection of colorectal 
adenomas at high risk of progression to CRC is central to the aim of reducing CRC 
deaths. However, current screening methods are compromised by either low cost-
effectiveness or limited diagnostic accuracy and detect many adenomas that will 
never progress to CRC as previously discussed (Hoff and Dominitz, 2010). Hence the 
importance of ongoing attempts to identify early diagnostic biomarkers, preferably 
present in patient stool or blood, thereby permitting non-invasive patient assessment. 
An additional benefit of this approach is the potential to detect synchronous CRCs, 
which can result in additional surgical interventions and may confer poor prognosis 
(Yang et al., 2011). Studies have focused on identifying clinically relevant 
information on epigenetic and genetic alterations of cancer cell derived DNA, 
microRNA expression, heteroplasmic mitochondrial DNA mutations, leukocyte 
transcriptome profiles, or protein and autoantibody expression. For example, 
hypermethylation of SPG20 promoter is detectable in 89% of CRC, 78% of adenomas 
but only 1% of normal colonic mucosa. Importantly, this biomarker is detectable in 
corresponding faecal samples (Lind et al., 2011). Another report describes a 7-gene 
biomarker panel (ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, VNN1 and 
IL2RB) for assessing an individual's risk of having CRC (Marshall et al., 2010). 
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However, as of yet no marker has progressed beyond the proof of principle or pilot 
study stage (Pawa et al., 2011). 
 
While the major genetic changes and mutations have been well characterised in CRC, 
much less is known at the protein and metabolome level. Conventional enzyme-linked 
immunosorbent assays that use a panel of protein biomarkers to detect inflammatory 
bowel disease in exfoliated cell samples collected from the surface of the rectal 
mucosa (Anderson et al., 2011) may also be useful for cancer screening in this 
relatively high-risk population. However, technical issues, mainly related with 
sensitivity and reproducibility, have limited such proteomic approaches. Nevertheless, 
recent advances in proteomic techniques and mass spectrometry systems have resulted 
in the characterisation of CRC proteomes (Kang et al., 2011; O'Dwyer et al., 2011) 
and rekindled the quest for new biomarkers in CRC (Ang et al., 2011). Hence a 
promising approach is to identify proteins secreted by the cancer (Klein-Scory et al., 
2010) or cell surface protein biomarkers with extracellular domains that could be 
targets for current or emerging technologies, especially novel molecular imaging 
modalities (de Wit et al., 2011). Since mutated proteins drive tumourigenesis, their 
accurate detection and quantification is likely to prove useful for diagnostic 
applications. A recent report has used mass spectrometry to quantify the number and 
fraction of mutant RAS protein present in CRC cell lines and tissue (Wang et al., 
2011). The relevance of detecting the presence or absence of a single protein is less 
clear, although detection of proteins such as CCR7 (Gunther et al., 2005), S100A4 
(Hemandas et al., 2006), CK20 (Wong et al., 2009), HIWI (Zeng et al., 2011), REG Iβ 
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and HIP/PAP (Zheng et al., 2011) or E-cadherin and β–catenin (Toth et al., 2011) is 
claimed to be a reliable prognostic marker. There are two interesting reports of 
biomarkers potentially useful for early diagnosis of CRC. One study used mass 
spectrometry to identify a serum protein fingerprint in CRC patients that can 
distinguish CRC from healthy controls with high sensitivity (92.85%) and specificity 
(91.25%) (Liu et al., 2011). Another report identified a five-peptide classifier obtained 
from a CRC phage expression library that was biopanned using serum pools and was 
able to discriminate between early CRC patients and healthy controls, with 
sensitivities of 90.0% - 92.7% and specificities of 91.7% - 93.3% (Chang et al., 2011). 
Clearly, there is huge promise afforded by a lengthening list of potential protein 
biomarkers and relevant detection techniques. However, more research and technical 
advances are needed, especially to investigate a range of low abundance proteins, 
which are likely to play strategic roles in CRC diagnostics and progression (Barderas 
et al., 2010). 
 
Successful linkage of tailored therapy and diagnostics requires careful consideration 
of the analytical and clinical validity, as well as utility, of these biomarkers in a 
specific therapeutic context, since otherwise diagnostic results will be unpredictable. 
It is important to remember that whilst markers such as KRAS have plausible 
mechanistic significance, the clinical significance of the marker requires validation in 
a prospective manner. Furthermore, findings from one study often cannot be 
extrapolated to a different study population due to variability, for example in genetic 
backgrounds, or if different tests are used for measuring that biomarker. Study 
  J Murphy – Chapter 1 
 
 
_____________________________________________________________________ 
 
47 
 
 
 
endpoints and study design are additional critical aspects of oncologic clinical trials 
that require careful attention when assessing the relevance of biomarkers and the 
efficacy of treatment (Wu et al., 2011).  
 
1.6 LOCATION OF CANCER BIOMARKERS 
 
1.6.1 FAECES 
 
Approximately 1.5 x106 colonic epithelial cells can be isolated per gram of stool 
(Iyengar et al., 1991). Faecal analysis thus constitutes a possible potent and non-
invasive method for the detection, monitoring and management of CRC (Ahlquist, 
2002), with the potential to detect cancer specific mutations significantly earlier than 
with endoscopic identification (Ogreid and Hamre, 2007). However, molecular 
analysis of exfoliated epithelial cells and free nucleic acids shed in the faeces poses a 
significant technical challenge, since faecal DNA is made up from an immense 
number and variety of bacteria and normal living cells including normal colorectal 
cells and lymphocytes. Furthermore, faeces contain nucleases as well as intrinsic 
substances that inhibit many molecular assays, particularly polymerase chain reaction 
(PCR)-based technologies. The ideal biomarker for the detection of CRC and 
premalignant lesions would be consistently positive in the presence of, and negative 
in the absence of, cancerous lesions, stable despite faecal toxicities, easily recoverable 
from the stool, and reproducibly assayed (Osborn and Ahlquist, 2005). Detection of 
mutated DNA holds the most promise, as DNA is fairly stable (Nechvatal et al., 2008; 
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Koga et al., 2009) and mutations are either present or absent. Nonetheless, high 
testing volume, frequently low tumour content, and the spectrum of rare mutations in 
many target genes can make mutation detection challenging (Arcila et al., 2011) and it 
is important to choose the method of detection carefully (Minamoto et al., 2000). 
Several studies have investigated the relevance of detecting single markers following 
the first report of the successful identification of KRAS in CRC patients in 1992 
(Sidransky et al., 1992). The most recent report used a chip-based temperature 
gradient capillary electrophoresis technique to demonstrate KRAS mutations in 57% 
of CRC patients and in 7% of controls (Zhang et al., 2011), results similar to those 
obtained using a different set of techniques, where mutations were found in 41% of 
cancers and 5% of controls (Chien et al., 2007). Other studies do not support the use 
of KRAS alone as a molecular marker for CRC screening (Atkin and Martin, 2001; 
Haug et al., 2007), suggesting that the most likely use for KRAS is as a component of 
multi-targeted assays.  
 
Several publications have used different methods to investigate the potential use of 
multiple DNA markers from faeces for the detection of CRC. An early report utilising 
KRAS, TP53, APC and Bat-26 claimed sensitivities of 91% and 83% for cancer and 
adenomas, respectively and target marker-dependent specificity of up to 100% 
(Ahlquist et al., 2000). A second report analysing the same four markers found that 
the assay identified 71% of patients with CRC, but did not report assay specificity 
(Dong et al., 2001). A third comparison looking only at APC, KRAS and TP53 
detected mutations in 55% of cancer patients, compared to 11% of healthy volunteers 
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(Onouchi et al., 2008). Although both specificity and sensitivity currently make these 
and similar assays clinically impractical (Rengucci et al., 2001; Calistri et al., 2003), 
they point towards the significant potential of this approach, assuming that the correct 
marker, or combination of markers, can be identified. 
 
Cancer specific epigenetic effects such as altered DNA methylation patterns provide 
another potential source for informative biomarkers for colorectal adenomas and CRC 
(Kim et al., 2010). A recent study investigated promoter hypermethylation of the 
CNRIP1, FBN1, INA, MAL, SNCA, and SPG20 genes in human faecal cells and 
found that this panel of epigenetic markers was characteristically altered in colorectal 
adenomas (35 - 91%) and cancers (65 - 94%), whereas normal mucosa samples were 
rarely (0 - 5%) methylated. The combined sensitivity of at least two positives among 
the six markers was 94% for colorectal cancers and 93% for adenoma samples, with a 
specificity of 98% (Lind et al., 2011). 
 
Although DNA-based assays pose significant technical obstacles, the relative stability 
of DNA and the fact that assays are qualitative, i.e. a mutation is present or not, makes 
their use relatively straightforward. In contrast, there are several additional reasons 
that make quantification of RNA markers from faecal samples extremely demanding 
(Yu et al., 2008). RNA expression is a continuum; hence its analysis relies on 
accurate quantification, rather than on qualitative assessment. This makes accurate 
and relevant normalisation and RNA quality control essential. Furthermore, RNA is 
highly labile and is likely to be readily degraded in faecal matter. Since most assays 
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require conversion of RNA to DNA, faecal inhibitors of reverse transcriptases could 
affect the accuracy of the results, especially when these assays depend on quantifying 
levels of RNA.  
 
Reports have proposed the use of single or limited markers, either cyclooxygenase 2 
(COX-2) mRNA on its own (Kanaoka et al., 2004), or COX-2 and matrix 
metalloproteinase 7 (MMP-7) mRNAs (Takai et al., 2009) for the detection of CRC 
from faecal samples, although a further report detected COX-2 mRNA in only 50% of 
CRC patients (Leung et al., 2007). Other single markers have been proposed, for 
example patients with high faecal KIAA0247 mRNA levels have a significantly 
greater five-year overall survival rate. In addition, mRNA levels were found to be 
associated with therapeutic benefit following administration of 5-FU (Huang et al., 
2011). However, the utility of detecting such a limited range of markers remains to be 
determined. 
 
Unsurprisingly, studies have attempted to use differentially expressed (Kalimutho et 
al., 2011) or epigenetically silenced (Kalimutho et al., 2011) miRNAs from faeces as 
screening and prognostic markers for CRC. An analysis of miRNA expression of 
exfoliated colonocytes identified the miR-17-92 cluster and miR-135 as significantly 
up-regulated in CRC tissues compared with normal tissues, although the overall 
sensitivity and specificity was only 74.1% and 79.0%, respectively (Koga et al., 
2010). In contrast, another study identified greater expression of miR-21 and miR-
106a in the stool of CRC patients (Link et al., 2010). 
  J Murphy – Chapter 1 
 
 
_____________________________________________________________________ 
 
51 
 
 
 
1.6.2 BLOOD / PLASMA 
 
Haematogenous spread of CRC cells from a primary tumour is a crucial step in the 
metastasis cascade, and circulating tumour cells (CTCs) have long been considered an 
indicator of tumour aggressiveness (Sleijfer et al., 2007). Hence they may provide a 
potential source of cells for real time monitoring of CRC patients through the course 
of their disease, enabling the detection of early dissemination of cancers, their 
molecular characterisation as well as monitoring treatment response or resistance. 
Consequently, attention has focused on the development of assays for the reliable 
detection and quantification of CTCs. The rarity of CTCs in peripheral blood, 
estimated as one tumour cell per 109 normal blood cells in patients with known 
metastatic cancer (Maheswaran and Haber, 2010), means that their detection requires 
a combination of reliable enrichment steps as well as robust, sensitive and specific 
detection techniques (Sun et al., 2011). There are several highly specific cytometric 
analysis methods available for the identification of CTCs, some of which can rapidly 
analyse large volumes of sample (fibre optic array scanning technology: FAST), 
viable cells (EPISPOT), allow genetic analysis (fluorescence in situ hybridization: 
FISH) or are semi-automated (CellSearch) (Alunni-Fabbroni and Sandri, 2010). In 
general, their main drawback is that detection is limited to specific subsets of CTCs. 
However, the absence of universal markers to discriminate colorectal CTCs and the 
heterogeneity of the tumours themselves makes the introduction of assays into routine 
clinical use highly challenging.  
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Quantitative polymerase chain reaction (qPCR) is the most widely utilised detection 
method for CTCs, although the use of several other different available technologies 
makes the clinical significance of CTC detection difficult to interpret (Alunni-
Fabbroni and Sandri, 2010). This is illustrated by a report that concludes that CK20 
mRNA detection in the blood samples of patients with stage II CRC identifies 
individuals with poor outcome (Koch et al., 2006). This result is interesting as 
approximately 20% of CRCs show no expression of CK20 despite more pronounced 
detection in high-grade carcinomas (Bayrak et al., 2011). In addition, although this 
study did not enrich for epithelial cells, it reports that 174 blood samples from 98 
controls consistently tested negative for CK20 expression. This contradicts published 
results (Bostick et al., 1998; Bustin et al., 1999; Champelovier et al., 1999; Jung et al., 
1999; Bustin et al., 2000), including a report that detects CK20 expression in 22% of 
normal healthy controls even after immunobead epithelial cell enrichment (Dandachi 
et al., 2005).  
 
Further contradictions are apparent when multiple markers are used. A recent review 
of nine studies in patients with non metastatic CRC showed that detection rates of 
CTC varied from barely detectable to 57%, with seven studies claiming the presence 
of CTC to be a prognostic marker of poor disease free survival (Thorsteinsson et al., 
2011). In CRC patients with metastatic cancers, detection of a combination of CEA / 
CK19 / CK20 / GCC expression suggests that these markers allow highly specific and 
sensitive CTC detection (Gervasoni et al., 2008) and that poor survival is associated 
with positive detection for CEA, CK20 and EGFR (Tsouma et al., 2010). However, 
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another publication found telomerase reverse transcriptase, CK19, CK20, and CEA 
mRNA expression to be an independent predictor for postoperative relapse (Wang et 
al., 2007).  
 
A meta-analysis assessing a further nine studies detecting (i) CEA, (ii) CK20, (iii) 
CEA with CK20, or (iv) CK19 with CK20 by quantitative polymerase chain reaction 
(qPCR) assays compared disease free survival in circulating tumour positive versus 
negative patients. The authors concluded that disease free survival was significantly 
higher in the CTC negative versus positive groups (Katsuno et al., 2008). On the other 
hand, a meta-analysis of 12 studies that used qPCR to detect the same markers 
concluded that detection of CTCs in peripheral blood is not an independent predictor 
of survival (Sergeant et al., 2008).  
 
Other markers being proposed as prognostic markers of one kind or another are 
EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 for postoperative CRC patients with 
unclear clinical selection criteria (Huang et al., 2011), with a subset, S100B, TM4SF3, 
and OLFM4 reported to correlate with liver metastasis (Huang et al., 2011). MMP / 
TIMP markers have also been investigated suggesting low serum levels of MMP-2 
and TIMP-2 correlate with reduced tumour stage (Groblewska et al., 2010). A 
longitudinal study of patients with metastatic CRC found that high plasma TIMP-1 
levels before and during treatment with an irinotecan / 5-FU combination were related 
to poor objective response, time to progression and poor overall survival (Aldulaymi 
et al., 2010). This finding was compatible with a recent meta-analysis, which found 
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that high TIMP-1 levels predicted overall survival in both univariate and multivariate 
analyses (Lee et al., 2011). Given the earlier findings concerning MMP-7, it is 
interesting that its serum levels are associated with progression free survival for CRC 
patients treated with anti-EGFR agents as third-line treatment, independent of KRAS 
status (Garcia-Albeniz et al., 2011). 
 
The most widely quoted evidence for an association between CTCs and survival 
comes from a prospective qPCR study that has demonstrated a significant adverse 
impact on survival with the presence of ≥3 CTC per 7.5 mL blood at baseline (Cohen 
et al., 2006) and a follow-up study, where CTCs in patients receiving first or second 
line therapy, or irinotecan, but not bevacizumab, were associated with poor overall 
survival and progression free survival (Cohen et al., 2009). These results are similar to 
those obtained using a different method, the immunodetection-based Veridex Cell 
search system, which established a cut off of ≥3 CTCs (Matsusaka et al., 2011) per 
7.5 ml blood. However, it is difficult to compare these methods, since they have 
different sensitivities, with qPCR reported as having both similar (Sato et al., 2011) as 
well as significantly higher (Gervasoni et al., 2011) sensitivity. Furthermore, another 
study identified a cut off of ≥2 CTCs (Maestro et al., 2009), which at the very least 
suggests that further refinement of cell measurement is required. However, it is best to 
remain unconvinced regarding the clinical validity of these data given the: (i) 
uncertainty surrounding immunobead detection described earlier; (ii) lack of 
correlation between CEA expression in tumour biopsies and CEA protein in the serum 
(Guadagni et al., 1997); and, (iii) utilisation of CTC detection techniques that exclude 
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the only two candidate genes in blood reportedly associated with CRC (Findeisen et 
al., 2008). There is simply too wide a range of experimental protocols, criteria for 
sample selection, poor quality of assay design, RNA quality control and lack of 
transparency in currently reported data, reflected in the huge variability of results 
(Bustin and Mueller, 2005; Bustin and Mueller, 2006). Interestingly, a recent meta-
analysis concludes that detection of CTCs in peripheral blood, but not in mesenteric 
blood or bone marrow indicates poor prognosis (Rahbari et al., 2010). However, this 
analysis does not examine experimental protocols or RNA and assay quality 
assessments and omits several relevant studies.  
 
Clearly there is an urgent need for standardised isolation and analysis techniques 
(Khair et al., 2007) as well as an international consensus on choice of detection 
method and markers (Thorsteinsson and Jess, 2011) with specific reference to the 
cancer stem cell hypothesis, which will be discussed later. Assuming the assays are 
detecting genuine CTCs, their clinical relevance must be verified in large-scale 
clinical trials (Takeuchi and Kitagawa, 2010) before their incorporation into risk 
stratification and treatment decision-making strategies in the clinical setting (Negin 
and Cohen, 2010). 
 
1.6.3 PRIMARY TUMOUR 
 
Since the first application of microarray analysis to CRC (Hegde et al., 2001; 
Takemasa et al., 2001), numerous studies have used mutation (Di Martino et al., 
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2011), methylation (Mori et al., 2011), antibody (Zhou et al., 2011), mRNA (Nannini 
et al., 2009), miRNA (Luo et al., 2011) and tissue (Spisak et al., 2009) microarrays to 
profile CRC. A meta-analysis of gene expression studies in patients with AJCC stage 
II CRC has concluded that gene expression profiling has promising potential as a 
predictor of poor clinical outcome for the chosen primary endpoints: disease 
recurrence or death within three-years (Lu et al., 2009). Interestingly, a new gene 
expression classifier for improved risk stratification of patients with stage II CRC, but 
not stage III, has just been published (Agesen et al., 2012). However, tumour risk and 
response to therapy is not just cancer dependent, but also associated with host 
characteristics. Hence the importance of a recent report describing a strong correlation 
between host immune and a 12 immune gene related signature associated with better 
assessment of patient survival, independent of tumour staging or microsatellite 
instability, suggesting some beneficial intra-tumoural immune cell priming (Coppola 
et al., 2011). Far less work has been undertaken for rectal cancers, where the major 
area of interest has been the accurate identification of patients that might benefit from 
preoperative chemoradiotherapy. Serial analysis of gene expression (SAGE) and 
qPCR analyses have identified a 13 gene signature from AJCC stage II / III patients 
that predicts preoperative chemoradiotherapy response and outcome in rectal cancers 
with an overall accuracy of 76% (Casado et al., 2011). 
 
Apart from being used to identify mutations in CRC associated genes such as APC 
(Cowie et al., 2004) and KRAS, microarrays have been applied to the search for 
prognostic markers. A meta-analysis of data obtained from 31 comparative genomic 
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hybridization (CGH) studies associates loss of 4p with the transition from AJCC stage 
I to stage II - IV CRC and correlates deletion of 8p and gains of 7p and 17q with the 
transition from primary tumour to liver metastasis (Diep et al., 2006). More recent 
microarray based CGH has identified two recurrently altered genomic regions as 
independent indicators of poor prognosis (Kim et al., 2006). A region on chromosome 
3q26 containing PIK3CA is amplified in 38% of cancers, and gains are associated 
with high levels of PIK3CA protein expression (Jehan et al., 2009). Survival of 
patients receiving adjuvant chemotherapy and  / or radiotherapy is significantly longer 
in PIK3CA-amplified cancers than in patients with cancers without amplification and 
was independent of stage, grade, histology, gender, and age categories. Another study 
identified DNA copy number loss at 18q12.2, harbouring a single gene, BRUNOL4 
that encodes the Bruno-like 4 splicing factor, as an independent prognostic indicator 
(Poulogiannis et al., 2010).  
 
Unlike mRNA, miRNAs are very stable in archival material and can be retrieved 
efficiently from samples as old as twenty-eight years (Bovell et al., 2012). The 
discovery that microRNAs (miRNAs) acting as oncogenes or tumour suppressors alter 
cell proliferation, apoptosis and metastasis through their interactions with intracellular 
signalling networks has initiated extensive research in the cancer field, leading to the 
identification of numerous miRNAs implicated in colorectal carcinogenesis and 
tumour progression (Wu et al., 2011). Altered expression of miRNA or 
polymorphisms in pre-miRNAs and within miRNA-binding sites have also been 
shown to be important in CRC development, progression and response to treatment 
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and correlate with CRC patient survival or treatment outcome (Aslam et al., 2009; 
Earle et al., 2010; Liu and Chen, 2010; Schee et al., 2010; Song and Ju, 2010; Nugent 
et al., 2011; Xing et al., 2011). The presence of KRAS mutation is associated with 
dysregulation of several miRNAs that target genes involved in apoptosis and 
proliferation (Mosakhani et al., 2012). Target prediction and pathway analyses 
suggest a possible role for deregulated miRNAs in Nicotinamide Adenine 
Dinucleotide Phosphate (NADPH) regeneration and G protein-coupled receptor 
signalling pathways. An analysis of 20 studies that assessed expression of miRNAs in 
CRC / adenoma tissue, normal colorectal mucosa and in the plasma of CRC / 
adenoma patients and healthy controls identified 160 miRNAs that were dysregulated 
in CRC (Luo et al., 2011). Combined with their chemical stability, this promises huge 
potential for their use as biomarkers for early diagnosis in blood and faecal tests 
(Mostert et al., 2011), and their association with progression and clinical phenotypes 
makes them candidate prognostic and predictive biomarkers (Ju, 2010; Manne et al., 
2010; Dong et al., 2011). For example, miR-34b/c hypermethylation found in 98% of 
primary colorectal tumours was also found in 75% faecal specimens (Kalimutho et al., 
2011). miRNA profiling has identified significantly elevated miR-17-3p and miR-92 
in the plasma and tumour samples of patients with CRC, with plasma levels 
significantly reduced after surgery (Ng et al., 2009) and a colon miRNA signature that 
may be involved in regulation of cell differentiation (Zhang et al., 2011). 
 
Targeted analyses of individual biological complexes have yielded results that are 
unclear, contradictory and do not readily translate into clinical practice. For example, 
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the matrix metalloproteinase (MMP) / tissue inhibitor of metalloproteinase (TIMP) 
system has a major, if unclear, role in tumour invasion and metastasis. The main 
groups of human MMPs include the collagenases (MMPs 1, 8 and 13), stromelysins 
(MMPs 3, 10 and 11), gelatinases (MMPs 2 and 9), membrane type MMPs (MMPs 14 
– 17, 24 and 25) and matrilysins (MMPs 7 and 26). MMPs 19, 20, 21, 23 and 26 – 28 
are grouped separately and TIMPs are the main physiological regulators of the 
MMPs. Genetically, there may be an association between MMP single nucleotide 
polymorphisms (SNPs) and CRC risk, prognosis and therapy response. However, 
there is no agreement on which SNPs are relevant, with one report suggesting that a 
specific SNP in MMP-9 may be associated with tumourigenesis but not metastatic 
progression (Park et al., 2011), whereas another report associates SNP independent 
MMP-9 levels, but not (a different) MMP-9 SNP, with worse survival (Langers et al., 
2008). Both reports also differ in the MMP-2 SNPs they claim to be associated with 
poorer survival. A third found that individuals with yet another MMP-9 SNP were 
more susceptible to CRC (Fang et al., 2010). 
 
Expression patterns of MMP / TIMP proteins in colonic epithelium and cancers are 
complex, with increased expression of individual MMPs and TIMPs occurring at the 
adenoma stage of CRC development, and further increased expression in specific 
MMPs and TIMPs in the transition to malignancy (Jeffery et al., 2009). A study using 
a combination of qPCR and immunohistochemistry reports higher levels of MMP-2 
expression in primary tumours is associated with lower overall survival, but fails to 
provide any clinical information on the patient group (Dong et al., 2011). There is 
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some corroboration though from a retrospective review of 141 consecutive AJCC 
stage II and III patients who had undergone radical resection of CRC, which found 
that MMP-2 was associated with a worse disease free survival and a poor overall 
survival (Zhou et al., 2011). Yet another study used immunohistochemistry to report 
that high tumour MMP-9 levels predict significantly worse disease free and overall 
survival of patients (Chu et al., 2011). In contrast, an earlier study suggests that 
MMP-2 and MMP-9 staining is of little value in staging and prognostic prediction 
(Ring et al., 1997). A third study used microarray and qPCR to show that higher 
expression of MMP-2, 9, 11 and 14 in liver metastases is associated with a favourable 
response to palliative, 5-FU based chemotherapy, whereas higher MMP-7, TIMP-1 
and TIMP-2 levels were found in the unfavourable group (Gentner et al., 2009). 
MMP-7 is of particular interest, since its expression is confined to carcinomatous 
epithelium and it has been reported as an independent prognostic factor for survival in 
advanced CRC (Maurel et al., 2007). Of the other MMPs investigated, MMP-21 may 
be an independent prognostic factor in patients with AJCC stage II as well as stage III 
CRC (Huang et al., 2011), while MMP-13 has been associated with postoperative 
relapse (Huang et al., 2010). For rectal cancers, higher expression of MMP-9 in 
parenchyma and lower expression of in stromal cells has been reported as a 
prognostic marker for overall survival (Svagzdys et al., 2011). 
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1.6.4 CRC BIOMARKERS AND (NEO)-ADJUVANT THERAPY  
 
5-FU, with or without leucovorin (LV), has been the foundation of the adjuvant 
treatment of CRC for nearly five decades. Unfortunately, patients undergoing this 
treatment have an overall response rate of only 10% and a median survival of up to 12 
months (Prenen et al., 2009). The introduction of the topoisomerase-1 inhibitor 
irinotecan (Saltz et al., 2000), the platinum derivative oxaliplatin (de Gramont et al., 
2000) and the oral fluoropyrimidine capecitabine (Van Cutsem et al., 2000) has 
increased the repertoire of drugs utilised for adjuvant treatment of advanced CRC 
(AJCC stage III - IV), and the neo-adjuvant treatment of rectal cancer (Hirsch and 
Zafar, 2011). 
 
There appears to be some link between KRAS status and therapy response as 
discussed previously, although its role as a prognostic and predictive biomarker 
remains unclear. Mutated KRAS is essential for maintenance of the transformed and 
invasive phenotype of human colon cancer cells (Pollock et al., 2005) and is present 
in 35 - 40% of patients with advanced CRC (Normanno et al., 2009). KRAS 
mutations are distributed homogeneously throughout tumour tissue (Ekelund et al., 
2011), implying that a single biopsy should be sufficient to determine the KRAS 
status of a cancer. An early meta-analysis found that G12V mutations were prognostic 
for AJCC stage III disease (Andreyev et al., 1998; Andreyev et al., 2001), with 
another study indicating the same for stage II disease (Belly et al., 2001). However, 
recent data from two major trials demonstrate that KRAS mutational status was not 
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associated with any significant influence on disease free or overall survival for 
patients treated with 5-FU (Ogino et al., 2009; Roth et al., 2010). In the adjuvant 
setting, there appears to be no link between KRAS status and response to standard 
chemotherapy (Bouzourene et al., 2000; Zauber et al., 2004; Ocvirk et al., 2010), 
although one group reports that patients with KRAS wild type tumours benefit from 
5-FU / LV therapy (Ahnen et al., 1998).  
 
One reason for the uncontrolled proliferation of cancer cells is the increased 
expression of growth factor receptors, for example EGFR, which is over-expressed in 
around 75% of colorectal cancers (Ciardiello and Tortora, 2008), although it is worth 
stating that EGFR expression levels vary with the detection method used (Nannini et 
al., 2011). This has made EGFR an attractive target for therapy and two monoclonal 
antibodies against EGFR, cetuximab and panitumumab, have been developed (Van 
Cutsem and Geboes, 2007). Vascular endothelial growth factor (VEGF), a factor 
associated with a worse prognosis and which is necessary for the development of 
aberrant blood vessels required for tumour progression (Hyodo et al., 1998), is 
targeted by another antibody, bevacizumab (Mulder et al., 2011). The combination of 
monoclonal antibodies with conventional polychemotherapy has a proven efficacy 
and has increased the median disease free survival of AJCC stage IV CRC patients to 
approximately 24 months (Prenen et al., 2009).  
 
Nevertheless, while a meta-analysis of data from seven randomised controlled trials of 
chemotherapy with or without cetuximab in patients with AJCC stage III - IV CRC 
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demonstrated that cetuximab increases the likelihood of a response to treatment and 
makes progression free survival more likely, overall survival data were of borderline 
significance (Liu et al., 2010). Furthermore, several phase III trials investigating the 
efficacy of adding irinotecan, bevacizumab, or cetuximab to 5-FU based regimens in 
the adjuvant setting have failed to demonstrate substantial improvement in overall 
survival in patients with AJCC stage III - IV CRC (Peeters et al., 2010; Fischer von 
Weikersthal et al., 2011; Maughan et al., 2011; Molinari et al., 2011; Papadimitriou et 
al., 2011; Price et al., 2011). Certainly, the clinical management of AJCC stage III - 
IV CRC has progressed to a complex range of pharmaceutical and interventional 
therapies that presents clinicians with many questions and challenges with regards to 
the choice of best treatment combination, or the optimal selection of patients eligible 
for the various treatment options (Field and Lipton, 2007). While these findings may 
be explained by the fact chemotherapy response is linked to tumour genotype, our 
knowledge of this subject remains poor (Walther et al., 2009). Attempts to identify 
predictive factors for efficacy to antiangiogenic therapies have been disappointing 
(Dienstmann et al., 2011) and no factor has been identified to predict the efficacy of 
bevacizumab (Asghar et al., 2010; Cacheux et al., 2011). However, mutated KRAS 
has been reported to be a factor of non-response, or even of deleterious response to 
the use of anti-EGFR antibodies (Lievre et al., 2006; Khambata-Ford et al., 2007; De 
Karapetis et al., 2008; Roock et al., 2008; Bokemeyer et al., 2009; Bokemeyer et al., 
2011; Van Cutsem et al., 2011), although, it is unclear whether this applies to patients 
with G13D-mutated tumours (De Roock et al., 2010). The KRAS link is most likely 
due to its role within the EGFR signalling pathway, since KRAS gene mutations 
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activate the EGFR signalling pathway independently of ligand stimulation of the 
receptor (Yarom and Jonker, 2011). A meta-analysis of 11 studies of cetuximab 
confirmed the benefit with regard to both progression free and overall survival among 
patients with wild type KRAS (Dahabreh et al., 2011), while another meta-analysis 
concluded that the addition of anti-EGFR treatment improves progression free, but not 
median overall survival in patients with wild type KRAS status (Lin et al., 2011), 
prompting the question as to what constitutes an appropriate primary endpoint for the 
evaluation of biological agents (Van Loon and Venook, 2011). 
 
Similar conclusions are reported for panitumumab (Amado et al., 2008) and 
confirmed by a recent meta-analysis (Dahabreh et al., 2011). One report suggests that 
panitumumab may be effective in refractory metastatic CRCs that have experienced 
failure with standard therapy including cetuximab based regimens (Saif et al., 2010), 
although this finding is not reproduced in another study (Wadlow et al., 2011). 
Unfortunately, there is a huge amount of variation and lack of published information 
in the study methods, with patient numbers, duration of follow up, absolute five-year 
disease free survival rates and percentage of patients undergoing resection of liver 
metastases after treatment not detailed in the meta-analyses. Another problem is 
chemotherapy associated hepatotoxicity induced by combination therapy: a 
randomised trial investigating the effects of oxaliplatin or irinotecan based 
chemotherapy and either bevacizumab alone or bevacizumab plus panitumumab 
found that panitumumab shortened progression free survival and increased toxicity 
(Hecht et al., 2009). Other investigators assessing the effect of chemotherapy plus 
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bevacizumab, or this combination plus cetuximab found that the addition of 
cetuximab decreased median progression free survival and increased the likelihood of 
serious adverse events, arguing against combining anti-VEGF and anti-EGFR 
monoclonal antibodies in metastatic colorectal cancer (Tol et al., 2009). The situation 
in rectal cancer is equally unclear, as one study found KRAS mutation status to be a 
predictive marker of pathologic response to neo-adjuvant cetuximab based 
chemoradiation in patients with locally advanced T4 rectal cancers (Grimminger et 
al., 2011), whereas another concluded that the presence of KRAS mutations are not 
associated with impaired response to cetuximab based chemoradiotherapy and three-
year disease free survival (Erben et al., 2011). 
 
In any case, most patients (80%) with KRAS wild-type tumours still do not respond, 
suggesting that additional genetic or epigenetic factors are critical determinants of 
therapy response. Indeed, alterations in other effectors downstream of EGFR, such as 
BRAF, and deregulation of the PIK3CA / PTEN pathway have been independently 
associated with resistance to therapy. BRAF acts as a downstream mediator of KRAS 
signalling, and BRAF mutations, which are mutually exclusive with those of KRAS 
(Fransen et al., 2004), are important in colorectal tumourigenesis (Rajagopalan et al., 
2002). The most frequently reported BRAF mutation, V600E is tightly associated 
with sporadic MSI caused by hMLH1 promoter hypermethylation (French et al., 
2008), induces a distinct expression profile compared with wild type BRAF tumours 
(Kim et al., 2006), and results in the inappropriate activation of the MEK–ERK 
pathway (Ikenoue et al., 2003). Studies have shown: (i) an association between BRAF 
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mutation and poor prognosis in patients with AJCC stage II – III (French et al., 2008), 
stage I – IV (Ogino et al., 2009) and stage IV (Van Cutsem et al., 2011; Yokota et al., 
2011) CRC; and, (ii) that this abrogates the better prognosis associated with MSI 
(French et al., 2008; Ogino et al., 2009). This contrasts with another study, of AJCC 
stage I - IV patients, which reported no influence of the V600E status on the five-year 
survival of MSI tumours (Samowitz et al., 2005). Two of the studies also differ in that 
one reports an association of the V600E mutation with poor survival in MSS CRC 
(Samowitz et al., 2005), in agreement with another one (Shaukat et al., 2010), 
whereas the other found no difference in this subset of patients (French et al., 2008). 
These discrepancies may be due to stage differences in the study populations, 
different racial groups and only the latter being in a randomised prospective clinical 
trial setting. It remains unclear whether patients with BRAF-mutated tumours 
experience a survival benefit from treatment with anti-EGFR antibodies (Yokota, 
2011), although a report concludes that BRAF mutations are a negative prognostic 
marker that predict of a lack of response to cetuximab in patients with AJCC stage IV 
CRC (Tol et al., 2009) and, whilst not prognostic of relapse free survival in stage II - 
III CRC patients, is prognostic for overall survival, particularly in patients with MSS 
tumours (Roth et al., 2010). 
 
A recent study suggests that a combination of BRAF, NRAS, and PIK3CA exon 20 
mutations (De Roock et al., 2010), or loss of PTEN combined with mutations of 
KRAS, BRAF and PIK3CA (Sartore-Bianchi et al., 2009) are significantly associated 
with a low response rate (Bohanes et al., 2011). Taking all the evidence together, the 
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prognostic or predictive relevance of these mutations remains unclear. Firstly, a 
systematic review of the literature suggests that the evidence regarding an association 
of BRAF mutations with poorer treatment response are of “ low quality”, that the 
evidence for NRAS and PIK3CA exon 20 mutations is based on a small number of 
identified mutations and the data on PTEN and AKT are limited by variable methods 
for assessing protein expression (Lin et al., 2011). Secondly, a retrospective 
evaluation of the efficacy of a cetuximab containing treatment in AJCC stage IV CRC 
found that while KRAS status significantly correlated with a worse outcome in 
patients treated with cetuximab, no definitive inference could be drawn about the role 
of BRAF mutations and loss of PTEN expression (Inno et al., 2011). Thirdly, it 
appears that in order to assess whether the mutation status of BRAF and other markers 
may be a valid prognostic marker in the adjuvant setting, its association with different 
molecular subgroups may have to be considered (Tejpar et al., 2010) and there is an 
urgent need for greater comparability and transparency of published studies. 
Furthermore, all of these studies need to be validated by large prospective randomized 
clinical trials, since the molecular alterations could be negative prognostic biomarkers 
independent of the targeted therapies, rather than being predictive biomarkers. In 
addition, PTEN expression is not a good biomarker candidate as it is a subjective, 
graded analysis with expression of PTEN demonstrating a relatively low concordance 
between primary and metastatic tumours. Nevertheless, an assessment of the cost 
effectiveness of predictive testing for KRAS and BRAF mutations, prior to cetuximab 
treatment of chemorefractory metastatic CRC patients, concludes that it is 
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economically favourable to identify patients with KRAS and BRAF wild type status 
(Blank et al., 2011). 
 
Similar controversy surrounds the role of thymidylate synthase (TYMS), whose 
activity is inhibited by 5-FU, leading to cell cycle arrest and apoptosis (Pinedo and 
Peters, 1988). Although early in vitro evidence links TYMS expression and 5-FU 
sensitivity, conflicting in vivo data make the role of this gene or its gene product as a 
prognostic or predictive marker in the adjuvant setting controversial (Tejpar et al., 
2010), despite the recent suggestion that increased expression of TYMS improves 
outcome stratification for patients with CRC liver metastases treated with resection 
and modern chemotherapy regimens (Maithel et al., 2011). 
 
1.7 PRACTICAL LIMITATIONS 
 
As has become clear, studies reporting the discovery of biomarkers useful for CRC 
management are retrospective, involve a small number of patients and are unable to 
predict accurately disease progression with a clinically adequate resolution and 
reproducibility (Lurje et al., 2007). Sample size is important as small studies can give 
inflated, over-promising results as a result of selection bias (Ioannidis et al., 2003) and 
while small study populations are likely to be more homogeneous and thus molecular 
classifiers may be more efficient, they are frequently underpowered to discriminate 
informative molecular signatures and may incorrectly reach negative conclusions. 
This limitation is further compounded by the majority of investigators paying little 
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attention to contemporary models of tumourigenesis, with biomarker discovery and 
validation frequently focussing upon traditional signalling targets firmly rooted in 
well-established stochastic pathways. As a consequence, although a combined 
approach to molecular prognostics, similar to that established for breast cancer 
patients may have significance and be used in future CRC patient management 
(Kahlenberg et al., 2003), current research has failed to yield consistent sets of 
externally validated markers (Lai et al., 2003; Govindarajan and Paty, 2011) that 
clinicians could practically use in clinical decision making (De Roock et al., 2009). 
Indeed, the findings of many of studies are contradictory and the current reality is that 
no molecular marker, other than the KRAS gene in the case of EGFR targeted therapy 
for metastatic disease, has translated into clinical practice (Deschoolmeester et al., 
2010). Consequently, additional strategies may be necessary in future to obtain 
validated clinically useful molecular biomarkers.  
 
1.8 FUTURE DIRECTIONS: THE CANCER STEM CELL HYPOTHESIS 
 
The case for CRC as a disease characterised by significant overall heterogeneity in 
terms of morphology, genetic lesions, gene expression profiles, cell proliferation 
kinetics and response to therapy (Palmqvist et al., 1998; Halvarsson et al., 2007; Jass, 
2007; Pohl et al., 2008; Goasguen et al., 2009) has been made previously in this 
chapter. However, it is worth emphasising that this extensive heterogeneity with 
respect to genetic and epigenetic abnormalities is also apparent between different cells 
and locations within an individual clonal tumour (Giovagnoli et al., 1999; Baisse et 
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al., 2001; Murphy et al., 2007; Ross, 2011), which further compounds the 
controversies surrounding the development of diagnostic, prognostic and predictive 
CRC biomarkers. Two broad molecular explanations are proposed for this 
heterogeneity: (i) the classical stochastic model that suggests all tumour cells are 
biologically equivalent and that variation arises from intrinsic or extrinsic influences 
that result in random responses (Fearon and Vogelstein, 1990; Knudson, 2001; Kai et 
al., 2009); or, (ii) the cancer stem-cell (CSC) model that proposes cancers retain a 
hierarchical organisation and originate from, and are sustained by, a select cell 
population of either normal stem or progenitor cells (Hamburger and Salmon, 1977; 
Dalerba et al., 2007a; O'Brien et al., 2007; Ricci-Vitiani et al., 2007). CSCs are 
hypothesised to maintain their inherent capacity for self-renewal whilst driving 
tumourigenesis through their acquisition of features such as uncontrolled growth, 
differentiation into phenotypically heterogeneous aberrant progeny that constitute the 
bulk of cells within a tumour and, finally, the capacity to form metastases (Wang and 
Dick, 2005; Dalerba et al., 2007b). Despite some recent plausible evidence supporting 
the use of stochastic modelling as a means to rationalise CRC colorectal 
tumourigenesis (Kai et al., 2009) there is now persuasive evidence for the general 
validity of the CSC model in CRC, with a less rigid interpretation of this concept 
incorporating previous models of tumour growth. The CSC model describes an 
attractive cellular mechanism to account for the therapeutic refractoriness 
characteristic of many tumours and so provides a potential target for novel biomarkers 
which might facilitate early detection and guide therapeutics (Ischenko et al., 2008).  
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However, many details about CSCs in general, and colorectal CSCs in particular, 
remain poorly understood, not least how to identify them reliably from amongst the 
bulk primary / metastatic tumour mass, in faeces or as CTC in blood. Several potential 
surrogate biomarkers of colorectal CSCs have been proposed, including PROM-
1/CD/AC133, B-cell-specific Moloney murine leukaemia virus integration site (BMI-
1), Musashi-1 (MSI-1), ABC-transporters (ABCB1; ABCG2), leucine-rich-repeat-
containing G-protein-coupled receptor 5 (LGR5), epithelial cell adhesion molecule 
(EpCAM), CD44, CD166 and aldehyde dehydrogenase (ADH). None are universally 
accepted, not least because preclinical assays utilised for CSC marker discovery can 
vary and results are potentially dependent on the type of xenotransplant tumour-
initiation assay used (Bankert et al., 2001). Consequently, the remainder of this 
chapter will consider the evidence surrounding colorectal CSC biomarkers proposed 
to date, including the animal / preclinical data which supports their biological validity 
and emerging clinical insights which highlight their potential role as a CRC 
biomarker, or their importance in future discoveries of such markers. 
 
1.9  PUTATIVE COLORECTAL CSC BIOMARKERS 
 
1.9.1  PROM-1/CD/AC133 
 
The prominin-1 (PROM-1) gene specifies the CD133 protein, originally identified as 
a haematopoietic / neuro-epithelial stem-cell marker (AC133 glycotype of CD133). 
CD/AC133 is a pentaspan cell surface membrane protein of unknown function present 
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on numerous human epithelial structures, e.g. central nervous system, gut and kidney. 
Studies assessing the function of neural tumour cells expressing PROM-1/CD/AC133 
suggest this marker enriches tumour populations for CSCs, which are approximately 6 
– 29% of the total tumour burden (Singh et al., 2004). Similarly, colorectal CSCs are 
proposed to be a small subset of undifferentiated tumourigenic PROM-
1/CD/AC133high cells (Ricci-Vitiani et al., 2007), which account for about 2.5% of the 
total tumour population. This premise is supported by the observation that 
subcutaneous injection of primary PROM-1/CD/AC133high colorectal carcinoma cells 
reproduces tumour phenotype following serial transplantation in NOD/SCID mice, 
whereas primary PROM-1/CD/AC133low cells are not reported to be tumourigenic 
(O’Brien et al., 2007; Ricci-Vitiani et al., 2007). PROM-1/CD/AC133high CRC stem 
cells are also thought to avoid apoptosis by producing and utilising Interleukin-4 (IL-
4), which confers a selective advantage to this tumour cell subset. Treatment with 
anti-IL-4 antibody significantly enhances the efficacy of chemotherapy through 
selective sensitisation of PROM-1/CD/AC133high CRC cells (Todaro et al., 2007). 
However, the utility of PROM-1/CD/AC133 as a marker for CRC stem-cells has been 
challenged by the report that both primary PROM-1/CD/AC133high and metastatic- 
PROM-1/CD/AC133low CRC cells initiate tumours in immunodeficient mouse models 
(Shmelkov et al., 2008). 
 
Nevertheless, qPCR / immunohistochemical studies assessing PROM-1/CD/AC133 
expression in the primary tumour mass have proposed this putative CSC marker may 
have utility as a prognostic biomarker for CRC patients (Horst et al., 2008; Kojima et 
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al., 2008; Horst et al., 2009a,b,c; Li et al., 2009; Artells et al., 2010; Saigusa et al., 
2011), with specific reference to AJCC stage IIIB disease (Li et al., 2009) and rectal 
cancer patients treated with neo-adjuvant chemoradiotherapy (Saigusa et al., 2009; 
Yasuda et al., 2009). However, an association between PROM-1/CD/AC133 and poor 
outcome has not been described by all investigators (Choi et al., 2009a). Further 
support for PROM-1/CD/AC133 based prognostication comes from a report detailing 
that semi-quantitative qPCR PROM-1 transcript detection in peripheral blood is 
capable of identifying patients at risk of recurrence independent of AJCC stage IV 
disease (Lin et al., 2007a), while expression levels in peripheral blood may be a 
suitable prognostic biomarker to stratify patients undergoing resection for CRC 
metastases (Pilati et al., 2012). Finally, PROM-1 expression levels and PROM-1 SNPs 
within the primary tumour have recently been reported as predictive CRC biomarkers 
for patients with metastatic CRC who are treated primarily with 5-FU, oxaliplatin and 
bevacizumab (Pohl et al., 2012). 
 
1.9.2  BMI-1 
 
The polycomb group BMI-1 protein maintains the proliferation and self-renewal 
potential of human stem-cells, with down-regulation resulting in lower proliferation 
and self-renewal ability both in vitro and in vivo (Park et al., 2003). Up-regulation of 
the BMI-1 protein results in greater proliferative capacity and self-renewal 
(Bruggeman et al., 2005). This is in part attributable to deregulated expression of 
genes associated with stem-cell self-renewal, cell survival, and cell proliferation in 
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Bmi-1-/- mice (Zencak et al., 2005), in particular BMI-1-mediated suppression of 
p16INK4A, p19ARF/p14ARF, and E4F1 (Molofsky et al., 2005; Chagraoui et al., 
2006; Akala et al., 2008). Furthermore, progeny derived from BMI-1 expressing cells 
generate long-lived BMI-1high clones within all intestinal cell types. This is in keeping 
with ablation of BMI-1high cells resulting in the depletion of all epithelial cell lineages 
within the intestinal crypt (Sangiorgi et al., 2008). 
 
Over-expression of this marker is noted in a number of human solid malignancies, 
including CRC (Kim et al., 2004), leading to the premise that BMI-1 might have an 
important role in tumourigenesis and / or metastasis (Vonlanthen et al., 2001; Dimri et 
al., 2002; Sawa et al., 2005; Song et al., 2006; Cui et al., 2007; Zhang et al., 2008). 
BMI-1 over-expression may also be of clinical value as a prognostic marker for 
multiple human cancers (Song et al, 2006; Mihic-Probst et al., 2007; Häyry et al., 
2008; Liu et al., 2008; Vrzalikova et al., 2008; Wang et al., 2008; Yang et al., 2010), 
while in haematological malignancies it is reported to identify tumour cell populations 
with stem-like properties (Lessard and Sauvageau, 2003). Finally, the oncogenic 
activity of BMI-1 may confer a selective advantage to cancer stem-cell populations by 
protecting them from apoptosis (Cui et al., 2007). 
 
To date, little information is available with regard to the utility of BMI-1 as a 
biomarker for CRC. One report has demonstrated that qPCR / immunohistochemical 
detection of BMI-1 in the primary tumour is a strong negative prognostic marker for 
patients with CRC (Du et al., 2010). This assertion is further supported by a 
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contemporaneous report from a different group indicating that BMI-1 expression in 
either the primary tumour bulk, or associated lymph node metastases, may confer a 
similarly poor prognosis (Li et al., 2010). 
 
1.9.3  Musashi-1  
 
Musashi-1 (MSI-1) is an RNA-binding protein which has been shown to increase 
stem-cell self-renewal through the wnt signalling pathway (Reya et al., 2003; Lee et 
al., 2009) and the sox transcription factor family (Ito and Hotta, 1992; Pincus et al., 
1998), both of which are implicated in the induction and maintenance of progenitor / 
stem-cell sub-populations. Furthermore, MSI-1 has been proposed as a marker of 
intestinal / colonic epithelial stem-cells (Potten et al., 2003). In the small intestine, 
expression of MSI-1 was observed in cells at the 4th – 6th position from the bottom of 
the crypt in addition to the cells at the base of the colonic crypt (Marshman et al., 
2002). These are the projected crypt positions of intestinal / colonic stem-cells 
respectively (Potten and Loeffler, 1990), suggesting MSI-1 can be used as a colonic 
stem-cell marker (Potten et al., 2003).  
 
The functional role of MSI-1 in human cancer is attracting increasing interest, with 
over-expression reported in numerous malignant tumour samples and cell lines 
(Kanemura et al., 2001; Toda et al., 2001; Shu et al., 2002; Yokota et al., 2004; 
Nakano et al., 2007; Seigel et al., 2007; Götte et al., 2008; Ma et al., 2008) and some 
reports suggesting that over-expression correlates with poor prognosis for glioma 
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patients (Kanemura et al., 2001; Ma et al., 2008). MSI-1 has been detected in both 
human CRC samples and a colorectal adenoma cell line (Schulenburg et al., 2007; 
Sureban et al., 2008). Down-regulation by its specific siRNA markedly inhibits the 
activation of the notch pathway, which cooperates with the wnt pathway to create a 
favourable environment for malignant transformation. Furthermore, it also 
significantly decreases proliferation, increases apoptosis, and markedly retards the 
growth of xenograft colon tumour in mice (Sureban et al., 2008). This has led to the 
suggestion that MSI-1 might play an important role in tumourigenesis and tumour 
progression, and thus MSI-1 has begun to emerge as a regulatory molecule that may 
also be a surrogate biomarker of the colorectal CSCs subtype. Currently, only one 
study has assessed its potential role as a biomarker in CRC, reporting that it serves as 
an independent prognostic marker of poor disease free and overall survival (Li et al., 
2011).  
 
1.9.4  ATP-Binding Cassette (ABC) transporters 
 
The ATP-binding cassette (ABC) transporter super-family is a group of membrane 
bound proteins that translocate a wide variety of metabolic products, lipids and drugs 
across both extra and intracellular membranes. Membrane transporter proteins reduce 
the intracellular concentrations of several prominent anticancer chemotherapeutic 
agents and are thus implicated in multi-drug chemoresistance, one of the most 
common reasons for chemotherapy failure. ABCB1 (MDR1) and ABCG2 subtypes 
are expressed by primitive stem-cell subsets within many different tissue types (Kim 
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et al., 2002; Norwood et al., 2004; Fuellen et al., 2005; Chiba et al., 2006; Haraguchi 
et al., 2006; Meissner et al., 2006; Mouthon et al., 2006). In vitro studies have 
suggested that a stem-cell phenotype might result from or be regulated by the 
expression of ABC transporters in stem-cells (Bunting et al., 2000; Zhou et al., 2001; 
Bunting, 2002; Lechner et al., 2002; Norwood et al., 2004; Naylor et al., 2005; Ueda 
et al., 2005; Chiba et al., 2006; Kawanabe et al., 2006; Konya et al., 2006; Ogihara et 
al., 2006; Tadjali et al., 2006). This has led multiple investigators to define putative 
stem-cell populations by the presence of ABC protein efflux pump activity, which 
results in transport of fluorescent dyes like Rhodamine 123 and Hoechst-33342 
through the cell membrane (McAlister et al., 1990; Chaudhary and Roninson, 1991; 
Wolf et al. 1993; Leemhuis et al., 1996; Bunting, 2002; Kim et al., 2002; Scharenberg 
et al., 2002; Matsuzaki et al., 2004; Norwood et al., 2004).  
 
This relationship has been further investigated by reports utilising ABCB1 and 
ABCG2 deficient mice (Israeli et al., 2005); although published data must be 
interpreted cautiously as humans have one ABCB1 gene (MDR1), while mice have 
two (MDR1A / MDR1B) (Chen et al., 1986; Gros et al., 1986; Hsu et al., 1989). 
Targeted disruptions of both the MDR1A / MDR1B genes resulted in no difference in 
the number of putative stem-cell subtypes relative to wild-type mice, demonstrating 
that ABCB1 is not required to maintain a CSC phenotype. In contrast, over-
expression of ABCB1 results in proliferation of the putative stem-cell sub-population, 
prolonging their survival in culture (Bunting et al., 2000). Loss of ABCG2 gene 
expression leads to a significant reduction in the number of putative stem-cells (Zhou 
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et al., 2001; Zhou et al., 2002; Zhou et al., 2003), supporting observations that 
ABCG2 transporter expression is highly regulated, with the greatest expression in 
primitive cells, and subsequent down-regulation following commitment to 
differentiation both in vitro and in vivo (Schinkel et al., 1994; Schinkel et al., 1997; 
Panwala et al., 1998; Zhou et al., 2003). Similarly, enforced expression of ABCG2 
inhibits tissue specific differentiation, resulting in fewer progeny (Ueda et al., 2005). 
 
ABCB1 expression, therefore, may characterize proliferating stem-cells, while 
ABCG2 expression may distinguish quiescent ones. Moreover, ABCB1/G2 may also 
confer additional functional properties to this cell subpopulation, including resistance 
to chemotherapeutic agents (Shen et al., 2005). In keeping with a possible role for 
ABCB1 and ABCG2 as determinants of the stem-cell phenotype, these transporters 
have been proposed as novel cell surface biomarkers, although their utility for 
detecting colorectal CSCs has been questioned (Burkert et al., 2008). 
 
At the present time no member of the ATP-binding cassette (ABC) transporter super-
family has been demonstrated as a useful CRC biomarker. Previous investigations 
have demonstrated no association between G2677T and C3435T polymorphisms of 
the ABCB1 transporter for patients with AJCC stage III – IV CRC treated for 6 
months with 5-FU plus LV (De Iudicibus et al., 2008), although there is some 
evidence that heterozygous carriers of the ABCG2 SNPs rs2622621 and rs1481012 
may have a moderately decreased risk of CRC (Campa et al., 2008). 
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1.9.5 LGR5 
 
LGR5, also known as GPR49, an orphan G-protein coupled receptor and wnt target 
gene, has been proposed as a putative marker of stem-cell populations at the base of 
intestinal and colonic crypts (Barker et al., 2007) in a murine knock-in LGR5-green 
fluorescent protein fusion model. Clonal analyses demonstrated that LGR5-positive 
progeny repopulate the crypt-villus axis with the entire hierarchy of all epithelial cell 
lineages (enterocytes, goblet cells, paneth cells, and enteroendocrine cells), 
demonstrating multipotency and the ability of this cell subset to undertake long-term 
crypt-villus maintenance (Barker et al., 2007; Barker et al., 2008) and thus has been 
proposed as a marker of intestinal epithelial stem-cells (Vermeulen et al., 2008). 
LGR5 has also been implicated in the development of CRC since (i) intestinal 
epithelial stem-cells expressing this marker are thought to undergo aberrant 
deregulation of molecular pathways resulting in CRC (van der Flier et al., 2009), and 
(ii) restricted LGR5 expression is noted within the most basal cellular layer of human 
adenomas localized at the adenoma-host interface (Takahashi et al., 2011). Recent 
studies have demonstrated that LGR5 expression quantitated by qPCR and 
immunohistochemistry correlates with overall disease free survival (Takahashi et al., 
2011), with time to tumour recurrence associated with the LGR5 SNP rs17109924 
T>C (Gerger et al., 2011). In particular, a specific gene variant profile including the 
SNPs LGR5 rs17109924, CD44 rs8193, and ADH1A1 rs1342024 represented a high-
risk subgroup, with particularly poor disease free survival rates (Gerger et al., 2011). 
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1.9.6  Additional CSC phenotype markers 
 
The phenotype of colon cancer stem-cells has also been reported by one group to be 
defined by EpCAM-CD44-CD166-positivity (Dalerba et al., 2007b). Furthermore, 
these authors suggest that expression of the ADH gene super family is useful for 
isolation of CRC-CSCs in some xenografts (Dalerba et al., 2007b), in addition to their 
role as detoxifying enzymes, which may confer a supplementary selection advantage 
to a tumour cell sub-population (Dylla et al., 2008). In addition to the data reported 
for CD44 and ADH above, an early report identified abnormal expression of CD44 
variants in the faeces of 60 - 70% of CRC patients before surgery and in 10 - 30% of 
patients after surgery (Yamao et al., 1998). Furthermore, the most widely quoted 
evidence for an association between CTCs and survival comes from a prospective 
qPCR study that has demonstrated a significant adverse impact on survival with the 
presence of ≥ 3 CTC per 7.5 mL blood based on selection for EpCAM and detection 
of CK19, 20, CEA, or EGFR (Cohen et al., 2006) and a follow-up study, where CTCs 
in patients receiving first or second line therapy, or irinotecan, but not bevacizumab, 
were associated with poor overall survival and progression-free survival (Cohen et al., 
2009). However, one relevant characteristic of EpCAM is that its expression levels 
are variable (van der Gun et al., 2010) and its down-regulation indicates increased 
metastatic potential in CRC (Gosens et al., 2007), making it a less than useful marker. 
Interestingly, when assessed together, loss rather than over-expression of 
membranous CD44, CD166, and EpCAM has been linked to tumour progression, with 
down-regulation of CD44 and CD166 also associated with unfavourable clinical 
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outcome (Lugli et al., 2010). However, further studies are awaited to confirm these 
findings. 
 
1.10  SUMMARY 
 
CRC develops and progresses through a systematic acquisition of, and selection for, 
(epi)-genetic alterations that drive the transformation from normal colon epithelium to 
adenocarcinoma and beyond. These affect a wide range of coding and non-coding 
RNAs, whose products function as oncogenes and tumour / metastasis suppressor 
genes. The clinical behaviour of cancer cells is predicated upon complex and dynamic 
interactions between their effects within a distinctive host genetic and environmental 
context. Although earlier diagnosis and more effective treatment modalities have 
decreased CRC mortality, prognostic stratification and adjuvant therapy selection 
remain dependent on broad classifications, opportune histological markers of poor 
prognosis and chemotherapy efficacy data derived from diverse CRC populations. 
Crucially, there is significant inter / intra individual variability in response to, and 
tolerance of, chemotherapy treatments.  
 
Application of molecular biology technology has the potential to address these 
constraints and as such there has been intense interest in the identification of 
biomarkers facilitating accurate early diagnosis, that have prognostic potential for the 
individual, or that can predict patient-specific responses to chemotherapy. However, 
in order to be useful, biomarkers must be easy to obtain and quantify, have biological 
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relevance and ideally represent steps in well-understood carcinogenic pathways or in 
host-response mechanisms. Some biomarkers already exist that can provide broad 
prognostic information based on CRC subtype (e.g. MSI status) or that can somewhat 
predict response to targeted therapies (e.g. KRAS). However, although numerous 
individual biomarkers as well as composite mRNA / miRNA signatures of CRC 
progression have been reported, few, if any, have been translated into routine clinical 
practice. The recent realisation that CRC stem cells appear to control tumour 
initiation, growth and metastasis has led to concerted attempts to identify biomarkers 
which will assist in the development of diagnostic, prognostic and predictive assays, 
in addition to new therapies that aim to target this fraction specifically. 
 
The cancer stem-cell hypothesis provides an important, albeit incomplete, conceptual 
framework for our understanding of tumourigenesis and metastasis, and promises a 
specific target for future biomarker and drug development. Despite the immense 
amount of work being undertaken to identify surrogate biomarkers for colorectal 
CSCs, no definitive marker(s) have emerged that can reliably identify and be used to 
isolate this cell subpopulation. This is limiting our ability to rationalise the effects of 
contemporary chemotherapeutic regimens on the differential levels of the tumour 
hierarchy, i.e. from CSCs to more limited tumour progeny with no ability to 
proliferate or self renew. 
 
Based on recent transplantation / tumourigenicity assays which support its use as a 
putative colorectal CSC biomarker, as well as its acceptance as a marker with high 
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prognostic impact for CRC, PROM-1/CD/AC133 appears to be a promising candidate 
for further evaluation. Unfortunately, however, its biological function remains 
unknown. Consequently, further investigations are necessary to identify a function for 
this molecule and to subsequently develop agents that target PROM-1/CD/AC133high 
CRC stem-cells.  
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1.11  AIMS OF THIS THESIS 
 
The aims of this thesis are to: 
 
1. investigate the association between PROM-1/CD/AC133 and tumourigenesis / 
metastasis by quantifying CD/AC133 protein expression levels in patient-
matched samples of colorectal cancer (CRC) and adjacent normal epithelium, 
lymph node metastases, and liver metastases; 
 
2. identify human CRC / sub-epithelial myofibroblast cell lines expressing 
PROM-1/CD/AC133, to allow studies of the downstream target genes 
associated with this marker to be performed in vitro; 
 
3. determine the true utility of PROM-1/CD/AC133 as a marker of colorectal 
cancer-cancer stem cells (CRC-CSCs) / immature sub-epithelial myofibroblast 
progenitor cells by analysing the co-expression of additional putative 
immature progenitor marker expression levels (ABCB1 / ABCG2 / BMI-1 / 
CD44 / LGR5 / MSI-1); 
 
4. assess the differential expression of established human PROM-1 mRNA 
isoforms by CRC and colonic sub-epithelial myofibroblast cell lines; 
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5. investigate a putative role for PROM-1/CD/AC133 within intracellular 
signalling cascades that are intimately associated with cellular proliferation 
and differentiation utilising RNA interference and PCR-array technology in 
CRC and colonic sub-epithelial myofibroblast cell lines; 
 
6. validate data derived from RNA interference and PCR-array technology in 
CRC and colonic sub-epithelial myofibroblast cell lines with a series of more 
defined qPCR assays. 
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2.1  PATIENT COHORT AND TISSUE PEPARATION 
 
2.1.1  Patient cohort 
 
Twenty-eight colorectal cancer (CRC) patients undergoing surgical resection with 
curative intent (R0) between the years 2005 - 2007 were selected. Demographic, 
staging and histopathological data were obtained from patient case records. Samples 
from all twenty-eight patients were used for immunohistochemistry analyses. The 
clinical characteristics of all the patients are detailed in Table 2.1. All studies were 
performed in accordance with the requirements of The East London and The City 
Research Ethics Committee (study number: P/04/322). 
 
2.2  CELL CULTURE METHODS 
 
2.2.1  Cell culture 
 
The human CRC cell lines CaCo-2 (HTB37) and HT-29 (HTB38) (American Type 
Culture Collection [ATCC], Virginia, USA) were cultured in T75 cell culture flasks in 
the following media: Dulbecco’s Eagle’s medium (DMEM); 10% (v/v) foetal bovine 
serum (FBS) (Bio-sera, East Sussex, UK); 1 g / L glucose (PAA, Pasching, Austria); 
2 MATERIALS AND METHODS  
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1% (v/v) L-glutamine 200 mM (PAA); 1% (v/v) penicillin-streptomycin (PAA). 
Tissue culture flasks were incubated at the following conditions: 37oC; 95% humidity; 
5% atmospheric CO2. Culture media was refreshed every second to third day with 
cells routinely passaged twice a week. The human colonic subepithelial myofibroblast 
(SEMF) cell line CDD18Co (ATCC) was also cultured in T75 cell culture flasks in 
the following media: DMEM; 1% (v/v) L-glutamine 200 mM (PAA); 10% (v/v) FBS 
(Bio-sera). Tissue culture flasks were incubated at the following conditions: 37oC; 
95% humidity; 5% atmospheric CO2. One month after the time that the DMEM 
culture medium was first used, 1% (v/v) L-glutamine 200 mM (PAA) was added as 
the original amino acids in the media would have been degraded. When cells were 75 
- 80% confluent they were passaged by washing in 0.01 M phosphate buffer saline 
(PBS) without calcium or magnesium (PAA). 2 - 3 ml of trypsin-EDTA (0.05% 
trypsin / 0.02% EDTA in 0.01 M PBS; PAA) mixture was added to T75 culture flasks 
for 2 - 3 minutes at 37°C to detach adherent cells. Trypsin-EDTA then was 
neutralised by adding an equal volume of media to prevent trypsin-EDTA from 
digesting the cells. Cells were centrifuged at 1000 rpm for 5 minutes, after which the 
cell pellet was re-suspended in DMEM and re-plated in a new T75 culture flask. 
When culturing cells for immunofluorescence labelling, 1×105 cells of each cell line 
were seeded in their respective media on glass histopathology cover slips for up to 
seven days. All cell lines were demonstrated by Clare Hall Laboratories (Cancer 
Research UK, Hertfordshire, UK) to be negative for mycoplasma infection prior to, 
and following the conclusion of, experiments conducted for the studies in this thesis. 
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Table 2.1 – Patient demographics. 
 
Abbreviations: W – well; M – moderate; P – poor; MSI – microsatellite instability; MSS – 
microsatellite stable; MACS – microsatellite and chromosome stable; T – tumour; VI – vascular 
invasion; LN – lymph node; LM – liver metastasis. 
 sex age site differentiation stage MSI p53 expression 
        
1. M 47 Rectum M T3N3M0 MSS T / VI / LN 
2. M 70 Sigmoid M T3N2M1 MACS T / VI / LN 
3. F 77 Rectum M T3N2MX MSS absent 
4. M 45 Sigmoid M T4N2M1 MACS absent 
5. M 63 Sigmoid M T3N2M1 MSS absent 
6. F 69 Right M T3N2MX MSS T / VI / LN 
7. F 77 Transverse P T4N2MX MSS absent 
8. F 91 Transverse P T3N2M0 MSS T / VI / LN 
9. M 48 Sigmoid P T4N1MX MSS absent 
10. M 57 Right M T4N2MX MSS T / VI / LN 
11. F 80 Rectum M T3N1M1 MACS T / VI / LN / LM 
12. M 86 Right M T4N1MX MSS T / VI / LN 
13. F 65 Right M T3N2MX MSS T / VI / LN 
14. M 61 Rectum M T3N2MX MSS T / VI / LN 
15. M 68 Sigmoid P T3N1M0 MSS T / VI / LN 
16. F 86 Right P T4N2MX MACS T / VI / LN 
17. F 77 Right M T4N2MX MSS T / VI / LN 
18. M 80 Right M T4N2MX MSS T / VI / LN 
19. M 64 Left M T3N1M1 MSS T / VI / LN / LM 
20. M 63 Left M T4N2M1 MSS T / VI / LN / LM 
21. F 76 Left M T3N1M1 MSS T / VI / LN / LM 
22 M 54 Rectum M T4N1M1 MSS T / VI / LN / LM 
23. F 82 Right P T3N1MX MSS absent  
24. M 76 Right M T3N1MX MSS T / VI / LN 
25. M 82 Rectum P T3N2M1 MACS T / VI / LN / LM 
26. F 60 Right W T3N2M1 MSS absent  
27. M 68 Right W T3N1MX MSS T / VI / LN 
28. M 64 Rectum M T3N1MX MACS T / VI / LN 
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2.2.2  Cryopreservation and recovery of the cells 
 
For cryopreservation, 75 - 85% confluent cells were detached from the surface of the 
flask using trypsin-EDTA and recovered by centrifugation at 1,000 rpm for 5 minutes, 
with the resulting pellet re-suspended in 90% FBS:10% (v/v) dimethyl sulphoxide 
solution (VWR Prolabo, West Sussex, UK). Cells aliquots were re-suspended at a 
density of 1×106 per ml. Cryovials were wrapped in tissue paper and stored at -70°C 
for long-term storage. 
 
2.3  siPROM-1 KNOCKDOWN 
 
CaCo-2, HT-29 and CCD18Co cell lines were individually seeded at approximate 
densities of 2×105 in six-well tissue culture plates (Falcon, Becton Dickinson, USA). 
Cells were incubated for 24 hours at the following conditions: 37oC; 95% humidity; 
5% atmospheric CO2. To achieve human PROM-1 ‘knock-down’ (siPROM-1) the 
siRNA SMARTpooltm (catalogue number - L-010630-00, Dharmacon, UK) reagent 
system was utilised. Transfection and silencing efficiency conditions were optimised 
using the positive control silencers siGLOtm Cyclophilin B siRNA (catalogue number 
- D-001610-01, Dharmacon). A final concentration of 80 nM was used. The HT-29 
cell line was transfected with an optimised final volume of 4.5 µl DharmaFect-
reagent-4 (Dharmacon), whereas DharmaFect-1 was used at the same concentration 
for the CaCo-2 and CDD18Co cell lines. Transfections were performed according to 
the ‘DharmaFECT general transfection protocol’ (Dharmacon) and optimised for the 
six-well plate format. Cells were plated in DMEM growth medium at a density of 
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2×105 / well approximately 24 hours prior to transfection and incubated at the 
following conditions: 37°C; 95% humidity; 5% CO2. Transfection reagents were 
diluted in serum-free media in separate tubes incubated at 37°C for 5 minutes. The 
contents of the tubes were mixed and incubated again at 37°C for 20 minutes. DMEM 
growth medium without penicillin and streptomycin was added to the transfection 
mixture to a total volume of 2 mls / well. Culture media was then removed from the 
six-well plate after which 2 mls of the appropriate transfection mixture was added to 
each well and incubated at: 37°C; 95% humidity; 5% CO2. The transfection media 
was replaced with DMEM growth media after 24 hours. Transfected cells were 
harvested at 48 hours for mRNA / protein extraction. Cells were transfected with 
scrambled ON-TARGET plus control pool (Non-Targeting pool, catalogue number D-
00181010-20 (Dharmacon, UK)) as a negative control at the optimised final 
concentration of 80 nM. 
 
2.4  RNA EXTRACTION AND QUANTIFICATION 
 
2.4.1  RNA extraction from cell line cultures 
 
Cells were twice washed with 0.01 M PBS (PAA) prior to lysis in 600 µl of RLT 
buffer (Quantace Sensimix, London, UK). The resulting lysate was centrifuged for 5 
minutes at 13,000 rpm, after which 600 µl of 70% ethanol was added to the 
supernatant. This sample was processed using an RNeasy mini column (Qiagen, 
Crawley, West Sussex, UK) after which the column was centrifuged at 10,000 rpm for 
15 seconds. The column was washed twice with 350 µl RW1 buffer (Qiagen). DNA 
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digestion was performed by incubating the column with RNase-free DNase-I for each 
sample (10 µl DNase; 70 µl RDD dilution buffer, Qiagen) at room temperature for 15 
minutes. The absence of DNA contamination in each sample was confirmed using the 
electrophoresis function of the Agilent® 2100 Bioanalyser (Agilent Technologies UK 
Ltd., South Queensferry, UK), in addition to the absence of amplicon in the no-RT 
controls run for every sample. Samples were then washed twice with 500 µl of RPE 
buffer. After centrifugation for 3 minutes at full speed, 50 µl RNase-free water was 
added to the columns and samples incubated at room temperature for 1 minute. Total 
RNA was eluted from the column by centrifuging at full speed for 1 minute. All 
samples were stored at -70°C for future use. The manufacturer did not make the 
composition of the buffers mentioned above available, as this information was 
deemed commercially sensitive. 
 
2.4.2  RNA quantification 
 
Total RNA preparations were quantified by the NanoDrop® ND-1000 (NanoDrop 
Technologies Inc, Delaware, USA) which was used to measure sample absorbance at 
the 260 nm and 280 nm wavelengths.  Samples were measured a minimum of three 
times with the mean absorbance reading at the 260 nm wavelength designated as the 
RNA concentration. RNA preparation purity was expressed by representing 
absorbance readings as a ratio, with readings taken at the 260 nm wavelength 
identified as the numerator, while readings at the 280 nm wavelength were designated 
as the denominator.  Preparations with ratios ranging from 1.8 - 2.1 were stored for 
further use at -70°C, all other samples were discarded. 
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2.4.3  RNA integrity assay 
 
RNA preparation integrity was determined using a Nano LabChip on an Agilent® 
2100 Bioanalyser (Agilent Technologies UK Ltd), a microfluidics-based platform for 
quantification and quality control of RNA. RNA analysis results obtained are 
displayed in form of a gel image, electropherograms and in a tabular format. Sample 
integrity is determined by the entire electrophoretic trace of the RNA sample, 
including the presence or absence of degradation products. An RNA nano ladder 
standard is run on every chip and is used as a reference for data analysis. During the 
chip run, the dye intercalates directly with the RNA and all bands pass the detector at 
different speeds. The software automatically compares the unknown samples to the 
ladder fragments to determine the concentration of the unknown samples and to 
identify the ribosomal RNA peaks. The Bioanalyzer electropherogram of total RNA 
shows two distinct ribosomal peaks corresponding to either 18S or 28S; ideally the 
height of the 28S rRNA peak should be at least twice that of the 18S rRNA peak, 
although this is not an absolute requirement. In addition, the baseline between the 
internal marker and the 18S rRNA peak should be relatively flat and free of small 
rounded peaks corresponding to smaller RNA molecules that are degradation products 
of the rRNA transcripts. In addition to calculating the ratio of the 18S to 28S 
ribosomal RNAs, a software algorithm calculates an RNA Integrity Number (RIN), 
which is based on a numbering system from 1 to 10, with 1 being the most degraded 
and 10 being the most intact. This facilitates comparison of samples and ensures 
better reproducibility. Samples with a RIN of less than 7 were discarded, with the 
remaining samples stored at -70°C for future use. 
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2.4.4  RT-qPCR assays 
 
The mRNA sequence for the target genes was determined by accessing the GenBank 
database (www.ncbi.nlm.nih.gov/sites/entrez?db=gene). Target specific primers as 
well as primers amplifying the three-reference genes beta 2-microglobulin (B2M), 
eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2) and Tyrosine 3-
monooxygenase (YWHAZ) were designed using Beacon Designer (Palo Alto, USA) 
(Table 2.2). Data demonstrating stable expression of these reference genes under the 
chosen experimental conditions have previously been reported by our group (H. Tian, 
PhD 2010 University of London). It was not possible to design primers targeting 
individual PROM-1 splice variants; however, primers identifying four overlapping 
PROM-1 splice variant subgroups were devised (Table 2.2; Figures 2.1, 2.2, 2.3 & 
2.4). All primers were synthesized by Sigma-Aldrich (Sigma-Aldrich Company Ltd., 
Dorset, UK). RT-qPCR assays targeting amplicons not detailed in Table 2.2 were 
performed using assays on demand (Corbett Life Sciences, West Sussex, UK). These 
primer sequences were not made available by the manufacturer, as this information 
was deemed commercially sensitive. 
 
Lyophilised primers were added to Tris-EDTA (TE) buffer solution (10 mM Tris-Cl, 
pH 7.5; 1 mM EDTA) to make a stock solution of 100 pmol / µl, with both forward 
and reverse primers further diluted in TE buffer to provide a working solution of 10 
pmol / µl. To achieve maximum assay efficiency optimization of several important 
factors was carried out for each gene. The optimal MgCl2 concentration was 
determined for each primer, with a final concentration of 3 mM found to be optimal 
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for all RT-qPCR analyses. Concentrations of forward and reverse primers were 
optimised for each gene using an optimization matrix. Primer concentrations were 
selected on the basis of: best quantification cycle (Cq) value (16-20), most specific 
melt curve, highest reaction efficiency (greater than 0.90) and the best slope (-3.2 to -
3.5) determined using dilution curves. Approximate annealing temperatures were 
determined for primer sets using the following equation: Tm = 2(A + T) + 4(G + C). 
The optimal annealing temperature was determined empirically by selecting a range 
of temperatures starting 2oC below and finishing 2oC above the calculated annealing 
temperatures for the forward and reverse primers and running optimisation assays 
using the block-gradient feature available on the BioRad CFX qPCR cycler (Bio-Rad 
Laboratories Ltd., Hertfordshire, UK). 
 
RT-qPCR reactions for all candidate genes were performed in a one-tube system 
using SYBR®-Green-I chemistry and were carried out on a Corbett Rotor-Gene 6000 
sequence detector (Corbett Life Sciences, Crawley, West Sussex, U.K.). Samples of 
50 ng of total RNA in 25 µl reaction volumes were used with a one-step kit 
(Quantace). Biological replicates obtained from three repeat experiments were 
analysed in triplicate. Reaction conditions were as follows: 60°C for 15 minutes, 92°C 
for 5 minutes followed by 40 cycles of 92°C for 20 seconds and 55ºC - 62°C 
(depending on the primer optimisation results) for 1 minute. Controls included no-
template and no enzyme negative controls and a target-specific dilution curve as 
positive controls for every run. 
  PhD Thesis 2012 – Chapter 2 
 
 
_____________________________________________________________________ 
 
95 
 
 
 
Table 2.2 – RT qPCR primers. 
 
 symbol primer sequences accession numbers 
    
1. PROM-1 FWD: ACTACCAAGGACAAGGCGTTCAC NM_006017 
 All REV: ATGTTGGGTCTCAGTCGGTCAAG  
    
2. PROM-1 FWD: AGCCAGAAACTGTAATCTTAGGTC NM_003202.3 
 Subgroup A REV: AAATACCCCACCAGAGGCATC  
    
3. PROM-1 FWD: TCACAATCCTGTTATGACAAGC NM_001145847 
 Subgroup B REV: TTTCCACTTTGAGTATCCTGATGC  
    
4. PROM-1 FWD: TTTGTTTTGGTTTGGCATAGG NM_001145851 
 Subgroup C REV: GGGTATAGTTTCAACATCATCG  
    
5. PROM-1 FWD: CGATGACCCATCACAACATTG NM_001145852.1 
 Subgroup D REV:  CTGGATTTGGAAAGTCCTTGTAG  
    
6. B2M FWD: TGTTTGATGTATCTGAGCAGGTTG NM_004048.2 
  REV: AAGATGTTGATGTTGGATAAGAGAATTC  
    
7. EIF4A2 FWD: ATTCTGGCACTTGGAGACTATATG NM_001967.3 
  REV: GGGTGTACCAACAACAATATGTG  
    
8. YWHAZ FWD: TACTAATATAACTACTGTTTCCATGTCC NM_003406 
  REV: AAATGCCATATGCCAAAATTTTAAATG  
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Figure 2.1 – Condensed alignment of the PROM-1 amplicon detecting all splice variants. Sequence alignment and the consensus of the seven transcripts was highlighted 
using CLL Workbench 4 software (CLC Bio, Aarhus, Denmark). Solid lines indicate primer-binding sequences for grouped splice variants as indicated by Table 2.2. 
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Figure 2.2 – Condensed alignment of the PROM-1 Splice variants. Sequence alignment and the consensus of the seven transcripts was highlighted using CLL Workbench 4 
software (CLC Bio, Aarhus, Denmark). Solid lines indicate primer-binding sequences for grouped splice variants as indicated by Table 2. 
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Figure 2.3 – Condensed alignment of the PROM-1 Splice variants. Sequence alignment and the consensus of the seven transcripts was highlighted using CLL Workbench 4 
software (CLC Bio, Aarhus, Denmark). Solid lines indicate primer-binding sequences for grouped splice variants as indicated by Table 2.2. 
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Figure 2.4 – Condensed alignment of the PROM-1 Splice variants. Sequence alignment and the consensus of the seven transcripts was highlighted using CLL Workbench 4 
software (CLC Bio, Aarhus, Denmark). Solid lines indicate primer-binding sequences for grouped splice variants as indicated by Table 2.2.
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2.4.5  mRNA target quantification 
 
Target mRNA levels were quantified relative to amplicon-specific standard curves 
generated by quantifying duplicate 10-fold serial dilutions of HT-29 RNA diluted into 
yeast tRNA (100 ng / µl). mRNA levels were expressed as target mRNA copy 
numbers relative to the geometric mean of the B2M / EIF4A2 / YWHAZ reference 
gene mRNA levels, whose reliability was validated for the experimental conditions 
analysed (H. Tian, PhD 2010 University of London). 
 
2.4.6  Biotrove RT-qPCR OpenArray  
 
The Biotrove OpenArray platform allows approximately 3,000 RT-qPCR reactions to 
be performed in parallel using nanofluidic*technology the size of a microscope slide 
(25 mm x 75 mm x 0.3 mm). RT-qPCR occurs in a computer-controlled light emitting 
diode based thermal cycler (OpenArray NT Cycler, Woburn, MA, USA). Under 
software control, approximately 3,000 RT-qPCR amplifications are performed within 
4 hours. Post-amplification data processing generates fluorescence amplification and 
melt curves from which Cq and melt temperature (Tm) values are automatically 
computed. 
 
Primers were preloaded upon BioTrove OpenArray plates (Biotrove, MA, USA). 
Transcripts containing PDZ binding domain sequences are listed in Table 2.3.  RNA 
samples of interest were converted to randomly primed cDNA using the High 
Capacity cDNA Kit (Applied BioSystems, Warrington, UK). Non-specific product 
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formation was minimised by heating cDNA to 75oC for 10 minutes causing enzyme 
inactivation. cDNA was then stored on ice for 5 minutes before treatment with 1.3 U / 
ml Exonuclease-I (Amersham, Buckinghamshire, UK) for 1 hour. Exonuclease-I was 
then heat inactivated at 85oC for 10 minutes.  
 
Biological replicates obtained from three repeat experiments were analysed in 
triplicate to allow technical replicates to be performed. cDNA samples at a 
concentration of 32 ng / ml were mixed with qPCR reagents for SYBR Green PCR 
(LightCyclertm FastStart DNA Master SYBR-Green-I (Roche Products Limited, 
Welwyn Garden City, UK); 0.2% (w/v) Pluronic F-68 (Invitrogen Ltd, Paisley, UK); 
1 mg / ml BSA (Sigma-Aldrich); 1:4000 SYBR-Green-I (Sigma-Aldrich); 0.5% (v/v) 
Glycerol (Sigma-Aldrich); 8% (v/v) Formamide (Sigma-Aldrich)). This solution was 
dispensed into each sub-array (one sample per sub-array) with an automated 48 
pipette tip dispensing device. The PCR-array thermal cycling protocol consisted of 
one 10 minute 92oC polymerase activation step followed by 35 cycles of 15 seconds 
at 92oC, 1 minute at 55oC and 1 minute at 72oC. Following amplification, amplicon 
dissociation was measured by cooling the PCR-array to 65oC then slowly heated to 
92oC at 1oC per minute, with images collected every 0.25oC. 
 
Analyses were carried out according to Biotrove specificiation: amplification was 
considered positive if the Cq was less than 28 for all three replicates and the 
experimental melt temperature was consistent. Assays were considered successful if 
they displayed a true-positive or true-negative signal, and an amplicon was deemed to 
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be present if two or more assays (targeting one amplicon) displayed amplification 
with a Cq less than 28 for all three replicates.  
 
The following statistical evaluation steps were performed courtesy of Biotrove on the 
raw output data files for each OpenArray plate: (i.) automated transformation of the 
data matrices and normalization of the Cq-values of individual PCR runs (each 
sample) for the average values of the reference genes on each subarray with Biotrove 
in-house developed software. Data for cycles where the Cq-values were above 28 and 
ΔCq-values were above 10 were eliminated from the evaluation; (ii.) in case too few 
data points had been obtained for a gene throughout all samples (i.e., <20% gave 
acceptable ΔCq), that gene was excluded from further analysis. Similarly, samples 
that had not given an acceptable ΔCq throughout >20% of all targets mRNA 
sequences were excluded; iii) having transformed the raw data, these were merged 
into one database. The average Cq for all negative control samples was calculated 
over each gene. This average was subtracted from each sample's expression level over 
each gene, resulting in the ΔΔCq values which were recalculated to allow relative 
quantification using a modified Pfaffl model (Pfaffl, 2001). 
 
2.4.7  Multiplexed tandem polymerase chain reaction (MT-PCR) 
 
Multiplexed tandem polymerase chain reaction (MT-PCR) is a two-step quantitative 
PCR process, with very good correlation between values measured by this technology 
and RT-qPCR previously reported (Stanley and Szewczuk, 2005). This was chosen at 
is a convenient and flexible platform in which to further assess targets in parallel that 
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had been putatively identified by the Biotrove OpenArray platform. In the first step 
RNA is converted into cDNA and amplified using multiplexed gene specific primers. 
In the second step each individual gene is quantitated by RT-qPCR using a pre-
fabricated gene-disc (Corbett Life Sciences). Bespoke gene-disc service is provided 
by the manufacturer and was utilised by the experiments conducted in this thesis. 
Primer sequences were not made available by the manufacturer, as this information 
was deemed commercially sensitive. Target genes are listed in Table 2.4.   
 
Lyophilized step one primers were reconstituted in 8 µl of sterile water, prior to 
addition of total RNA and reverse transcription reaction reagents (10 µl Quantace 
Step 1 Master mix; 2 µl Quantace Step 1 additives). While the prescribed reverse-
transcription reaction was performed during the experiments conducted for this thesis, 
the pre-amplification step was omitted. The primary advantage of pre-amplification is 
its ability to produce several micrograms of cDNA starting from a few nanograms of 
total RNA, which is unnecessary when utilising large quantities of homogenous total 
RNA generated by cell culture techniques. Furthermore, since different targets will 
inevitably be pre-amplified with different amplification efficiencies, highly accurate 
transcript expression analysis is only possible before pre-amplification is performed. 
Gene specific RT-qPCR assays were established in a 1.5 mL tube (20 µl product from 
step 1; water 710 µl; Quantace Step 2 Master mix 750 µl; Quantace Step 2 additive 20 
µl). The plastic covering was then removed from the MT-PCR gene-disc and 20 µl of 
the above reaction mix was pipetted into each position of the disc, prior to thermal 
sealing of the gene-disc with the MT-PCR Gene-Disc sealer (Corbett Life Sciences) 
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and placement of the disc within the Corbett Rotor-Gene 6000 sequence detector 
(Corbett Life Sciences). Reaction conditions were specified within the manufacturer 
provided run template:  holding temperature - 95°C for 1 minute; followed by 45 
cycles of 95°C for 1 second, 60°C for 10 seconds, and 72°C for 10 seconds; amplicon 
dissociation sequence - temperature increased from 72 - 95°C by 1°C every 0.5 
seconds. No-template and no-reverse transcriptase controls were included as standard, 
with biological replicates obtained from three repeat experiments analysed in 
triplicate.  
 
Each MT-PCR kit is supplied with a customised MT-PCR analysis template. 
Unfortunately that template did not contain the same reference genes used for the 
standard RT-qPCR assays; instead mRNA levels were normalised according to three 
separate samples of a comparator gene on the assay disc (NONO), which had 
previously been demonstrated to be stable under the experimental conditions 
employed (R.E. Hands, PhD 2010 University of London). Those amplicons with a 
ratio of less than 0.4 for area under the dF / dT peak (rate of change in fluorescence as 
a function of temperature) over total area under the dF / dT plot were deemed primer 
dimers, and thus excluded from analyses. 
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2.5  PROTEIN EXTRACTION AND QUANTIFICATION 
 
2.5.1  Protein extraction 
 
To extract total protein from the cultured cell lines, culture medium was decanted 
from T75 tissue culture flasks and cells washed in 0.01 M PBS without calcium or 
magnesium (PAA). Extraction reagents were added to each tissue culture flask 
containing approximately 1x106 cells and shaken gently for 5 minutes (400 µl of M-
PER® reagent; 1x Halttm Protease Inhibitor Cocktail; DTT buffer) (Perbio Science 
UK, Northumberland, UK). Lysate was collected and transferred to a microcentrifuge 
tube for centrifugation at 13,000 rpm for 10 minutes to pellet the cell debris. The 
supernatant was stored at 0°C for future use. 
 
2.5.2  Protein quantification 
 
Samples were quantified using the Micro BCA Protein Assay (Perbio). A standard 
curve was generated by two-fold serial dilution of BSA from 200 µg / ml to 0.8 µg / 
ml in distilled water. 5 µl of protein extract was diluted in 95 µl of distilled water. 100 
µl of Micro BCA™ Working Reagent (Perbio) was then added (50 parts Micro 
BCAtm Reagent A; 1 part Reagent B) to every 100 µl of diluted sample and incubated 
at 60oC for one hour. 90 µl of each sample was dispensed into a 96 well plate and 
absorbance measured at 562 nm on a Wallac Ultra Multifunctional Microplate Reader 
(PerkinElmer, Cambridge, UK). 
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Table 2.3 – PDZ binding domain proteins studied by Biotrove OpenArray platform. 
 
 
 symbol gene name  symbol gene name 
 AIP1 actin-related protein T1  
HTRA1 
 
HtrA serine 
peptidase 1 
      
 CASK  
calcium/calmoduli
n-dependent 
serine protein 
kinase 
 HTRA2  
HtrA serine 
peptidase 2 
      
 DVL1  
dishevelled 
homologue  
HTRA3 
 
HtrA serine 
peptidase 3 
      
 DVL1L1  
dishevelled 1-like 
homologue  HTRA4 
HtrA serine 
peptidase 4 
      
 DVL2  
dishevelled 2-like 
homologue  IL16 interleukin 16 
      
 DVL3  
dishevelled 3-like 
homologue  NOS1 
nitric oxide 
synthase 1 
      
 GIPC1  
regulator of G-
protein signalling 
19 interacting 
protein 1 
 SIPA1 
signal-induced 
proliferation-
associated 1 
      
 GIPC2  
regulator of G-
protein signalling 
19 interacting 
protein 2 
 SLC9A3R1 
solute carrier family 
9 (sodium/hydrogen 
exchanger), member 
3 regulator 1 
      
 GIPC3 
regulator of G-
protein signalling 
19 interacting 
protein 3 
   
  PhD Thesis 2012 – Chapter 2 
 
 
_____________________________________________________________________ 
 
107 
 
 
 
Table 2.4 – targets selected for validation of PCR-array data by MT-PCR analysis following siPROM-
1 or AC133high/low FACS cell sorting as discussed in Chapter 7.1.1. §10 major transcripts; †down stream 
targets of PROM-1/CD/AC133 identified from literature; ∞transcripts association with CRC but not 
previously with PROM-1/CD/AC133; ≠targets demonstrated not to be differentially regulated by 
siPROM-1. 
 
symbol gene name symbol gene name 
AKT3§ v-akt murine thymoma viral oncogene homolog 3 FZD6
† frizzled family receptor 6 
ARAF≠ v-raf murine sarcoma 3611 viral oncogene homolog FAS
† tumor necrosis factor receptor superfamily member 6 
BCL2§ b-cell lymphoma protein 2 FST≠ follistatin 
BMP7† bone morphogenetic protein 7 GRB10§ epidermal growth factor receptor 10 
BUB1† budding uninhibited by benzimidazoles 1 ICAM1
† intercellular adhesion molecule 1 
CCNB1† cyclin B1 HGF† hepatocyte growth factor 
CDH1† e-cadherin HIF1A† hypoxia-inducible factor 1, alpha subunit 
CDH2† n-cadherin HOXB13§ homeobox B13 
CDKN1A† cyclin-dependent kinase inhibitor 1 IL16§ interleukin 16 
CES1∞ carboxylesterase 1 ITGB6§ integrin, beta 6 
COL1A2† alpha-2 collagen type I KNTC2∞ kinetochore associated 2 
CTNNB1† beta-catenin MK167† ki-67 
DNMT3B† DNA (cytosine-5-)-methyltransferase 3 beta MMP2
§ matrix metaloproteinase 2 
EGFR† epidermal growth factor receptor precursor MMP7
† matrix metaloproteinase 7 
EGR1§ early growth response 1 MMP9† matrix metaloproteinase 9 
ERBB2† receptor tyrosine-protein kinase erbB-2 precursor MUC1
∞ mucin-1 
ELK4≠ serum response factor accessory protein 1 MYC
§ c-Myc 
FAD≠ flavin adenine dinucleotide synthase NAT1∞ n-acetyltransferase 1 
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Table 2.4 (cont.) – targets selected for validation of PCR-array data by MT-PCR analysis following 
siPROM-1 or AC133high/low FACS cell sorting as discussed in Chapter 7.1.1. §10 major transcripts; 
†down stream targets of PROM-1/CD/AC133 identified from literature; ∞transcripts association with 
CRC but not previously with PROM-1/CD/AC133; ≠targets demonstrated not to be differentially 
regulated by siPROM-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
symbol gene name symbol gene name 
NDRG1† n-myc downstream regulated gene 1 protein TCF7
† transcription factor 7 
PGR† progesterone receptor TERT† telomerase reverse transcriptase 
POU5F1† oct-3 TGFBR3† transforming growth factor, beta receptor III 
RNF2∞ ring finger protein 2 TM4SF1∞ membrane component surface marker 
S100A2∞ S100 calcium binding protein A2 TP53§ tumour suppressor p53 
S100A4∞ S100 calcium binding protein A4 USP22∞ ubiquitin-specific-processing protease 
SOX4† sex determining region Y box 4 WNT3† wingless-type MMTV integration site family, member 3 
SPP1† osteopontin   
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2.6  IMMUNOHISTOCHEMISTRY 
 
2.6.1  Cell culture fixation and endogenous peroxidase blocking 
 
The cell lines were cultured with or without siRNA reagents at a density of 1x105 in a 
12 well plate containing 18 mm diameter glass cover slips (VWR International, West 
Sussex, UK). Cells were washed with 0.01 M PBS and then fixed in cold 4% 
Paraformaldehyde (Sigma Aldrich) for 10 minutes. The cells were washed three times 
with 0.01 M PBS for 5 minutes. After fixation, the peroxidase enzyme activity of the 
cells was inhibited by incubation with 0.3% hydrogen-peroxide solution (H2O2) 
(Sigma Aldrich) diluted in 0.01 M PBS, for 10 minutes. Cells were then washed in 
PBS-milk 1% for 15 minutes then washed with PBS with Tween-20 at 0.05% (Sigma 
Aldrich) for 2 minutes. Cells were blocked for 30 minutes with 5% serum in 0.01 M 
PBS corresponding to the conjugated secondary antibody species. The cover slips 
were then placed in a humid chamber and incubated with the primary antibody diluted 
in PBS in 5% serum at 4°C, overnight. 
 
2.6.2  FFPE slide deparaffinization and antigen retrieval 
 
The paraffin section was baked at 40oC for overnight then deparaffinised and 
rehydrated using a xylene and ethanol series as follows: (i) incubation with xylene for 
5 minutes, performed twice; (ii) incubation with 100% ethanol for 5 minutes, 
performed twice; (iii) incubation with 90% ethanol for 3 minutes; (iv) incubation with 
70% ethanol for 3 minutes; (v) The section was then incubated in 0.3% H2O2 in 0.01 
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M PBS for 10 minutes. For antigen retrieval 10 mM citrate buffer (pH 6.0) was boiled 
in a pressure cooker for 12 minutes within a microwave, operating at full power. Once 
boiled, a plastic rack containing the slides was placed in the boiled citrate buffer. The 
lid of the pressure cooker was then heated for 4 minutes at full power. The sections 
were then washed in tap water. Endogenous peroxidase enzyme activity was blocked 
by incubation with 0.3% H2O2, before incubating the slides with neat horse serum for 
5 minutes. 
 
2.6.3  Immunohistochemical staining 
 
Sections of human kidney were used as a positive control in each run. Specificity of 
the immunocytochemistry was confirmed by the absence of reactivity following pre-
incubation of the antibody with its specific blocking peptide. Primary antibodies with 
an optimal dilution in 5% horse serum were incubated (Table 2.5) with slides in a 
humid chamber overnight at 4oC.  
 
For 3,3'-Diaminobenzidine (DAB) staining    
After washing off the primary antibody three times in 0.01 M PBS for 10 minutes, 
slides were incubated with biotinylated secondary antibody (1 drop blocking serum 
stock Y; 1 drop biotinylated antibody stock B; 2.5 ml 0.01 M PBS) for 30 minutes at 
room temperature, then washed in 0.01 M PBS for 5 minutes. Sections were then 
incubated with avidin-biotin-peroxidase complex (1 drop reagent A; 1 drop reagent B; 
2.5 ml 0.01 M PBS) (Vectastain Elite ABC kit, Vector Laboratories, Peterborough, 
UK) for 30 minutes at room temperature in PBS 5% goat serum buffer. Sections were 
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washed again in 0.01 M PBS for 5 minutes before incubation with DAB Substrate Kit 
for peroxidase (2 drops buffer solution; 5 mL distilled water; 4 drops DAB solution; 2 
drops H202 solution) (Vector Laboratories, Peterborough, UK) for 1 - 5 minutes. 
Sections were counterstained by serial immersion in Gill’s Haematoxylin for 30 
seconds and 1% Acid-Alcohol for 1 second before being washed in tap water for 2 
minutes. This was followed by washes in 70% ethanol, 90% ethanol and absolute 
ethanol, and then mounting xylene twice for 2 minutes respectively. Slides were 
mounted with DPX mounting medium (Fisher Scientific, Loughborough, UK). 
 
For fluorescein isothiocyanate (FITC) staining 
Cells were incubated with the secondary antibody in 0.01 M PBS for 1 hour at in a 
dark room (1:800 dilution FITC conjugated goat polyclonal to rabbit IgA) (ab2760, 
AbCam. Cambridge, UK). The secondary antibody solution was removed and 
samples washed three times with 0.01 M PBS for 5 minutes in a dark room. 1 µg / ml 
of 4'-6-Diamidino-2-phenylindole (DAPI) diluted in 0.01 M PBS buffer was then 
added for 5 minutes before one 5 minute wash in 0.01 M PBS buffer. The slides or 
cover slips were mounted with Vectashield (Vector Laboratories, Peterborough, UK) 
and stored in the dark at 4°C overnight. 
 
2.6.4  Haematoxylin and eosin staining 
 
Haematoxylin and eosin staining was performed as follows: the nuclei were stained 
with haematoxylin for 5 minutes and washed with running tap water for 5 minutes, 
samples differentiated by immersing briefly in 1% acid alcohol, before being rinsed in 
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tap water. The cytoplasm was then stained with eosin for 3 minutes. Samples were 
then dehydrated for 2 minutes each in ascending grades of ethanol at 70%, 90%, and 
100% twice each, before two final washes in xylene. Slides were mounted with 
DePex mounting medium (Fisher Scientific) and allowed to dry over night in the 
fume extraction hood. 
 
2.6.5  Image acquisition 
 
Images were examined and acquired from DAB immunohistochemistry using a Leica 
DC200 microscope (Leica Microsystems (UK) Ltd, Buckinghamshire, UK). 
Immunofluorescence images generated by FITC labelling were acquired using a LSM 
510s laser-scanning microscope (Carl Zeiss, Welwyn Garden City, UK). 
 
2.6.6  Scoring immunohistochemical staining 
 
Assessment of AN, tumour, LN and LM was performed in a blinded manner and a 
score was attributed based on the intensity of staining (1 = absent / weak, 2 = 
moderate, or 3 = strong) and the percentage of positive staining cells (1 = less than 
5%, 2 = 5 – 50%, or 3 = more than 50%). A total score (maximum of 6) was then 
generated for each section. VI samples were not assessed in this manner due to the 
small cross sectional areas associated with foci of malignant intravasation. Two 
independent observers scored immunohistochemical staining in order to calculate 
inter-observer variation. This was repeated after three months by both observers 
(blinded) to assess intra-observer variation. 
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Table 2.5 – antibodies used by studies in this thesis. Abbreviations: IH – immunohistochemistry; WB – 
western blotting. 
 
 
 
 
 
 
 
 
 
Antibody target IH WB source 
anti-human ABCB1 
rabbit polyclonal ABCB1 1:100 1:100 Novus Biologicals, Inc 
     
anti-human ABCG2 
mouse monoclonal ABCG2 1:200 1:200 Santa Cruz 
     
anti-human BMI-1 
mouse monoclonal BMI-1 1:100 1:500 Cell Signaling 
     
anti-human CD44 
rabbit polyclonal CD44 1:100 1:5000 AbCam 
     
anti-human CD133/1 
(AC133) AC133 1:30 - Miltenyi-Biotec 
     
anti-human CD133/1 
(W6B3C1) AC133 - 1:100 Miltenyi-Biotec 
     
anti-human LGR5 
mouse monoclonal LGR5 1:30 1:30 Gigma 
     
anti-human MSI-1 
rabbit polyclonal MSI-1 1:200 1:1000 Gigma 
     
anti-human p53 
mouse monoclonal 
 
p53 1:1000 1:1000 CRUK 
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2.7  WESTERN BLOTTING 
 
Protein samples were analysed along with PageRuler pre-stained protein molecular 
weight markers (Fermentas, York, UK) by sodium dodecyl sulfate-Polyacrylamide 
Gel Electrophoresis (SDS-PAGE). Protein extracts were run on freshly made gels 
(375 mM Tris [pH 8.8] 12% (v/v) polyacrylamide SDS with 125 mM Tris [pH 6.8] 
stacking gel), with running buffer (25 mM Tris; 0.19 M glycine; 3.5 mM SDS). SDS 
loading dye (125 mM Tris aminomethane pH 6.8; 5% beta-mercaptoethanol; 20% 
(v/v) glycerol; 4% (w/v) SDS; 0.02% (w/v) bromophenol blue) was added to an equal 
volume of 100 µg of protein extract and loaded on to the gel. The PageRuler protein 
marker was loaded into a separate lane to allow protein size to be determined. Gels 
were run at a current of 120 V for approximately 90 minutes. Protein was transferred 
electrophoretically from the gel to a Hybond C-Extra PVDF membrane (Amersham) 
in transfer buffer (25 mM Tris; 0.19 M glycine; 20% (v/v) methanol), with a current 
of 25 V overnight. The membrane was washed three times in 0.1% (v/v) Tween-20 in 
TBS (TBS-T) for 5 minutes, before incubation in blocking solution (5% (w/v) milk 
powder in 0.1% (v/v) Tween-20 in PBS) at room temperature for 1 hour. The 
membrane was probed with primary antibodies listed in Table 2.5, diluted in blocking 
solution and incubated overnight at 4°C. After three 10 minute washes with TBS-T, 
membranes were incubated with rabbit anti-mouse secondary antibody conjugated 
with horseradish peroxidase (P0161, Dako, Cambridge, UK), diluted 1:1000 in 
blocking solution at room temperature for 90 minutes. Subsequently, membranes were 
washed three times for 10 minutes with TBS-T. Bound antibodies were visualised 
using the ECL Chemilluminescence Detection Reagent (Amersham) in a dark room 
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by exposing X-ray film (Kodak, New York, USA) to the membrane placed within two 
transparent plastic sheets for between 20 seconds and 15 minutes depending on band 
intensity. X-ray film was then developed using a Hyperprocessor Automatic 
Autoradiography Film Processor (GE Healthcare, Buckinghamshire, UK). Figures 
were cropped / annotated using Microsoft PowerPoint software (Microsoft, Mountain 
View, California, USA). 
 
2.8  FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
 
Cells were washed in 10 ml of 0.01 M PBS before adding 3 ml of Accutase (PAA) to 
tissue culture flasks placed in an incubator. 10 ml of medium was added to the flask 
allowing transfer of the solution into a 50 ml tube.  Repeated pipetting was used to 
fully separate cell aggregates. 9 µl of sample was then removed, the cells counted by 
haemocytometer, and the sample centrifuged at 1,500 rpm for 5 minutes. The aspirate 
was discarded and the cells re-suspended at approximately 100,000 cells per 100 µl 
with the cell concentration recorded. 
 
Three cell preparations were generated per experiment: (i.) cells only - which were 
necessary for technical calibration of the FACS machine; (ii.) isotype control – 
containing cells and the secondary antibody, thus demonstrating background 
fluorescence; and, (iii.) the sample to be assessed. 100 µl of cells were transferred into 
every FACS analysis tube on ice. 5 µl control antibody (1:200 dilution FITC 
conjugated goat polyclonal to rabbit IgA) (ab2760, AbCam. Cambridge, UK) was 
added to each of the negative isotype control tubes. Similarly, 5 µl of primary 
  J Murphy – Chapter 2 
 
 
_____________________________________________________________________ 
 
116 
 
 
 
antibody (CD133/1 (AC133) human (pure), Miltenyi-Biotec; dilution 1:50) was added 
to each tube containing samples for FACS analysis. Cell populations were incubated 
in a dark room for approximately 20 minutes. Prior to analysis 350 µl of cold 0.01 M 
PBS was added to each tube and mixed with cells. FACS analyses were performed at 
the London Research Institute (FACS Aria system, Becton Dickinson, Oxford, UK). 
Sorts were performed into sterile FACS tubes. 
 
Flow cytometric sorting was performed until 2x106 cells were obtained for 
CD/AC133high/low fractions of CaCo-2, HT-29 and CCD18Co cell lines, respectively 
(Figure 2.5). Gates were set during sorting of cell preparations that lacked the 
primary antibody, with 15% or less of processed cells present in gate P1 / P2 
considered as acceptable. Sample repeat FACS sorts were conducted confirming 
accuracy of each sort was > 90%. Western blots were performed after each FACS run 
to confirm CD/AC133high/low fractions had been successfully isolated (Figure 2.6). 
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Figure 2.5 - Representative example of CD/AC133 expression in the assessed cell lines. Gate P1 – 
AC133high cells, Gate P2 AC133low cells. Flow cytometric analysis of CD133 expression by a.) CaCo-2 
cells lacking the primary antibody, b.) CaCo-2 cells with primary and secondary antibody harvested at 
two-, and c.) seven-days following culture; d.) HT-29 cells lacking the primary antibody, e.) HT-29 
cells with primary and secondary antibody harvested at two-, and f.) seven-days following culture; g.) 
CCD18Co cells lacking the primary antibody; h.) CCD18Co with primary and secondary antibody 
harvested at two-, and i.) seven-days following culture. A representative event count for each 
individual experiment is indicated at the top of all panels; however flow cytometric sorting was 
continued until 2x106 cells were obtained for AC133high/low fractions of CaCo-2, HT-29 and CCD18Co 
cell lines.  
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Figure 2.6 – Representative example of CD/AC133 expression detected by western blotting in the 
assessed cell lines following fluorescence-activated cell sorting into AC133high/low subpopulations. The 
primary band was identified at c. 120-130 kDa in keeping with published data (Weigmann et al., 1997).  
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2.9  TUMOUR ASSIGNATION 
 
Individual tumour microsatellite instability status and ploidy analyses were validated 
previously and were performed as described elsewhere (Banerjea et al., 2009).  
 
2.10  STATISTICAL ANALYSES 
 
All experiments were repeated a minimum of three times. Results were expressed as 
the mean with standard deviation relative to controls from untreated cells unless 
otherwise specified. All values of RT-qPCR mRNA expression were corrected 
relative to the geometric mean of three internal reference mRNAs (B2M, EIF4A2, and 
YWHAZ). mRNA copy numbers quantitated by OpenArray and MT-PCR assays were 
normalised to average values of the reference genes on each subarray or the internal 
reference gene NONO, respectively. All measurements of protein level were corrected 
relative to the level of GAPDH. Data demonstrating stable expression of these 
reference genes under the chosen experimental conditions have previously been 
reported by our group (H. Tian, PhD 2010 University of London). Statistical analysis 
software was used (GraphPad Prism Inc., version 4, La Jolla, USA) for analyses. 
Power calculations were performed for Chapter 3 and indicated that recruitment of 
eight patients was necessary to compare PROM-1/CD/AC133 expression by primary 
tumour, adjacent normal, vascular invasion and lymph node / liver metastases (95% 
C.I.; beta error level: 25%).  The Wilcoxon rank-sum test was used when comparing 
two dependent variables, if these variables were not normally distributed. Intra-
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observer and inter-observer agreement were determined and expressed by use of the 
Wilcoxon rank-sum test. Repeated measures one-way ANOVA was used when 
comparing the means of three or more matched groups. Fisher exact test was used 
when performing gene match statistics. A p value < 0.05 was considered statistically 
significant. 
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3.1  ASSOCIATION BETWEEN PROM-1/CD/AC133 EXPRESSION 
 AND COLORECTAL TUMOURIGENESIS / METASTASIS 
 
3.1.1  INTRODUCTION 
 
Colorectal cancer (CRC) comprises a heterogeneous spectrum of diseases that cluster 
into at least three molecularly distinct subclasses based on different epigenetic and 
genetic profiles, which have been discussed previously (Figure 1.3). Tumour 
progression is dependent on epithelial–mesenchymal transition (EMT) of tumour 
cells, which is essential for motility, cellular vascular intra/extravasation and 
contributes to a malignant cell phenotype. This involves the effects of secreted 
polypeptides and their corresponding intracellular transduction pathways that form 
highly interconnected networks, ultimately resulting in cell-cycle dysregulation and 
uncontrolled growth (Murphy et al., 2007). Hence proliferation is sustained by 
complex interactions between a tumour and its environment and involves signalling 
between distinct cell types as well as discrete physiological parameters exerting their 
influence within a defined physical milieu (Royston et al., 2009). There is good 
evidence that only a phenotypic subset of tumour cells is capable of the self-renewal 
required for the production of the heterogeneous lineages of cancer cells that 
constitute a tumour (Dalerba et al., 2007a,b). These cancer stem-cells (CSC) are 
3 PROM-1/CD/AC133 in colorectal cancer 
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themselves heterogeneous (Botchkina et al., 2009), demonstrating highly variable 
patterns and levels of ostensible stem-cell marker expression (Vermeulen et al., 2008). 
Non-malignant intestinal stem-cells are central to the development this CSC subtype, 
with tissue specific stem-cells transforming through mutation into CSCs that 
constitute a small percentage of the tumour overall (Medema and Vermeulen, 2011). 
Asymmetric CSC division may further sustain carcinogenesis by producing malignant 
daughter progenitor cells that proliferate into a mutated transit amplifying cell 
population (mTAP). Thereafter, the mTAP population may contribute to increased 
malignant cell numbers by undergoing de-differentiation to regain the stem-cell 
property of self-renewal (Reya et al., 2001; Jordan et al., 2006; Shaker and Rubin, 
2010; Delitala and Lorenzi, 2011), although the long-term effect of these transformed 
cells may be limited (Barker et al., 2009).  
 
In CRC the functional assessment of mTAPs and / or CSCs relies upon the 
identification of appropriate candidate biomarkers (reviewed by Willis et al., 2008; 
Kemper et al., 2010; Chapter 1). CD133 (AC133 epitope), specified by the PROM-1 
gene, is a key potential therapeutic marker for CSCs, since it initially appeared to 
identify tumour cell populations within primary CRCs that were capable of generating 
malignant xenografts with long-term tumourigenic potential (O'Brien et al., 2007; 
Ricci-Vitiani et al., 2007). The function of CD133 remains unknown, but its location 
in apical plasma membrane protrusions (Mizrak et al., 2008) and the ganglioside-
binding domain at its N-terminal extracellular region (Taieb et al., 2009) suggest a 
role in maintaining stem-cell properties. This may be through loss or disposal of 
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“stem cell-specific membrane microdomains” which may modify the status or even 
the fate of cells expressing this marker (Fargeas et al., 2011). This proposed role in 
the maintenance of stem-cell properties is further supported by PROM-
1/CD/AC133high cells producing and utilising IL-4 to protect themselves from 
apoptosis (Todaro et al., 2007), PROM-1/CD/AC133 mediated peri-tumoural 
angiogenesis (Bao et al., 2006) and an association between cancer-specific 
demethylation and increased CD/AC133 expression (Hibi et al., 2009). 
 
However, PROM-1/CD/AC133 expression is detected in only 15 - 28% of CRCs and 
is not limited to putative stem-cell compartments, leading some authors to question 
the true significance of this marker in CRC (Kojima et al., 2008; Shmelkov et al., 
2008; Choi et al., 2009; Saigusa et al., 2010). This is particularly pertinent given that 
the role of PROM-1/CD/AC133 in tumourigenesis / metastasis remains poorly 
understood, with: (i) PROM-1/CD/AC133 ubiquitously expressed by luminal 
epithelial cells in normal colon (Barker et al., 2007; Shmelkov et al., 2008); (ii) 
malignant cell populations derived from both PROM-1/CD/AC133high and PROM-
1/CD/AC133low CRC metastases initiating tumourigenesis in animal models 
(Shmelkov et al., 2008); (iii) more aggressive PROM-1/CD/AC133low tumours 
expressing the cancer-initiating phenotype CD44high/CD24low, when compared with 
PROM-1/CD/AC133high fractions that demonstrate CD44low/CD24high labelling 
(Shmelkov et al., 2008); and, (iv) PROM-1/CD/AC133high/CD44high CRCs producing 
tumours in NOD/SCID mice, whilst PROM-1/CD/AC133high/CD44low do not 
(Haraguchi et al., 2008). These reports are further supported by lung cancer studies, 
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wherein PROM-1/CD/AC133high and PROM-1/CD/AC133low cells display similar 
ability with regard to colony formation, self-renewal, proliferation, differentiation, 
invasion, resistance to chemotherapy drugs and tumour formation in nude mice (Meng 
et al., 2009). Some of the discrepancies reported above may arise because the 
antibodies used differ and may not recognize the full range of CD133 surface antigens 
(Hermansen et al., 2011). Methodological flaws in studies utilising animal models 
may also in part explain these failures as their use may lead to systematic bias, 
inadequate data and incorrect efficacy assessments. Failures may also occur because 
of critical disparities, usually disease specific, between animal models and the clinical 
setting used to assess the treatment strategy (van der Worp et al., 2010). 
 
Despite the discrepancies in the scientific literature discussed above, clinical data 
strongly suggest a possible prognostic significance to the expression of PROM-
1/CD/AC133 by CRCs since: (i) primary tumour over-expression of PROM-1 
(Saigusa et al., 2009; Yasuda et al., 2009; Artells et al., 2010; Saigusa et al., 2011) 
and / or AC133 (Horst et al., 2008; Kojima et al., 2008; Horst et al., 2009a,b,c; Li et 
al., 2009; Saigusa et al., 2009; Yasuda et al., 2009; Kojima et al., 2010; Saigusa et al., 
2010; Saigusa et al., 2011) predicts significantly poorer survival, although this 
association has not been demonstrated by all investigators (Choi et al., 2009); (ii) 
CD133high colorectal tumours appear more resistant to 5-fluorouracil / oxaliplatin 
based chemotherapy regimens (Liu et al., 2010; Ong et al., 2010; Hongo et al., 2011); 
and, (iii) a higher percentage of CRC liver metastases express AC133-positive cells 
when compared with primary colorectal tumours (Puglisi et al., 2009). Furthermore, 
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elevated PROM-1 mRNA levels in the systemic or portal circulatory systems have 
been reported to predict CRC recurrence (Iinuma et al., 2011; Shimada et al., 2012) 
independent of AJCC stage IV disease (Mehra et al., 2006; Lin et al., 2007), leading 
to the hypothesis that circulating CSC en route to distant organs may be identified by 
assays quantitating the expression of this marker. However, it is necessary to be 
cautious when interpreting the biological relevance of these data since none of these 
manuscripts above include information that is essential for reliable quantification of 
RNA, such as nucleic acid quality assessment (Fleige and Pfaffl, 2006a; Fleige et al., 
2006b; Nolan et al., 2006) and the quantities of RNA that were compared during each 
assay run (Stahlberg et al., 2004). These limitations are further compounded by none 
of these studies utilising appropriate reference gene normalisation methodologies or 
biological replicates (Bustin, 2000; Vandesompele et al., 2002; Dheda et al., 2005; 
Huggett et al., 2005). In addition, the suggestion of a correlation between PROM-1 
mRNA levels in systemic or portal blood and AJCC stage IV-independent recurrence 
has also been challenged (Gazzaniga et al., 2010).  
 
Nevertheless, given that half of all CRC patients develop incurable metastatic disease, 
the ability to identify a cell surface marker characterising a rare subset of CRC cells 
that drive tumourigenesis and subsequent metastasis would be a critical first step 
towards developing new therapies. Thereafter, the ability to target this tumour cell 
population by therapies tailored to CRC cells expressing PROM-1/CD/AC133 would 
in turn hold great promise for the improvement of cancer survival rates. However, 
before the development of therapeutic interventions targeting this marker are justified, 
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meticulous studies will be necessary to resolve the apparent inconsistencies within the 
scientific and clinical literature. In particular, it is essential to examine the proposed 
association between PROM-1/CD/AC133 expression and development of the 
malignant phenotype. This study aims to investigate the association between PROM-
1/CD/AC133 and tumourigenesis by quantifying CD133 (AC133 epitope) protein 
expression levels in patient-matched samples of CRC and adjacent normal epithelium. 
Similarly, the relationship between CD/AC133 expression and metastasis is examined 
by comparing expression of AC133 in primary tumours and the following matched 
metastatic tumour compartments: lymph node metastases, and liver metastases. 
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3.2  MATERIALS AND METHODS 
 
3.2.1  Clinicopathological data 
 
This study received ethics committee approval (Chapter 2.1.1). Following written 
consent, archival tissue was obtained from 28 tumours, with patient matched adjacent 
normal (AN) tissue available from 20 samples. Matched vascular invasion (VI), 
lymph node (LN) or liver metastasis (LM) samples were obtained from 13, 28 and 9 
patients, respectively. In addition, 14 archival LM from non-matched patient samples 
were processed and analysed. Table 2.1 shows the clinicopathological characteristics 
of the CRC samples used in this analysis. None of the assessed CRCs were found to 
display microsatellite instability (MSI-H) as assessed by ploidy analyses or 
mononucleotide markers. Immunohistochemical analysis demonstrated p53 
expression in 21/28 primary tumours, with concomitant expression noted in VI, LN 
and LM. 
 
3.2.2   Immunohistochemistry 
 
Sections were cut from paraffin-embedded blocks of the tumour compartments of 
interest / adjacent normal colonic tissue and deparaffinised using xylene (Chapter 
2.6.2). PROM-1/CD/AC133 antigen retrieval, blocking of non-specific binding, 
incubation of primary and secondary antibodies and visualisation steps were 
performed in accordance with the previously discussed protocol (Chapter 2.6.3; 
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Chapter 2.6.4; Chapter 2.6.5). Assessment of PROM-1/CD/AC133 labelling was 
performed in a blinded manner and a score was attributed based on the intensity of 
staining as previously discussed (Chapter 2.6.6). 
 
3.2.3  Statistical analyses 
 
Data were assembled using Microsoft Excel software and are expressed as a median 
with the associated data range. Data were analysed using the Prism statistical package 
(GraphPad Prism Inc., version 5.0, La Jolla, USA). All statistics were performed with 
Analysis of Variance (Dunn's multiple comparison) tests, after using the D'Agostino 
& Pearson omnibus normality test to determine whether data were normally 
distributed. Differences between variables were considered significant at p < 0.05 
(Chapter 2.10). 
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3.3 RESULTS 
 
3.3.1  Normal and malignant colon expression of CD133 (AC133 epitope) 
 
Detection of the PROM-1/CD/AC133 protein glycotype was assessed by 
immunocytochemistry (Figure 3.1; Appendix 1). Expression in adjacent normal colon 
or rectum was limited to epithelial cells (median score 6 [range 5-6]), with immune 
cells and vascular endothelium of stromal tissue weakly displaying this marker. 
Similarly, assessment of primary tumour samples demonstrated that the PROM-
1/CD/AC133 glycotype was predominantly confined to the epithelial component (5 
[4-6]) with minimal expression in the stroma. In keeping with transcript copy 
numbers from laser-capture microdissected tissue samples previously reported by our 
group, overall no significant difference in PROM-1/CD/AC133 glycotype expression 
was detected between primary tumour and AN colon / rectum (ANOVA Dunn’s post 
test; p>0.05), although heterogeneous expression was noted in primary tumour 
samples. Comparison of paired normal and malignant samples demonstrated that 
PROM-1/CD/AC133 glycotype expression scores were higher (≥1-point) in 1 of the 
20 (5%) matched tumour samples and lower in 3 of 20 (15%). 
 
Grouped data demonstrated that decreasing PROM-1/CD/AC133 glycotype 
expression was significantly associated with the metastatic process (ANOVA; 
p<0.0001). In particular, PROM-1/CD/AC133 glycotype detection scores in LN (2 [0-
6]; p=0.047) and LM (14 un / matched patients; 1 [0-6]; p=0.001) were significantly 
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lower than those of primary tumour. Paired data (Figure 3.2) demonstrated that 
expression scores were higher (≥1-point) in 1 of 28 (4%) patients with LN metastases, 
but none of the 9 patients with LM, when compared with primary tumours. 
Conversely, scores were lower (≤1-point) in 4 (14%) and 6 (67%) of the samples 
mentioned above as compared with primary tumours, respectively. 
 
There was minimal intra-observer error (difference = +1 (range, -1 to +1, p = 0.0001; 
Spearman's rho = 0.85)) and inter-observer error (difference = +1 (range, -1 to +2, p = 
0.0002; Spearman's rho = 0.80)). 
 
3.3.2  Comparison with clinical phenotype 
 
There was no association between tumour CD/AC133 glycotype expression and 
patient age, location (proximal / distal colon or rectum), TNM classification, Dukes’ 
staging, or microsatellite instability status.  
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Figure 3.1 – CD/AC133 glycotype expression in the assessed tissue samples. Adjacent normal - (a.)  
H&E; (b.) peptide blocked negative control; (c.) PROM-1/CD/AC133 labelled sample; primary 
tumour - (d.) H&E; (e.) peptide blocked negative control; (f.) PROM-1/CD/AC133 labelled sample; 
lymph node - (g.) H&E; (h.) peptide blocked negative control; (i.) PROM-1/CD/AC133 labelled 
sample; and, liver metastasis - (j.) H&E; (k.) peptide blocked negative control; (l.) PROM-
1/CD/AC133 labelled sample. 
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Figure 3.2 – Median AC133 immunocytochemistry scores in the assessed tumour compartment 
samples presented as paired data. Annotations indicate the number of patients with increased or 
decreased expression of AC133 when compared with the adjacent matched tumour compartment 
sample. Abbreviations: AN – adjacent normal; PT- primary tumour; LN – lymph node; LM – liver 
metastasis.
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3.4  DISCUSSION 
 
Despite clinical data strongly suggesting a possible prognostic significance to the 
expression of PROM-1/CD/AC133 by CRC some authors have questioned the true 
significance of this marker given the discrepancies in the scientific literature 
discussed in Chapter 3.1.1 (Kojima et al., 2008; Shmelkov et al., 2008; Choi et al., 
2009; Saigusa et al., 2010) To further explore these issues, our group has previously 
investigated PROM-1 expression in a range of normal human colon and CRC tissues 
using best practice protocols for RT-qPCR analysis. The results of the RT-qPCR 
assays are described in a previous thesis (R.E. Hands, PhD 2010 University of 
London). This showed that: (i) the protocols used for tissue sampling, RNA extraction 
and the selected assay conditions generate reliable data and consequently any 
differences in mRNA levels were biologically relevant, rather than experimental 
artefacts; (ii) PROM-1 mRNA transcript levels were statistically similar between 
grouped data for AN, primary tumour, VI and LN samples; and, (iii) in contrast, 
median PROM-1 transcript levels were significantly lower between grouped data in 
LM when compared with AN as well as primary tumour, VI and LN. 
 
However, since RT-qPCR data provide information only about RNA and not about 
functionally relevant protein levels, the work described in this chapter provides a 
detailed analysis of CD/AC133 expression in the various CRC tissue compartments. 
The results presented above reveal not only universal expression of the PROM-
1/CD/AC133 glycotype throughout the AN colonic epithelium (Figure 3.1c; 
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Appendix 1), but also that expression is clearly detected in the proliferating and non-
proliferating crypt compartments. In contrast, PROM-1/CD/AC133 glycotype 
distribution in primary tumour and LN is extraordinarily heterogeneous and limited to 
expression “foci” (Figure 3.1f & 3.1i). Conversely, LM staining is uniformly weak, 
with no foci discernable (Figure 3.1l). 
 
Among the numerous factors that determine the metastatic potential of CRC, the 
acquisition of a migratory mesenchymal phenotype during epithelial-mesenchymal 
transition (EMT) is a critical event (Thiery, 2003; Bates et al., 2007; Morra and Moch, 
2011). Since there may be a direct link between the EMT and acquisition of stem-cell 
properties (Kaplan et al., 2005; Marotta and Polyak, 2009; Biddle and Mackenzie, 
2012), some of the cells in EMT could be the precursors to metastatic cancer cells. 
The data presented by this study do not support the supposition that PROM-
1/CD/AC133 expression is specific to stem-cells in the human colon, or identify CRC 
or metastasis stem-cells. This concurs with a previous report demonstrating extensive 
expression of PROM-1/CD/AC133 on the luminal surface of the majority of 
differentiated epithelial cells in normal human colon (Shmelkov et al., 2008). It also 
fits with the finding that in metastatic CRC, PROM-1/CD/AC133 does not 
specifically mark the CSC subset, since both PROM-1/CD/AC133high and PROM-
1/CD/AC133low cells give rise to tumours and PROM-1/CD/AC133low cells form more 
aggressive tumours (Shmelkov et al., 2008). Furthermore, the same authors also 
reported PROM-1/CD/AC133low LM. In keeping with the results of Shmelkov et al. 
the data presented in this chapter demonstrate CD/AC133 protein glycotype levels 
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were significantly lower in LM when compared with matched primary tumours. 
Consequently, although it is currently unknown whether PROM-1/CD/AC133 plays a 
role in supporting the growth of CRC, the data presented in this chapter and the work 
of Shmelkov et al. raise serious concerns about the functionality of CD/AC133 as a 
CRC-CSC marker. 
 
Finally, PROM-1/CD/AC133 is not a specific marker for the wnt-target gene leucine-
rich-repeat-containing G-protein-coupled receptor 5 (LGR5) cell subset (Snippert et 
al., 2009). LGR5 has previously been shown to identify normal intestinal stem-cells 
from which all cellular lineages of the gastrointestinal epithelium can be derived 
(Barker et al., 2007). Furthermore, in mice most descendants of PROM-1-marked 
cells disappear rapidly from the gut, and thus must have descended from short-lived 
progenitors, with only a smaller fraction representing the progeny of bona fide stem-
cells. This suggests that mouse PROM-1 is expressed broadly in intestinal crypts 
including rare long-lived stem-cells, and not exclusively in the latter (Montgomery 
and Shivdasani, 2009), correlating with reports that PROM-1/CD/AC133 identifies 
transit amplifying populations / mTAP rather than stem-cells / CSCs in other tissue 
types (Grey et al., 2009). 
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3.5  CONCLUSION 
 
PROM-1/CD/AC133 was found to be widely transcribed / expressed in both CRC and 
adjacent normal colon samples and cannot be considered as a precise marker for a rare 
subpopulation of colon or rectal CSCs. Similarly, expression of this marker inversely 
correlated with the metastatic process and is thus unlikely to identify migrating 
tumour initiating cells. These data are supported by previous studies suggesting this 
marker detects mTAPs. Consequently, further robust studies will be required to: (i) 
assess additional cell surface markers and determine an accurate CRC-CSC 
phenotype(s) for future therapeutic / prognostic advances; and, (ii) to determine the 
biological function of PROM-1/CD/AC133. 
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4.1  ABCB1 / ABCG2 / BMI-1 / CD44 / LGR5 / MSI-1 EXPRESSION 
 PROFILES ASSOCIATED WITH DIFFERENTIAL REGULATION OF 
 PROM-1/CD/AC133 BY COLORECTAL CANCER AND 
 COLONIC SUB – EPITHELIAL MYOFIBROBLAST  CELL LINES. 
 
4.1.1  INTRODUCTION 
 
PROM-1/CD/AC133 has gained a great deal of attention as a putative cancer stem-
cell (CSC) marker; nevertheless, its biological function remains largely unknown 
since: (i) in vivo data following targeted activation of the PROMININ–1 gene in 
animal models (homologue of human PROM-1) have been equivocal (Shmelkov et 
al., 2008); (ii) in vitro studies have not yet identified ligand(s) that might suggest a 
receptor function for this cell surface marker; indeed, there is no evidence that 
PROM-1 specifies a receptor; and, (iii) any intracellular interactions expected from an 
activated receptor have yet to be elucidated. However, some limited insights into the 
biological function of the PROM-1/CD/AC133 protein have emerged from descriptive 
studies identifying its sub–cellular localization (Corbeil et al., 2010) including the 
possibility that PROM-1/CD/AC133 has a possible function in endocytosis 
(Bourseau-Guilmain et al., 2011).  
 
4 Correlation between PROM-1 / CD / AC133 & putative immature progenitor 
markers  
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Murine PROMININ-1/CD/AC133 localizes to the apical microvilli of epithelial cells, 
with human PROM-1/CD/AC133 displaying a similar membrane protrusion–
restricted localization in transient transfection experiments (Miraglia et al., 1997). 
While the mechanism by which PROM-1/CD/AC133 is delivered to cell membrane 
projections remains unclear (Fargeas et al., 2011), functional studies have 
demonstrated that both the apical membrane sorting of this marker, and its association 
with epithelial microvilli, involves a novel cholesterol based lipid raft (Röper et al., 
2000; Corbeil et al., 2010; Fargeas et al., 2011). These observations imply that 
PROM-1/CD/AC133 has a role in the organisation of specialized cell membrane 
projections. Although the reported role for PROM-1/CD/AC133 in the organisation of 
cellular membrane protrusions is yet to be fully integrated with its use as a CSC 
marker, the CaCo-2 colorectal cancer (CRC) cell line has been demonstrated to 
discharge PROM-1/CD/AC133high vesicles upon differentiation (Marzesco et al, 
2005). This finding has led to the premise that expression of PROM-1/CD/AC133 
may sustain the CSC phenotype through “stem cell-specific membrane 
microdomains” (Fargeas et al., 2011) and that upon their release tumour cells become 
differentiated aberrant progeny (Mizrak et al., 2008).  
 
Following the initial discovery of a subpopulation of PROM-1/CD/AC133high 
glioblastoma cells with CSC properties (Singh et al., 2003; Singh et al., 2004), the 
search for analysing expression patterns of this marker in other solid tumours has 
been aggressively pursued. PROM-1/CD/AC133high subpopulations reported to 
possess CSC properties have now been isolated from primary tumours and cancer cell 
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lines of ependymoma (Taylor et al., 2005; Mao et al., 2009; Aizawa et al., 2011), 
Ewing′s sarcoma (Suva et al., 2009; Jiang et al., 2010), gallbladder carcinoma (Shi et 
al., 2010), hepatocellular carcinoma (Suetsugu et al., 2006; Ma et al., 2007; Yin et al., 
2007; Ma et al., 2008; Kohga et al., 2010; Hagiwara et al., 2011; Piao et al., 2012), 
laryngeal carcinoma (Yu et al., 2009a; Yang et al., 2011), lung cancer (Eramo et al., 
2008; Woo et al., 2010), melanoma (Monzani et al., 2007; Al Dhaybi et al., 2010), 
ovarian cancer (Ferrandina et al., 2008; Zhang et al., 2011), pancreatic cancer 
(Olempska et al., 2007; Lee et al., 2011), prostate cancer (Collins et al., 2005; 
Shepherd et al., 2008), and renal cell cancer (Bruno et al,. 2006; da Costa et al., 2011). 
 
PROM-1/CD/AC133 is also reported to be an important marker identifying the CRC 
CSC population (O'Brien et al., 2007; Ricci-Vitiani et al., 2007). However, this 
assertion is challenged both by the data reported in Chapter 3 and others (Barker et 
al., 2007; Shmelkov et al., 2008). Consequently, the aims of this study are to: (i) 
identify human CRC / intestinal cell lines expressing PROM-1/CD/AC133, to allow 
future studies of the downstream target genes associated with this marker in vitro; 
and, (ii) to determine the true utility of PROM-1/CD/AC133 as a marker of CRC 
CSCs / intestinal immature progenitor cells. The first aim was achieved by 
corroborating CaCo-2 / HT-29 cell line expression of PROM-1/CD/AC133 in 
accordance with previous reports (Florek et al., 2005; Ieta et al., 2008; Gaiser et al., 
2011), with CCD18Co cell line expression of this marker also investigated as 
previous studies suggest mesenchymal progenitor cell populations express PROM-
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1/CD/AC133 (Bühring et al., 2004). The second aim was achieved by analysing the 
co-expression of additional putative immature progenitor marker expression levels.  
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4.2   MATERIALS AND METHODS 
 
4.2.1  Cell culture 
 
The human intestinal epithelial cell lines CaCo-2 (HTB37), HT-29 (HTB38) and the 
colonic sub-epithelial myofibroblast cell line (CCD18Co) were obtained from the 
American Type Culture Collection and cell culture was undertaken as described 
previously (Chapter 2.2.1). Cells were harvested at two- and seven-days after culture. 
 
4.2.2  Flow cytometry 
 
Cell lines were harvested and stained with anti-AC133 antibody after which AC133 
labelling was analyzed by flow cytometry as per previous protocol (Chapter 2.8). 
 
4.2.3  RNA extraction and RT-qPCR 
 
Total cellular RNA was extracted and RNA quality was assessed (Chapter 2.4.1; 
Chapter 2.4.2; Chapter 2.4.3). Commercially available RT-qPCR assays on demand 
were used targeting: ABCB1, ABCG2, BMI-1, CD44, LGR5, and MSI-1. Sequence-
specific primers targeting PROM-1 and three reference sequences (B2M: Beta-2-
microglobulin; YWHAZ: Phospholipase A2; EIF4A2: Eukaryotic translation initiation 
factor 4A, isoform 2) were designed using Beacon Designer software (Premier 
Biosoft, Palo Alto, USA), and commercially synthesized (Chapter 2.4.4). RT-qPCR 
assays were performed using SYBER-Green chemistry and copy numbers quantitated 
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as previously described (Chapter 2.4.5). Target gene expression was normalised for 
each sample by converting mRNA copy numbers to a ratio, with the target copy 
number designated as the numerator, and the geometric mean of mRNA copy 
numbers for all three reference genes in that sample designated as the denominator. 
 
4.2.4  Immunohistochemistry / Confocal microscopy 
 
Cells were grown on sterile glass coverslips and labelled using a primary AC133 
antibody as previously described (Chapter 2.2.1; Chapter 2.6.1). AC133 antigen 
retrieval, blocking of non-specific binding, incubation of primary and secondary 
antibodies and visualisation steps were performed in accordance with the previously 
discussed protocols (Chapter 2.6.1; Chapter 2.6.3; Chapter 2.6.5).  
 
4.2.5  Western blotting 
 
Whole cell proteins lysates were extracted from cell lines (Chapter 2.5.1). Protein 
concentrations were determined using the BCA assay (Chapter 2.5.2). Samples were 
analysed by SDS–PAGE and western blotting with a polyclonal mouse antibody 
against human ABCB1 / ABCG2 / BMI-1 / CD44 / LGR5 / MSI-1 (Chapter 2.7). 
Data imaging and band densitometry analyses were performed using the public 
domain National Institute for Health Image program (http://rsb.info.nih.gov/nih-
image). 
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4.3   RESULTS 
 
4.3.1  PROM-1/CD/AC133 expression 
 
Two and seven-day cultures of CaCo–2 and HT-29 CRC cell lines were subjected to 
FACS sorting into AC133high/low cell subtypes. PROM-1 mRNA expression was 
detected in all samples with mRNA levels higher in AC133high cell subpopulations 
(Figure 4.1). A similar result was obtained with the CCD18Co colonic sub-epithelial 
myofibroblast cell line when FACS sorted into AC133high/low sub-populations (Figure 
4.1). Immunohistochemistry confirmed appropriate AC133 expression by CaCo-2 
(Figure 4.2), HT-29 (Figure 4.3) and CCD18Co (Figure 4.4) cell lines in vitro, 
which resembled a punctate pattern that is characteristic of this membrane bound 
microvilli-associated antigen (Florek et al., 2005). Western blot assays confirmed 
AC133 expression in all three-cell lines (Figure 2.6; Figure 4.2 - 4.4), respectively. 
 
4.3.2  Stem-cell associated gene expression pattern for CaCo-2 cells 
 
The expression profile of seven genes reported to identify CRC cell populations with 
key stem-cell functions was assessed in CaCo–2 cells that had been FACS sorted into 
AC133high and AC133low cell populations two-days after culture. In addition to 
PROM-1, only one of the seven assessed targets, ABCB1, was differentially regulated 
in AC133high CaCo–2 cells when compared with AC133low cells (Figure 4.1; Figure 
4.5a). Elevated ABCB1 translation was confirmed by western blotting (Figure 4.8a). 
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Gene expression profiling was repeated on CaCo–2 cells harvested seven-days after 
culture (Figure 4.5b). Again ABCB1 and PROM-1 were the only genes up-regulated 
by a factor of two or more in AC133high cells; however, two of the remaining five 
transcripts were down-regulated (ABCG2; BMI-1). Up-regulated ABCB1 translation 
was again confirmed by western blotting (Figure 4.8b); in contrast, decreased 
expression of ABCG2 and BMI-1 mRNA was not associated with changes in the 
expression levels of the respective protein (Figure 4.9b; Figure 4.10b). 
  
4.3.3  Stem-cell associated gene expression pattern for HT–29 cells 
 
Differential gene expression patterns for the HT–29 cell subtypes at the two-day time 
point are summarized in Figure 4.1 & 4.6a. Four of the seven assessed genes were 
differentially regulated in AC133high HT–29 cells harvested two days after culture 
when compared with cells which expressed this marker at relatively low levels: three 
of these transcripts were up-regulated (ABCB1; LGR5; PROM-1), with the remaining 
transcript down-regulated (BMI-1). Up-regulated ABCB1 and LGR5 translation was 
associated with increased translation of these proteins (Figure 4.8c; Figure 4.12c); 
however, decreased expression BMI-1 copy numbers did not correlate with BMI-1 
protein expression levels (Figure 4.10c). 
 
A total of five of the seven assessed transcripts were differentially expressed in 
AC133high HT–29 cells harvested at seven days after culture, when compared with 
AC133low cells (Figure 4.1 & 4.6b). Two of the seven genes were up-regulated 
(ABCB1; PROM-1), with three of the remaining five transcripts down-regulated 
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(ABCG2; BMI-1; MSI-1). ABCB1 copy numbers again correlated with increased 
translation of the ABCB1 protein (Figure 4.8d); however, decreased ABCG2, BMI-1 
and MSI-1 transcript numbers did not correlate with the respective protein expression 
levels (Figure 4.9d; Figure 4.10d; Figure 4.13d). 
 
4.3.4  Stem-cell associated gene expression pattern for CCD18Co cells 
 
Gene expression patterns detected in the CCD18Co cell population at the two-day 
time point are summarized in Figure 4.1 & 4.7a. Four of the seven assessed targets 
were differentially regulated according to AC133 epitope expression in CCD18Co 
cells all of which were up-regulated in AC133high cells (ABCB1; BMI-1; MSI-1; 
PROM-1), with no change in copy numbers of the remaining three transcripts. Up-
regulated ABCB1 translation was confirmed by western blotting (Figure 4.8e); 
however, altered expression of BMI-1 and MSI-1 transcripts was not associated with 
changes in expression levels of the respective protein (Figure 4.10e; Figure 4.13e). 
 
Five of the seven assessed transcripts were differentially expressed according to the 
presence of the AC133 epitope in CCD18Co cells harvested seven days after culture 
(Figure 4.1 & 4.7b). Four of the seven genes were up-regulated in AC133high cells 
(ABCB1; BMI-1; MSI-1; PROM-1), with one of the remaining three down-regulated 
(ABCG2). Up-regulated ABCB1 translation was again confirmed by western blotting 
(Figure 4.8f); however, altered expression of ABCG2, BMI-1 and MSI-1 transcripts 
was not associated with changes in expression levels of the respective proteins 
(Figure 4.9f; Figure 4.10f; Figure 4.13f).  
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Figure 4.1 – PROM-1 expression identified by real time quantitative polymerase chain reaction, 
performed after fluorescence activated cell sorting of the CaCo–2, HT-29 and CCD18Co cell lines by 
AC133 status. Cell lines were harvested at two days (D2) and seven days after culture (D7). Following 
mRNA copy number normalisation procedures documented previously (Chapter 2.4.5); PROM-1 
transcript copy numbers have been presented as a ratio with expression of the amplicon in the 
AC133high population used as the numerator, while that of the AC133low cell subpopulation was taken 
as the denominator. Experiments were performed in triplicate with three biological replicates for each 
experiment. Pictograms represent a linear scale with mean values, while error bars denote standard 
deviation. 
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 a.      b. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 – (a.) AC133 expression identified by confocal microscopy following 
immunohistochemical staining of the CaCo–2 cell line (magnification x40); (b.) negative control 
(magnification x40). Immunohistochemical labelling of this marker demonstrates a punctate pattern, 
which is characteristic of the cell membrane localisation reported for this microvilli-associated antigen 
(Florek et al., 2005). Cells seven days after culture are presented in this figure, since these results were 
also representative of cells fixed for staining two days after culture. The inset above (a.) demonstrates a 
western blot assay confirming AC133 expression by the CaCo-2 cell line. All experiments were 
performed in triplicate. 
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 a.      b. 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 – (a.) AC133 expression identified by confocal microscopy following 
immunohistochemical staining of the HT–29 cell line (magnification x40); (b.) negative control 
(magnification x40). Immunohistochemical labelling of this marker demonstrates a punctate pattern, 
which is characteristic of the cell membrane localisation reported for this microvilli-associated antigen 
(Florek et al., 2005). Cells seven days after culture are presented in this figure, since these results were 
also representative of cells fixed for staining two days after culture. The inset above (a.) demonstrates a 
western blot assay confirming AC133 expression by the HT-29 cell line. All experiments were 
performed in triplicate. 
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 a.      b. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 – (a.) AC133 expression identified by confocal microscopy following 
immunohistochemical staining of the CCD18Co cell line (magnification x40); (b.) negative control 
(magnification x40). Immunohistochemical labelling of this marker demonstrates a punctate pattern, 
which is characteristic of the cell membrane localisation reported for this microvilli-associated antigen 
(Florek et al., 2005). Cells seven days after culture are presented in this figure, since these results were 
also representative of cells fixed for staining two days after culture. The inset above (a.) demonstrates a 
western blot assay confirming AC133 expression by the CCD18Co cell line. All experiments were 
performed in triplicate. 
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Figure 4.5 – expression of putative stem-cell marker transcripts identified by real time quantitative 
polymerase chain reaction, performed after fluorescence activated cell sorting of the CaCo–2 cell line 
by AC133 status. Cell lines were harvested at two (a.) and seven (b.) days after culture. Following 
mRNA copy number normalisation procedures documented previously (Chapter 2.4.5); transcript copy 
numbers have been presented as a ratio with expression of the amplicon in the AC133high population 
used as the numerator, while that of the AC133low cell subpopulation was taken as the denominator. 
Experiments were performed in triplicate with three biological replicates for each experiment. 
Pictograms represent a logarithmic scale with mean values, while error bars denote standard deviation. 
  PhD Thesis 2012 – Chapter 4 
 
 
_____________________________________________________________________ 
 
151 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 – expression of putative stem-cell marker transcripts identified by real time quantitative 
polymerase chain reaction, performed after fluorescence activated cell sorting of the HT–29 cell line by 
AC133 status. Cell lines were harvested at two (a.) and seven (b.) days after culture. Following mRNA 
copy number normalisation procedures documented previously (Chapter 2.4.5); transcript copy 
numbers have been presented as a ratio with expression of the amplicon in the AC133high population 
used as the numerator, while that of the AC133low cell subpopulation was taken as the denominator. 
Experiments were performed in triplicate with three biological replicates for each experiment. 
Pictograms represent a logarithmic scale with mean values, while error bars denote standard deviation. 
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Figure 4.7 – expression of putative stem-cell marker transcripts as identified by real time quantitative 
polymerase chain reaction, performed after fluorescence activated cell sorting of the CCD18Co cell 
line by AC133 status. Cell lines were harvested at two (a.) and seven (b.) days after culture. Following 
mRNA copy number normalisation procedures documented previously (Chapter 2.4.5); transcript copy 
numbers have been presented as a ratio with expression of the amplicon in the AC133high population 
used as the numerator, while that of the AC133low cell subpopulation was taken as the denominator. 
Experiments were performed in triplicate with three biological replicates for each experiment. 
Pictograms represent a logarithmic scale with mean values, while error bars denote standard deviation. 
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Figure 4.8 – Western blot analysis demonstrating association between AC133 status and expression of 
the putative stem-cell marker ABCB1. Immunoblots performed using a primary antibody targeting 
ABCB1 are seen in the upper panels, with sample specific GAPDH control blots found underneath. 
Unsorted control, AC133low and AC133high extracts are shown for CaCo-2 (a. Day 2 [AC133high 5.3+/-
0.7 fold > AC133low]; b. Day 7 [AC133high 3.7+/-0.3 fold > AC133low], HT-29 (c. Day 2 [AC133high 
2.2+/-0.2 fold > AC133low]; d. Day 7 [AC133high 1.8+/-0.0 fold > AC133low]) and CCD18Co (e. Day 2 
[AC133high 9.8+/-1.2 fold > AC133low]; f. Day 7 [AC133high 3.5+/-0.3 fold > AC133low]) cell lines. 
Band densitometry analyses were performed by normalising the target immunoblot against the 
corresponding GAPDH blot, after which a ratio was calculated with the AC133high sample designated 
as the numerator and the AC133low sample as the denominator. A 1.5 fold difference in expression was 
defined as significant, as such these results highlighted in bold. Experiments were performed in 
triplicate with three biological replicates for each experiment. 
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Figure 4.9 – Western blot analysis demonstrating association between AC133 status and expression of 
the putative stem-cell marker ABCG2. Immunoblots performed using a primary antibody targeting 
ABCG2 are seen in the upper panels, with sample specific GAPDH control blots found underneath. 
Unsorted control, AC133low and AC133high extracts are shown for CaCo-2 (a. Day 2 [AC133high 1.3+/-
0.2 fold > AC133low]; b. Day 7 [AC133high 1.0+/-0.0 fold = AC133low], HT-29 (c. Day 2 [AC133high -
0.2+/-0.3 fold < AC133low]; d. Day 7 [AC133high -0.1+/-0.1 fold < AC133low]) and CCD18Co (e. Day 2 
[AC133high -0.1+/-0.1 fold < AC133low]; f. Day 7 [AC133high -0.1+/-0.6 fold < AC133low]) cell lines. 
Band densitometry analyses were performed by normalising the target immunoblot against the 
corresponding GAPDH blot, after which a ratio was calculated with the AC133high sample designated 
as the numerator and the AC133low sample as the denominator. A 1.5 fold difference in expression was 
defined as significant, as such these results highlighted in bold. Experiments were performed in 
triplicate with three biological replicates for each experiment. 
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Figure 4.10 – Western blot analysis demonstrating association between AC133 status and expression 
of the putative stem-cell marker BMI-1. Immunoblots performed using a primary antibody targeting 
BMI-1 are seen in the upper panels, with sample specific GAPDH control blots found underneath. 
Unsorted control, AC133low and AC133high extracts are shown for CaCo-2 (a. Day 2 [AC133high -0.3+/-
0.3 fold < AC133low]; b. Day 7 [AC133high -0.4+/-0.5% < AC133low], HT-29 (c. Day 2 [AC133high 
1.2+/-0.4% > AC133low]; d. Day 7 [AC133high 1.1+/-0.2% > AC133low]) and CCD18Co (e. Day 2 
[AC133high 1.4+/-0.2% > AC133low]; f. Day 7 [AC133high  -0.1+/-0.1% > AC133low]) cell lines. Band 
densitometry analyses were performed by normalising the target immunoblot against the corresponding 
GAPDH blot, after which a ratio was calculated with the AC133high sample designated as the numerator 
and the AC133low sample as the denominator. A 1.5 fold difference in expression was defined as 
significant, as such these results highlighted in bold. Experiments were performed in triplicate with 
three biological replicates for each experiment. 
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Figure 4.11 – Western blot analysis demonstrating association between AC133 status and expression 
of the putative stem-cell marker CD44. Immunoblots performed using a primary antibody targeting 
CD44 are seen in the upper panels, with sample specific GAPDH control blots found underneath. 
Unsorted control, AC133low and AC133high extracts are shown for CaCo-2 (a. Day 2 [not expressed]; b. 
Day 7 [not expressed], HT-29 (c. Day 2 [AC133high -1.2+/-0.3 fold > AC133low]; d. Day 7 [AC133high 
1.3+/-0.8 fold > AC133low]) and CCD18Co (e. Day 2 [AC133high 1.4+/-0.5 fold > AC133low]; f. Day 7 
[AC133high -0.3+/-0.5 fold < AC133low]) cell lines. Band densitometry analyses were performed by 
normalising the target immunoblot against the corresponding GAPDH blot, after which a ratio was 
calculated with the AC133high sample designated as the numerator and the AC133low sample as the 
denominator. A 1.5 fold difference in expression was defined as significant, as such these results 
highlighted in bold. Experiments were performed in triplicate with three biological replicates for each 
experiment. 
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Figure 4.12 – Western blot analysis demonstrating association between AC133 status and expression 
of the putative stem-cell marker LGR5. Immunoblots performed using a primary antibody targeting 
LGR5 are seen in the upper panels, with sample specific GAPDH control blots found underneath. 
Unsorted control, AC133low and AC133high extracts are shown for CaCo-2 (a. Day 2 [not expressed]; b. 
Day 7 [AC133high -0.3+/-0.0% fold < AC133low], HT-29 (c. Day 2 [AC133high 7.9+/-0.6 fold > 
AC133low]; d. Day 7 [AC133high 1.3+/-0.3% fold > AC133low]) and CCD18Co (e. Day 2 [not 
expressed]; f. Day 7 [not expressed]) cell lines. Band densitometry analyses were performed by 
normalising the target immunoblot against the corresponding GAPDH blot, after which a ratio was 
calculated with the AC133high sample designated as the numerator and the AC133low sample as the 
denominator. A 1.5 fold difference in expression was defined as significant, as such these results 
highlighted in bold. Experiments were performed in triplicate with three biological replicates for each 
experiment. 
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Figure 4.13 – Western blot analysis demonstrating association between AC133 status and expression 
of the putative stem-cell marker MSI-1. Immunoblots performed using a primary antibody targeting 
MSI-1 are seen in the upper panels, with sample specific GAPDH control blots found underneath. 
Unsorted control, AC133low and AC133high extracts are shown for CaCo-2 (a. Day 2 [AC133high 0.1+/-
0.1 fold < AC133low]; b. Day 7 [AC133high 1.0+/-0.0 fold = AC133low], HT-29 (c. Day 2 [AC133high 
0.1+/-0.2 fold < AC133low]; d. Day 7 [AC133high 0.2+/-0.2 fold < AC133low]) and CCD18Co (e. Day 2 
[AC133high 0.3+/-0.2 fold < AC133low]; f. Day 7 [AC133high 1.0+/-0.0 fold = AC133low]) cell lines. 
Band densitometry analyses were performed by normalising the target immunoblot against the 
corresponding GAPDH blot, after which a ratio was calculated with the AC133high sample designated 
as the numerator and the AC133low sample as the denominator. A 1.5 fold difference in expression was 
defined as significant, as such these results highlighted in bold. Experiments were performed in 
triplicate with three biological replicates for each experiment. 
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4.4   DISCUSSION 
 
The complexity of in vivo interactions between stem-cells and their environment 
(Moore et al., 2006) has resulted in much of our understanding of cancer stem-cell 
(CSC) biology being derived from in vitro studies (Saleh and Genever, 2011). 
Common methods to isolate ex vivo CSCs include functional characteristics, such as 
efflux of fluorescent dyes, or observation means, i.e. the use of cell surface marker 
phenotypes. Isolation of cell subpopulations based upon fluorescent dye efflux, for 
example Rhodamine–123 or Hoechst–33342, has been described as an efficient 
method to identify immature progenitors by some authors (McAlister et al., 1990; 
Chaudhary and Roninson, 1991; Wolf et al., 1993; Leemhuis et al., 1996; Bunting, 
2002; Kim et al., 2002; Scharenberg et al., 2002; Matsuzaki et al., 2004; Norwood et 
al., 2004; Allen et al., 2009; Inoda et al., 2011), although this is not universally 
supported (Burkert et al., 2008). Membrane associated ATP–binding cassette 
transporter (ABC) subtypes ABCB1 and ABCG2 are reported to be involved in the 
exclusion of these fluorescent compounds (Huls et al., 2009). Interestingly, analyses 
conducted as part of this study demonstrated that the PROM-1/CD/AC133 status of 
CRC and subepithelial myofibroblast (SEMF) cell lines corresponded with the 
transcription and translation of ABCB1, in keeping with published data derived from 
glioma, hepatocellular, neural progenitor and prostate cell lines (Yamamoto et al., 
2009; Angelastro and Lamé, 2010; Rentala and Mangamoori, 2010; Zhu et al., 2010; 
Shankar et al., 2011); however, no such relationship was identified between AC133 
and ABCG2. This finding was independent of cellular differentiation as determined 
by extended culture of the CaCo-2 cell line in vitro (Wice et al., 1985). To date, 
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PROM–1 has not been demonstrated to effect transcriptional regulation of ABCB1. 
Therefore, it is unclear whether differential regulation of ABCB1 is directly mediated 
by PROM-1, related to culture methods necessary for FACS analyses, or secondary to 
more general phenotypic changes associated with grade of tumour differentiation 
(Jiang et al., 2012) as is the case for gastric cancer or up-regulation of AC133 as 
discussed above (Angelastro and Lamé, 2010; Rentala and Mangamoori, 2010; Zhu et 
al., 2010; Shankar et al., 2011). However, ABCB1 activity has previously been 
implicated in the chemoresistance of CRC (Xu et al., 2007; Angelastro and Lamé, 
2010; Calcagno et al., 2010). Thus a correlation between PROM-1/CD/AC133 and 
ABCB1, a protein that transports various substrates across the cell membrane, 
warrants further investigation to determine whether this association may in part 
explain reports suggesting that AC133high putative colorectal CSC populations are 
relatively resistant to standard chemotherapy regimens (Yu et al., 2009b; Kawamoto 
et al., 2010; Liu et al., 2010).  
 
 
Nevertheless, the utility of AC133 identification as method for CSC enrichment of 
CRC cell line populations must remain controversial, given the results of studies 
assessing PROM-1/CD/AC133 as a marker for tissue specific stem-cells (Barker et 
al., 2007; Shmelkov et al., 2008). Therefore, before AC133 labelling can be relied 
upon to identify CSCs, AC133high CRC cell line populations will need to be 
demonstrated to exhibit stem-like properties. The first of these properties is the ability 
to self–renew. The mechanisms that regulate self-renewal remain obscure, although 
several markers have been implicated in this process. One such factor is the B–Cell–
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specific Moloney murine leukaemia virus integration site 1 (BMI-1) transcript, which 
is a member of the polycomb transcription factor group, and has been demonstrated to 
be essential for haematopoietic stem-cell self renewal (Lessard et al., 2003; Park et 
al., 2003). BMI-1 expression in the human gastrointestinal tract has previously been 
immunohistochemically localized to the crypt base, leading to the premise that this 
marker may also be necessary for gastrointestinal epithelial stem-cell self–renewal 
(Reinisch et al., 2006), with decreasing expression presumably signifying epithelial 
differentiation (Umar, 2010). Neither AC133 nor CaCo-2 differentiation in vitro 
(Wice et al., 1985) was found to correlate with BMI-1 expression in this study, 
despite altered BMI-1 copy numbers (CaCo-2: down-regulated day 7; HT-29: down-
regulated day 2 & 7; CCD18Co: up-regulated day 2 & 7). Consequently, the 
presented data suggest that AC133 status cannot be assumed to actively identify a 
CRC cell line subpopulation with the ability to self–renew, although further work will 
be necessary to confirm this supposition. 
 
The second specific property of a CSC population is the ability to differentiate into a 
phenotypically heterogeneous, although aberrant, progeny. In keeping with the 
mechanisms underlying self-renewal, plasticity remains a poorly understood property 
of progenitor populations. In recent years the leucine-rich repeat-containing G 
protein-coupled receptor-5-positive (LGR5) receptor has been identified as a specific 
marker for individual murine intestinal and colonic crypt cells capable of generating 
all epithelial lineages (Barker et al., 2007; Barker et al., 2008; Sato et al., 2009), and 
has therefore become the ‘gold-standard’ individual marker for tissue specific 
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intestinal stem-cells. In addition, LGR5 has been implicated in colorectal adenoma 
formation (Barker et al., 2009) and is deregulated in CRC (McClanahan et al., 2006; 
Uchida et al., 2010; Takahashi et al., 2011). In the present study, with the exception of 
the HT-29 cell line two-days after culture, LGR5 transcription / translation did not 
correlate with AC133 status in the assessed cell lines, or cellular differentiation, as 
determined by extended culture of the CaCo2 cell line in vitro (Wice et al., 1985). 
Consequently, CRC and SEMF AC133high subpopulations do not seem to be 
universally enriched for LGR5 expressing cells that have previously been 
demonstrated to exhibit long-term plasticity. 
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4.5  CONCLUSION 
 
This study has identified a clear and consistent association between AC133 status and 
ABCB1 expression in human CRC and subepithelial myofibroblast cell lines, a 
finding which warrants further investigation to determine whether ABCB1 may have 
a role in the chemoresistance exhibited by AC133high colorectal cancer cell 
populations. AC133high cell populations did not universally exhibit up / down-
regulated translation of the other studied putative stem-cell markers, particularly 
BMI-1 and LGR5. Therefore, when data presented in both Chapter 3 & 4 are 
interpreted together, it is clear that the colorectal AC133high subtype does not identify 
a rare population of colorectal tumour cells, is not associated with altered regulation 
of factors which control plasticity or influence the ability to self-renew, and thus by 
implication, PROM-1/CD/AC133 is an unlikely colorectal CSC marker. 
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5.1  EXPRESSION OF PROM-1 mRNA SPLICE ISOFORMS BY  
 COLORECTAL CANCER AND COLONIC SUBEPITHELIAL 
 MYOFIBROBLAST CELL LINES. 
 
5.1.1  INTRODUCTION 
 
Gene splicing is a post-transcriptional modification where regions of pre-mRNA are 
differentially included or excluded from the final mRNA transcript (Douglas and 
Wood, 2011). It constitutes an important source of protein diversity as it allows a 
single gene to specify the synthesis of protein isoforms that are structurally and 
functionally distinct. There are several types of common gene splicing events: (i) 
exon skipping is the most common mechanism, which results from exons being 
included or excluded from the final gene transcript, leading to extended or shortened 
mRNA variants; (ii) intron retention describes an event in which an intron is not 
spliced out of the final transcript; and, (iii) alternative 3' and 5' site splicing refers to 
the competition by two or more alternative 5' splice sites to join two or more alternate 
3' splice sites (Pillmann et al., 2011). PROM-1 exists as a single-copy gene on human 
chromosome 4 (4p15.33) and is composed of at least 27 exons that span 
approximately 160 kb (Weigmann et al., 1997). The primary mRNA transcript is 4.4 
5 Colorectal cell line PROM-1 splicing  
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kb long and encodes the 865 amino acid CD/AC133 glycoprotein, which has a 
molecular weight of 120 kDa (Fargeas et al., 2003b). This protein consists of an N-
terminal extracellular domain, five transmembrane domains with two large 
extracellular loops, and a 59 amino acid cytoplasmic tail (Fargeas et al., 2004; 
Shmelkov et al., 2005; Figure 5.1).  
 
PROM-1 exon structures (Maw et al., 2000; Yu et al., 2002; Fargeas et al., 2003a) and 
exon / intron boundaries (Fargeas et al., 2003a) are generally conserved between 
species. This has led to the utilisation of murine models to assess the in vivo 
regulation and differential splicing of PROM-1 mRNA. Following the initial 
description of the PROM-1 transcript (Weigmann et al., 1997) several splice variants 
that affect the coding sequence have been identified (Miraglia et al., 1997; Yu et al., 
2002; Fargeas et al., 2007) and their expression characterized (Fargeas et al., 2004). 
PROM-1 splicing occurs at multiple locations, including the 5’ untranslated region 
and the first extracellular and transmembrane domains. The 3' boundary of exon 24, 
which encodes the cytoplasmic tail of CD/AC133, appears to be the most significant 
site of regulation, as alternate splicing at this position results in four disparate C-
terminal sequences (Table 5.1). This occurs by: (i) generation of two alternate 
cytoplasmic tail sequences via extension of exon 25 through an acceptor site within 
intron 24, resulting in isoforms s1, s2, s10, s12; or (ii) the creation of a further distinct 
C-terminus sequence by exon skipping, generating isoforms s7, s11 (Fargeas et al., 
2007). Although the functions of different CD/AC133 isoforms remain obscure, 
alternate splice variants are thought to be delivered to the cell membrane, and localise 
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to the microvilli of epithelial cells, in the same manner as the original description of 
the s1 variant (Weigmann et al., 1997). This raises the possibility that proteins 
translated from different PROM-1 isoforms may interact with distinct cytoplasmic 
proteins.  
 
The transcription of differentially spliced PROM-1 mRNA isoforms is driven by five 
alternative tissue-specific promoters (Fargeas et al., 2004) (Figure 5.2). The PROM-1 
promoter regions reported in mice have been investigated in human tissue specimens 
demonstrating that the alternative promoter region 1 (P1 – Figure 5.2) is invariably 
hypermethylated, in contrast to promoter 2 (P2 – Figure 5.2), which contains 
scattered methylation of CpGs sites (Tabu et al., 2008). These findings are 
complemented by methylation studies in a number of disparate human cell lines 
(Pleshkan et al., 2008; Jeon et al., 2010).  Furthermore, aberrant PROM-1 promoter 
methylation is believed to be associated with tumourigenesis, since promoter 
hypomethylation is a feature of many tumours including colorectal cancer (CRC) 
(Tabu et al., 2008; Yi et al., 2008; Baba et al., 2009; Hibi et al., 2009; Friel et al., 
2010; Hibi et al., 2010) and PROM-1 methylation is influenced by TGF-β signalling 
(You et al., 2010) which is a central pathway in colorectal carcinogenesis 
(Lampropoulos et al., 2012). However, rather typically some authors, who propose 
that regulation of PROM-1/CD/AC133 is independent of DNA methylation, have 
questioned the association between promoter methylation and tumourigenesis. 
PROM-1 methylation independent gene regulation is proposed to result from the 
dynamic structural control of chromatin by histone acetylase / histone deacetylase 
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enzymes which relax or contract the chromatin structure and in turn facilitate PROM-
1 expression or repression, respectively (Pellacani et al., 2011). 
 
In humans, the expression of two PROM-1 splice variants, initially termed CD133.s1 
and CD133.s2, has been characterised in several tissues: CD133.s2 is mainly found in 
neuronal structures, whereas CD133.s1 has been reported as the predominant splice 
variant in abdominal organs and CRC cell lines (Yu et al., 2002; Fargeas et al., 2003a 
& 2003b). However, molecular cloning studies suggest the significant presence of 
more than two PROM-1/CD/AC133 variants (Miraglia et al., 1997; Yu et al., 2002) 
and aberrant transcript splicing of numerous mRNA targets can be detected in a large 
proportion of tumours (Skotheim et al., 2007; He et al., 2009) although it remains 
uncertain which PROM-1/CD/AC133 variants are expressed in CRC (Kemper et al., 
2010). The observation that aberrant splicing mechanisms, especially intron retention 
but also exon skipping, are observed in cancers (Kim et al., 2008) is of particular 
relevance to PROM-1 splicing since both mechanisms are reported to generate 
alternate CD/AC133 C-termini. Consequently, the aim of this study is to assess the 
differential expression of established human PROM-1 mRNA isoforms by CRC and 
colonic sub-epithelial myofibroblast cell lines. 
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Figure 5.1 - Structure of the CD/AC133 protein. (a.) E1 - E3 depict extracellular domains, while I1 - I3 
represent intracellular and T1 - T5 transmembrane domains, respectively. The number of amino acids 
in each domain is indicated; (b.) prediction of protein secondary structure, with putative glycosylation 
sites marked by a trident pictogram. Figure adapted from Fargeas et al. 2004 & Shmelkov et al. 2005. 
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Table 5.1 - Translation of PROM-1 mRNA isoforms results in four distinct cytoplasmic C-terminal 
tails for PROM-1/CD/AC133. Sequences from exons 25, 26b, and 27 are given in blue, green, and 
purple, respectively. Table adapted from Fargeas et al. 2007. 
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Figure 5.2 - Organization of the PROM-1 promoter region. 5′ untranslated region exons 1A–1E are 
alternatively spliced to a common exon 2. Translation initiation site is located in exon 2. P1 – P5 are 
alternative promoters for the human PROM-1 gene, and are reported to result in both developmental 
and tissue specific PROM-1 splicing. While factors that control alterative PROM-1 splicing have yet to 
be fully elucidated, promoters P1 – P3 are located within a CpG island, and are likely regulated by 
methylation as discussed in Chapter 5.1. Figure adapted from Shmelkov et al. 2005. 
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5.2  MATERIALS AND METHODS 
 
5.2.1  Cell culture  
 
The human CRC cell lines CaCo-2 (HTB37) and HT-29 (HTB38) and the intestinal 
sub-epithelial myofibroblast cell line (SEMF) (CCD18Co) were obtained from the 
American Type Culture Collection. Cell culture was undertaken as described 
previously (Chapter 2.2.1). Cells were harvested at two- and seven-days after culture. 
 
5.2.2  Flow cytometry 
 
Cell lines were harvested and stained with anti-AC133 antibody after which AC133 
labelling was analyzed by flow cytometry as per previous protocol (Chapter 2.8). 
 
5.2.3  RNA extraction and RT-qPCR 
 
Total cellular RNA was extracted and RNA quality was assessed (Chapter 2.4.1; 
Chapter 2.4.2; Chapter 2.4.3). Sequence-specific primers targeting total PROM-1 or 
PROM-1 isoform subgroups were designed using proprietary software, and 
commercially synthesized in addition to three previously designed reference 
sequences (B2M: Beta-2-microglobulin; EIF4A2: Eukaryotic translation initiation 
factor 4A, isoform 2; YWHAZ: Phospholipase A2) (Chapter 2.4.4). RT-qPCR assays 
were performed using SYBER-Green chemistry and copy numbers quantitated as 
previously described (Chapter 2.4.5). Target gene expression was normalised for each 
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sample by converting mRNA copy numbers to a ratio, with the target copy number 
designated as the numerator, and the geometric mean of mRNA copy numbers for all 
three reference genes in that sample designated as the denominator. 
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5.3  RESULTS 
 
5.3.1  CRC / SEMF cell lines express PROM-1 mRNA 
 
Primers amplifying all isoforms demonstrated expression of PROM-1 in both CRC 
(CaCo-2 and HT-29) as well as CCD18Co colonic SEMF cell lines (Figure 5.3). A 
comparison of the relative expression between AC133high and AC133low cells 
confirmed previous correlations between total PROM-1 and AC133 glycotype 
expression (Chapter 4.3.1; Figure 4.1). 
 
5.3.2  Differential splice variant expression 
 
In CaCo-2 cells the relative expression levels (AC133high:AC133low) of splice variant 
subgroups B (isoforms s1 and s2), C (s1, s2, s9, s10 and s12) and D (s7 and s11) were 
similar to those previously observed for all isoforms and not affected by prolonged 
culture (Figure 5.4). However relative expression levels of splice variant subgroup A 
(s2, 11, 12) were more markedly increased (eight-fold) after seven days of culture. 
That pattern was similar to the one observed with HT-29 (Figure 5.5), except that 
splice variant group A showed higher levels of expression in the AC133high cells at 
day 2, with no further increase after seven days. When attempting to determine the 
contribution of each splice variant to the relative expression levels of the four 
subgroups, PROM-1 isoforms s9, s10 and s12 did not appear to be obviously 
expressed by either the CaCo-2 or HT-29 cell populations. In addition, no clear 
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evidence for expression of the PROM-1 isoform s11 could be identified when 
assessing the CaCo-2 cell line data.  
 
The relative expression of all four splice variant subgroups (A - D) was three to five 
fold greater in AC133high CCD18Co subpopulations compared with the corresponding 
AC133low cells (Figure 5.6). There was no significant difference between the splice 
variant groups and no increase in apparent relative expression in group A. When again 
attempting to determine the contribution of each splice variant to the relative 
expression levels of the four subgroups, PROM-1 isoforms s11 and possibly s9 and 
s12 did not appear to be obviously expressed when the CCD18Co cell line data were 
assessed.  
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Figure 5.3 – Presence of total PROM-1 transcript in FACS sorted cells. The amount of PROM-1 is 
shown as a ratio taking expression of PROM-1 in AC133low control cells as the denominator. 
Experiments were performed in triplicate with three biological replicates per run. Pictograms represent 
a linear scale with mean values, while error bars denote standard deviation. Oligonucleotide primers 
targeting a nucleotide sequence conserved in all reported PROM-1 mRNA isoforms confirmed 
expression of this gene in both of the assessed CRC cell lines (CaCo-2 & HT-29), in addition to a 
colonic sub-epithelial myofibroblast cell line (CCD18Co).  PROM-1 transcription was higher in 
AC133high cells when compared with AC133low cells. Extended culture in vitro did not significantly 
affect PROM-1 mRNA levels in AC133high cells (CaCo-2 Day 2 vs. Day 7, ANOVA: p=NS [0.08]).  
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Figure 5.4 – Presence of PROM-1 splice variants in AC133high FACS sorted CaCo-2 cultures. The 
amount of PROM-1 splice variant was expressed as a ratio taking expression of the splice variant of 
interest in AC133low control cells as the denominator. Experiments were performed in triplicate with 
three biological replicates per run. Pictograms represent a linear scale with mean values, while error 
bars denote standard deviation. All PROM-1 isoforms were up-regulated by approximately 2 – 3 fold in 
AC133high cells, when compared with those that were AC133low. Extended culture in vitro did not affect 
PROM-1 isoform expression in AC133high cells, with the exception of variants s2, s11, s12 (CaCo-2 
Day 2 vs. Day 7, ANOVA: p=0.0002). 
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Figure 5.5 – Presence of PROM-1 splice variants in AC133high FACS sorted HT-29 cultures. The 
amount of PROM-1 splice variant was expressed as a ratio taking PROM-1 isoform copy numbers in 
AC133low control cells as the denominator. Experiments were performed in triplicate with three 
biological replicates per run. Pictograms represent a linear scale with mean values, while error bars 
denote standard deviation. All PROM-1 isoforms were up-regulated by approximately 2 – 3 fold in 
AC133high cells, when compared with those that were AC133low, with the exception of splice s2, 11 and 
12. Extended culture in vitro did not affect PROM-1 isoform expression.  
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Figure 5.6 – Presence of PROM-1 splice variants in AC133high FACS sorted CCD18Co cultures. The 
amount of PROM-1 splice variant was expressed as a ratio taking PROM-1 isoform copy numbers in 
AC133low control cells as the denominator. Experiments were performed in triplicate with three 
biological replicates per run. Pictograms represent a linear scale with mean values, while error bars 
denote standard deviation. All PROM-1 isoforms were up-regulated by approximately 3 – 5 fold in 
AC133high cells, when compared with cells which were AC133low. Extended culture in vitro did not 
affect PROM-1 splice variant expression in AC133high CCD18Co cells.  
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5.4  DISCUSSION 
 
The data presented in this study confirm previous reports that the CaCo-2 (Florek et 
al., 2005) and HT-29 (Ieta et al., 2008) CRC cell lines express PROM-1, and confirm 
the findings of Chapter 4.3.1 by demonstrating that the CCD18Co colonic SEMF cell 
line also expresses this mRNA. For all cell lines assessed in this study, total PROM-1 
expression was found to correlate positively with AC133 status. Furthermore, no 
consistently significant difference was identified when cells were harvested two- or 
seven-days after culture to assess the effect of relative cellular differentiation (Wice et 
al., 1985) upon total PROM-1 transcript regulation.  
 
Assessment of PROM-1 isoform expression was complicated by the inability to 
devise primer sets specific for individual splice variants. However, the results 
revealed that all four splice variant subgroups (A-D) were represented in the total 
mRNA pool of CaCo-2, HT-29 and CCD18Co cells and expressed at higher levels in 
the AC133high cells. However, when attempting to determine the contribution of each 
splice variant to the relative expression levels of the four subgroups, PROM-1 
isoforms s9, s10, s11 and s12 did not appear to be obviously expressed in CaCo-2 cell 
preparations, while no clear evidence could be identified for expression of variants s9, 
s10 and s12 in the HT-29 CRC cell line. Similar assessment of the CCD18Co cell line 
data did not appear to definitively support expression of the s11 splice variant, with 
further uncertainty regarding variant s9 and s12 amplification also. This suggests that 
two of the four PROM-1/CD/AC133 isoforms encoding distinctive cytoplasmic C-
terminal tails (Table 5.1) may be present in the CaCo-2 cell line (s1 / s2 and s7), 
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while two may also be present in HT-29 cell preparations (s1 / s2, s7 and s11). Three 
of the four PROM-1/CD/AC133 isoforms encoding unique cytoplasmic tails (Table 
5.1) are also likely to be present in CCD18Co cell preparations (s1 / s2, s7 and s10).  
 
Progressive cellular differentiation, as assessed by harvesting cells at two- and seven-
days after culture (Wice et al., 1985), did not appear to alter the relative expression of 
the subgroups studied, with the exception of the PROM-1 isoform subgroup A (s2, 
s11, 12) in the CaCo-2 cell line. In keeping with results for total PROM-1 expression, 
up-regulation of three subgroups (B, C and D) was noted to correlate positively with 
AC133 epitope expression by a factor of two–three fold in CRC cells, and by 
approximately three–five fold in SEMF cell populations. Interestingly, subgroup A 
isoforms, which encode three different C-termini, were found to be markedly up-
regulated (two–eight fold) in CaCo-2 and HT-29 cell lines when compared with the 
other PROM-1 isoforms. However, when the individual splice variants making up the 
different subgroups were assessed, this finding did not appear to be due to the relative 
contribution of any individual, or combination of, the splice variant(s) studied. 
Furthermore, since the PCR assay efficiencies for each primer set were essentially 
equivalent, this result cannot simply be dismissed as a technical artifact. It is possible 
that the subgroup A primer set may identify additional as yet unknown PROM-1 
isoform(s), which if true would explain the inability to identify the amplicon(s) 
responsible for up-regulation of subgroup A. Nevertheless, further work will be 
necessary to confirm this premise. 
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While no information is currently available regarding potential cytoplasmic partners 
for the CD/AC133 glycoprotein encoded by PROM-1, interspecies conservation of 
PROM-1 splice variants has led to the suggestion that distinct CD/AC133 cytoplasmic 
sequences may interact with alternative intracellular proteins / pathways. 
Interestingly, the C-terminal peptide sequence encoded by the s1, s2, and s7 variants 
(Table 5.1: PSQH), which may potentially be widely available in CRC and SEMF cell 
lines as discussed above, corresponds with the class I PDZ-binding domain (X-S/T-X-
φ; [φ = azimuth vector]) (Harris and Lim, 2001; Sheng and Sala, 2001; Fargeas et al., 
2007). In addition, the last four C-terminal amino acids of the s9 variant (SVQC) are 
highly related to the class III PDZ-binding domain (X-X-C) (Fargeas et al., 2007), but 
given the low levels at which this isoform is likely transcribed, it is doubtful whether 
it plays a significant role in the CRC or SEMF cell lines studied. The possibility that 
PROM-1/CD/AC133 intracellular signalling occurs through interactions with PDZ-
domain-containing proteins is further supported by the report that a member of the 
Prominin family (Fargeas et al., 2003a), binds to a splice variant of the glutamate 
receptor-interacting protein, via PDZ-domain-interaction. However, again further 
studies will be required to determine whether PROM-1/CD/AC133 isoforms interact 
with PDZ-domain-containing proteins, and what the biological relevance of such 
interactions may be. 
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5.5  CONCLUSION 
 
This study reports two important observations: (i) it shows that PROM-1/CD/AC133 
is expressed in human CRC / colonic sub-epithelial cell lines, as previously reported 
in Chapter 4; and, (ii) demonstrates there are multiple splice variant transcripts of 
PROM-1 in these cell lines. Unfortunately it was not possible to assign expression 
patterns unequivocally to any individual splice variant, but disparate expression of 
these PROM-1 isoforms may mediate differential PROM-1/CD/AC133 intracellular 
signalling, with PDZ-domain-containing proteins emerging as potential distinct 
cytoplasmic partners for individual isoform subgroups. Further studies will be 
necessary to confirm the above hypothesis. 
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6.1  GENE EXPRESSION PROFILES OF COLORECTAL CANCER 
 AND COLONIC SUB–EPITHELIAL MYOFIBROBLAST CELL 
 LINES ASSOCIATED WITH PROM-1/CD/AC133 SILENCING. 
 
6.1.1  INTRODUCTION 
 
PROM-1/CD/AC133 is the first reported member of a novel evolutionarily conserved 
pentaspan membrane glycoprotein family (Miraglia et al., 1997; Weigmann et al., 
1997; Fargeas et al., 2003a). Although widely expressed in various differentiated 
tissues (Weigmann et al., 1997; Florek et al., 2005; Karbanová et al., 2008), several 
organ-specific somatic stem and cancer stem-cells (CSC) have been identified and 
isolated based on PROM-1/CD/AC133 expression (reviewed in Chapter 4). 
Nevertheless, a functional role for PROM-1/CD/AC133, possibly as part of 
intracellular signalling cascades, remains elusive. 
 
Studies assessing the biological function of PROM-1/CD/AC133 have primarily 
focused on the sub-cellular localisation of this marker. Retention of PROM-
1/CD/AC133 in the microvilli of the epithelial cell membrane is thought to reflect its 
association with a cholesterol-based cell membrane micro-domain. Here PROM-
1/CD/AC133 directly interacts with plasma membrane cholesterol to form lipid rafts 
(Röper et al., 2000; Thiele et al., 2000; Giebel et al., 2004; Corbeil et al., 2010), a 
6 Screening for putative downstream targets of PROM-1/CD/AC133  
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premise raised by authors utilising photoaffinity labelling (Thiele et al., 2000). These 
cholesterol-based membrane micro-domains are thought to be more tightly packed 
than the surrounding phase of the membrane bi-layer (Lingwood et al., 2010), and are 
believed to play an important role in the retention of PROM-1/CD/AC133 within 
plasma membrane protrusions (Röper et al., 2000; Thiele et al., 2000; Giebel et al., 
2004; Corbeil et al., 2010). Associations between specific peptides and plasma 
membrane lipid rafts are not without precedent, and interactions between cell 
membrane micro-domains and numerous microvilli associated hydrolytic enzymes 
have previously been reported (Fiedler et al., 1993; Chayet et al., 1997; Danielsen and 
Hansen, 2006). 
 
Observations describing the plasma membrane / extracellular membrane particle 
distribution of PROM-1/CD/AC133 suggest a critical role for assemblies containing 
this marker and other specific membrane components, in particular cholesterol and 
gangliosides, in maintaining epithelial cell membrane polarity in the absence of 
functional tight junctions (Marzesco et al., 2005; Corbeil et al., 2010). This may 
explain why PROM-1/CD/AC133 maintains its polarized distribution in 
neuroepithelial cells at the neural tube stage, when tight junction activity is down-
regulated (Marzesco et al., 2005). Furthermore, PROM-1/CD/AC133 membrane 
micro-domains have been suggested to play a role in signal transduction and a variety 
of membrane trafficking events (e.g. apical delivery, membrane budding and fission) 
(Simons et al., 2000; Huttner et al., 2001; Corbeil et al., 2010; Bauer et al., 2011). 
However, the precise cellular mechanisms governing these occurrences require further 
investigation.  
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The aim of this chapter is to investigate a possible role for PROM-1/CD/AC133 
within intracellular signalling cascades that are intimately associated with cellular 
proliferation and differentiation. To achieve this objective, PROM-1 expression was 
‘knocked-down’ by RNA interference (RNAi) in two colorectal cancer (CRC) and 
one colonic sub-epithelial myofibroblast (SEMF) cell line(s). Gene expression 
profiles were then assessed using high-density qPCR-array technology. A Biotrove 
OpenArray platform was selected for expression profiling as this technology allows 
tailored high throughput mRNA transcript expression analysis whilst retaining much 
of the sensitivity, dynamic range and specificity of PCR-based technology (Brenan et 
al., 2005; Dixon et al., 2009; Grigorenko et al., 2011). Approximately 3000 mRNA 
targets were selected from pathways proposed either to: (i) influence PROM-
1/CD/AC133high cell populations; or, (ii) be significantly involved in colorectal 
tumourigenesis, in order to screen for the potential biological functions of PROM-
1/CD/AC133. When selecting targets, specific reference was made to transcripts 
containing PDZ-binding domains, since the study reported in Chapter 5 highlighted 
PDZ domain mediated signalling as one potential mechanism allowing PROM-
1/CD/AC133 to interact with presumed intracellular partners (Table 2.3). 
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6.2  MATERIALS AND METHODS 
 
6.2.1  Cell culture 
 
The human intestinal epithelial cell lines CaCo-2 (HTB37) and HT-29 (HTB38) and 
the intestinal sub-epithelial myofibroblast cell line (CCD18Co) were obtained from 
the American Type Culture Collection and cell culture was performed in accordance 
with the protocol(s) listed previously (Chapter 2.2.1). Cells were harvested at 48 
hours after siRNA transfection (discussed below). 
 
6.2.2  siRNA transfection 
 
Three separate siRNA transfections of CaCo-2, HT-29 and CCD18Co cell lines, 
resulting in three replicate samples for each cell line, were undertaken using a 
commercially available pool of synthetic siRNAs targeting different conserved 
regions in the PROM-1 mRNA as per the protocol discussed previously (Chapter 
2.3). Similarly, a pool of four non-targeting siRNAs was transfected into the cell lines 
as negative controls each time (Chapter 2.3). The extent of PROM-1 down-regulation 
in transfected cell lines was quantified at both the mRNA and protein levels 48 hours 
after transfection (discussed below; Figure 6.1).  
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6.2.3  RNA extraction and RT-qPCR analyses 
 
Total cellular RNA was extracted and RNA quality assessments were carried out 
(Chapter 2.4.1; Chapter 2.4.2; Chapter 2.4.3). The differential expression of 
approximately 3000 putative target genes involved in signal transduction was assessed 
using the Biotrove OpenArray system (Chapter 2.4.6) utilising SYBR-Green 
chemistry. Seventeen of these target mRNAs have previously been identified to 
contain PDZ binding domains (Table 2.3). Target gene expression was quantitated for 
each sample using a ΔΔCq method presented as fold change (Chapter 2.4.6). 
Following advice from Biotrove, a 50% or greater change in relative expression level 
was considered significant. 
 
6.2.4  Western blotting 
 
Whole cell proteins lysates were extracted from cell line preparations (Chapter 2.5.1). 
Protein concentrations were determined using the BCA assay (Chapter 2.5.2). 
Samples were analysed by SDS–PAGE and western blotting with a polyclonal mouse 
antibody against human CD/AC133 (Chapter 2.7). Data were imaged and band 
densitometry analyses were performed on an Apple Macintosh computer using the 
public domain NIH Image program (developed at the U.S. National Institutes of 
Health and available via the Internet at http://rsb.info.nih.gov/nih-image). 
 
  J Murphy – Chapter 6 
 
 
_____________________________________________________________________ 
!
188 
 
 
!
6.2.5  Bioinformatic analyses 
 
Interpretation of gene lists generated by PCR-array experiments was performed 
utilising the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) version 6.7 (developed at the U.S. National Institute of Allergy and 
Infectious Diseases and available via the Internet at http://david.niaid.nih.gov). Gene 
match statistics were performed as part of this process using the Fisher Exact test, 
with p values less than 0.05 considered to be statistically significant. Gene matches 
were manually checked to: (i.) identify targets conformed to the proposed pathways; 
and, (ii.) confirm that altered regulation of a given mRNA did not contradict 
expression changes of other matched targets in that pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  PhD Thesis 2012 – Chapter 6 
 
 
_____________________________________________________________________ 
!
189 
 
 
 
6.3  RESULTS 
 
6.3.1  Analysis of PROM–1 down–regulation 
 
The extent of PROM–1 down–regulation following each siRNA transfection was 
assessed to establish a satisfactory decrease in transcript copy numbers, prior to gene 
expression pattern analyses. Significant PROM-1 mRNA down–regulation was noted 
in extracts from all cell lines treated with siPROM–1 (Figure 6.1.(a.)). This translated 
into reduced AC133 expression by all assessed cell lines as demonstrated by western 
blotting, which was used to verify the RT–qPCR data (Figure 6.1.(b.)).  
 
6.3.2  Differential expression of siPROM–1 treated CaCo-2 cell line 
 
The expression profile of approximately 3000 putative downstream target genes was 
first assessed in the CaCo–2 cell line following siRNA–mediated PROM–1 
knockdown (Figure 6.2; Table 6.1). Expression of 53 assessed mRNA targets was 
affected by siPROM–1, of which 40 transcripts were up-regulated and 13 transcripts 
were down-regulated. 
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6.3.3  Differential expression of siPROM–1 treated HT-29 cell line 
 
Next, HT-29 cells treated with siPROM-1 were analysed and gene expression 
profiling produced comparable data in terms of differentially regulated mRNA 
numbers (Figure 6.3; Table 6.2), with 51 assessed transcripts differentially expressed 
in siPROM-1 treated cells, when compared with cell populations incubated with non-
targeting scrambled control sequences. Thirty transcripts were up–regulated and 21 
transcripts were down-regulated. 
 
6.3.4  Differential expression of siPROM–1 treated CCD18Co cell line 
 
Finally, the expression profile of the same 3000 genes reported to be associated with 
cell signalling cascades was determined in CCD18Co cells that had been treated with 
siPROM-1 (Figure 6.4; Table 6.3). Again a similar number of mRNAs were 
differentially affected (60), of which 51 transcripts were up-regulated and nine 
transcripts were down-regulated. 
 
6.3.5  Expression pattern of three siPROM–1 treated cell lines overall 
 
The differential expression profile of transcripts reported to be associated with cell 
signalling cascades in all three cell lines treated with siPROM-1 is summarised in 
Figure 6.5. Eleven assessed targets were differentially regulated (ten concordant 
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between cell lines) in the CaCo-2, HT-29 and CCD18Co cell lines. Six targets were 
differentially regulated for both CaCo-2 and HT-29 cell lines alone (four concordant 
between cell lines), three targets were differentially regulated for both CaCo-2 and 
CCD18Co cell lines (two concordant), with only one target differentially regulated for 
the HT-29 and CCD18Co cell lines in a concordant manner. 
 
6.3.6  Bioinformatic assessment of the CaCo-2 PCR-array dataset alone 
 
Bioinformatic assessment of the CaCo-2 PCR-array dataset was performed using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID). This 
analysis identified 11 putative siPROM-1 mediated pathways: adherens junction (4 
gene match; modified Fisher Exact P-Value p=0.018; Table 6.4); central cancer 
pathway (10 gene match; p<0.001; Table 6.5); colorectal cancer (4 gene match; 
p=0.023; Table 6.6); epidermal growth factor receptor (5 gene match; p=0.003; Table 
6.7); gonadotropin-releasing hormone (4 gene match; p=0.034; Table 6.8); insulin (7 
gene match; p<0.001; Table 6.9); JAK-STAT (3 gene match; p=0.048; Table 6.10); 
mitogen activated protein kinase (4 gene match; p=0.012; Table 6.11); transforming 
growth factor beta (4 gene match; p=0.025; Table 6.12); toll-like receptor (4 gene 
match; p=0.036; Table 6.13); and, wnt (7 gene match; p<0.001; Table 6.14).  
 
Gene matches were manually checked to confirm that the transcripts in each assessed 
pathway did not functionally contradict expression changes of other matched targets. 
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6.3.7  Bioinformatic assessment of the HT-29 PCR-array dataset alone 
 
Assessment of the HT-29 PCR-array dataset was similarly performed using the 
DAVID bioinformatic system. This analysis identified 11 putative siPROM-1 
mediated pathways: apoptosis (3 gene match; p=0.043; Table 6.15); central cancer 
pathway (8 gene match; p<0.001; Table 6.16); colorectal cancer (6 gene match; 
p<0.001; Table 6.17); epidermal growth factor receptor (4 gene match; p=0.023; 
Table 6.18); insulin (5 gene match; p=0.002; Table 6.19); mitogen activated protein 
kinase (8 gene match; p=0.002; Table 6.20); mammalian target of rapamycin (4 gene 
match; p=0.006; Table 6.21); NF-kB (3 gene match; p=0.033; Table 6.22); 
transforming growth factor beta (4 gene match; p=0.023; Table 6.23); toll like 
receptor (5 gene match; p=0.005; Table 6.24); and, wnt (5 gene match; p<0.001; 
Table 6.25).  
 
Gene matches were again manually checked to confirm that the transcripts in each 
assessed pathway did not functionally contradict expression changes of other matched 
targets. 
 
6.3.8  Bioinformatic assessment of the CCD18Co PCR-array dataset alone 
 
The CCD18Co PCR-array dataset was similarly assessed using the DAVID 
bioinformatic system. This analysis identified 10 putative siPROM-1 mediated 
pathways: cell cycle (6 gene match; p=0.005; Table 6.26); central cancer pathway (15 
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gene match; p<0.001; Table 6.27); colorectal cancer (6 gene match; p<0.001; Table 
6.28); gonadotropin-releasing hormone (5 gene match; p=0.011; Table 6.29); JAK-
STAT (6 gene match; p=0.002; Table 6.30); mitogen activated protein kinase (8 gene 
match; p=0.032; Table 6.31); p53 (3 gene match; p<0.001; Table 6.32); transforming 
growth factor beta (5 gene match; p=0.008; Table 6.33); toll like receptor (6 gene 
match; p=0.002; Table 6.34); and, wnt (10 gene match; p<0.001; Table 6.35).  
 
Gene matches were checked manually to confirm that the transcripts in each assessed 
pathway did not functionally contradict expression changes of other matched targets. 
 
6.3.9  Bioinformatic assessment of the PCR-array dataset overall 
 
Assessment of the total PCR-array dataset was performed using the DAVID 
bioinformatic system. Eighteen potential pathways were identified when assessing 
transcripts differentially regulated by siPROM-1 in any of the three studied cell lines: 
adherens junction (10 gene match; p<0.001; Table 6.36); apoptosis (6 gene match; 
p=0.003; Table 6.37); cell-cycle (10 gene match; p=0.013; Table 6.38); central cancer 
pathway (25 gene match; p<0.001; Table 6.39); colorectal cancer (11 gene match; 
p<0.001; Table 6.40); epidermal growth factor receptor (11 gene match; p<0.001; 
Table 6.41); gonadotropin-releasing hormone (10 gene count; p<0.001; Table 6.42); 
hedgehog (7 gene match; p=0.001; Table 6.43); insulin (17 gene match; p<0.001; 
Table 6.44); JAK-STAT (10 gene match; p=0.002; Table 6.45); mitogen activated 
protein kinase (13 gene match; p<0.001; Table 6.46); mammalian target of rapamycin 
  J Murphy – Chapter 6 
 
 
_____________________________________________________________________ 
!
194 
 
 
!
(5 gene match; p=0.034; Table 6.47); NF-kB (5 gene match; p=0.044; Table 6.48); 
p53 (5 gene match; p=0.030; Table 6.48); transforming growth factor beta (5 gene 
match; p=0.010; Table 6.49); toll-like receptor (6 gene match; p=0.046; Table 6.50); 
vascular endothelial growth factor (7 gene match; p=0.006; Table 6.51); and, wnt (21 
gene count; p<0.001; Table 6.52) pathways. Gene matches were manually checked 
confirming that the overwhelming majority of transcripts within each pathway did not 
functionally contradict expression changes of other matched targets. Two exceptions 
were identified: the adherens junction pathway (1 gene – CDC42), and the wnt 
pathway (1 gene – SENP2).  
 
When analysing targets regulated by siPROM-1 in all three cell lines this process 
identified five putative pathways: apoptosis (2 gene match; p=0.083 [not significant]; 
Table 6.53); central cancer pathway (3 gene match; p=0.002; Table 6.54); colorectal 
cancer (3 gene match; p=0.003; Table 6.55); NF-kB (3 gene match; p=0.006; Table 
6.56); and, p53 (2 gene match; p=0.047; Table 6.57). 
 
A summary of siPROM-1 regulated pathways across all three of the assessed cell lines 
is presented in Table 6.58. 
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Figure 6.1 (a.) 
 
 
Figure 6.1 (b.) 
 
 
Figure 6.1 (a.) & (b.) – siPROM-1 knockdown. a.) RT-qPCR data demonstrate transfection with 
siPROM-1 significantly diminishes PROM-1 mRNA levels in the assessed cell lines after 48 hours. The 
amount of PROM-1 was expressed as a ratio taking expression of PROM-1 in siScrambled transfected 
control cells as the denominator; b.) western blot confirming CD/AC133 protein knockdown at 48 
hours (mean CaCo-2 fold reduction +/- SD: 2.1+/-0.07 fold; HT-29: 11.8+/-4.17; CCD18Co: 15.2+/-
3.5). All experiments were performed in triplicate with three biological replicates per run. Pictograms 
represent mean values, while error bars denote standard deviation. 
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Figure 6.2 – expression of differentially expressed target transcripts as identified by the Biotrove 
OpenArray system, performed after siPROM-1 of the CaCo-2 cell line. Cells were harvested at 48 
hours after RNA silencing. Following mRNA copy number normalisation procedures documented 
previously (Chapter 2.4.6); transcript copy numbers have been presented as a ratio with expression of 
the amplicon in the siPROM-1 treated cells used as the numerator, while that of the siScrambled cells 
was taken as the denominator. Experiments were performed in triplicate with three biological replicates 
per run. Pictograms represent mean values, while error bars denote standard deviation. Asterisks denote 
transcripts concordantly regulated in all three cell lines.  
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Figure 6.3 – expression of differentially expressed target transcripts as identified by the Biotrove 
OpenArray system, performed after siPROM-1 of the HT-29 cell line. Cells were harvested at 48 hours 
after RNA silencing. Following mRNA copy number normalisation procedures documented previously 
(Chapter 2.4.6); transcript copy numbers have been presented as a ratio with expression of the 
amplicon in the siPROM-1 treated cells used as the numerator, while that of the siScrambled cells was 
taken as the denominator. Experiments were performed in triplicate with three biological replicates per 
run. Pictograms represent mean values, while error bars denote standard deviation. Asterisks denote 
transcripts concordantly regulated in all three cell lines. 
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Figure 6.4 – expression of differentially expressed target transcripts as identified by the Biotrove 
OpenArray system, performed after siPROM-1 of the CCD18Co cell line. Cells were harvested at 48 
hours after RNA silencing. Following mRNA copy number normalisation procedures documented 
previously (Chapter 2.4.6); transcript copy numbers have been presented as a ratio with expression of 
the amplicon in the siPROM-1 treated cells used as the numerator, while that of the siScrambled cells 
was taken as the denominator. Experiments were performed in triplicate with three biological replicates 
per run. Pictograms represent mean values, while error bars denote standard deviation. Asterisks denote 
transcripts concordantly regulated in all three cell lines. 
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Figure 6.5 – Venn diagram demonstrating overall expression of differentially expressed target 
transcripts as identified by the Biotrove OpenArray system, performed after siPROM-1 of the CaCo-2, 
HT-29 and CCD18Co cell lines. Official gene name colours indicate target expression pattern: black – 
up-regulated; white – down-regulated; orange – differentially regulated by two cell lines.  
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Table 6.1 – Gene expression profile of siPROM-1 treated CaCo-2 cells (fold change +/-SD). 
Transcripts highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines. 
 
 symbol expression  symbol expression 
 CSNK2A1 up – x 6.7 ± 5.6  TRADD up – x 2.1 ± 1.9 
 HOXB13 up – x 5.8 ± 1.2  HMBS up – x 2.0 ± 1.5 
 IKBKE up – x 4.7 ± 3.1  PDGFB up – x 2.0 ± 1.5 
 JAK3 up – x 4.3 ± 1.9  PTGS2 up – x 2.0 ± 0.1 
 PTCH2 up – x 4.2 ± 0.1  EDG5 up – x 2.0 ± 0.8 
 BCL2 up – x 4.0 ± 1.7  MAPK9 up – x 1.5 ± 1.2 
 MAP3K3 up – x 4.0 ± 0.4  SMAD2 down – x 2.6 ± 0.2 
 GRM4 up – x 4.0 ± 3.3  GRB10 down – x 2.9 ± 0.1 
 IRF1 up – x 3.8 ± 2.3  WNT3 down – x 3.6 ± 0.1 
 WNT1 up – x 3.2 ± 1.1  PRKAR1A down – x 4.7 ± 0.0 
 FOSB up – x 3.1 ± 1.8  POLR2A down – x 5.5 ± 0.1 
 PTPN1 up – x 3.1 ± 2.3  AMD1 down – x 5.8 ± 0.0 
 STUB1 up – x 3.1 ± 1.3  MAPK6 down – x 6.1 ± 0.1 
 MYC up – x 3.0 ± 0.1  HMGA1 down – x 6.3 ± 0.1 
 GHR up – x 3.0 ± 1.7  RHOU down – x 6.7 ± 0.1 
 ELK1 up – x 2.9 ± 1.6  NRAS down – x 6.9 ± 0.0 
 TLR3 up – x 2.8 ± 1.0  RBL2 down – x 7.0 ± 0.0 
 RBP2 up – x 2.8 ± 2.0  EP300 down – x 10.7 ± 0.0 
 TP53 up – x 2.7 ± 0.4  NF1 down – x 10.8 ± 0.0 
 BIRC5 up – x 2.6 ± 0.6    
 EGR1 up – x 2.5 ± 1.1    
 AKT3 up – x 2.4 ± 0.3    
 RPLP0 up – x 2.4 ± 0.9    
 ITGB6 up – x 2.4 ± 0.5    
 GEM up – x 2.4 ± 0.6    
 PLAU up – x 2.3 ± 1.5    
 IRF3 up – x 2.3 ± 0.6    
 FOXO3 up – x 2.3 ± 0.7    
 PRKCZ up – x 2.3 ± 0.0    
 G6PD up – x 2.3 ± 2.2    
 EDG4 up – x 2.2 ± 0.5    
 EIF4EBP1 up – x 2.2 ± 0.3    
 MMP2 up – x 2.2 ± 0.0    
 IL16 up – x 2.1 ± 0.9    
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Table 6.2 – Gene expression profile of siPROM-1 treated HT-29 cells (fold change +/-SD). Transcripts 
highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines. 
 
 symbol expression  symbol expression 
 MAPK13 up – x 12.5 ± 1.2  
 
LEF1 down – x 3.1 ± 0.3 
 G6PD up – x 9.4 ± 0.3  BAMBI down – x 3.2 ± 0.2 
 FZD6 up – x 7.7 ± 2.9  TSC1 down – x 3.2 ± 0.4 
 MYC up – x 5.0 ± 0.6  SOCS5 down – x 3.2 ± 0.3 
 EGR1 up – x 5.0 ± 1.5  PLAU down – x 3.4 ± 0.2 
 HMBS up – x 4.7 ± 2.7  BRAF down – x 3.6 ± 0.2 
 IL16 up – x 4.7 ± 1.3  MAPK3 down – x 3.6 ± 0.1 
 IRF3 up – x 4.5 ± 2.4  GRM4 down – x 3.6 ± 0.1 
 PDK2 up – x 4.4 ± 3.2  TLR7 down – x 3.7 ± 0.1 
 PDK1 up – x 4.0 ± 1.4  SLC9A3R1 down – x 3.9 ± 0.1 
 ID1 up – x 3.9 ± 0.5  SP1 down – x 4.0 ± 0.2 
 SOX4 up – x 3.7 ± 0.7  RPL19 down – x 4.5 ± 0.1 
 BRCA1 up – x 3.5 ± 0.7  GRB10 down – x 4.8 ± 0.2 
 TCF7 up – x 3.5 ± 0.6  WNT3 down – x 5.7 ± 0.0 
 AKT3 up – x 3.3 ± 0.1  WNT7A down – x 9.3 ± 0.0 
 FOSB up – x 3.2 ± 2.0  HK2 down – x 9.5 ± 0.0 
 SOD2 up – x 3.1 ± 1.1    
 SRF up – x 3.0 ± 1.8    
 CEBPB up – x 2.9 ± 1.6    
 HOXB13 up – x 2.9 ± 0.7    
 TP53 up – x 2.9 ± 0.9    
 ITGB6 up – x 2.8 ± 0.8    
 PCK2 up – x 2.5 ± 0.5    
 BCL2 up – x 2.4 ± 0.2    
 PGR up – x 2.4 ± 0.4    
 SCTR up – x 2.4 ± 1.0    
 TNFRSF1A up – x 2.4 ± 0.8    
 USF1 up – x 2.2 ± 0.5    
 FOXA2 up – x 2.2 ± 1.0    
 MMP2 up – x 2.1 ± 0.2    
 CXXC4 down – x 2.0 ± 0.4    
 FOXO3 down – x 2.7 ± 0.4    
 PTHR1 down – x 2.7 ± 0.4    
 TCL1A down – x 2.7 ± 0.4    
 DDIT3 down – x 2.8 ± 0.4    
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Table 6.3 – Expression profile of siPROM-1 treated CCD18Co cells (fold change +/-SD). Transcripts 
highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines. 
 symbol expression  symbol expression 
 SENP2 up – x 13.8 ± 10.8  MAPK10 up – x 4.7 ± 3.5 
 TRAF6 up – x 13.6 ± 9.6  SOCS4 up – x 4.7 ± 4.2 
 WASL up – x 13.2 ± 4.3  ETS1 up – x 4.5 ± 3.4 
 FOSL1 up – x 12.5 ± 7.9  IL16 up – x 4.5 ± 1.5 
 TGFBI up – x 10.5 ± 7.1  CSNK1G1 up – x 4.4 ± 0.2 
 THBS1 up – x 9.2 ± 5.3  APC up – x 4.4 ± 4.1 
 AKT3 up – x 8.7 ± 4.0  BIRC5 up – x 4.3 ± 0.3 
 CCL20 up – x 8.7 ± 5.0  MAP2K4 up – x 4.2 ± 1.5 
 HMBS up – x 8.7 ± 7.9  ACVR2A up – x 3.9 ± 1.6 
 TGFBR3 up – x 8.3 ± 7.2  PDK1 up – x 3.8 ± 0.3 
 ADRB2 up – x 7.7 ± 3.1  TCF7L1 up – x 3.7 ± 0.6 
 MAP2K1 up – x 7.5 ± 5.0  MMP2 up – x 3.7 ± 0.8 
 CDK4 up – x 6.8 ± 5.4  HSP90AA1 up – x 3.5 ± 0.4 
 ATF1 up – x 6.5 ± 0.2  RUNX1 up – x 3.4 ± 0.5 
 BCL2 up – x 6.5 ± 0.6  EGR1 up – x 1.8 ± 0.1 
 GRM4 up – x 6.5 ± 1.3  HOXB13 up – x 1.8 ± 0.1 
 F2R up – x 6.3 ± 3.5  ITGB6 up – x 1.7 ± 0.1 
 CTGF up – x 6.3 ± 5.5  CCL2 down – x 1.5 ± 0.3 
 PPP2CA up – x 6.0 ± 0.1  CDC25A down – x 1.6 ± 0.1 
 CREB1 up – x 5.8 ± 3.5  DKK1 down – x 1.6 ± 0.1 
 SMURF1 up – x 5.7 ± 1.0  IFNAR1 down – x 1.7 ± 0.2 
 PDPK1 up – x 5.7 ± 4.3  CCNB1 down – x 1.7 ± 0.1 
 CDK2 up – x 5.5 ± 4.4  TLR6 down – x 1.7 ± 0.2 
 LTBP1 up – x 5.5 ± 1.9  ELK4 down – x 1.8 ± 0.1 
 WNT2B up – x 5.5 ± 4.8  GRB10 down – x 4.6 ± 0.1 
 PRLR up – x 5.4 ± 1.6  TP53 down – x 6.1 ± 0.0 
 NR3C1 up – x 5.4 ± 3.5    
 CCND3 up – x 5.3 ± 4.6    
 CDC42 up – x 5.0 ± 2.8    
 TRIM25 up – x 4.8 ± 2.8    
 LDHA up – x 4.8 ± 3.4    
 MYC up – x 4.8 ± 1.7    
 WNT5A up – x 4.8 ± 1.9    
 MAPK6 up – x 4.7 ± 0.0    
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Table 6.4 – CaCo-2 siPROM-1 regulated transcripts matched to the adherens pathway.  
 symbol gene name  
 CSNK2A1 
casein kinase 2, 
alpha 1  
 EP300 
E1A binding protein 
p300  
 PTPN1 
protein tyrosine 
phosphate, non-
receptor 1 
 
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
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Table 6.5 – CaCo-2 siPROM-1 regulated transcripts matched to the central cancer pathway.  
 symbol gene name  
 BIRC5 
baculoviral inhibitor 
of apoptosis repeat-
containing 5 
 
 EP300 
E1A binding protein 
p300  
 MAPK9 
mitogen-activated 
protein kinase 9  
 MYC myc viral oncogene  
 NRAS 
neuroblastoma RAS 
viral (v-ras) 
oncogene homolog 
 
 PDGF 
platelet-derived 
growth factor 
receptor 
 
 PTCH2 
patched homologue 
2  
 PTGS2 
prostaglandin-
endoperoxide 
synthase 2 
 
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
 
 WNT 
wingless-type 
MMTV integration 
site family 
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Table 6.6 – CaCo-2 siPROM-1 regulated transcripts matched to the CRC cancer pathway.  
 
 symbol gene name  
 BIRC5 
baculoviral inhibitor 
of apoptosis repeat-
containing 5 
 
 MAPK9 
mitogen-activated 
protein kinase 9  
 MYC myc viral oncogene  
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
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Table 6.7 – CaCo-2 siPROM-1 regulated transcripts matched to the ERBB pathway.  
 symbol gene name  
 EIF4EBP1 
eukaryotic 
translation initiation 
factor 4E binding 
protein 1 
 
 ELK1 ETS like gene 1  
 MAPK9 
mitogen-activated 
protein kinase 9 
 
 MYC myc viral oncogene  
 NRAS 
neuroblastoma RAS 
viral (v-ras) 
oncogene homolog 
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Table 6.8 – CaCo-2 siPROM-1 regulated transcripts matched to the GnRH pathway.  
 symbol gene name  
 ELK1 ETS like gene 1  
 MAP3K3 
mitogen activated 
protein kinase 
kinase kinase 3 
 
 MAPK9 
mitogen-activated 
protein kinase 9 
 
 NRAS 
neuroblastoma RAS 
viral (v-ras) 
oncogene homolog 
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Table 6.9 – CaCo-2 siPROM-1 regulated transcripts matched to the insulin pathway. 
 symbol gene name  
 EIF4EBP1 
eukaryotic 
translation initiation 
factor 4E binding 
protein 1 
 
 ELK1 ETS like gene 1  
 MAPK9 
mitogen-activated 
protein kinase 9 
 
 NRAS 
neuroblastoma RAS 
viral (v-ras) 
oncogene homolog 
 
 PRKAR1A 
protein kinase, 
cAMP-dependent, 
regulatory, type I, 
alpha 
 
 PRKCZ protein kinase C  
 PTPN1 
protein tyrosine 
phosphate, non-
receptor 1 
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Table 6.10 – CaCo-2 siPROM-1 regulated transcripts matched to the JAK-STAT pathway.  
 
 symbol gene name  
 CSNK2A1 
casein kinase 2, 
alpha 1 polypeptide 
 
 ELK1 ETS like gene 1  
 JAK3 janus kinase 3  
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Table 6.11 – CaCo-2 siPROM-1 regulated transcripts matched to the MAP Kinase pathway.  
 
 symbol gene name  
 ELK1 ETS like gene 1  
 MAP3K3 
mitogen activated 
protein kinase 
kinase kinase 3 
 
 MAPK6 mitogen-activated 
protein kinase 6 
 
 MAPK9 mitogen-activated 
protein kinase 9 
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Table 6.12 – CaCo-2 siPROM-1 regulated transcripts matched to the TGF-beta pathway.  
 
 symbol gene name  
 EP300 
E1A binding protein 
p300 
 
 MYC myc viral oncogene  
 RBL2 
retinoblastoma-like 
2 (p130) 
 
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
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Table 6.13 – CaCo-2 siPROM-1 regulated transcripts matched to the toll receptor pathway.  
 symbol gene name  
 IKBKE 
inhibitor of nuclear 
factor kappa-B 
kinase subunit 
epsilon 
 
 IRF3 
interferon 
regulatory factor 3  
 MAPK9 
mitogen-activated 
protein kinase 9  
 TLR3 toll like receptor 3  
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Table 6.14 – CaCo-2 siPROM-1 regulated transcripts matched to the wnt pathway.  
 symbol gene name  
 CSNK2A1 
casein kinase 2, 
alpha 1 polypeptide 
 
 EP300 
E1A binding protein 
p300 
 
 MAPK9 
mitogen-activated 
protein kinase 9  
 MYC myc viral oncogene  
 RBL2 
retinoblastoma-like 
2 (p130) 
 
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
 
 WNT 
wingless-type 
MMTV integration 
site family 
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Table 6.15 – HT-29 siPROM-1 regulated transcripts matched to the apoptosis pathway.  
 symbol gene name  
 FOXO3 forkhead box O3  
 MAPK3 
mitogen-activated 
protein kinase 3  
 PDK2 
pyruvate 
dehydrogenase 
kinase, isozyme 2 
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Table 6.16 – HT-29 siPROM-1 regulated transcripts matched to the central cancer pathway.  
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 BCL2 B-cell lymphoma 2  
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 FZD6 frizzled homolog 6  
 MAPK3 
mitogen-activated 
protein kinase 3 
 
 MYC myc viral oncogene  
 TCF7 
transcription factor 
7 
 
 WNT 
wingless-type 
MMTV integration 
site family 
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Table 6.17 – HT-29 siPROM-1 regulated transcripts matched to the CRC cancer pathway.  
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 BCL2 B-cell lymphoma 2  
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 MAPK3 
mitogen-activated 
protein kinase 3  
 MYC myc viral oncogene  
 TCF7 
transcription factor 
7  
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Table 6.18 – HT-29 siPROM-1 regulated transcripts matched to the ERBB pathway.  
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 MAPK3 
mitogen-activated 
protein kinase 3  
 MYC myc viral oncogene  
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Table 6.19 – HT-29 siPROM-1 regulated transcripts matched to the insulin pathway. 
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 HK2 hexokinase 2  
 MAPK13 
mitogen-activated 
protein kinase 13 
 
 TSC1 tuberous sclerosis 1  
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Table 6.20 – HT-29 siPROM-1 regulated transcripts matched to the MAP Kinase pathway.  
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 DDIT3 
DNA-damage-
inducible transcript 
3 
 
 MAPK13 mitogen-activated 
protein kinase 13 
 
 MAPK3 
mitogen-activated 
protein kinase 3 
 
 MYC myc viral oncogene  
 SRF 
c-fos serum 
response element-
binding 
transcription factor 
 
 TNFRSF1A 
tumour necrosis 
factor receptor 
superfamily, 
member 1A 
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Table 6.21 – HT-29 siPROM-1 regulated transcripts matched to the mTOR pathway.  
 
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 MAPK3 
mitogen-activated 
protein kinase 3  
 TSC1 tuberous sclerosis 1  
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Table 6.22 – HT-29 siPROM-1 regulated transcripts matched to the NF-kB pathway.  
 symbol gene name  
 BCL2 
B-cell lymphoma 
protein 2  
 MYC myc viral oncogene  
 TNFRSF1A 
tumor necrosis 
factor receptor 
superfamily, 
member 1A 
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Table 6.23 – HT-29 siPROM-1 regulated transcripts matched to the TGF-beta pathway.  
 symbol gene name  
 ID1 
DNA-binding 
protein inhibitor  
 MAPK3 
mitogen-activated 
protein kinase 3 
 
 MYC myc viral oncogene  
 SP1 
Sp1 transcription 
factor  
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Table 6.24 – HT-29 siPROM-1 regulated transcripts matched to the toll receptor pathway.  
 
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 IRF3 
interferon 
regulatory factor 3  
 MAPK13 
mitogen-activated 
protein kinase 13  
 MAPK3 
mitogen-activated 
protein kinase 3 
 
 TLR7 toll like receptor 7  
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Table 6.25 – HT-29 siPROM-1 regulated transcripts matched to the wnt pathway.  
 symbol gene name  
 CXXC4 
CXXC finger 4 
protein 
 FZD6 frizzled homolog 6  
 MYC myc viral oncogene  
 TCF7 
transcription factor 
7 
 WNT 
wingless-type 
MMTV integration 
site family 
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Table 6.26 – CCD18CO siPROM-1 regulated transcripts matched to the cell cycle pathway.  
 symbol gene name  
 CCNB1 cyclin B1  
 CCND3 cyclin D3  
 CDC25A 
cell division cycle 
25 homolog A  
 CDK2 
cyclin-dependent 
kinase 2  
 CDK4 
cyclin-dependent 
kinase 4 
 
 TP53 tumour protein p53  
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Table 6.27 – CCD18Co siPROM-1 regulated transcripts matched to central cancer pathway. 
 
 
 
 symbol gene name  symbol gene name 
 APC 
adenomatous 
polyposis coli  BIRC5 
baculoviral inhibitor 
of apoptosis repeat-
containing 5 
 CDC42 
cell division cycle 
42 
 CDK2 
cyclin-dependent 
kinase 2 
 CDK4 
cyclin-dependent 
kinase 4 
 ETS1 
v-ets 
erythroblastosis 
virus E26 oncogene 
homolog 1 (avian) 
 HSP90AA1 
heat shock protein 
90kDa alpha 
(cytosolic), class 
A member 1 
 MAP2K1 
mitogen-activated 
protein kinase  
kinase 1 
 MAPK10 
mitogen-activated 
protein kinase 10 ! MMP2 
matrix 
metalloproteinase-2 
 RUNX1 
runt-related 
transcription 
factor 1 
 TCF7L1 
transcription factor 
7-like 1 
 TRAF6 
TNF receptor-
associated factor 6 
 TP53 tumour protein 53 
 WNT 
wingless-type 
MMTV 
integration site 
family, member 1 
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 Table 6.28 – CCD18Co siPROM-1 regulated transcripts matched to CRC cancer pathway.  
 
 symbol gene name  
 APC 
adenomatous 
polyposis coli  
 BIRC5 
baculoviral inhibitor 
of apoptosis repeat-
containing 5 
 
 MAP2K1 
mitogen-activated 
protein kinase  
kinase 1 
 
 MAPK10 
mitogen-activated 
protein kinase 10 
 
 TCF7L1 
transcription factor 
7-like 1 
 TP53 tumour protein p53  
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Table 6.29 – CCD18Co siPROM-1 regulated transcripts matched to the GnRH pathway.  
 symbol gene name  
 CDC42 
cell division cycle 
42 
 
 MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
 
 MAP2K4 
mitogen-activated 
protein kinase 
kinase 4 
 
 MAPK10 
mitogen-activated 
protein kinase 10 
 
 MMP2 
matrix 
metalloproteinase-2  
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Table 6.30 – CCD18Co siPROM-1 regulated transcripts matched to the JAK-STAT pathway.  
 symbol gene name  
 IFNAR1 
interferon (alpha, 
beta and omega) 
receptor 1 
 
 MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
 
 MAP2K4 
mitogen-activated 
protein kinase 
kinase 4 
 
 MAPK10 
mitogen-activated 
protein kinase 10  
 TLR6 toll like receptor 6  
 TRAF6 
TNF receptor-
associated factor 6  
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Table 6.31 – CCD18Co siPROM-1 regulated transcripts matched to the MAPK pathway.  
 symbol gene name  
 CDC42 
cell division cycle 
42 
 
 ETS1 
v-ets 
erythroblastosis 
virus E26 oncogene 
homolog 1 (avian) 
 
 MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
 
 MAP2K4 
mitogen-activated 
protein kinase 
kinase 4 
 
 MAPK10 
mitogen-activated 
protein kinase 10 
 
 MAPK6 
mitogen-activated 
protein kinase 6 
 
 TP53 tumour protein p53  
 TRAF6 
TNF receptor-
associated factor 6 
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Table 6.32 – CCD18Co siPROM-1 regulated transcripts matched to the p53 pathway.  
!
 
 
 symbol gene name  
 CDK2 cyclin-dependent 
kinase 2 
 
 CDK4 cyclin-dependent 
kinase 4 
 
 TP53 tumour protein p53  
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Table 6.33 – CCD18Co siPROM-1 regulated transcripts matched to the TGF-beta pathway.  
 symbol gene name  
 ACVR2A 
activin A receptor, 
type IIA 
 
 PPP2CA 
protein phosphatase 
2 (formerly 2A) 
 
 SMURF1 
SMAD specific E3 
ubiquitin protein 
ligase 1 
 
 TGFB1 
transforming growth 
factor beta 1 
 
 THBS1 thrombospondin 1  
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Table 6.34 – CCD18Co siPROM-1 regulated transcripts matched to the toll receptor pathway.  
 symbol gene name  
 IFNAR1 
interferon (alpha, 
beta and omega) 
receptor 1 
 
 MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
 
 MAP2K4 
mitogen-activated 
protein kinase 
kinase 4 
 
 MAPK10 
mitogen-activated 
protein kinase 10 
 
 TLR6 toll like receptor 6  
 TRAF6 
TNF receptor-
associated factor 6 
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Table 6.35 – CCD18Co siPROM-1 regulated transcripts matched to the wnt pathway.  
 symbol gene name  
 APC 
adenomatous 
polyposis coli  
 CCND3 cyclin D3  
 DKK1 dickkopf homolog 1  
 FOSL1 FOS-like antigen 1  
 MAPK10 
mitogen-activated 
protein kinase 10 
 
 PPP2CA 
protein phosphatase 
2 (formerly 2A) 
 
 SENP2 
SMT3 specific 
peptidase 2 
 
 TCF7L1 
transcription factor 
7-like 1  
 TP53 tumour protein p53  
 WNT 
wingless-type 
MMTV integration 
site family 
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Table 6.36 – all siPROM-1 regulated transcripts matched to the adherens junction pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 symbol gene name  
 CDC42 
cell division cycle 
42 
 
 CSNK2A1 
casein kinase 2, 
alpha 1 
 
 EP300 
E1A binding protein 
p300  
 LEF1 
lymphoid enhancer-
binding factor 1  
 MAPK3 
mitogen-activated 
protein kinase 3  
 PTPN1 
protein tyrosine 
phosphate, non-
receptor 1 
 
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
 
 TCF7 
transcription factor 
7 
 
 TCF7L1 
transcription factor 
7-like 1 
 
 WASL 
wiskott-aldrich 
syndrome-like 
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Table 6.37 – all siPROM-1 regulated transcripts matched to the apoptosis pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 BCL2 
B-cell lymphoma 
protein 2  
 PRKAR1A 
protein kinase, 
cAMP-dependent, 
regulatory, type I, 
alpha 
 
 TNFRSF1A 
tumour necrosis 
factor receptor 
superfamily, 
member 1A 
 
 TP53 tumour protein p53  
 TRADD 
TNFRSF1A-
associated via death 
domain 
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Table 6.38 – all siPROM-1 regulated transcripts matched to the cell cycle pathway.  
 symbol gene name  
 CCNB1 cyclin B1  
 CCND3 cyclin D3  
 CDC25A 
cell division cycle 
25 homolog A 
 
 CDK2 
cyclin-dependent 
kinase 2 
 
 CDK4 
cyclin-dependent 
kinase 4  
 EP300 
E1A binding protein 
p300  
 MYC myc viral oncogene  
 RBL2 retinoblastoma-like 
2 
 
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
 
 TP53 tumour protein p53  
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Table 6.39 – all siPROM-1 regulated transcripts matched to the central cancer pathway.  
 symbol gene name  symbol gene name 
 AKT3 
v-akt murine 
thymoma viral 
oncogene 
homolog 3 
 APC 
adenomatous 
polyposis coli 
 BCL2 
B-cell lymphoma 
2  BIRC5 
baculoviral inhibitor 
of apoptosis repeat-
containing 5 
 BRAF 
v-raf murine 
sarcoma viral 
oncogene 
homolog B1 
 CDC42 
cell division cycle 
42 
 CDK2 
cyclin-dependent 
kinase 2 
 CDK4 
cyclin-dependent 
kinase 4 
 EP300 
E1A binding 
protein p300 
 ETS1 
v-ets 
erythroblastosis 
virus E26 oncogene 
homolog 1 (avian) 
 FZD6 
frizzled homolog 
6 ! HSP90AA1 
heat shock protein 
90kDa alpha 
(cytosolic), class A 
member 1 
 MAP2K1 
mitogen-activated 
protein kinase  
kinase 1 
 MAPK10 
mitogen-activated 
protein kinase 10 
 MAPK3 
mitogen-activated 
protein kinase 3 ! MMP2 
matrix 
metalloproteinase-2 
 MYC myc viral 
oncogene 
! PDGFB 
platelet-derived 
growth factor 
receptor 
 PTCH2 
patched 
homologue 2 
 RUNX1 
runt-related 
transcription factor 
1 
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
 TCF7L1 
transcription factor 
7-like 1 
 TP53 tumour protein 53  TRAF6 
TNF receptor-
associated factor 6 
 WNT 
wingless-type 
MMTV 
integration site 
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Table 6.40 – all siPROM-1 regulated transcripts matched to the CRC cancer pathway.  
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 APC 
adenomatous 
polyposis coli 
 
 BCL2 B-cell lymphoma 2  
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 MAPK6 
mitogen-activated 
protein kinase 6 
 
 MAPK10 
mitogen-activated 
protein kinase 10 
 
 MAP3K3 
mitogen-activated 
protein kinase  
kinase  kinase 3 
 
 MYC myc viral oncogene  
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
 
 TCF7 
transcription factor 
7 
 
 TP53 tumour protein p53  
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Table 6.41 – all siPROM-1 regulated transcripts matched to the ERBB pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 EIF4EBP1 
eukaryotic 
translation initiation 
factor 4E binding 
protein 1 
 
 ELK1 ETS like gene 1  
 MAPK10 
mitogen-activated 
protein kinase 10 
 
 MAP2K1 
mitogen-activated 
protein kinase  
kinase 1 
 
 MAP2K4 
mitogen-activated 
protein  kinase  
kinase 4 
 
 MAPK3 
mitogen-activated 
protein kinase 3  
 MAPK9 
mitogen-activated 
protein kinase 9  
 MYC myc viral oncogene  
 NRAS 
neuroblastoma RAS 
viral (v-ras) 
oncogene homolog 
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Table 6.42 – all siPROM-1 regulated transcripts matched to the GnRH pathway.  
 
 symbol gene name  
 CDC42 
cell division cycle 
42 
 
 ELK1 ETS like gene 1  
 MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
 
 MAP2K4 
mitogen-activated 
protein kinase 
kinase 4 
 
 MAP3K3 
mitogen activated 
protein Kinase 
Kinase Kinase 3 
 
 MAPK10 
mitogen-activated 
protein kinase 10  
 MAPK13 
mitogen-activated 
protein kinase 13  
 MAPK3 
mitogen-activated 
protein kinase 3  
 MAPK9 
mitogen-activated 
protein kinase 9 
 
 NRAS 
neuroblastoma RAS 
viral (v-ras) 
oncogene homolog 
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Table 6.43 – all siPROM-1 regulated transcripts matched to the hedgehog pathway.  
 symbol gene name  
 CSNK1G1 
casein kinase 1, 
gamma 1  
 PTCH2 
patched homologue 
2 
 
 WNT1 
wingless-type 
MMTV integration 
site family, member 
1 
 
 WNT2B 
wingless-type 
MMTV integration 
site family, member 
2B 
 
 WNT3 
wingless-type 
MMTV integration 
site family, member 
3 
 
 WNT5A 
wingless-type 
MMTV integration 
site family, member 
5A 
 
 WNT7A 
wingless-type 
MMTV integration 
site family, member 
7A 
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Table 6.44 – all siPROM-1 regulated transcripts matched to the insulin pathway.  
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog3 
 
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 EIF4EBP1 
eukaryotic 
translation initiation 
factor 4E binding 
protein 1 
 
 ELK1 ETS like gene 1  
 HK2 hexokinase 2  
 MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
 
 MAPK10 
mitogen-activated 
protein kinase 10  
 MAPK3 
mitogen-activated 
protein kinase 3  
 MAPK9 
mitogen-activated 
protein kinase 9  
 NRAS 
neuroblastoma RAS 
viral (v-ras) 
oncogene homolog 
 
 PCK2 
phosphor-
enolpyruvate 
carboxykinase 2 
 
 PDPK1 
3-phosphoinositide 
dependent protein 
kinase-1 
 
 PRKAR1A 
protein kinase, 
cAMP-dependent, 
regulatory, type I, 
alpha 
 
 PRKCZ protein kinase C  
 PTPN1 
protein tyrosine 
phosphate, non-
receptor 1 
 
 SOCS4 suppressor of 
cytokine signaling 4 
 
 TSC1 tuberous sclerosis 1  
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Table 6.45 – all siPROM-1 regulated transcripts matched to the JAK-STAT pathway.  
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 CCND3 cyclin D3  
 EP300 
E1A binding protein 
p300 
 
 GHR 
growth hormone 
receptor 
 
 IFNAR1 
interferon (alpha, 
beta and omega) 
receptor 1 
 
 JAK3 janus kinase 3  
 MYC myc viral oncogene  
 PRLR prolactin receptor  
 SOCS4 
suppressor of 
cytokine signaling 4 
 
 SOCS5 suppressor of 
cytokine signaling 5 
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Table 6.46 – all siPROM-1 regulated transcripts matched to the MAP Kinase pathway.  
 symbol gene name  
 BRAF 
v-raf murine 
sarcoma viral 
oncogene homolog 
B1 
 
 CREB1 
cAMP responsive 
element binding 
protein 1 
 
 ELK1 ETS like gene 1  
 MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
 
 MAP2K4 
mitogen-activated 
protein kinase 
kinase 4 
 
 MAP3K3 
mitogen activated 
protein Kinase 
Kinase Kinase 3 
 
 MAPK10 
mitogen-activated 
protein kinase 10  
 MAPK13 
mitogen-activated 
protein kinase 13  
 MAPK3 
mitogen-activated 
protein kinase 3  
 MAPK6 mitogen-activated 
protein kinase 6 
 
 MAPK9 mitogen-activated 
protein kinase 9 
 
 SP1 
Sp1 transcription 
factor 
 
 TRADD 
TNFRSF1A-
associated via death 
domain 
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Table 6.47 – all siPROM-1 regulated transcripts matched to the mTOR pathway.  
 symbol gene name  
 EIF4EBP1 
eukaryotic 
translation initiation 
factor 4E binding 
protein 1 
 
 PDK2 
pyruvate 
dehydrogenase 
kinase, isozyme 2 
 
 PDPK1 
3-phosphoinositide 
dependent protein 
kinase-1 
 
 PPP2CA 
protein phosphatase 
2 (formerly 2A) 
 
 TSC1 tuberous sclerosis 1  
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Table 6.48 – all siPROM-1 regulated transcripts matched to the NF-kB & TP53 pathways.  
 symbol gene name  
 MYC myc viral oncogene  
 TNFRSF1A 
tumor necrosis 
factor receptor 
superfamily, 
member 1A 
 
 TP53 tumour protein p53  
 TRADD 
TNFRSF1A-
associated via death 
domain 
 
 TRAF6 
TNF receptor-
associated factor 6  
  J Murphy – Chapter 6 
 
 
_____________________________________________________________________ 
!
248 
 
 
!
Table 6.49 – all siPROM-1 regulated transcripts matched to the TGF-beta pathway.  
 symbol gene name  
 MYC myc viral oncogene  
 TNFRSF1A 
tumour necrosis 
factor receptor 
superfamily, 
member 1A 
 
 TP53 tumour protein p53  
 TRADD 
TNFRSF1A-
associated via death 
domain 
 
 TRAF6 
TNF receptor-
associated factor 6 
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Table 6.50 – all siPROM-1 regulated transcripts matched to the toll like receptor pathway.  
 symbol gene name  
 ELK1 ETS like gene 1  
 MAP2K4 
mitogen-activated 
protein kinase 
kinase 4 
 
 TLR3 toll like receptor 3  
 TLR6 toll like receptor 6  
 TLR7 toll like receptor 7  
 TRAF6 
TNF receptor-
associated factor 6 
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Table 6.51 – all siPROM-1 regulated transcripts matched to the VEGF pathway.  
 symbol gene name  
 AKT3 
v-akt murine 
thymoma viral 
oncogene homolog 
3 
 
 CDC42 
cell division cycle 
42 
 
 MAP2K1 
mitogen-activated 
protein kinase 
kinase 1 
 
 MAPK13 
mitogen-activated 
protein kinase 13 
 
 MAPK3 
mitogen-activated 
protein kinase 3 
 
 NRAS 
neuroblastoma RAS 
viral (v-ras) 
oncogene homolog 
 
 PTGS2 
prostaglandin-
endoperoxide 
synthase 2 
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Table 6.52 – all siPROM-1 regulated transcripts matched to the wnt pathway.!
 
 
 
 
 
 symbol gene name  symbol gene name 
 APC 
adenomatous 
polyposis coli  CCND3 cyclin D3 
 CSNK2A1 
casein kinase 2, 
alpha 1 
 CXXC4 
CXXC finger 4 
protein 
 DKK1 
dickkopf homolog 
1 
 EP300 
E1A binding protein 
p300 
 FOSL1 
FOS-like antigen 
1 
 FZD6 frizzled homolog 6 
 LEF1 
lymphoid 
enhancer-binding 
factor 1 
 MAPK10 
mitogen-activated 
protein kinase 10 
 MAPK9 
mitogen-activated 
protein kinase 9 
 MYC myc viral oncogene 
 PPP2CA 
protein 
phosphatase 2 
(formerly 2A) 
 SENP2 
SMT3 specific 
peptidase 2 
 SMAD2 
mothers against 
decapentaplegic 
homolog 2 
 TCF7 
transcription factor 
7 
 TCF7L1 
transcription 
factor 7-like 1 
 TP53 tumour protein 53 
 WNT3 
wingless-type 
MMTV 
integration site 
family, member 3 
 WNT5A 
wingless-type 
MMTV integration 
site family, member 
5A 
 WNT7A 
wingless-type 
MMTV 
integration site 
family, member 
7A 
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Table 6.53 – CaCo-2, HT-29 & CCD18Co transcripts matched to apoptosis pathway.  
 
 
 symbol gene name  
 BCL2 
B-cell lymphoma 
protein 2  
 TP53 tumour protein p53  
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Table 6.54 – CaCo-2, HT-29 & CCD18Co transcripts matched to central cancer pathway.  
 
 
 symbol gene name  
 BCL2 
B-cell lymphoma 
protein 2  
 MYC myc viral oncogene  
 TP53 tumour protein p53  
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Table 6.55 – CaCo-2, HT-29 & CCD18Co transcripts matched to CRC cancer pathway.  
 
 
 symbol gene name  
 BCL2 
B-cell lymphoma 
protein 2 
 
 MYC myc viral oncogene  
 TP53 tumour protein p53  
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Table 6.56 – CaCo-2, HT-29 & CCD18Co transcripts matched to NF-kB pathway.  
 
 
 
 symbol gene name  
 BCL2 
B-cell lymphoma 
protein 2 
 
 MYC myc viral oncogene  
 TP53 tumour protein p53  
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Table 6.57 – CaCo-2, HT-29 & CCD18Co transcripts matched to p53 pathway.  
 
 
 
 
 symbol gene name  
 BCL2 
B-cell lymphoma 
protein 2  
 TP53 tumour protein p53  
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 Table 6.58 –siPROM-1 regulated pathways in each, any & all of the three-cell lines. ns – not significant.!
pathway  CaCo-2 HT-29 CCD18Co 
siPROM-1 mediated pathways identified       
in any of the three cell lines 
siPROM-1 mediated pathways         
identified in all of the three cell lines 
adherens  p = 0.018 - - p < 0.001 - 
apoptosis  - p = 0.043 - p = 0.003 p = 0.083 (ns) 
cell-cycle  p = 0.061 (ns) - p = 0.005 p = 0.013 - 
central cancer  p < 0.001 p < 0.001 p < 0.001 p < 0.001 p = 0.002 
colorectal cancer  p = 0.023 p < 0.001 p < 0.001 p < 0.001 p = 0.003 
ERBB  p = 0.003 p = 0.023 - p < 0.001 - 
GnRH  p = 0.034 - p = 0.011 p < 0.001 - 
hedgehog  p = 0.062 (ns) - p = 0.091 (ns) p = 0.001 - 
insulin  p < 0.001 p = 0.002 - p < 0.001 - 
JAK-STAT  p = 0.048 - p = 0.002 p = 0.002 - 
MAP kinase  p = 0.012 p = 0.002 p = 0.032 p < 0.001 - 
mTOR  - p = 0.006 - p = 0.034 - 
NF-kB  - p = 0.033 - p = 0.044 p = 0.006 
p53  - - p < 0.001 p = 0.030 p = 0.047 
TGF-beta  p = 0.025 p = 0.023 p = 0.008 p = 0.010 - 
toll-like receptor  p = 0.036 p = 0.005 p = 0.002 p = 0.046 - 
VEGF  - p = 0.098 (ns) - p = 0.006 - 
wnt  p < 0.001 p < 0.001 p < 0.001 p < 0.001 - 
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6.1  DISCUSSION 
 
Detection of PROM-1/CD/AC133 expression in colorectal cancer (CRC) specimens, 
or PROM-1 circulating mRNA levels, have been proposed as prognostic markers that 
identify patient groups with poor overall survival (Lin et al., 2007; Horst et al., 2008; 
Kojima et al., 2008; Horst et al., 2009a,b; Li et al., 2009; Saigusa et al., 2009; Wang 
et al., 2009; Yasuda et al., 2009; Artells et al., 2010; Huh et al., 2010; Nakamura et 
al., 2010; Ong et al., 2010; Saigusa et al., 2010; Takahashi et al., 2010; Iinuma et al., 
2011; Xi and Zhao, 2011). The cancer stem-cell (CSC) hypothesis provides an 
attractive explanation for this apparent correlation, since PROM-1/CD/AC133 has 
been reported to identify a rare population of CRC cells which can serially engraft in 
murine models (O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Ieta et al., 2008; 
Puglisi et al., 2009). However, upon close reading only approximately 1 in 262 
CD/AC133high cells had tumour-initiating capabilities (O'Brien et al., 2007), which 
suggests CD/AC133 may not be highly specific for these cells. Furthermore, other 
authors have been unable to replicate these findings (Shmelkov et al., 2008; Chu et 
al., 2009) and thus the association between PROM-1/CD/AC133 expression and 
clinical outcome may be more complex than its proposed ability to identify a CRC-
CSC population. A greater understanding of this potential link is hampered by a lack 
of demonstrable functional relevance for this marker in the process of CRC 
tumourigenesis. Indeed, it is unclear whether ‘knock-down’ of PROM-1/CD/AC133 
compromises the tumour-initiating capabilities of colon cancer cells, further 
questioning the functional role of this molecule for the CRC-CSC phenotype (Feng et 
al., 2011; Puglisi et al., 2011). This apparent dichotomy is buttressed by an additional 
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study demonstrating that PROM-1/CD/AC133 over-expression correlates strongly 
with synchronous liver metastasis, but that PROM-1 ‘knock-down’ does not affect 
proliferation, migration, invasion, and colony formation in CRC cell lines (Horst et 
al., 2008). Taken together, for now it is probably best to conclude that although there 
clearly is prognostic significance associated with PROM-1/CD/AC133 expression, 
any correlation between this marker and stem-cells remains obscure and while 
PROM-1/CD/AC133 may roughly enrich for CRC-CSCs, there remains a lack of 
functional relevance for tumour-initiating capability. 
 
Since the identification of a regulatory cascade should help shed some light upon the 
biological function of PROM-1/CD/AC133, the purpose of this study is to identify 
putative downstream intracellular targets of PROM-1/CD/AC133 mediated signalling 
and thus determine potential roles for this marker in CRC. In order for gene 
expression profiling results to be valid, a careful evaluation of the data set is 
necessary due to a number of biological and technical considerations. The first 
consideration is biological variability, which was minimised through the choice of 
CRC and immortalised colonic SEMF cell lines for use in PCR-array experiments, 
rather than human tissue biopsies. This decision resulted in the generation and use of 
homogenous total RNA preparations. Biological variability was quantified by the use 
of three biological replicates for each cell line, with the use of three technical 
replicates per run allowing an assessment of the experimental variability (Chapter 
2.4.6). Overall, the PCR-array experiments produced reproducible results across both 
technical and biological replicates as indicated by the error bars denoting standard 
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deviation in Figures 6.2 - 6.4, and as highlighted by siPROM-1 ‘knock-down’ of only 
a fraction of approximately 3000 target mRNAs, notably: (i.) CaCo-2: fifty-three 
transcripts; (ii.) HT-29: fifty-one transcripts; and, (iii) CCD18Co: sixty transcripts. 
 
Review of the PCR-array data set generated by the Biotrove OpenArray platform 
reveals a considerable number of putative siPROM-1 mediated targets. Full 
concordance was demonstrated for ten targets regulated by siPROM-1 in all three cell 
lines (Figure 6.5). The identification of this select list of transcripts that are 
apparently regulated by siPROM-1 is made more credible by their identification in 
CaCo-2, HT-29 and CCD18Co cell lines that exhibit malignant and immortalised 
‘normal’ phenotypes, respectively. Further credence is lent to this target list when the 
relative sensitivity of PCR-array based platforms is considered, as this technology 
conducts thousands of annealing reactions in parallel with uniform experimental 
conditions that can never be perfectly optimised for each individual assay, however 
extensive the research, development and validation of this technology may have been. 
Therefore, it is possible that this technology will derive results that may underestimate 
the true effect of treatments such as RNA interference (RNAi) for a significant 
number of targets, when compared with optimised quantitative technologies such as 
real time polymerase chain reaction assays. This qualification of the presented data 
raises the further important possibility that targets with less dramatic siPROM-1 
mediated regulation may not have been detected using this assay platform, as the 
resulting alteration in target copy numbers did not reach the necessary threshold 
following primer annealing. This phenomenon, in combination with the variability 
inherent in any biological system, may in part explain why additional siPROM-1 
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mediated targets reported by this study were identified in only one or two cell lines, 
although further investigation with optimised RT-qPCR assays will be required to 
confirm this supposition.  
 
When considering the possible role of PDZ domain binding proteins in PROM-
1/CD/AC133 mediated signalling, two of the seventeen assessed targets known to 
contain PDZ binding domains were found to be regulated by siPROM-1: interleukin 
16 (IL16; up-regulated CaCo-2, HT-29 and CCD18Co), and the solute carrier family 9 
member 3 (SLC9A3R1; down-regulated HT-29) transcripts. Unfortunately, these 
mRNAs contain both a PDZ-1 and PDZ-2 binding domain, and therefore the reported 
observations provide no real insight as to whether PROM-1 splicing may control 
intracellular signalling through differential PDZ binding domains. As a result further 
studies will be necessary to further investigate the role of PROM-1 splicing in CRC.  
 
Concordance was demonstrated for ten targets regulated by siPROM-1 in all three cell 
lines (Figure 6.5), raising a number of intriguing possible insights into the function of 
PROM-1/CD/AC133. The first of these targets is AKT3, an important participant in 
the AKT signalling cascade and a well characterised downstream target of the 
PI3K/AKT/mTOR pathway, which in turn is a central pathway in colorectal 
carcinogenesis due to its role in intra-cellular processes such increasing cell survival, 
proliferation, invasion, and angiogenesis. The AKT pathway phosphorylates several 
downstream targets, including NF-κB and the Fas/Fas-ligand system, to promote 
tumourigenesis (Ozes et al., 1999; Uriarte et al., 2005) by increasing tumour cell 
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resistance to apoptosis, in addition to regulating cellular invasiveness and peri-
tumoural angiogenesis (Boye et al., 2008). Furthermore, AKT-mediated signalling 
blocks the tumour suppressor protein TP53 via activation of the MDM2 oncogene 
(Trotman and Pandolfi, 2003). Therefore, a great deal of interest has arisen in the 
identification of small molecule inhibitors of the AKT pathway (Zhao, 2008). AKT 
also regulates cell survival through the mitochondrial pathway, blocking the pro-
apoptotic protein BAD by phosphorylation to increase expression of the anti-apoptotic 
protein BCL2 (Pastorino et al., 1999), the second siPROM-1 regulated target in all 
three cell lines studied by this thesis, which in turn increases cell survival. 
Consequently, an association between siPROM-1 and the AKT pathway strongly 
supports a potential role for PROM-1/CD/AC133 in colorectal carcinogenesis. 
 
BCL2 is a cytoplasmic protein that resides at the mitochondrial level, endoplasmic 
reticulum or the nuclear envelope (Krajewski et al., 1993) and which acts as an 
oncogene that inhibits apoptosis and thus contributes to tumourigenesis, having 
initially been discovered in B-cell follicular lymphomas (Stewart, 1994). 
Subsequently, it has also been demonstrated to promote tumour growth in a number of 
epithelial malignancies including breast, hepatocellular, lung and thyroid cancers. In 
normal colorectal mucosa, BCL2 expression can be demonstrated at the level of the 
putative ‘stem-cell niche’ (Sinicrope et al., 1995). However, its expression by 
dysplastic colorectal adenomas has been reported to be greater than that of CRC 
specimens, leading to the hypothesis that abnormal activation of BCL2 is a frequent 
early step in CRC carcinogenesis (Bronner et al., 1995; Huerta et al., 2006). In light of 
these and other published reports, the presented data reveal a link between siPROM-1 
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and BCL2 expression that further reinforces a proposed function for CD/AC133 in 
CRC, a central concept explored by this thesis. 
 
The third siPROM-1 regulated target in all three cell lines was the tumour suppressor 
gene EGR1. This transcription factor has been implicated in tumour progression and 
inhibition of apoptosis via a diverse range of EGR1 target genes including the TP53 
and BCL2 pathways mentioned above (Baron et al., 2006; Zagurovskaya et al., 2009). 
Several authors have reported that EGR1 is constitutively expressed by CRC cell lines 
and is up-regulated at the mRNA level in early CRC (Hong et al., 2007; Mahalingam 
et al., 2010; Wilson et al. 2010). Furthermore, EGR1 is induced by radiation and 
chemotherapeutic agents and is responsible for the growth arrest induced by these 
treatments; thus, inactivation of EGR1 response confers chemoradiotherapy resistance 
(Ahmed et al., 2001; Parra and Ferreira, 2010). However, EGR1 tumour suppressor 
function is impaired by the frequent inactivation of two EGR1 targets: PTEN and 
TP53 (Das et al., 2001; Virolle et al., 2001). In addition, EGR1 expression may be 
blocked in certain tumour cell lines including CRC by a number of mechanisms, 
which include activation of the AKT pathway, resulting in degradation of serum 
response factor (SRF) that in turn prevents ELK-1 transcription factor mediated 
expression of EGR1 (Chen et al., 2004); or, mutational activation of the wnt pathway 
preventing SRF-mediated expression of EGR1 (Tice et al., 2002). On the other hand, 
EGR1 over-expression has been reported to directly promote tumour growth and 
cancer progression through mechanisms that require p53 mutations or constitutive 
activation of the ERK pathway, due to mutations of the epidermal growth factor 
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receptor or BRAF genes (Gaggioli et al., 2007; Maegawa et al, 2009; Sauer et al., 
2010). Since both CRC cell lines studied in this thesis are documented to have p53 
mutations (Mariadason et al., 2003), it is unsurprising to find an association between 
EGR1 and PROM-1/CD/AC133, given an emerging role for PROM-1/CD/AC133 as a 
prognosticator for patients with CRC as discussed previously by this chapter. 
 
RNAi technology also demonstrated an association between PROM-1 down-
regulation and expression of the IL16 transcript. Interleukin-16 is a cytokine that can 
stimulate the production of several pro-inflammatory cytokines by mononuclear cells, 
including tumour necrosis factor α, interleukin 1b, interleukin 6 (Mathy et al., 2000), 
all of which play an important role in apoptosis and cell survival (Apte et al., 2006; 
van Horssen et al., 2006). Few authors have directly examined potential cellular 
mechanisms implicating IL16 in colorectal carcinogenesis (Gao et al., 2009), although 
deregulation of its expression has been proposed to promote the development and 
progression of CRC (Mochizuki et al., 2004; Apte et al., 2006; Muc-Wierzgon et al., 
2006). One such example are patients with inflammatory bowel disease who are at 
risk of CRC (Itzkowitz and Yio, 2004) and the association between this spectrum of 
pathology and IL16 may in part explain the increased risk of colorectal malignancy in 
this patient group (Seegert and Schreiber, 2002). Therefore, siPROM-1 mediated 
regulation of IL16 lends further credence to a potential link between CD/AC133 and 
the critical properties of CRC cells. However, the relationship between these two 
proteins becomes somewhat less distinct when considering a report that demonstrates 
IL16 may have a role in promoting the expansion of haematopoietic stem cells from 
cord derived blood (Rofani et al., 2009). Conceptually, this association could be 
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extended to hypothesise that IL16 may enrich other cell populations for stem-cell 
characteristics, possibly including cancer cells from solid tumours. However, it should 
be stressed that any theoretical significance this report might lend to a potential role 
for PROM-1/CD/AC133 as a CRC stem cell marker would be at odds with more 
recently published literature. Furthermore, given no such association has yet been 
reported between this cytokine and any solid or epithelial tumour, at the present time 
the ‘burden of proof’ lies firmly with the experiments presented in this thesis that 
demonstrate PROM-1/CD/AC133 does not identify a rare CSC population. 
 
RNA silencing technology also identified siPROM-1 mediated regulation of ITGB6, 
which is a finding of considerable interest. ITGB6 is a cell adhesion molecule that is 
part of the integrin family, a series of cell membrane proteins that transmit messages 
through a variety of intracellular protein kinases and adaptor molecules. Integrin over-
expression, or indeed down-regulation, contributes to several diseases including CRC 
(Parise et al., 2000), with up-regulation of integrins reported to account for increased 
adhesion of tumour cells in the process of metastasis, while reduced integrin levels 
may promote cell detachment from the primary tumour and invasive growth. This 
promotion of invasion and metastasis by integrins has been shown to substantially 
influence the prognosis of CRC in animal models (Wang et al., 2004). Furthermore, 
the possibility that integrin expression may be responsible for tumour cell resistance 
to oxaliplatin chemotherapy regimens remains the subject of ongoing investigation 
(Dia and Gonzalez de Mejia, 2011) with an association between ITGB8 and the 
AC133high CRC cell subtype recently reported (Chao et al., 2012). Therefore, 
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siPROM-1 mediated expression of ITGB6 as reported by this study supports a 
significant potential role for CD/AC133 signalling in critical CRC properties 
including intra- or extravasation, with some published data suggesting PROM-
1/CD/AC133 may be associated with tumour cell chemoresistance (Dallas et al., 
2009). 
 
A further target regulated by siPROM-1 in this study was MMP2. This transcript 
belongs to the matrix metalloproteinase (MMP) family, which is a class of structurally 
related zinc-dependent proteases involved in cellular infiltration, cytokine activation, 
cell migration, tissue damage, remodelling, and repair (Brinckerhoff and Matrisian, 
2002; Mott and Werb, 2004). MMP2 is constitutively expressed in almost all human 
tissues and is central to the regulation of extracellular matrix turnover, since this 
protein has the ability to cleave the majority of extracellular matrix proteins. 
Importantly, deregulated MMP expression has been demonstrated to have a central 
role in the development of a number of diseases including CRC (Islekel et al., 2007). 
Investigation of MMP2 function within CRC cell lines has demonstrated that the 
integrin / ERK pathway influences MMP2 extracellular matrix proteolysis, an event 
that is critical for cellular invasion and metastasis, by increasing mRNA expression 
levels of this target (Peng et al., 2008). Moreover, MMP2 mediated cellular invasion 
is influenced by the wnt / ß-catenin pathway, a pivotal signalling system in CRC 
(Planutiene et al., 2011), supporting the purported role for MMP2 in CRC 
progression. Consequently, data presented in this chapter identifying siPROM-1 
mediated regulation of the MMP2 transcript once again highlight an important 
potential role for CD/AC133 in CRC.   
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Excitingly, this study also demonstrated that the MYC transcription factor, a pivotal 
regulator of cellular proliferation and apoptosis (Grandori et al., 2000), is regulated by 
siPROM-1. MYC is a member of a family of transcription factors that bind to DNA 
and activate gene expression by recruiting acetyltransferases and chromatin 
remodelling complexes (Eisenman, 2001). However, MYC may also suppress gene 
transcription by interacting with DNA when MYC is bound to the MYC-interacting 
zinc finger 1 protein (Kleine-Kohlbrecher et al., 2006). The significance of MYC 
mediated signalling has been revealed by genome-wide profiling studies indicating 
that expression of many thousands of genes may be directly regulated by MYC (Eilers 
and Eisenman, 2006). Therefore, it is unsurprising that the MYC gene is frequently 
over-expressed in a wide range of cancers including approximately 80% of CRCs 
(Nesbit et al., 1999; Prochownik, 2004) with ß-catenin / TCF4 cellular complexes, 
which are down stream effectors of the wnt pathway, demonstrated to regulate MYC 
expression in CRC cells through two proximal wnt / ß-catenin responsive enhancers 
in the MYC promoter region (He et al., 1998; Yochum et al., 2008). The identification 
by this study of an association between the MYC transcription factor and PROM-
1/CD/AC133 contributes significantly to the burden of evidence that proposes PROM-
1/CD/AC133 may play a crucial part in colorectal carcinogenesis, and with the 
identification of additional siPROM-1 mediated transcripts discussed above, the 
presented data are beginning to unravel the complex interactions of CD/AC133 in 
CRC cells. 
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While not concordantly regulated in all three cell lines following PROM-1 ‘knock-
down’, the most significant siPROM-1 mediated target identified by this study may in 
fact be TP53, the transcript which encodes the tumour suppressor protein TP53. 
Mutation of the p53 gene is thought to play an important role in the progression of 
CRC with an estimated frequency for TP53 mutations in CRC of approximately 50-
70% (Iacopetta, 2003; Brosh and Rotter, 2009). While TP53 has a broad range of 
biological functions, its key role as a tumour suppressor is to block cell cycle 
progression and to induce apoptosis. One signalling cascade thought to mediate the 
association between TP53 and apoptosis is the mitochondrial pathway, discussed 
previously, since TP53 binds the BAX gene promoter region regulating its 
transcription (Miyashita et al., 1994; Miyashita and Reed, 1995) directing BAX 
heterodimer formation with BCL2, which in turn modulates the activity of BCL2 
(Oltvai et al., 1993). However, other signalling cascades are involved in the regulation 
of this process, for example, the conflicting apoptotic signals transduced by the AKT 
and TP53 pathways are rationalised and integrated through negative feedback loops 
that interlink these two cascades (Gottlieb et al., 2002). TP53 mutations have also 
been demonstrated to result in up-regulation of the EGR1 transcript discussed 
previously, which specifies a transcription factor implicated in growth control, cancer 
and importantly regulation of apoptosis (Weisz et al., 2004). MMP2, a transcript also 
discussed above, has been identified as a downstream target of the p53 protein, since 
TP53 binds to the MMP2 promoter region and thereby regulates its expression (Bian 
and Sun, 1997). Finally, TP53 is thought to repress the MYC transcription factor also 
discussed previously through a mechanism that involves histone deacetylation (Ho et 
al., 2005). The associations between the p53 pathway and the siPROM-1 mediated 
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transcripts mentioned above strengthen the conceptual legitimacy of each of these 
markers, which generally have been discussed in isolation, while beginning to allow a 
rudimentary understanding of the complex web of interacting pathways that 
CD/AC133 orchestrates. At first glance, siPROM-1 up-regulation of TP53 in CRC 
cell lines and down-regulation in SEMF cells might appear discordant. However, 
when contrasting the presence of TP53 mutations in CaCo-2 / HT-29 cells 
(Mariadason et al., 2003) and their malignant phenotype with that of the CCD18Co 
cell line, differing responses in TP53 expression levels following RNAi might well be 
expected. It is intriguing that siPROM-1 affects the expression of both the wild-type 
and mutant TP53 isoforms in this manner and further work will be required to 
elucidate the biological significance of these results.     
 
In addition to the results discussed above, four siPROM-1 transcripts were identified 
exclusively in the CaCo-2 and HT-29 CRC cell lines. The first of these transcripts 
was FOSB, which was up-regulated following PROM-1 ‘knock-down’. The FOSB 
protein dimerises with Jun proteins to form the AP-1 transcription factor complex, 
which has been implicated in carcinogenesis (Milde-Langosch, 2005) and is required 
for the motility and invasiveness of CRC cells (Vial et al., 2003). The second 
siPROM-1 transcript identified in the CRC cell lines was G6PD, a key enzyme for 
ribose-5-phosphate production via the pentose phosphate pathway, which is essential 
for DNA and RNA synthesis within rapidly growing cells (Kuo et al., 2000). G6PD 
expression and activity is frequently elevated in a number of epithelial cancers 
including CRC, with some evidence that this marker functions as an oncogene 
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(Koudstaal et al., 1975; Kuo et al., 2000). A further transcript identified by RNAi 
technology in these cell lines was IRF3. This protein is involved in a large number of 
diverse cellular pathways, with over-expression of IRF3 reported to block DNA 
synthesis, thereby exerting a negative affect upon cell division and growth, in addition 
to the induction of apoptosis and cellular senescence (Heylbroeck et al., 2000; Kim et 
al., 2003; Kim et al., 2007). The final transcript mediated by siPROM-1 in the CRC 
cell lines was WNT3A, a signalling protein responsible for activation of a pathway 
that is synonymous with CRC: the wnt / ß-catenin transduction cascade (Le et al., 
2008; Mizrak et al., 2008). Given the fundamental role of the wnt pathway in adult 
tissue homeostasis, it is not surprising that deregulation of this pathway is critically 
involved in the pathogenesis of CRC (Kinzler et al., 1991; Le et al., 2008; Mizrak et 
al., 2008). Inactivation of the APC gene and / or activating mutations of β-catenin are 
a vital initiating step in malignant transformation and are reported in essentially all 
patients presenting with CRC (Miyoshi et al., 1992; Powell et al., 1992). More 
specifically recent work suggests that WNT3A is necessary to maintain normal 
human colon stem-cells (Sato et al., 2011). If this report is viewed in light of the 
currently accepted model of tumourigenesis, i.e. arrested differentiation of tissue-
based stem-cells, it would seem likely that the WNT3A protein also may play an 
essential part in the maintenance of the CRC-CSC subtype. In summary, taken 
together these four associations provide a persuasive argument supporting a role for 
PROM-1/CD/AC133 in the pathogenesis of CRC. However, it must be remembered 
that these transcripts were regulated by siPROM-1 exclusively in CRC cell lines and 
while a lack of concordance for these markers in the SEMF cell line may be argued as 
supportive evidence of their role in the maintenance of a malignant phenotype, RNAi 
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mediated regulation for only two of the three assessed cell lines also raises questions 
concerning the validity of the reported observations. Therefore, the association 
between these four targets and siPROM-1 requires further investigation before any 
definite conclusions can be drawn from these data.   
 
Bioinformatic assessment of the PCR-array data generated by this study was also 
performed but is complex. While a number of potential signalling cascades regulated 
by PROM-1 ‘knock-down’ were uncovered, only the following siPROM-1 mediated 
pathways were identified for all three cell lines: central cancer, colorectal cancer, NF-
kB and TP53 signalling cascades. PROM-1/CD/AC133 interaction with these four 
corroborated signal transduction pathways provides some intriguing hypotheses 
concerning the biological function of this marker. One interesting aspect of the 
involvement of PROM-1/CD/AC133 in these pathways is that they participate in 
epithelial-mesenchymal transition (EMT) (Huber et al., 2004; Jiang et al., 2007; Kim 
et al., 2011). EMT is a critical early event during cancer invasion and metastasis. 
Remodelling of the extracellular matrix affects tumour growth, survival, invasiveness 
and metastasis through its role in the development of blood supply and interaction 
with the mesenchymal stroma upon which tumour cells grow. Morphologically, EMT 
is characterised by a decrease of e-cadherin, loss of cell adhesion, and increased cell 
motility leading to the promotion of metastatic behaviour from cancer cells. Shmelkov 
et al. have hypothesized that PROM-1/CD/AC133low cells derive from PROM-
1/CD/AC133high cells in the process of tumour progression and suggest that the 
emergence of PROM-1/CD/AC133low cells results from down-regulation of the 
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molecules specific for the mature, differentiated epithelium, consistent with early 
signs of EMT. The bioinformatic associations presented in this chapter suggest that 
expression of PROM-1/CD/AC133 is likely to be important during the process of 
EMT, although its precise role remains to be determined.  
 
Evasion of apoptosis is one of the hallmarks of human cancers (Hanahan and 
Weinberg, 2000) and has been discussed extensively above, thus siPROM-1 mediated 
regulation of the TP53 pathway, a key regulator of cellular proliferation and 
apoptosis, may partly explain AC133-epitopehigh subtype chemoresistance (Dallas et 
al., 2009). The NF-kB pathway has also been associated with inhibition of apoptosis 
(Perkins, 2007; Hayden et al., 2008; Baud et al., 2009) and therefore the finding that 
PROM-1/CD/AC133 ‘knock-down’ affects the regulation of both this and the TP53 
pathway in all three assessed cell lines, in addition to the previously presented data, 
lends powerful support to a potential role for this marker in apoptotic signalling. 
  
Moreover, tumour growth is necessary for local invasion or distant metastasis and is 
recognised as being driven by a number of pathways, some of which have been 
demonstrated by this study to be affected by siPROM-1. One such signalling cascade 
is the ‘colorectal cancer pathway’, which has previously been linked with PROM-
1/CD/AC133 expression (Ernst et al., 2011). It is thought that activation of this 
pathway results in EGR1 mediated regulation of the wnt transduction cascade through 
up-regulation of the TCF4 transcription factor, further sustaining tumour growth, 
invasion and the spread of tumour-initiating cells. The finding by this study that 
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siPROM-1 influences components of the wnt signalling pathway complements the 
association between PROM-1/CD/AC133 and p53 discussed previously, and is in 
keeping with observations that regulation of the differentiation and proliferation status 
of PROM-1/CD/AC133high subpopulations is influenced by wnt signalling (reviewed 
by Mizrak et al., 2008). Overall, these conclusions fit with a significant role for 
PROM-1/CD/AC133 in CRC tumourigenesis, specifically since aberrant wnt 
signalling due to loss of function mutations in downstream targets, such as APC or 
beta-catenin, underpins the pathogenesis of CRC (Le et al., 2008; Mizrak et al., 2008). 
 
When considering all siPROM-1 mediated transcripts identified in either one or two 
of the assessed cell lines only, a further network of 14 putative siPROM-1 mediated 
pathways was identified, each of which has previously been implicated in CRC 
tumourigenesis: adherens junction (Jankowski et al., 1997), apoptosis (Prabhudesai et 
al., 2007), cell-cycle (Jackson and Evers, 2009), epidermal growth factor receptor 
(Kumar, 2005), gonadotropin-releasing hormone (GnRH; Szepeshazi et al., 2007), 
hedgehog (Varnat et al., 2009), insulin (Donovan and Kummar, 2008), JAK-STAT 
(Spano et al., 2006), mammalian target of rapamycin (mTOR; Ma and Hidalgo, 
2007), mitogen activated protein kinase (MAP kinase; Fang and Richardson, 2005), 
toll-like receptor (Clevers, 2004), transforming growth factor beta (TGF-ß; Xu & 
Pasche, 2007), vascular endothelial growth factor (Winder and Lenz, 2010) and wnt 
(Macheda and Stacker, 2008) signal transduction cascades. While these pathways 
complement previously discussed associations their identification in only one or more 
cell lines raises questions with regard to the validity of these observations. It currently 
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remains to be established if previously discussed issues concerning the relative 
sensitivity of this PCR-array platform may explain the failure of the advanced 
bioinfomatic techniques utilised in this study to corroborate these additional fourteen 
putative siPROM-1 mediated pathways in all three cell lines. 
 
 
!
!
!
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6.2 CONCLUSION 
 
To summarize, the data reported in this chapter are beginning to build a framework 
for reconstructing a genetic regulatory network affecting four relevant pathways 
identified in all three assessed cell lines from bioinformatic analyses of 11 major 
siPROM–1 mediated transcripts. The discussion of these pathways has established a 
clear rationale for an involvement of PROM-1/CD/AC133 in CRC tumourigenesis as 
well as for the apparent association with poor survival. Additional targets and 
pathways were potentially identified, although not universally affected by PROM-1 
‘knock-down’ treatment across each cell line, due to technical and biological factors 
discussed previously. While PROM-1/CD/AC133 associated differences in cell 
signalling cascade activation may not inevitably reflect causal events of 
carcinogenesis, such changes may, nevertheless, regulate genes important in tumour 
pathogenesis. Further studies will be necessary to corroborate the presented PCR-
array data. 
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7.1  ANALYSIS OF PCR OPEN ARRAY GENE EXPRESSION  
 PROFILES ASSOCIATED WITH siPROM-1 IN COLORECTAL 
 CANCER AND SUB–EPITHELIAL MYOFIBROBLAST CELL 
 LINES. 
 
7.1.1  INTRODUCTION 
 
Regulation of the differentiation / proliferation status of PROM-1/CD/AC133high cells 
is influenced by the notch (Fan et al., 2006), bone morphogenetic protein (Piccirillo et 
al., 2006) and wnt / ß-catenin signalling pathways (Nikolova et al., 2007), all of which 
have well-established roles in all human cell types (Hansson et al., 2004). PCR-array 
data presented in the previous chapter (Chapter 6.3.9) extend the findings of these 
reports by suggesting a role for three additional regulatory networks in PROM-
1/CD/AC133high colorectal cancer (CRC) and colonic sub-epithelial myofibroblast 
cell population (SEMF) cell lines: the central cancer, colorectal cancer, NF-kB and 
p53 signalling pathways. Additionally, Chapter 6.3.9 PCR-array data analyses point 
towards several other cascades as potential targets for PROM-1/CD/AC133 mediated 
signalling, all of which have previously been associated with colorectal 
tumourigenesis by studies using DNA microarray technology: adherens junction 
(Jankowski et al., 1997), apoptosis (Prabhudesai et al., 2007), cell-cycle (Jackson and 
Evers, 2009), epidermal growth factor receptor (Kumar, 2005), gonadotropin-
7 Validation of SIPROM-1 PCR array analyses 
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releasing hormone (Szepeshazi et al., 2007), hedgehog (Varnat et al., 2009), insulin 
(Donovan and Kummar, 2008), JAK-STAT (Spano et al., 2006), MAP kinase (Fang 
and Richardson, 2005), mammalian target of rapamycin (Ma and Hidalgo, 2007), 
transforming growth factor-ß (Xu and Pasche, 2007), toll-like receptor (Clevers, 
2004) and vascular endothelial growth factor (Winder and Lenz, 2010) signalling 
pathways. However, unlike the central cancer, colorectal cancer, NF-kB and p53 
signalling pathways, the evidence for an involvement of these pathways is not 
unequivocal, with inconsistencies observed in the results obtained from the three cell 
lines. These have been discussed in Chapter 6.4. 
 
Although PCR-arrays such as the OpenArray platform utilise parallel qPCR-based 
assays, they are a relatively new technology with little information provided 
concerning primer sequences, extent of primer dimers generating false positive results 
and individual PCR amplification efficiencies. Furthermore, normalisation procedures 
are not necessarily optimal or appropriate for individual tissues or cell types under 
investigation. Reference genes used for normalisation may be differentially regulated, 
hence their use may distort the expression profiles of any genes of interest. Therefore, 
PCR-array data need to be treated with caution, similar to any results obtained from 
microarray studies, which have been widely used for gene expression analyses even 
though issues concerning the sensitivity, accuracy, specificity and reproducibility of 
data generated by this technique have yet to be fully resolved (Carter et al., 2005; Kim 
et al., 2010). To overcome the limitations encountered by microarrays, qPCR assays 
targeting individual candidate genes are usually utilised to render microarray-derived 
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profiles into more accurate and quantitative, clinically relevant data (Murphy et al., 
2009). Therefore, the aim of the work presented in this chapter is to analyse gene 
expression profiles associated with siPROM-1 treatment of CRC and colonic SEMF 
cell lines using a series of more defined qPCR assays. This was performed using the 
recently developed multiplex tandem polymerase chain reaction technique (MT-
PCR), since this procedure allows the rapid, simultaneous evaluation of multiple 
targets at the mRNA level (Stanley and Szewczuk, 2005). Furthermore, primer 
sequences, specificity and amplification efficiencies are well documented for this 
technology.  
 
Consequently, 51 genes (Table 2.4) from pathways proposed to influence PROM-
1/CD/AC133high cell subtypes were selected and assessed in siPROM-1 treated cell 
populations to validate the reported PCR array expression patterns, and ascertain 
potential biological functions for PROM-1/CD/AC133. Ten transcripts assessed by 
Chapter 6 were specifically included (Table 2.4) since they were regulated by 
siPROM-1 in all three cell lines. However, the remaining transcript (HMBS) up-
regulated in all three cell lines by siPROM-1 was excluded, as the assay quantifying 
its expression did not produce reliable results when performed at the experimental 
conditions optimised for the ten major transcripts. An additional 41 genes (Table 2.4) 
with similar experimental conditions to those of the 10 major transcripts were selected 
on the basis of: (i) previous reports in the published literature indicating they were 
down stream targets of PROM-1/CD/AC133 (28 transcripts – 20 assessed by the 
Biotrove platform); (ii) their association with CRC despite no previous reports 
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indicating they were influenced by PROM-1/CD/AC133 status (9 transcripts all 
assessed by the Biotrove platform); and, (iii) a small random selection of targets 
demonstrated in Chapter 6 not to be differentially regulated by siPROM-1 (4 targets), 
in order to challenge the validity of negative results generated by the Biotrove 
platform. 
 
Although every siRNA transfection was accompanied by a scrambled siRNA control, 
this approach cannot exclude off-target effects of PROM-1 siRNA that inadvertently 
influence the expression of genes that are not regulated by CD/AC133 in vivo.  Hence, 
an alternative validation strategy was pursued by sorting near confluent, non-siRNA 
treated CRC and colonic SEMF cell lines into AC133high and AC133low cell 
subpopulations using fluorescence-activated cell sorting (FACS), and determining the 
expression patterns of the 51 target transcripts discussed above. The expectation was 
that if the expression of any of these targets was regulated by CD/AC133, they should 
be differentially expressed between the CD133high and CD133low populations.   
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7.2  MATERIALS AND METHODS 
 
7.2.1  Cell culture 
 
The human CRC cell lines CaCo-2 (HTB37) and HT-29 (HTB38) and the intestinal 
SEMF cell line (CCD18Co) were obtained from the American Type Culture 
Collection and cell culture was performed in accordance with the protocol(s) listed 
previously (Chapter 2.2.1). Cells were harvested at 48 hours after siRNA transfection 
(discussed below). 
 
7.2.2  siRNA transfection 
 
siRNA transfection of CaCo-2, HT-29 and CCD18Co cell lines was undertaken using 
a commercially available pool of synthetic siRNAs targeting different conserved 
regions in the PROM-1 mRNA as per the protocol discussed previously (Chapter 
2.3). Similarly, a pool of four non-targeting siRNAs, were transfected into the cell 
lines as a negative control (Chapter 2.3). The degree of PROM-1 down-regulation in 
transfected cell lines was determined at both the mRNA and protein levels 48 hours 
after transfection (discussed below; Figure 7.1).  
 
7.2.3  RNA extraction and RT-qPCR 
 
Total cellular RNA was extracted and RNA quality was assessed (Chapter 2.4.1; 
Chapter 2.4.2; Chapter 2.4.3). Sequence-specific primers targeting PROM-1 were 
designed using proprietary software, and commercially synthesized in addition to 
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three previously designed reference sequences (B2M: Beta-2-microglobulin; YWHAZ: 
Phospholipase A2; EIF4A2: Eukaryotic translation initiation factor 4A, isoform 2) 
(Chapter 2.4.4). RT-qPCR assays were performed using SYBR-Green chemistry and 
copy numbers quantitated as previously described (Chapter 2.4.4; Chapter 2.4.5). 
Target gene expression was normalised for each sample by converting mRNA copy 
numbers to a ratio, with the target copy number designated as the numerator, and the 
geometric mean of mRNA copy numbers for all three reference genes in that sample 
designated as the denominator. 
 
7.2.4  Western blotting 
 
Whole cell proteins lysates were extracted from tissue samples (Chapter 2.5.1). 
Protein concentrations were determined using the BCA assay (Chapter 2.5.2). 
Samples were analysed by SDS–PAGE and western blotting with a polyclonal mouse 
antibody against human CD/AC133 (Chapter 2.7). Data were imaged and band 
densitometry analyses were performed on a Macintosh computer using the public 
domain NIH Image program (developed at the U.S. National Institutes of Health and 
available on the Internet at http://rsb.info.nih.gov/nih-image). 
 
7.2.5  Flow Cytometry 
 
Cell lines were grown to near confluence, harvested and stained with anti-AC133 
antibody after which AC133 labelling was analyzed by flow cytometry as per 
previous protocol (Chapter 2.8). 
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7.2.6  Multiplexed tandem polymerase chain reaction (MT-PCR) 
 
 
An overview of the multiplexed tandem polymerase chain reaction technique has been 
presented previously (Chapter 2.4.7). RNA was extracted from cell lines as discussed 
above (Chapter 7.2.3). Sample RNA preparations were added to a primer and reagent 
mixture and SYBR-Green chemistry assays undertaken as described (Chapter 2.4.7). 
Transcript expression was normalised for each sample by converting fluorescence 
intensity to a ratio, with the target transcript as the numerator, and the designated 
reference gene (NONO) in that sample as the denominator. 
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7.3  RESULTS 
 
Data have been summarised and are presented for the siPROM-1 experiments 
performed with the CaCo-2 (Figure 7.2 / Table 7.1), HT-29 (Figure 7.3 / Table 7.2) 
and CCD18Co (Figure 7.4 / Table 7.3) cell lines.  
 
Similarly, data are summarised and presented for the FACS experiments sorting the 
following cell lines into AC133high and AC133low subpopulations at two- (D2) and 
seven-days (D7) after culture: CaCo2 (D2: Figure 7.5 / Table 7.4; D7: Figure 7.6 / 
Table 7.4), HT-29 (D2: Figure 7.7 / Table 7.5; D7: Figure 7.8 / Table 7.5) and 
CCD18Co (D2: Figure 7.9 / Table 7.6; D7: Figure 7.10 / Table 7.6). 
 
The relative expression levels of ten major transcripts reported by Chapter 6 are 
presented in Figure 7.11 to demonstrate the level of concordance between the 
Biotrove and MT-PCR technologies. This concordance was further investigated in 
Figure 7.12 by comparing these data with the relative expression levels of the ten 
major transcripts in the AC133high and AC133low subpopulations outlined above.  
 
7.3.1  Relative expression of putative siPROM–1 targets by MT–PCR 
 
The expression profile of 51 putative PROM-1/CD/AC133 target genes was assessed 
in the CaCo–2 cell line following siPROM–1 knock-down (Figure 7.2 / Table 7.1). 
Expression of 15 of the assessed targets was affected by siPROM–1, of which six 
transcripts were up-regulated, with a further nine down-regulated. siPROM-1 
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mediated regulation of two genes previously identified by Biotrove OpenArray 
system analyses (Chapter 6.3.5) could not be corroborated using MT-PCR assays 
(GRB10; EGR1).  
 
Gene expression profiling identified that 14 of the assessed transcripts were 
differentially expressed in HT-29 treated cells as compared with cell populations 
incubated with non-targeting scrambled control sequences (Figure 7.3 / Table 7.2). 
Six of the 14 genes were up–regulated following siPROM-1 knock-down with a 
further eight transcripts down-regulated. siPROM-1 mediated regulation of three 
genes previously identified by Biotrove OpenArray system analyses (Chapter 6.3.5) 
could not be corroborated using MT-PCR assays (HOXB13; EGR1; GRB10). 
 
Finally, the expression profile of 51 putative PROM-1/CD/AC133 target genes was 
assessed in the CCD18Co cell line following siRNA–mediated PROM–1 knock-down 
(Figure 7.4 / Table 7.3). Expression of 15 of the 51 assessed targets was affected by 
siPROM–1, of which ten transcripts were up-regulated with the remaining five down-
regulated. Again, siPROM-1 mediated regulation of three genes previously identified 
by Biotrove OpenArray system analyses (Chapter 6.3.5) could not be corroborated 
using MT-PCR assays (ITGB6; HOXB13; MMP2). 
 
7.3.2  AC133high CaCo-2 MT-PCR gene expression pattern 
 
The expression profile of a total of 51 genes was assessed in CaCo-2 cells, which had 
been FACS sorted into CD/AC133high/low cell populations two- and seven-days after 
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culture. At the two-day time point (Figure 7.5 / Table 7.4), eleven of the assessed 
targets were differentially regulated in CD/AC133high CaCo-2 cells when compared 
with CD/AC133low cells, of which five transcripts were up-regulated by a factor of 
50% or more with the remaining six transcripts down-regulated to a similar degree. 
Five transcripts regulated by siPROM-1 (Chapter 6.3.5) were not differentially 
expressed in CD/AC133high CaCo-2 cells when compared with CD/AC133low cells 
(MMP2; EGR1; IL16; ITGB6; GRB10). 
 
Gene expression profiles were assessed in a similar pattern for CaCo-2 cells harvested 
seven-days after culture, with 20 of the assessed transcripts differentially expressed in 
CD/AC133high when compared with CD/AC133low cells (Figure 7.6 / Table 7.4). Nine 
of the 20 genes were up-regulated in CD/AC133high cells while a further eleven 
transcripts were down-regulated. Three siPROM-1 regulated transcripts (Chapter 
6.3.5) were not differentially regulated in CD/AC133high CaCo-2 cells when compared 
with CD/AC133low cell populations (EGR1; IL16; ITGB6). 
  
7.3.3  AC133high HT-29 MT-PCR gene expression pattern 
 
Nineteen of the assessed genes were differentially regulated in CD/AC133high HT-29 
cells harvested two-days after culture when compared with cells that expressed this 
marker at relatively low levels (Figure 7.7 / Table 7.5). In CD/AC133high cells, eight 
of these transcripts were up-regulated by 50% or more while a further eleven 
transcripts were down-regulated by a similar margin. Three transcripts regulated by 
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siPROM-1 (Chapter 6.3.5) were not differentially regulated in CD/AC133high HT-29 
cells when compared with CD/AC133low cells (HOXB13; EGR1; MMP2). 
 
A total of 17 of the assessed transcripts were differentially expressed in CD/AC133high 
HT-29 cells harvested at seven-days after culture, when compared with CD/AC133low 
cells (Figure 7.8 / Table 7.5). Seven of the 17 genes were up-regulated with ten 
transcripts down-regulated by a factor of at least 50%. Three siPROM-1 regulated 
transcripts (Chapter 6.3.5) were not differentially regulated in CD/AC133high HT-29 
cell populations when compared with CD/AC133low cells (ITGB6; MMP2; HOXB13). 
 
7.3.4  AC133high CCD18Co MT-PCR gene expression pattern 
 
At the day-two time point, 23 of the assessed targets were differentially regulated 
according to CD/AC133 expression in CCND18Co cells (Figure 7.9 / Table 7.6). The 
majority of the transcripts were up-regulated in CD/AC133high cells by a factor of 
50% or more with the remaining eight transcripts down-regulated to a similar extent. 
Three transcripts regulated by siPROM-1 (Chapter 6.3.5) were not differentially 
regulated in CD/AC133high CCND18Co cell populations when compared with 
CD/AC133low cells (MMP2; HOXB13; ITGB6). 
 
Twenty-one of the 51 assessed transcripts were differentially expressed according to 
the presence of the AC133 epitope in CCD18Co cells harvested seven-days after 
culture (Figure 7.10 / Table 7.6). Fifteen of the 21 genes were up-regulated in 
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AC133high cells with the remaining six transcripts down-regulated. Three siPROM-1 
regulated transcripts (Chapter 6.3.5) were again not differentially regulated in 
CD/AC133high CCND18Co cell populations when compared with CD/AC133low cells 
(HOXB13; MMP2; IL16). 
 
7.3.5  Comparison of PCR-array and MT-PCR technology data  
 
When comparing the expression levels of 43 transcripts assessed by both PCR-array 
and MT-PCR technologies, good correlation was noted for a number of genes (Figure 
7.11 – concordant data highlighted by elliptical dotted lines above x-axis). Four of the 
ten major transcripts were identified as up-regulated by both technologies (AKT3; 
BCL2; IL16; MYC). In contrast, one major transcript was consistently demonstrated 
by both technologies to be differentially regulated in different cell lines (TP53 – 
highlighted by elliptical dotted lines above and below x-axis of Figure 7.11; up-
regulated in CaCo-2 & HT-29, down-regulated in CCD18Co). However, PCR-array 
expression analyses of siPROM-1 treated cell lines were not universally validated by 
MT-PCR assays, with expression of five major transcripts discordant between the two 
studies as can be seen in Figure 7.11 (EGR1; GRB10; HOXB13; ITGB6; MMP2). 
 
7.3.6  Biological analysis of MT-PCR technology derived data 
 
The correlation in transcript expression levels identified by both technologies outlined 
above was further investigated for biological validity. This was achieved by 
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performing identical MT-PCR analyses and quantitating expression levels for these 
targets of interest in FACS sorted CD/AC133high/low cell populations (Figure 7.12 / 
Table 7.7). Of the four major transcripts identified as being up-regulated by both 
technologies following siPROM-1 (AKT3; BCL2; IL16; MYC – highlighted by 
elliptical dotted lines in Figure 7.11 & Figure 7.12 above x-axis), three were 
demonstrated to be down-regulated in CD/AC133high cell populations (AKT3; BCL2; 
MYC– highlighted by elliptical dotted lines in Figure 7.12 below x-axis). IL16 
expression was not inversely expressed when comparing siPROM-1 treated and 
CD/AC133high cell populations. TP53 expression levels inversely correlated when 
comparing all three siPROM-1 and CD/AC133high FACS sorted cell lines (highlighted 
by additional elliptical dotted lines above and below x-axis of Figure 7.12). 
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Figure 7.1 (a.) 
 
Figure 7.1 (b.) 
 
 
Figure 7.1 – siPROM-1 knockdown. a.) reverse transcription- quantitative polymerase chain reaction 
(RT-qPCR) demonstrated that siPROM-1 inhibits transcript expression in the assessed cell lines after 
48 hours. The amount of PROM-1 was expressed as a ratio taking expression of PROM-1 in 
siScrambled transfected control cells as the denominator; b.) western blot confirming CD/AC133 
protein knockdown at 48 hours (mean CaCo-2 fold reduction +/- SD: 6.24+/-0.44; HT-29: 3.76+/-0.38; 
CCD18Co: 1.97+/-0.03). All experiments were performed in triplicate with three biological replicates 
per run. Pictograms represent mean values, while error bars denote standard deviation. 
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Figure 7.2 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after siPROM-1 of the CaCo-2 cell line. Cells were harvested at 48 hours after 
RNA silencing. Following mRNA copy number normalisation procedures documented previously 
(Chapter 2.4.7); transcript copy numbers have been presented as a ratio with expression of the 
amplicon in the siPROM-1 treated cells used as the numerator, while that of the siScrambled cells was 
taken as the denominator. Experiments were performed in triplicate with three biological replicates per 
run. Pictograms represent mean values, while error bars denote standard deviation. Asterisks denote 
transcripts concordantly regulated by siPROM-1 in all three cell lines when assessed by Biotrove and 
MT-PCR technologies. 
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Figure 7.3 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after siPROM-1 of the HT-29 cell line. Cells were harvested at 48 hours after RNA 
silencing. Following mRNA copy number normalisation procedures documented previously (Chapter 
2.4.7); transcript copy numbers have been presented as a ratio with expression of the amplicon in the 
siPROM-1 treated cells used as the numerator, while that of the siScrambled cells was taken as the 
denominator. Experiments were performed in triplicate with three biological replicates per run. 
Pictograms represent mean values, while error bars denote standard deviation. Asterisks denote 
transcripts concordantly regulated by siPROM-1 in all three cell lines when assessed by Biotrove and 
MT-PCR technologies. 
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Figure 7.4 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after siPROM-1 of the CCD18Co cell line. Cells were harvested at 48 hours after 
RNA silencing. Following mRNA copy number normalisation procedures documented previously 
(Chapter 2.4.7); transcript copy numbers have been presented as a ratio with expression of the 
amplicon in the siPROM-1 treated cells used as the numerator, while that of the siScrambled cells was 
taken as the denominator. Experiments were performed in triplicate with three biological replicates per 
run. Pictograms represent mean values, while error bars denote standard deviation. Asterisks denote 
transcripts concordantly regulated by siPROM-1 in all three cell lines when assessed by Biotrove and 
MT-PCR technologies. 
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Figure 7.5 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after FACS sorting of the CaCo-2 cell line into CD/AC133high/low subpopulations. 
Cells were harvested at two-days after culture. Following mRNA copy number normalisation 
procedures documented previously (Chapter 2.4.7); transcript copy numbers have been presented as a 
ratio with expression of the amplicon in the CD/AC133high subgroup used as the numerator, while that 
of the CD/AC133low subgroup was taken as the denominator. Experiments were performed in triplicate 
with three biological replicates per run. Pictograms represent mean values, while error bars denote 
standard deviation. Asterisks denote transcripts concordantly regulated by siPROM-1 in all three cell 
lines when assessed by Biotrove and MT-PCR technologies.  
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Figure 7.6 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after FACS sorting of the CaCo-2 cell line into CD/AC133high/low subpopulations. 
Cells were harvested at seven-days after culture. Following mRNA copy number normalisation 
procedures documented previously (Chapter 2.4.7); transcript copy numbers have been presented as a 
ratio with expression of the amplicon in the CD/AC133high subgroup used as the numerator, while that 
of the CD/AC133low subgroup was taken as the denominator. Experiments were performed in triplicate 
with three biological replicates per run. Pictograms represent mean values, while error bars denote 
standard deviation. Asterisks denote the transcripts concordantly regulated by siPROM-1 in all three 
cell lines when assessed by Biotrove and MT-PCR technologies. 
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Figure 7.7 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after FACS sorting of the HT-29 cell line into CD/AC133high/low subpopulations. 
Cells were harvested at two-days after culture. Following mRNA copy number normalisation 
procedures documented previously (Chapter 2.4.7); transcript copy numbers have been presented as a 
ratio with expression of the amplicon in the CD/AC133high subgroup used as the numerator, while that 
of the CD/AC133low subgroup was taken as the denominator. Experiments were performed in triplicate 
with three biological replicates per run. Pictograms represent mean values, while error bars denote 
standard deviation. Asterisks denote the transcripts concordantly regulated by siPROM-1 in all three 
cell lines when assessed by Biotrove and MT-PCR technologies. 
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Figure 7.8 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after FACS sorting of the HT-29 cell line into CD/AC133high/low subpopulations. 
Cells were harvested at seven-days after culture. Following mRNA copy number normalisation 
procedures documented previously (Chapter 2.4.7); transcript copy numbers have been presented as a 
ratio with expression of the amplicon in the CD/AC133high subgroup used as the numerator, while that 
of the CD/AC133low subgroup was taken as the denominator. Experiments were performed in triplicate 
with three biological replicates per run. Pictograms represent mean values, while error bars denote 
standard deviation. Asterisks denote the transcripts concordantly regulated by siPROM-1 in all three 
cell lines when assessed by Biotrove and MT-PCR technologies. 
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Figure 7.9 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after FACS sorting of the CCD18Co cell line into CD/AC133high/low 
subpopulations. Cells were harvested at two-days after culture. Following mRNA copy number 
normalisation procedures documented previously (Chapter 2.4.7); transcript copy numbers have been 
presented as a ratio with expression of the amplicon in the CD/AC133high subgroup used as the 
numerator, while that of the CD/AC133low subgroup was taken as the denominator. Experiments were 
performed in triplicate with three biological replicates per run. Pictograms represent mean values, 
while error bars denote standard deviation. Asterisks denote the transcripts concordantly regulated by 
siPROM-1 in all three cell lines when assessed by Biotrove and MT-PCR technologies. 
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Figure 7.10 – expression of target transcripts as identified by multiplexed tandem polymerase chain 
reaction, performed after FACS sorting of the CCD18Co cell line into CD/AC133high/low 
subpopulations. Cells were harvested at seven-days after culture. Following mRNA copy number 
normalisation procedures documented previously (Chapter 2.4.7); transcript copy numbers have been 
presented as a ratio with expression of the amplicon in the CD/AC133high subgroup used as the 
numerator, while that of the CD/AC133low subgroup was taken as the denominator. Experiments were 
performed in triplicate with three biological replicates per run. Pictograms represent mean values, 
while error bars denote standard deviation. Asterisks denote the transcripts concordantly regulated by 
siPROM-1 in all three cell lines when assessed by Biotrove and MT-PCR technologies. 
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Figure 7.11 – expression patterns of the PROM-1/CD/AC133 target transcripts identified by Chapter 
6. After siPROM-1, total RNA preparations from all three cell lines (CaCo-2; HT-29; and, CCD18Co) 
were analysed using Biotrove and MT-PCR technologies. Technology specific mRNA copy number 
normalisation procedures were performed (Chapter 2.4.6; Chapter 2.4.7) and transcript copy numbers 
were converted to a ratio with expression of the amplicon in the siPROM-1 treated subgroup used as 
the numerator, while that of the negative control siScrambled subgroup was taken as the denominator, 
respectively. Experiments were performed in triplicate with three biological replicates per run. Data 
points represent mean values, while error bars denote standard deviation. Data generated by the 
Biotrove OpenArray system is denoted on the graph legend by the letter B, while multiplexed tandem 
polymerase chain reaction data is denoted on the graph legend by the letter M. Elliptical dotted lines 
highlight targets with concordant expression when assessed by the Biotrove OpenArray system and 
multiplexed tandem polymerase chain reaction technologies as discussed in Chapter 7.3.5 (AKT3, 
BCL2, IL16, MYC, TP53).  
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Figure 7.12 – expression patterns of the PROM-1/CD/AC133 target transcripts identified by Chapter 
6. Data from Figure 7.11 are included in the figure above as before. Multiplexed tandem polymerase 
chain reaction data were compared for all three cell lines (CaCo-2; HT-29; and, CCD18Co) after FACS 
sorting into AC133high and AC133low subpopulations. Following mRNA copy number normalisation 
procedures documented previously (Chapter 2.4.7) transcript copy numbers have been presented as a 
ratio with expression of the amplicon in the AC133high subgroup used as the numerator, while the 
AC133low subgroup was taken as the denominator, respectively. Experiments were performed in 
triplicate with three biological replicates per run. Data points represent mean values, while error bars 
denote standard deviation. The data generated by the MT-PCR system is denoted on the graph legend 
by D2 for preparations from cells two-days after culture, while D7 denotes cell preparations derived 
from cells seven-days after culture. The elliptical dotted lines from Figure 7.11 are present and 
highlight targets with concordant expression when assessed by the Biotrove OpenArray system and 
multiplexed tandem polymerase chain reaction technologies as discussed in Chapter 7.3.5 (above the 
x-axis: AKT3, BCL2, MYC; above and below the x-axis: TP53). However, there are now additional 
elliptical dotted lines that highlight transcripts with differential expression between the CD133high and 
CD133low populations (below the x-axis: AKT3, BCL2, MYC; above and below the x-axis: TP53) that 
provide alternate validation for the data presented in Figure 7.11. 
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Table 7.1 – Gene expression profile of CaCo-2 cells following siPROM-1. Numbers represent mean 
fold changes and standard deviation in siPROM-1 treated cells as compared with siScrambled treated 
cells. Transcripts highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines 
when assessed by Biotrove and MT-PCR technologies. 
 
 
 
 
 
 
 
 
 
symbol expression 
BCL2 up – x 3.3 ± 0.01 
TP53 up – x 3.0 ± 0.02 
AKT3 up – x 2.5 ± 0.03 
IL16 up – x 2.3 ± 0.30 
BUB1 up – x 1.7 ± 0.17 
MYC up – x 1.7 ± 0.03 
USP22 unchanged – x 1.4 ± 0.06 
GRB10 unchanged – x 1.2 ± 0.30 
EGR1 unchanged – x 1.1 ± 0.05 
KNTC2 down – x 2.0 ± 0.17 
POU5F1 down – x 2.0 ± 0.03 
ESR1 down – x 2.0 ± 0.21 
ITGB6 down – x 2.5 ± 0.05 
HIF1A down – x 2.5 ± 0.02 
HOXB13 down – x 5.0 ± 0.01 
MMP2 down – x 5.0 ± 0.03 
MMP9 down – x 5.0 ± 0.03 
NAT1 down – x > 10.0 ± 0.00 
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Table 7.2 – Gene expression profile of HT-29 cells following siPROM-1. Numbers represent mean 
fold changes and standard deviation in siPROM-1 treated cells as compared with siScrambled treated 
cells. Transcripts highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines 
when assessed by Biotrove and MT-PCR technologies. 
 
 
 
 
symbol expression 
AKT3 up – x 5.0 ± 0.07 
IL16 up – x 4.7 ± 0.92 
TP53 up – x 4.5 ± 1.27 
BCL2 up – x 3.5 ± 1.16 
MYC up – x 3.2 ± 0.76 
EGFR up – x 2.4 ± 0.93  
HOXB13 unchanged – x 1.1 ± 0.02 
EGR1 unchanged– x 1.1 ± 0.06 
GRB10 unchanged– x 1.1 ± 0.16 
CCNB1 down – x 2.5 ± 0.13 
HIF1A down – x 2.5 ± 0.22 
ITGB6 down – x 3.3 ± 0.06 
NDRG1 down – x 5.0 ± 0.07 
MMP2 down – x 5.0 ± 0.06 
S100A4 down – x 5.0 ± 0.07 
MMP9 down – x 10.0 ± 0.08 
MMP7 down – x >10.0 ± 0.03 
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Table 7.3 – Gene expression profile of CCD18Co cells following siPROM-1. Numbers represent mean 
fold changes and standard deviation in siPROM-1 treated cells as compared with siScrambled treated 
cells. Transcripts highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines 
when assessed by Biotrove and MT-PCR technologies. 
 
 
 
 
 
 
 
 
 
symbol expression 
GATA3 up – x 6.2 ± 4.30 
GRB10 up – x 5.1 ± 1.45 
EGR1 up – x 5.0 ± 2.23 
DNMT3B up – x 4.9 ± 1.75 
IL16 up – x 4.5 ± 2.09 
MYC up – x 4.4 ± 0.21 
CTNNB1 up – x 3.8 ± 1.43 
AKT3 up – x 3.4 ± 0.11 
BCL2 up – x 3.3 ± 0.36 
CDH2 up – x 2.4 ± 0.75 
ITGB6 unchanged – x 1.1 ± 0.05 
HOXB13 unchanged – x 1.1 ± 0.03 
MMP2 unchanged – x 1.1 ± 0.20 
FGFR2 down – x 5.0 ± 0.16 
S100A4 down – x 5.0 ± 0.17 
TP53 down – x 5.0 ± 0.15 
RNF2 down – x 5.0 ± 0.15 
POU5F1 down – x >10.0 ± 0.04 
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Table 7.4 – Gene expression profile of CaCo-2 cells at day-two and day-seven. Numbers represent 
mean fold changes and standard deviation in AC133high cells as compared with AC133low cells. 
Transcripts highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines when 
assessed by Biotrove and MT-PCR technologies. 
  
 
symbol expression day 2 expression day 7 
CDH2 up – x 8.9 ± 1.15 up – x 2.4 ± 0.76 
TM4SF1 up – x 5.3 ± 1.93 – 
COL1A2 – up – x 3.0 ± 0.17 
S100A2 up – x 2.9 ± 0.37 up – x 2.4 ± 0.76 
ETS1 up – x 2.8 ± 0.51 – 
MMP2 unchanged – x 1.4 ± 0.02  up – x 2.6 ± 0.22 
MMP9 – up – x 2.4 ± 0.05 
PGR – up – x 2.3 ± 0.05 
CDKN1A up – x 2.0 ± 0.13 up – x 2.2 ± 0.79 
NAT1 – up – x 2.0 ± 0.08 
GRB10 unchanged – x 1.1 ± 0.01 up – x 1.6 ± 0.00 
EGR1 unchanged – x 1.3 ± 0.05 unchanged – x 1.1 ± 0.01 
IL16 unchanged – x 1.3 ± 0.02 unchanged – x 1.1 ± 0.07 
ITGB6 unchanged – x 1.3 ± 0.02 unchanged – x 1.1 ± 0.07 
BUB1 – unchanged – x 1.4 ± 0.07 
HOXB13 down – x 2.0 ± 0.01 down – x 2.0 ± 0.03 
TP53 down – x 2.2 ± 0.23 down – x 2.1 ± 0.01 
S100A4 down – x 1.7 ± 0.07 down – x 2.5 ± 0.00 
BCL2 down – x 2.5 ± 0.24 down – x 2.1 ± 0.05 
GBX2 – down – x 3.3 ± 0.02 
CES1 – down – x 3.3 ± 0.01 
TERT – down – x 3.3 ± 0.01 
ESR1 – down – x 5.0 ± 0.02 
POU5F1 – down – x 5.0 ± 0.01 
MYC down – x 2.0 ± 0.02 down – x 5.0 ± 0.01 
AKT3 down – x 3.3 ± 0.06 down – x 10 ± 0.00 
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Table 7.5 – Gene expression profile of HT-29 cells at day-two and day-seven. Numbers represent 
mean fold changes and standard deviation in AC133high cells as compared with AC133low cells. 
Transcripts highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines when 
assessed by Biotrove and MT-PCR technologies. 
 
symbol expression day 2 expression day 7 
CDH2 – up – x 4.0 ± 0.78 
S100A2 up – x 3.4 ± 0.40 up – x 3.4 ± 0.23 
TERT up – x 3.0 ± 0.07 – 
MUC1 up – x 2.2 ± 0.09 up – x 2.6 ± 0.05 
SPP1 – up – x 2.6 ± 0.07 
DNMT3B – up – x 2.5 ± 0.01 
IL16 up – x 1.6 ± 0.13 up – x 2.4 ± 0.01 
CDKN1A – up – x 2.2 ± 0.09 
ESR1 up – x 1.8 ± 0.11 – 
NAT1 up – x 1.6 ± 0.04 – 
POU5F1 up – x 1.6 ± 0.01 – 
ITGB6 up – x 1.5 ± 0.02 unchanged – x 1.4 ± 0.04 
HOXB13 unchanged – x 1.2 ± 0.10 unchanged – x 1.4 ± 0.05 
MMP2 unchanged – x 1.3 ± 0.06 unchanged – x 1.2 ± 0.05 
EGR1 unchanged – x 1.0 ± 0.02 down – x 2.0 ± 0.15 
FGFR2 down – x 2.0 ± 0.04 down – x 2.2 ± 0.07 
KNTC2 down – x 2.5 ± 0.04 – 
TP53 down – x 2.7 ± 0.23 down – x 2.1 ± 0.07 
BCL2 down – x 3.3 ± 0.05 down – x 3.3 ± 0.21 
AKT3 down – x 3.3 ± 0.01 down – x 3.3 ± 0.04 
GRB10 down – x 2.0 ± 0.10 down – x 5.0 ± 0.05 
HCFC1 down – x 5.0 ± 0.01 down – x 2.5 ± 0.07 
S100A4 down – x 5.0 ± 0.01 down – x 5.0 ± 0.01 
MYC down – x 2.4 ± 0.23 down – x 10.0 ± 0.00 
CES1 down – x 2.5 ± 0.06 down – x 10.0 ± 0.00 
BUB1 down – x 10 ± 0.14 – 
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Table 7.6 – Gene expression profile of CCD18Co cells at day-two and day-seven. Numbers represent 
mean fold changes and standard deviation in AC133high cells as compared with AC133low cells. 
Transcripts highlighted in bold are concordantly regulated by siPROM-1 in all three cell lines when 
assessed by Biotrove and MT-PCR technologies. 
 
 
 
 
 
symbol expression day 2 expression day 7 
KNTC2 up – x 8.7 ± 0.32 up – x 4.3 ± 0.29 
GRB10 up – x 6.5 ± 0.07 up – x 3.4 ± 0.04 
HCFC1 up – x 3.1 ± 0.00 up – x 6.1 ± 0.41 
POU5F1 up – x 3.4 ± 0.05 up – x 4.4 ± 0.57 
SPP1 – up – x 3.9 ± 0.72 
BUB1 – up – x 3.7 ± 0.10 
S100A4 up – x 3.5 ± 0.02 up – x 2.6 ± 0.18 
TERT up – x 3.5 ± 0.00 – 
FGFR2 up – x 2.6 ± 0.07 – 
ITGB6 unchanged – x 1.4 ± 0.23 up – x 2.6 ± 0.13 
RNF2 up – x 2.5 ± 0.10 – 
CTNNB1 up – x 2.3 ± 0.00 up – x 2.5 ± 0.32 
ERBB2 up – x 2.2 ± 0.10 up – x 2.2 ± 0.10 
ESR1 up – x 2.1 ± 0.03 up – x 2.2 ± 0.07 
CDH2 up – x 2.1 ± 0.03 up – x 2.1 ± 0.02 
MK167 – up – x 2.1 ± 0.14 
ETS1 up – x 2.1 ± 0.07 up – x 2.1 ± 0.10 
TP53 up – x 2.1 ± 0.02 up – x 1.6 ± 0.13 
IL16 up – x 1.5 ± 0.07 unchanged – x 1.4 ± 0.23 
HOXB13 unchanged – x 1.3 ± 0.36 unchanged – x 1.2 ± 0.01 
MMP2 unchanged – x 1.1 ± 0.02 unchanged – x 1.1 ± 0.05 
EGR1 down – x 2.0 ± 0.07 down – x 2.0 ± 0.07 
BCL2 down – x 3.3 ± 0.26 down – x 2.5 ± 0.12 
DNMT3B down – x 3.3 ± 0.02 down – x 2.5 ± 0.00 
HGF down – x 3.3 ± 0.02 – 
NDRG1 down – x 3.3 ± 0.02 – 
AKT3 down – x 3.3 ± 0.02 down – x 3.3 ± 0.02 
CDH1 down – x 3.3 ± 0.06 down – x 3.3 ± 0.00 
MYC down – x 5.0 ± 0.07 down – x 3.1  ± 0.07 
  J Murphy – Chapter 7 
 
 
_____________________________________________________________________ 
 
307 
 
 
 
Table 7.7 – expression patterns of the PROM-1/CD/AC133 target transcripts identified during the 
experiments reported within both Chapter 6 & 7. Data generated by the Biotrove OpenArray system 
and multiplexed tandem polymerase chain reactions were compared for each cell line (CaCo-2; HT-29; 
and, CCD18Co) following siPROM-1. MT-PCR data are presented following FACS sorting of each 
cell line into CD/AC133high/low subpopulations at two- and seven-days after culture. 
 
 
 
 
 
 
 
 
 
 
symbol siPROM-1 
biotrove 
siPROM-1   
mt-pcr 
mt-pcr day 2 
AC133high 
mt-pcr day 7 
AC133high 
AKT3 – CaCo-2 up – x 2.4 ± 0.3 up – x 2.5 ± 0.03 down – x 3.3 ± 0.06 down – x 10 ± 0.00 
AKT3 – HT-29 up – x 3.3 ± 0.1 up – x 5.0 ± 0.07 down – x 3.3 ± 0.01 down – x 3.3 ± 0.04 
AKT3 – CCD18Co up – x 8.7 ± 4.0 up – x 3.4 ± 0.11 down – x 3.3 ± 0.02 down – x 3.3 ± 0.02 
     
BCL2 – CaCo-2 up – x 4.0 ± 1.7 up – x 3.3 ± 0.01 down – x 2.5 ± 0.24 down – x 2.1 ± 0.05 
BCL2 – HT-29 up – x 2.4 ± 0.2 up – x 3.5 ± 1.16 down – x 3.3 ± 0.05 down – x 3.3 ± 0.21 
BCL2 – CCD18Co up – x 6.5 ± 0.6 up – x 3.3 ± 0.36 down – x 3.3 ± 0.26 down – x 2.5 ± 0.12 
     
MYC – CaCo-2 up – x 3.0 ± 0.1 up – x 1.7 ± 0.03 down – x 2.0 ± 0.02 down – x 5.0 ± 0.01 
MYC – HT-29 up – x 5.0 ± 0.6 up – x 3.2 ± 0.76 down – x 2.4 ± 0.23 down – x 10.0 ± 0.00 
MYC – CCD18Co up – x 4.8 ± 1.7 up – x 4.4 ± 0.21 down – x 5.0 ± 0.07 down – x 3.1  ± 0.07 
     
TP53 – CaCo-2 up – x 2.7 ± 0.4 up – x 3.0 ± 0.02 down – x 2.2 ± 0.23 down – x 2.1 ± 0.01 
TP53 – HT-29 up – x 2.9 ± 0.9 up – x 4.5 ± 1.27 down – x 2.7 ± 0.23 down – x 2.1 ± 0.07 
TP53 – CCD18Co down – x 6.1 ± 0.0 down – x 5.0 ± 0.15 up – x 2.1 ± 0.02 up – x 1.6 ± 0.13 
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7.4  DISCUSSION 
 
In this study, MT-PCR analyses of siPROM–1 treated cell lines were performed in an 
attempt to validate PCR-array data presented previously. The results clearly identify 
four target genes that are associated with CD/AC133 expression: AKT3, BCL2, IL16 
and MYC. Concordance between these two technologies was also demonstrated for 
the TP53 transcript, with up-regulation noted in the CaCo-2 and HT-29 CRC cell lines 
and down-regulation in CCD18Co SEMF cells. This is an intriguing result, as CaCo-2 
and HT-29 cell lines harbour TP53 mutations (Mariadason et al., 2003) and thus a 
differential response between these CRC cell populations and immortalised ‘normal’ 
SEMFs perhaps is in someway to be expected. A further four transcripts were 
demonstrated by both the Biotrove and MT-PCR platforms to be independent of 
siPROM-1 (ARAF; ELK4; FAD; FST). In contrast, five differentially expressed targets 
identified by the PCR-array were not validated by the MT-PCR experiments (EGR1; 
GRB10; HOXB13; ITGB6; MMP2). 
 
Consequently, an overall concordance of 21% (9/43) was demonstrated between these 
technologies. Considering that both are significantly different in terms of reagents, 
methodology as well as normalisation procedures, this provides strong support for a 
association between PROM-1/CD/AC133 status and AKT3, BCL2, IL16, MYC and 
TP53 expression. The biological significance of the associations reported in this 
chapter was further investigated by performing MT-PCR assays to quantitate 
expression of the AKT3, BCL2, IL16, MYC and TP53 transcripts in PROM-
1/CD/AC133high cell subpopulations. The expectation from the PCR-array data was 
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that AKT3, BCL2, IL16 and MYC should be down regulated in all three cell lines, 
whereas TP53 should be down regulated in the CRC cell lines and up-regulated in the 
SEMF cell line. With the exception of IL16, the presented results confirm these 
predictions and demonstrate that expression levels of four targets of interest were as 
expected (Table 7.7), further increasing the likelihood that these findings represent 
biologically significant results. 
 
A critical appraisal of these data gives rise to several strands that support the premise 
that CD/AC133 expression may play an important direct regulatory role in CRC 
tumourigenesis: (i) siPROM-1 mediated AKT signalling demonstrated in Chapter 6 & 
7 suggests this marker may be important for both initiation and progression of CRC; 
(ii) siPROM-1 up-regulation of BCL2 may indicate PROM-1/CD/AC133 influences 
CRC progression, via ectopic expression of the BCL2 anti-apoptotic protein, resulting 
in increased metastatic capacity of cancer cells by inhibiting anoikis and amorphosis; 
(iii) siPROM-1 deregulation of MYC mediated signalling may imply that PROM-
1/CD/AC133 is capable of increasing the cellular motility of extravasating and 
intravasating cells; and finally, (iv) that siPROM-1 interaction with the tumour 
suppressor p53 protein (TP53) may suggest a possible role for PROM-1/CD/AC133 in 
direct control of the cell cycle, apoptosis and DNA repair. 
 
The AKT pathway (Figure 7.13) has been implicated in tumourigenesis and the 
progression of numerous human tumours, since AKT regulates many of the key 
effector molecules involved in apoptosis, anoikis, and cell cycle
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Figure 7.13 – AKT pathway (BioCarta http://www.biocarta.com). AKT promotes cell survival and 
opposes apoptosis by a variety of routes. Phosphatidylinositol (3,4,5)-triphosphate (PIP3) signalling 
activates phosphoinositide-dependent kinase-1 (PDK1), which in turn activates AKT. Proteins 
phosphorylated by activated AKT promote cell survival. Phosphorylation of I-Kappa-B (I-kB) leads to 
activation of the transcription factor NF- Kappa-B (NF-kB), which in turn opposes apoptosis. BCL2-
associated agonist of cell death (BAD) is a protein in the BCL2 gene family that opposes BCL2 in 
order to induce apoptosis. Phosphorylation of BAD by AKT blocks its anti-apoptotic activity to 
promote cell survival. Similarly, phosphorylation of the Caspase-9, or Forkhead, transcription factor(s) 
by AKT blocks their induction of apoptosis.  
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progression (Cantley and Neel, 1999). The AKT signalling cascade has also been 
attributed an important role in the regulation of colorectal tumourogenesis and CRC 
growth. It is an integral downstream target of the phosphatidylinositol-3-kinase–
AKT–mTOR pathway (Figure 7.13), which was proposed in the previous chapter to 
be an siPROM-1 mediated signalling cascade in the HT-29 cancer cell line (Table 
6.58). AKT activity may be varied by negative regulation of phosphatidylinositol-3-
kinase levels brought about by inactivation of the PTEN tumour suppressor protein 
(Cantley and Neel, 1999). AKT also blocks p53 (Whiteside, 2007) and controls cell 
survival pathways via phosphorylation of downstream targets that include NF-kB 
(Ozes et al., 1999), an siPROM-1 mediated pathway in all three assessed cell lines 
(Table 6.58). However, the prognostic significance of AKT activation in CRC 
remains unclear as this has been associated with decreased survival by some authors 
(Lugli et al., 2006; Kato et al., 2007; Schmitz et al., 2007; Colakoglu et al., 2008) 
while a much larger and more recent study suggests that AKT signalling is associated 
with favourable outcome data (Baba et al., 2011). Therefore, activation of the AKT 
signalling cascade by PROM-1/CD/AC133 might plausibly explain the malignant 
behaviour of CRC through increased cell survival, proliferation, tumour cell invasion 
and peritumoural angiogenesis (Khaleghpour et al., 2004). This hypothesis is also 
supported by a publication utilising DNA microarray technology demonstrating that 
AKT pathway activation enhances the tumourigenicity of CD133high CRC cells 
(Wang et al., 2010), although this study used an antibody that targets a CD133 
glycosylated epitope (CD/AC141) other than AC133. However, any discussion at the 
present time concerning the prognostic significance of AKT mediated signalling, 
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based on the data derived from these CRC cell lines, would be highly speculative and 
further studies will be required to investigate this matter. In contrast, PROM-
1/CD/AC133 mediated regulation of the AKT pathway in a SEMF cell line supports a 
possible role for PROM-1/CD/AC133 as a marker of actively replicating SEMF cells, 
in keeping with reports for cancer cell lines (Jaksch et al., 2008), especially given the 
role for AKT in cellular processes such as cell survival and proliferation that have 
been outlined above.   
 
The proto-oncogene BCL2 (Figure 7.14), a 24-kDa intracellular membrane protein 
that is able to inhibit programmed cell death without affecting cell proliferation, has 
been demonstrated to influence a wide range of signalling cascades, in addition to its 
more generally appreciated anti-apoptotic function. BCL2 has also been implicated in 
pathways central to tumourogenesis, including promotion of metastasis formation 
(Martin and Leder, 2001; Schmitt et al., 2002; Pinkas et al., 2004; Choi et al., 2005) 
and peritumoural angiogenesis via modulation of vascular endothelial growth factor 
expression (Biroccio et al., 2000). Moreover, increased expression of BCL2 has also 
been reported in colorectal adenocarcinoma and its precursor lesions (Bronner et al., 
1995). BCL2 also has an emerging role in immunosilencing, with inhibition of this 
apoptotic regulatory protein demonstrated to provide an antitumoural response to 
activated immune cells (Lickliter et al., 2007). Many drug-resistant or apoptotisis-
resistant cancers such as B-cell lymphoma, gastric and lung cancer are associated with 
BCL2 deregulation (Vanden et al. 2003; Zhu et al., 2011). Therefore, it is 
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Figure 7.14 – BCL2 pathway (BioCarta http://www.biocarta.com). BCL2 promotes cell survival and 
opposes apoptosis by a variety of mechanisms. The function of the pro-apoptotic molecule BCL2-
associated agonist of cell death (BAD) is regulated by phosphorylation of three sites (Serine 112, 136 
and 155) resulting in it losing the ability to heterodimerize with the survival proteins BCL2-like protein 
1 (BCLXL) or BCL2. Phosphorylated BAD binds to the 14-3-3 protein and is sequestered in the 
cytoplasm. While Serine-136 phosphorylation is concordant with the activation of AKT, Serine-112 
phosphorylation requires activation of the RAS-mitogen-activated protein kinase pathway, which is 
also an important pathway in CRC. 
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unsurprising that a number of clinical studies have been published evaluating the use 
of BCL2 expression as a prognostic marker in CRC (Bosari et al., 1995; Ofner et al., 
1995; Sinicrope et al., 1995; Baretton et al., 1996; Bhatavdekar et al., 1997). Review 
of the associations described above supports a putative role for PROM-1/CD/AC133 
mediated regulation of BCL2 in CRC subpopulations, which may enhance avoidance 
of cell death, dampen anti-tumour immune response and decrease the efficacy of 
chemotherapeutic agents. PROM-1/CD/AC133 mediated regulation of the BCL2 
transcript in the CCD18Co cell line may strengthen the possible role for PROM-
1/CD/AC133 as a marker of actively replicating SEMF cells (Jaksch et al., 2008) 
discussed in the previous paragraph. The widely established anti-apoptotic function 
attributed to BCL2, which is critical for accurate regulation of somatic progenitor cell 
activity in order to maintain long-term maintenance of tissue homeostasis, particularly 
supports this hypothesis. However, further work will be necessary to fully investigate 
this premise. 
 
Similarly, MYC (Figure 7.15) influences a plethora of effectors of tumourigenesis 
through its proto-oncogene function as a global regulator of transcription (He et al., 
1998; van de Wetering et al., 2002; Sansom et al., 2004). MYC has been reported as a 
transcriptional regulator that controls approximately 15% of the genome, including 
genes involved in: apoptosis, cell cycle regulation, metabolism, ribosome biogenesis, 
protein synthesis, and mitochondrial function (Dang et al., 2006). MYC also acts as a 
transcriptional repressor of genes involved in cell adhesion and growth (Dang et al., 
2006) and has been shown to regulate numerous additional critical processes  
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Figure 7.15 – Example of a pathway mediated by MYC signalling (BioCarta 
http://www.biocarta.com). Telomeres, which define the ends of chromosomes, consist of short, 
tandemly repeated DNA sequences that are loosely conserved in eukaryotes. These regions protect the 
end of the chromosome from deterioration or from fusion with neighbouring chromosomes. 
Telomerase is a ribonucleoprotein complex that recognizes the single-stranded guanine-rich telomere 
region and adds DNA sequence repeats to the 3' end of DNA strands. This overcomes the shortening of 
telomere region that occurs when a cell divides via mitosis and prevents cellular senescence. The 
telomerase protein has a high turnover rate and its expression is regulated by factors that promote 
growth including the MYC proto-oncogene. It appears that the regulation of active telomerase occurs at 
many levels. Additional modulation is due to phosphorlyation by Protein kinase C and AKT or 
dephosphorylation by Protein phosphatase 2. 
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including cellular proliferation, DNA repair and angiogenesis (Dang et al., 2006; 
Dominguez-Sola et al., 2007). The central role of MYC in colorectal carcinogenesis is 
demonstrated by its function as a target of the wnt signalling cascade via regulation by 
TCF4, which is a downstream effector of nuclear β-catenin signalling (Gordon, 1998). 
Furthermore, APC mutations in CRC produce increased β-catenin / TCF4 activity, 
leading to over-expression of MYC and promotion of neoplastic growth (He et al., 
1998). Elevated expression of the MYC proto-oncogene also occurs frequently in 
primary human CRC when compared with normal colonic mucosa (Erisman et al., 
1985) with some evidence suggesting MYC is up-regulated in metastatic CRC (Yang 
et al., 1996). In addition, the regulatory mechanism controlling expression of this 
transcript is altered in a number of CRC tumour-derived cell lines (Erisman et al., 
1985) with down-regulation of MYC inhibiting CRC cell line growth, inducing 
apoptosis and increasing the cell subpopulation in the G0 – G1 phase (Hongxing et 
al., 2008). Given the excess of functions that MYC influences which are central to 
tumourigenesis, it might be hypothesised that siPROM-1 mediated regulation of this 
transcription factor demonstrates the pivotal function of PROM-1/CD/AC133 in CRC 
signalling. The previously discussed role for PROM-1/CD/AC133 as a marker of 
actively replicating SEMF cells is also reinforced by siPROM-1 mediated regulation 
of the MYC transcript in CCD18Co cells, especially in light of its function as a global 
regulator of transcription, which is fundamental for strict regulation of cellular 
proliferation in replicating normal tissues. 
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Figure 7.16 – p53 pathway (BioCarta http://www.biocarta.com). p53 is a transcription factor regulated 
by phosphorylation. The function is p53 is to prevent the cell from progressing through the cell cycle if 
there is damage to DNA present. It performs this task by a variety of routes, including cell cycle arrest 
until adequate DNA repairs can be made, or by causing the cell to initiate apoptosis if the damage 
cannot be repaired. The critical role of p53 is evidenced by the fact that it is mutated in a very large 
fraction of tumours from nearly all sources, including CRC. 
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Finally, siPROM-1 was also demonstrated to regulate expression of the transcription 
factor TP53. This target encodes a nuclear protein that is regarded as one of the most 
important tumour suppressor genes, responsible for a number of key intra-cellular 
functions including: DNA repair, initiation of apoptosis and cell cycle checkpoint 
control (Russo et al., 2005). Phosphorylation of the TP53 (Figure 7.16) product 
results in stabilisation of the protein, which then acts transcriptional regulator for a 
variety of genes that cause cell-cycle arrest such as p21 and genes involved in 
mediating apoptosis including BCL2 (Hemann and Lowe, 2006). The TP53 transcript 
was up-regulated in the CaCo-2 and HT-29 CRC cell lines which harbour innate TP53 
mutations (Mariadason et al., 2003): CaCo-2 cell line - G to T mutation of codon 204; 
HT-29 cell line - G to A mutation in codon 273 (ATCC, Virginia, USA). TP53 
mutations are frequent events in primary CRC; furthermore, they are often associated 
with the CIN phenotype and are inversely correlated with the MSI tumour phenotype 
(Elsaleh et al., 2001; Westra et al., 2005). While TP53 mutations have been widely 
studied by a number of investigators, reported associations with prognosis and 
response to adjuvant chemotherapy have been contradictory (Petersen et al., 2001; 
Munro et al., 2005). However, studies that detected TP53 mutations by gene 
sequencing technology, rather than immunohistochemical techniques, report an 
association with poor prognosis in CRC patients (Goh et al., 1995; Russo et al., 2005; 
Westra et al., 2005). Therefore, PROM-1/CD/AC133 activation or suppression of 
mutant p53 signalling may in part explain reports linking over-expression of PROM-
1/CD/AC133 and a poor prognosis for CRC, since failure to activate wild-type p53 
dependent downstream targets may ultimately result in tumourigenesis and / or 
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tumour progression. In contrast, the ‘normal’ phenotype CCD18Co SEMF cell line 
expresses wild-type TP53, which has been demonstrated by this study to also be 
regulated by PROM-1/CD/AC133. TP53 regulation by PROM-1/CD/AC133 may 
support a role for this protein in the strict control of cellular proliferation that is 
required in actively replicating normal tissues, through influence upon p53 dependent 
downstream targets that regulate the cell cycle, apoptosis and DNA repair. 
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7.5 CONCLUSION 
 
The results of the MT-PCR data presented in this chapter corroborate the differential 
expression of five target genes implicated in Chapter 6 for the first time as being 
regulated by PROM-1/CD/AC133. The reliability of this association, and the 
biological relevance of this finding, is further enhanced by the FACS-sorting 
experiments, that resulted in concordant expression patterns for four of the five-target 
genes in AC133high and AC133low sub populations. Importantly, these specify 
transcripts reported to be involved with tumour cell plasticity, self-renewal, and 
cellular migration, suggesting that CD/AC133 could play a role in influencing the 
critical properties of CRC cells. 
 
Although, many of the targets identified by the Biotrove PCR-array platform were not 
corroborated by MT-PCR assays, this is not surprising, since the methods used are 
radically different technologies and utilise different methods for data normalisation 
and analysis. Nevertheless, this makes it even more likely that the concordant 
expression of approximately 21% of targets assessed by these technologies represents 
biological significant results.  
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8.1 CHAPTER 3: ASSOCIATION BETWEEN PROM-1/CD/AC133 
EXPRESSION AND COLORECTAL TUMOURIGENESIS / METASTASIS 
 
 
8.1.1 Discussion 
 
Effective treatment for cancer patients requires a systematic understanding of the 
molecular mechanisms that lead to tumour development and drug resistance. The 
cancer stem-cell (CSC) hypothesis provides a practical explanation, albeit in need of 
constant refinement, for the cellular heterogeneity, aggressiveness and treatment 
resistance of most cancers (Pietras, 2011). CSCs are capable of self-renewal and 
multi-lineage differentiation and have been proposed as the initiators of tumour 
growth and subsequent metastasis. In several cancers, putative CSCs have been 
identified using a range of markers, including PROM-1/CD/AC133 (reviewed in 
Chapter 4). However, the appropriateness of this and other markers remains an open 
question. Read et al. have identified a tumour-initiating cell population that does not 
have the stem-like properties normally seen in CSCs, namely the ability to grow 
spheres in suspension culture (Read et al., 2009), while other authors report 
phenotypic heterogeneity among tumourigenic cells that is both reversible and not 
hierarchically organized (Quintana et al., 2010). Clearly, tumour initiation is not a 
8 DISCUSSION  
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property exclusive to CSCs, but rather applies to certain populations of non-stem 
cancer cells that make up the tumour mass. 
 
CD133 is the first member of a class of novel pentaspan membrane proteins, also 
named Prominin for its prominent location on the protrusions of cell membranes 
(Miraglia et al., 1997; Weigmann et al., 1997; Fargeas et al., 2003a). Its physiological 
function remains unknown: originally classified as a marker of primitive 
haematopoietic and neural stem-cells, PROM-1/CD/AC133 expression has been 
widely reported in relation to somatic stem-cells, and has been proposed as a marker 
inherent to a number of types of cancer stem / initiating cells (Bauer et al., 2008; 
Burkert et al., 2008; Keysar et al., 2010). However, other reports suggest that it is 
widely expressed in differentiated tissues, questioning its function as a marker for 
CSCs (Weigmann et al., 1997; Corbeil et al., 1998; Florek et al., 2005; Immervoll et 
al., 2008; Karbanová et al., 2008; Shmelkov et al., 2008; Zhu et al., 2009; Meregalli et 
al., 2010). At least five monoclonal antibodies have been raised against CD133 
(Hermansen et al., 2011). The most commonly used are AC133 and 293C/AC14, 
which are reported to recognise distinct epitopes (Green et al., 2000). AC133 was 
originally suggested to recognise a glycosylated epitope of CD133 that contains eight 
putative N-linked glycosylation sites (Miraglia et al., 1997) until work by Kemper et 
al. indicated that this was not the case (Kemper et al., 2010). However, a recent study 
has cast doubt upon this premise by suggesting CD133 N-glycosylation processing 
may still contribute to the post-translational structure of this marker (Mak et al., 
2011).  
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In colorectal cancer (CRC), studies assessing the function of colorectal tumour cells 
expressing AC133 originally suggested that this marker enriches tumour populations 
for CSCs, with the AC133high subtype representing approximately 2.5% of the total 
tumour population (O'Brien et al., 2007; Ricci-Vitiani et al., 2007). These studies 
proposed that this cell subtype is likely to initiate tumour development and subsequent 
metastasis, although only 1 in 262 of this AC133high cell sub-population was thought 
to represent bona fide tumour initiating cells (O'Brien et al., 2007). More recently the 
role of the AC133high subtype in CRC tumourigenesis has been linked to its enhanced 
interaction with the peri-tumoural stromal microenvironment in general, and cancer 
associated SEMF populations in particular (Chao et al., 2012). Early reports 
suggesting that AC133 enriches CRC populations for CSCs initially gained 
widespread acceptance (O'Brien et al., 2007; Ricci-Vitiani et al., 2007), since they 
support the currently accepted model of tumourigenesis – arrested differentiation of 
tissue-based stem-cells. This implies CRC is a disease of deregulated self-renewal, as 
this cell population is the only subtype with a documented ability to self-renew 
(Radtke et al., 2005). However, the utility of PROM-1/CD/AC133 as a marker for 
CRC-CSCs has been challenged, with some authors reporting that both primary 
PROM-1/CD/AC133high and metastatic- PROM-1/CD/AC133low CRC cells initiate 
colorectal tumours in immunodeficient mouse models (Shmelkov et al., 2008). 
Similar results have also been reported when using CRC cell lines to instigate 
tumourigenesis in immunodeficient animal models (Tsurumi et al., 2010). 
 
The many contradictory results published in the scientific literature have cast some 
doubt on the universal validity of the CSC hypothesis in general, and the role of   
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CD/AC133 in particular. It certainly is clear that CSCs do not comprise only PROM-
1/CD/AC133high cells, but also a heterogeneous PROM-1/CD/AC133low population 
expressing a wide range of markers (Soeda et al., 2009; Tsurumi et al., 2010). Work 
by Chen et al. suggests that CSCs are organized in a three-tiered hierarchy similar to 
endogenous stem-cells, where generally slow-dividing sphere-forming “stem-cells” 
higher up in the hierarchy could differentiate into a more lineage restricted 
“progenitor” population at the bottom of the hierarchy that generally divides faster, 
but produces a slower and less expansive tumour growth in vivo that correlates with 
low tumour grade (Chen et al., 2010). On the other hand, other recent studies have 
demonstrated that drug-induced genomic instability in cancer cells can drive the 
emergence of PROM-1/CD/AC133high CSCs (Liang et al., 2009; Achuthan et al., 
2011) and that these CSCs constitute a volatile population arising from the profound 
epigenetic instability of cancer cells (Sharma et al., 2010). Importantly, the former 
study by Liang et al. also demonstrated that cancer cell ‘stemness’ can be turned on 
and off through DNA methylation. This helps explain both the volatility of the CSC 
population and how a CSC phenotype can emerge from seemingly non-stem cancer 
cells. These last three studies provide evidence for the clonal evolution hypothesis, 
which suggests that all cancer cells can initiate tumour formation and that the tumour 
initiating cells are only a product of the profound genomic instability of cancer cells. 
Triggers of genomic instability could arise from the dysfunctional DNA repair 
machinery and mitotic checkpoints in cancer cells, causing random mutations to 
emerge in the genome. Hence the inherent genomic instability of cancer cells results 
in phenotypic changes as adaptive responses to environmental pressures, such as 
Mycoplasma Hyorhinis infection (Mariotti et al., 2010) or oxygen tension (Platet et 
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al., 2007). Genomic instability has also been demonstrated to influence CSC 
chemosensitivity (Liang et al., 2009; Lee et al., 2011). While conventional cytotoxic 
chemotherapy targets rapidly dividing cells, slowly proliferating CSCs enriched with 
multidrug-resistant proteins may escape cell death. The resulting volatile PROM-
1/CD/AC133high CSCs tumour cell population may account for the failure of current 
adjuvant anti-cancer treatments to cure micro-metastatic disease, with clinically 
evident local recurrence and / or systemic metastases developing thereafter (Ahuja, 
2012). 
 
Of course, it is likely that both the CSC and clonal evolution hypotheses can be 
combined into a unified model, where the emergence of a CSC is the result of the 
inherent genomic and epigenetic instability of tumour cells in response to selective 
pressures in vivo, after which the CSCs can undergo continuous self-renewal and 
multi-lineage differentiation to produce heterogeneous cell populations that make up 
the tumour mass. In this view CSC are not “masterminds” of cancer initiation and 
aggressive progression, but instead act as “accessories in crime” to enable most 
tumours to undergo malignant progression, and to resist conventional anti-cancer 
treatments. An important consequence of this unified theory is that even precise 
targeting of CSCs may not eradicate the tumour, since it is not CSCs per se, but the 
inherent genomic and epigenetic instability of cancer cells from which CSCs arise that 
brings about tumour survival and metastasis (Figure 8.1). 
 
The studies conducted by our group clarify some of these issues and at the same time 
provide an interesting insight into the potential pitfalls associated with molecular
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Figure 8.1 - schematic representation of the initiation of malignant transformation in normal colon 
(adapted from Lagasse, 2008). Genomic instability results in the development of a cancer stem cell 
following the mutation of normal somatic cell (red external ring). Genomic instability accelerates the 
development of many genetically variable cancer stem cells. Upon exposure to chemotherapeutic 
agents, selection takes place and resistant cancer stem cells emerge following treatment. 
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techniques. RT-qPCR assays suggest a ubiquitous presence of PROM-1 mRNA (R.E. 
Hands, PhD 2010 University of London), and whilst this is consistent with my own 
complementary western and immunohistochemistry data as well as some published 
reports, the results are clearly different from those reported in some other 
publications. A detailed and critical analysis of the RT-qPCR data quantifying 
PROM-1 shows that, whilst there are differences in mRNA levels, there is also 
considerable overlap between the different tissue types (normal, tumour, metastases), 
making its quantification somewhat unpredictable. Targeting splice variants may 
provide some degree of stratification, but again quantification, expression and 
distribution across different cell types is changeable and, perhaps most importantly, 
not associated with any obvious biological function. Moreover, since the studies 
reported in this thesis were designed and conducted the role of miRNA in cancer has 
become more established, providing a new avenue through which additional 
regulatory mechanisms governing CSCs can be explored. However, while CD/AC133 
associated miRNA signatures have been reported in CRC cell lines (Song et al., 2009; 
Zhang et al., 2011) further experiments assessing PROM-1 mRNA degradation or 
translational repression by miRNA in CRC are currently awaited. 
 
The study presented in Chapter 3 was designed primarily to assess the expression 
pattern of PROM-1/CD/AC133 in adjacent normal colon, CRC samples and the 
associated tumour metastatic compartments; with specific reference to whether 
PROM-1/CD/AC133 could be considered as a robust marker for CRC-CSCs. When 
the study was initiated, the published literature suggested that PROM-1/CD/AC133 
was confined to colorectal tumour tissues, and not significantly expressed by normal 
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colon (O'Brien et al., 2007; Ricci-Vitiani et al., 2007). However, the data presented in 
Chapter 3 demonstrate unequivocally that this marker is widely expressed in normal 
colon adjacent to a colorectal tumour, as demonstrated in Figure 3.1. While it might 
be argued that this could be due to so called ‘field-change’, i.e. (epi)-genetic 
instability around the primary tumour, PROM-1/CD/AC133 was similarly expressed 
in biopsies taken during benign colonic resections (Appendix 1), suggesting this is not 
the case. Indeed, following the initial demonstration of the presence of PROM-
1/CD/AC133 in the normal gastrointestinal tract (Hou et al., 2001) more recent 
studies have confirmed this (Shmelkov et al., 2008; Samuel et al., 2009; Snippert et 
al. 2009), contesting other reports that suggest significant expression of this marker is 
confined to neoplastic colonic tissues only (O'Brien et al., 2007; Ricci-Vitiani et al., 
2007).  
 
The proposed utility of CD/AC133 as a robust marker for CRC-CSCs is further 
questioned by Chapter 3 since group data suggest little difference in CD/AC133 
protein expression levels between adjacent normal and CRC biopsies. This was not 
universally true as discussed in Chapter 3.4; however, expression levels for matched 
samples were not sufficiently diverse as to make the case for differential regulation of 
this marker between these tissue types (Figure 3.2). Consequently, the data presented 
in Chapter 3 do not support previous assertions that significant   CD/AC133 hindgut 
expression is restricted to colorectal tumours, a finding of this thesis that is again 
supported by relatively more recently published data (Shmelkov et al., 2008; Samuel 
et al., 2009). 
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Determining the significance of PROM-1/CD/AC133 in the metastatic process is an 
altogether more difficult matter, necessitating either a functional or a quantitative 
approach. Some authors have favoured the former, utilising permissive 
immunodeficient models into which tumour xenografts are introduced. While such 
studies theoretically allow each stage of the metastatic process to be investigated, the 
mechanisms revealed by these studies may potentially bear no resemblance to those 
that occur in human carcinogenesis, despite the use of human tumour grafts. In 
contrast, the study reported within Chapter 3 was designed to investigate the process 
of metastasis within the human microenvironment and thus was performed 
quantitatively.  
 
Once again, no significant difference in PROM-1/CD/AC133 expression was noted 
when comparing primary CRC biopsies with those samples from metastatic tumour 
cells that had intravasated into the vascular and lymphatic channels within the 
resected surgical specimens. Consequently, it might reasonably be assumed that 
altered regulation of PROM-1/CD/AC133 is not associated with basement membrane 
invasion / tumour intravasation. This conclusion is further supported by murine 
studies demonstrating human PROM-1/CD/AC133low tumours may exhibit more 
aggressive growth (Shmelkov et al., 2008; Navarro-Alvarez et al., 2010). The findings 
of Shmelkov et al and Navarro-Alvarez et al are in keeping with the data presented in 
Chapter 3 demonstrating that PROM-1/CD/AC133 mRNA and protein expression 
levels derived from liver metastasis are significantly reduced when compared with 
those of matched primary tumour samples. Nevertheless, it is unclear whether altered 
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regulation of this marker is a necessary part of the metastatic process or in fact occurs 
as a ‘bystander effect’. Thus, further studies will be required to investigate this matter.  
 
Certainly the discordance in the published literature, with some studies reporting 
AC133 as a CSC marker whereas others, including Chapter 3 of this thesis, have 
found widespread CD/AC133 protein expression raises serious concerns about the 
functionality of CD/AC133 as a specific CSC marker. There are a number of reasons 
that may account for the contradictory data including the use of different antibodies to 
detect the presence of the CD133 antigen (Hermansen et al., 2011) and different 
antigen retrieval protocols and detection techniques (Sgambato et al., 2010). An 
additional rather intriguing possibility is that CD133 is expressed on the cell surface 
of CSCs and differentiated tumour cells, with differential folding masking specific 
epitopes, including the one recognised by AC133 (Kemper et al., 2010). 
 
However, this discordance between published data must also be viewed in light of the 
fact that CRC is postulated to be a molecularly heterogeneous disease. As a result, it 
is difficult to unify molecular theories which explain the variable biology and 
behaviour of colorectal tumourigenesis and in turn the function and significance of 
putative CRC biomarkers, such as PROM-1/CD/AC133. Studies reporting molecular 
profiling of primary CRC support a hypothesis that requires multiple cellular 
programmes to be capable of directing tumour initiation and progression. This results 
in a level of complexity that has largely impeded the introduction of assays capable of 
identifying reliable biomarkers, or generating uniform prognostic data that might be 
useful clinically. However, a recent paper reports the results of an unsupervised, first 
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principal component (PC1) analysis of gene expression patterns that may prove to be 
a more reliable classification for predicting disease recurrence, advancing AJCC stage 
and poor prognosis based on the biology of epithelial to mesenchymal transition 
(EMT; reviewed in Chapter 3.1.1) (Loboda et al., 2011). The PC1 score is closely 
linked to EMT biology, suggesting that CRC may be resolved into two principal 
molecular subtypes: epithelial and mesenchymal. The mesenchymal subtype is linked 
to transforming growth factor-ß activation and is associated with a higher AJCC 
stage, poorly differentiated tumours as well as metastatic disease, but is not linked to 
activation of the proto-oncogenes RAS and MYC, the presence of microsatellite 
instability (MSI) or increased tumour proliferation. PC1 predicted recurrence for both 
AJCC stage II and stage III CRC. MSI tumours, which have a better prognosis, had 
relatively low PC1 scores in agreement with the finding that microsatellite instability 
does not correlate with EMT (Pino et al., 2010). The proliferation signature 
previously used to identify poor prognosis breast and lung cancers also identifies good 
prognosis CRCs, suggesting proliferation may not play a critical role in CRC 
progression. This hypothesis is consistent with the recent observation that CRC 
metastases have a lower proliferative index than primary non-metastatic tumours 
(Ganepola et al., 2010). While this premise will clearly require further investigation, 
one possible explanation for this may be that metastatic CRCs undergo a reversal of 
phenotype, with mesenchymal to epithelial transition taking place (Vincan and 
Barker, 2008). Although the CRC-CSC hypothesis has been allied with the process of 
EMT (Varnat et al., 2009) the CRC-CSC concept has yet to be fully embraced within 
strategies aimed at stratifying CRC into prognostic categories determined by epithelial 
or mesenchymal genotypes. Consequently, PC1 gene expression analyses have yet to 
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identify a coherent role for PROM-1/CD/AC133 as a prognostic CRC biomarker 
(Varnat et al., 2009). 
 
Limitations of the data presented in Chapter 3 include: (i) their descriptive nature; (ii) 
sample size; (iii) the use of unmatched samples; and, (iv) prognostication. The 
quantitative nature of this study has been discussed above, and this design was 
selected due to the inherent difficulties associated with the use of ‘functional’ animal 
models. The value of animal experiments remains controversial, mainly because of a 
recurrent failure to translate interventions apparently promising in animal models to 
clinical practice. Failures also result because of critical disparities, usually disease-
specific, between animal models and human pathologies (van der Worp et al., 2010). 
The approach adopted for this study seems justified since a highly significant finding, 
that PROM-1/CD/AC133 expression is down-regulated in CRC metastases, can now 
be investigated in vitro using human cell lines with organotypic culture techniques to 
establish the mechanism(s) by which this occurs.  
 
When considering the study size in Chapter 3 there may seem at first to be relatively 
few samples taken from matched tumour groups, specifically those from the vascular 
invasion (n=13), lymph node metastasis (n=28) and liver metastasis (n=9; n=14 
unmatched) groups. However, as discussed in Chapter 2.10, power calculations were 
undertaken which calculated that tissue from a minimum of 8 patients was required 
for each of the tumour groups above to be compared in an appropriate statistical 
manner with matched primary tumour samples. This calculation did not include 
biological or technical replicates, which have been performed to confirm the validity 
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of data presented in Chapter 3. Unmatched CRC liver metastasis samples were 
included in the study due to the statistically valid but relatively low number of 
patients with both a primary tumour and paired CRC metastases available. The need 
for inclusion of such tissues reflects: (i) the historically low number of patients who 
undergo liver resection for CRC metastases; (ii) the fact that few patients undergo 
synchronous resection of a colorectal primary and hepatic metastases in our unit if 
detected at diagnosis; and, (iii) the logistical difficulties of identifying and acquiring 
tissue samples from those patients who later develop metastases and undergo 
metastectomy. 
 
Finally, the study in Chapter 3 did not yield any prognostic data despite previous 
reports that PROM-1/CD/AC133 over-expression predicts significantly poorer 
survival (Horst et al., 2008; Kojima et al., 2008; Horst et al., 2009a,b,c; Li et al., 
2009; Saigusa et al., 2009; Yasuda et al., 2009; Artells et al., 2010; Saigusa et al., 
2011). While the study recorded clinical outcomes with a median follow up of two 
years, this work was powered to detect significant differences in PROM-1/CD/AC133 
expression. Consequently, recruitment of many more patients would be required to 
investigate a putative relationship between expression of this marker and clinical 
cancer outcome measures. 
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8.2 CHAPTER 4: CORRELATION BETWEEN CD/AC133 EXPRESSION 
AND OTHER PUTATIVE IMMATURE PROGENITOR MARKERS 
 
8.2.1 Discussion 
 
CD/AC133 has received much attention as a putative CRC-CSC marker; however, its 
biological function remains largely unknown, although some insights have recently 
emerged. Numerous experiments have demonstrated that murine CD/AC133 localizes 
to the apical microvilli of epithelial cells (Miraglia et al., 1997; Weigmann et al., 
1997; Dubreuil et al., 2007; Florek et al., 2007) and that the human analogue displays 
a similar membrane protrusion–restricted localization (Corbeil et al., 2000). These 
and other observations (reviewed in Chapter 4) have led to the premise that   
CD/AC133 has a role in the organisation of specialized cell membrane projections 
(Fargeas et al., 2011). The selective localisation of CD/AC133 in distinct types of 
plasma membrane protrusions probably reflects a cell type-specific adaptation of a 
membrane transport process common to most eukaryotic cells, given its remarkably 
conserved genomic organization throughout metazoan evolution (Fargeas et al., 
2007). If so, this would be of interest given that some of the cytoskeletal components 
that organise plasma membrane protrusions differ between various cell types. For 
example, the actin-bundling protein villin occurs only in microvilli of epithelial cells, 
in which it has a key role in organising the morphology of microvilli (Craig & Powell, 
1980). Yet profound alteration of the cytoskeletal architecture of microvilli, as 
observed in CaCo-2 expressing a villin anti-sense cDNA (Costa de Beauregard et al., 
1995), does not abolish the preferential localisation of CD/AC133 in microvilli, which 
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in these cells are reduced in number (Röper et al., 2000). Furthermore, deletion of the 
C-terminal cytoplasmic domain of CD/AC133 does not impair the concentration of 
murine CD/AC133 in microvilli of an animal cell line (Corbeil et al., 1999). It appears 
the primary cause of the selective localization of CD/AC133 in plasma membrane 
protrusions is its interaction with membrane lipids, notably cholesterol and certain 
gangliosides, rather than direct interaction with the actin-based cytoskeleton (Corbeil 
et al., 2001; Corbeil et al., 2010). However, while these experiments shed some light 
upon the biological function of PROM-1/CD/AC133 in the regulation of non-
malignant epithelial cell polarity (Fargeas et al., 2011), they do not obviously support 
a coherent role for this protein as a robust marker for CRC-CSCs as previously 
suggested (O'Brien et al., 2007; Ricci-Vitiani et al., 2007).    
 
The role of CD/AC133 in the organisation of cellular membrane protrusions of 
immature progenitor populations is rarely addressed in the published literature, with 
the notable exception of the “stem cell-characteristic membrane micro-domain” 
hypothesis (Marzesco et al., 2005; Corbeil et al., 2010). This hypothesis proposes that 
CD/AC133-containing membrane micro-domains might carry and / or functionally 
organize molecular determinants essential to maintain the stem cell, its 
undifferentiated cell properties and their loss or disposal (Fargeas et al., 2011). More 
recently this hypothesis has been extended to include CSCs, although mechanisms 
that might allow CD/AC133 membrane micro-domains to confer tumour-initiating 
properties remain considerably more obscure (Lathia et al., 2011). Consequently, the 
pivotal role for PROM-1/ CD/AC133 in CRC reported initially (O'Brien et al., 2007; 
Ricci-Vitiani et al., 2007) has not only been contradicted by data in Chapter 3 but 
  J Murphy – Chapter 8 
 
 
_____________________________________________________________________ 
 
336 
 
 
 
also by other reports (Shmelkov et al., 2008). Thus, the aims of the study presented in 
Chapter 4 were: (i) to identify appropriate human cell lines expressing PROM-
1/CD/AC133 to allow in vitro study of this marker; prior to, (ii) conducting further 
experiments to determine the utility of CD/AC133 as a marker of CRC and intestinal 
immature progenitor cells.  
 
The first aim of the study in Chapter 4 was achieved by identifying three human cell 
lines, two of which were CRC derived, CaCo-2 (Figure 4.1; Figure 4.2) and HT-29 
(Figure 4.1; Figure 4.3) and one sub-epithelial myofibroblast (SEMF) cell line 
CCD18Co (Figure 4.1; Figure 4.4) that constitutively express PROM-1/CD/AC133. 
The expression of PROM-1/CD/AC133 has previously been confirmed for the CaCo-
2 (Florek et al., 2005; Tabu et al., 2010) and HT-29 (Ieta et al., 2008; Sgambato et al., 
2010) cell lines, but colonic SEMFs have not been shown to express this marker 
either in vivo or in vitro. The CCD18Co cell line was investigated as previous studies 
suggest mesenchymal progenitor cell populations express PROM-1/CD/AC133 
(Bühring et al., 2004). Clearly, detection of this marker in the CCD18Co cell line 
supports this observation, but in itself does not shed light upon the function of PROM-
1/CD/AC133 in proliferation or differentiation of the SEMF cell line, i.e. organisation 
of specialized cell membrane projections (De Wever et al., 2004) or as a marker of 
immature progenitor status (Kordes et al., 2007; Lin et al., 2007). 
 
Identification of these cell lines was a necessary step prior to investigating the second 
aim, namely correlation of PROM-1/CD/AC133 expression with six putative markers 
of immature progenitor status (ABCB1 / ABCG2 / BMI-1 / CD44 / LGR5 / MSI-1). 
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In order to perform the correlation experiments sub-populations of each cell line were 
separated by fluorescence-activated cell sorting into fractions that were either AC133-
epitopehigh or AC133-epitopelow (Chapter 2.8; Figure 2.5 & Figure 2.6). The study 
presented in Chapter 4 demonstrated that expression levels of five of these putative 
markers of immature progenitor status did not reliably correlate with AC133 status, in 
keeping with recent studies that identified infrequent cellular co-expression of AC133 
and CD44 by primary CRC samples (Galizia et al. 2012) and CRC cell lines (Gisina 
et al., 2011; Schneider et al., 2012). However, the ATP–binding cassette transporter 
sub-type B1 (ABCB1) was consistently up-regulated in AC133-epitopehigh subtypes of 
all three assessed CRC / SEMF cell lines. This novel finding is supported by previous 
studies of glioma and acute myeloid leukaemia that suggest a similar correlation 
between P-glycoprotein, a pseudonym for ABCB1, and PROM-1/CD/AC133 & 
AC141, respectively (Guenova and Balatzenko, 2008; Christensen et al., 2010). 
However, it should be appreciated that the latter study used an antibody targeting a 
different glycosylated epitope (PROM-1/CD/AC141) to that used by the study 
reported in Chapter 4. This is of importance as the epitopes the antibodies recognise 
differ significantly and thus the antibodies may not identify the same range of PROM-
1/CD/AC133 surface antigens (Hermansen et al., 2011). 
 
This finding is of considerable translational significance, since the HT-29 AC133-
epitopehigh subtype has been demonstrated to exhibit chemoresistance to both 5-
Fluorouracil and Oxaliplatin (Dallas et al., 2009), which are standard agents for the 
treatment of CRC patients with adverse prognostic factors or metastatic disease. 
Furthermore, PROM-1 single nucleotide polymorphisms have been identified as a 
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marker of progression-free survival for patients with metastatic CRC who are treated 
with 5-Fluorouracil, Oxaliplatin and Bevacizumab (Pohl et al., 2012). Over-
expression of ABCB1 is reported to confer chemoresistance to CRC cell lines treated 
with either 5-Fluorouracil (Takechi et al., 2001) or platinum based chemotherapy 
agents (Theile et al., 2009). Therefore, it might reasonably be suggested that ABCB1 
may confer this property to CRC cell lines expressing PROM-1/CD/AC133 in 
addition to other cancers, since a number of solid tumour subpopulations expressing 
this marker have been reported to exhibit chemoresistance (Jiang et al., 2010; 
Tomuleasa et al., 2010; Yao et al., 2010). However, it must be stressed that the exact 
relationship between PROM-1/CD/AC133 and ABCB1 cannot be determined from the 
data presented by this study. Thus further work assessing the chemoresistance of 
AC133high CRC cell lines with up- or down-regulated ABCB1 expression will be 
necessary before this premise can be asserted.  
 
LGR5 expression, arguably the most significant of the assessed markers, was not 
found to correlate reliably with PROM-1/CD/AC133 expression in this study, a 
finding supported by a recent article demonstrating that co-localisation of these 
markers in the human colon is a rare event (Ernst et al., 2011). While the HT-29 
AC133-epitopehigh subtype harvested at two-days after culture demonstrated up-
regulation of LGR5 (Figure 4.12c), this was not replicated in the other assessed cell 
lines. LGR5 identifies very long-term self-renewing colonic epithelial cells (Barker et 
al., 2007; Barker et al., 2008) with multi-lineage differentiation capacity and thus has 
been proposed as a marker of intestinal epithelial stem-cells (Vermeulen et al., 2008). 
LGR5 has also been implicated in the development of CRC since: (i) intestinal 
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epithelial stem-cells expressing this marker are thought to undergo aberrant 
deregulation of molecular pathways resulting in CRC (van der Flier et al., 2009); (ii) 
restricted LGR5 expression is noted within the most basal cellular layer of human 
adenomas localized at the adenoma-host interface (Takahashi et al., 2011); and, (iii) 
the presence of LGR5high tumour cell populations significantly correlates with a poor 
prognosis (Merlos-Suárez et al., 2011). Consequently, the fact Chapter 4 data 
demonstrate no significant correlation between PROM-1/CD/AC133 and LGR5 
suggests that expression of PROM-1/CD/AC133 alone cannot dependably isolate 
CRC cell populations highly enriched for CSCs, in keeping with expression data from 
Chapter 3. Therefore, there is a need for additional markers that better identify this 
cell population (Catalano et al., 2012). Nevertheless, a subtle role for PROM-
1/CD/AC133 in tumourigenesis may still exist. CRC tumour cells expressing both this 
marker and LGR5 may be derived from solid tissue stem-cells that are susceptible to 
neoplastic transformation (Zhu et al., 2009); however, while rare AC133high / LGR5high 
CRC cell populations have been identified (Ernst et al., 2009) this premise has yet to 
be investigated in human tumours. Consequently, the experiments described in 
Chapters 5-7 of this thesis centre upon identification of down-stream targets of 
PROM-1/CD/AC133, in an attempt to shed light upon its role in CRC and / or 
immature progenitor status. 
 
Limitations of the data presented in Chapter 4 include: (i) the use of fluorescence-
activated sorting to identify AC133-epitopehigh/low populations, as opposed to 
inducible PROM-1/CD/AC133 and siPROM-1 to generate populations with over / 
decreased expression of this marker; (ii) the use of single antibody fluorescence-
  J Murphy – Chapter 8 
 
 
_____________________________________________________________________ 
 
340 
 
 
 
sorting and subsequent use of western blotting to confirm the expression of other 
putative markers; and (iii) a lack of functional assays to assess the proliferative / 
engraftment capacity of the isolated cell populations. 
 
Firstly, fluorescence-activated cell sorting was used to identify cell populations with 
elevated / decreased expression of PROM-1/CD/AC133 primarily due to its 
reliability, speed and ease of use. In addition, this technique requires relatively 
minimal modification of tissue culture conditions, when compared to the extensive 
modifications required to select for and maintain genetically modified cell lines to 
incorporate inducible promoter and target sequences, or using RNA interference. This 
aspect is crucial when assessing cell populations for putative stem-cell markers, since 
cues for cell survival, proliferation and differentiation are poorly understood 
(Bjerknes and Cheng, 2006; Shaker and Rubin, 2010). Thus, unnecessary cell 
processing may alter the differentiation status of the experimental cell population, 
questioning the validity of subsequent results (Unternaehrer and Daley, 2011). 
 
Single, rather than multiple, antibody fluorescence sorting was undertaken to 
minimise the complexity of the reported sorting experiments since there are several 
widely recognised technical problems identified with the use of CD/AC133 antibodies 
as markers for CSCs. Discordant expression of the AC133 and AC141 epitopes has 
been observed, and the epitopes can be absent despite the presence of CD133 protein 
(Bidlingmaier et al., 2008; Kemper et al., 2010). In addition, oxygen levels have been 
shown to modulate CD/AC133 expression (Blazek et al., 2008; Barr et al., 2010).  
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Finally, cell cycle-dependent variation assessments of PROM-1/CD/AC133 
expression were not conducted during fluorescence-activated sorting. Similarly, post 
sorting proliferation and colony forming unit assays were not undertaken. These 
functional assays were not performed due to time constraints, given published data 
already demonstrate CD/AC133 expression is associated with actively cycling cells, 
with continued cultivation of cells sorted on the basis of high and low reactivity 
resulting in normalization of cell reactivity profiles (Jaksch et al., 2008). 
 
8.3 CHAPTER 5: EXPRESSION OF PROM-1 mRNA SPLICE ISOFORMS BY 
COLORECTAL CANCER AND COLONIC SUBEPITHELIAL 
MYOFIBROBLAST CELL LINES (CaCo-2 / HT-29 / CCD18Co) 
 
8.3.1 Discussion 
 
Published data from both human and animal studies demonstrate that PROM-
1/CD/AC133 is associated with CRC tumourigenesis and metastasis (Lin et al., 2007; 
O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Kojima et al., 2008; Puglisi et al., 
2009), even if its role as a CRC-CSC marker is less certain (Shmelkov et al., 2008; 
Chapter 3; Chapter 4). Consequently, the remainder of the work presented in this 
thesis has concentrated upon possible molecular mechanisms through which this 
influence may occur. The study reported in Chapter 5 begins this process by assessing 
splicing patterns of the PROM-1 transcript. 
 
PROM-1 is a single-copy gene and is composed of at least 27 exons (Weigmann et al., 
1997; Figure 5.1). Following the original description of this transcript, several splice 
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isoforms which affect the PROM-1 open reading frame have been identified (Miraglia 
et al., 1997; Yu et al., 2002) and their expression characterized (Fargeas et al., 2004; 
Corbeil et al., 2009). Data gathered from murine models suggest that five alternative 
tissue-specific promoters drive transcription of differentially spliced PROM-1 mRNA 
isoforms (Fargeas et al., 2004; Figure 5.2). Additional studies have demonstrated that 
PROM-1 splicing occurs at multiple locations. However, the 3' boundary of exon 24, 
which encodes the cytoplasmic tail of CD/AC133, appears potentially to be the most 
significant site of regulation, as alternate splicing at this position results in four 
putative variants with disparate C-termini sequences (Table 5.1). The function of 
individual PROM-1/CD/AC133 isoforms remains obscure, although alternate splice 
variants are delivered and localise to the cell membrane in the same manner as the 
original description of the s1 variant (Weigmann et al., 1997; Fargeas et al., 2004). 
This suggests that proteins translated from different PROM-1/CD/AC133 isoforms 
may interact with distinct cytoplasmic proteins.  
 
Abnormally spliced mRNAs are found in a high proportion of malignancies 
(Skotheim et al., 2007; He et al., 2009; Miura et al., 2011), and a limited set of mis-
spliced genes are recognised to contribute toward tumour development (Hui et al., 
2004; Ferreira et al., 2010). However, the presence of PROM-1 splice variants in the 
human gastrointestinal tract remains relatively unexplored, with the exception of a 
single preliminary report (Kemper et al., 2010). Therefore, the study reported in 
Chapter 5 was designed to assess the differential expression of established human 
PROM-1 mRNA isoforms by CRC and SEMF cell lines, and correlate this with cell 
PROM-1/CD/AC133 status, as assessed by fluorescence-activated cell sorting. 
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Initial observations reported by Chapter 5 demonstrate that all four splice variant 
subgroups were represented in the total mRNA pool of CaCo-2, HT-29 and 
CCD18Co cell line preparations. For ease of reference they are as follows: (a.) s2, 
s11, s12; (b.) s1, s2; (c.) s1, s2, s9, s10, s12; and, (d.) s7, s11. Isoform subgroup A 
was most commonly expressed by day-7 CaCo-2 and day-2 / day-7 HT-29 AC133-
epitopehigh cell populations, while the CCD18Co AC133-epitopehigh subtype expressed 
marginally more transcripts identified by the primers for isoform subgroup C. Overall, 
the presented data demonstrate that two distinctive cytoplasmic C-terminal tails may 
be present in CaCo-2 (s1/s2 & s7) and HT-29 (s1/s2, s7 & s11) cell lines, while three 
such C-termini are likely to be present in the CCD18Co colonic SEMF (s1/s2, s7 & 
s10) cell line. In particular, it is the truncated PROM-1 isoform incorporating the 
sequence from exons 25 & 26b that is negligibly expressed by all three-cell lines. 
 
The biological significance of this distribution in cytoplasmic C-termini expression is 
difficult to determine, since despite the identification of some downstream target 
pathways (Fan et al., 2006; Piccirillo et al., 2006; Nikolova et al., 2007; Tang et al., 
2011), the immediate intracellular partners of CD/AC133 remain unclear. Analyses of 
intracellular signalling mediated by CD/AC133 have focused upon a possible tyrosine 
phosphorylation site, with site-directed mutagenesis experiments utilising 
medulablastoma cell lines identifying tyrosine-828 and tyrosine-852 as 
phosphorylation targets in vitro (Boivin et al., 2009). This effect is reported as being 
mediated by SRC-family tyrosine kinases, suggesting CD/AC133 may be a substrate 
of this protein class (Boivin et al., 2009). Since published data suggest a link between 
CD/AC133 and several pathways associated with CRC development, including wnt 
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(Nikolova et al., 2007) and transforming growth factor-ß (Qiu et al., 2011), tyrosine 
phosphorylation of CD133 in response to an as yet unknown extracellular ligand 
might activate, or inhibit these intracellular signalling pathways, thus influencing cell 
growth, mobility, and metastatic potential. 
 
In silico assessment of the protein C-termini sequences generated by differential 
splicing of the PROM-1 transcript has also been conducted. These studies suggest the 
predominant C-termini present within all three assessed cell lines are likely to contain 
putative PDZ binding sites (Harris and Lim, 2001; Sheng et al., 2001; Chapter 5), an 
observation supported by PDZ mediated binding by a member of the CD/AC133 
family (Fargeas et al., 2003a). Different splice variants specify different classes of 
PDZ-binding domains, which are short structural domains that allow proteins to 
interact with peptides, lipids or heterodimerize with the PDZ domains of other 
peptides, thus helping to anchor transmembrane proteins to the cytoskeleton and 
holding together signalling complexes. PDZ domains are divided into separate classes 
according to their specificity and rank as number 19 among the most abundant 
domain families in humans (Lander et al., 2001). The abundance of PDZ domains in 
metazoan genomes together with the scarcity of canonical PDZ domains in non-
metazoans indicates a possible critical function for PDZ domains in multi-cellular 
organisation (Harris and Lim, 2001). By far the most common targets for PDZ 
domain binding are short specific sequences at the extreme C-termini of their 
interacting partners, which are frequently transmembrane receptors such as G protein-
coupled receptors or ion channels. Recognition of C-termini allows for organisation of 
the transport, localisation, sorting and spatial arrangement of proteins by their 
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individual sequences, as recognised and handled by various PDZ domains 
(Ranganathan and Ross, 1997). Perhaps not surprisingly, many PDZ domain proteins 
function as scaffolds at the specialized membrane regions in the cell, where they 
manage organisation and maintenance of large macromolecular complexes. In most 
cases, interaction between a PDZ domain and its target is constitutive, although 
agonist-dependent activation of cell surface receptors is sometimes required to 
promote interaction with a PDZ domain containing protein (Ranganathan and Ross, 
1997). Hence CD133 / PDZ domain interaction might implicate CD/AC133 further in 
the organisation of specialized cell membrane projections. The potential role for 
CD/AC133-PDZ mediated signalling is in part further examined by the study 
presented in Chapter 6. 
 
Limitations of the data presented in Chapter 5 include: (i) analysis of splice variants 
as subgroups rather than individual variants; (ii) data analysis of splice variant 
expression by PROM-1/CD/AC133 status; and, (iii) limited ability to interpret data 
due to a paucity of identified CD/AC133 intracellular partners. Splice variant analyses 
reported in Chapter 5 were performed using RT-qPCR technology. Initially, it had 
been hoped that custom designed primers to target sequences specific to individual 
splice variants could be developed to allow novel qPCR assays for each variant. 
Unfortunately, this could not be performed due to the extensive sequence homology 
between splice variants, and thus assays targeting splice isoform subgroups were 
developed. The major limitation of this system is that analyses conducted in this 
manner negate the quantitative benefits of qPCR, since expression levels of each 
variant must be inferred from its expression between subgroups. It is likely that with 
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the use of high throughput next generation sequencing techniques (Ross and Cronin, 
2011) these limitations can be overcome. This technology was unfortunately not 
available to our group during the time when the study was conducted. 
 
Splice variant data are presented in Chapter 5 by PROM-1/CD/AC133 status, rather 
than absolute expression values by cell line. The data was represented in this fashion 
as the splice variant assays were being performed to identify intracellular C-termini in 
cell subpopulations over-expressing PROM-1/CD/AC133, and thus attempt to identify 
a potential biological role for this marker. Genetically modified cell lines 
incorporating inducible promoter / splice variant sequences and RNA interference 
techniques were not used in this study as they would not have provided biologically 
relevant data. 
 
With regard to the difficulty in interpreting splice variant data due to the scarcity of 
recognised CD/AC133 intracellular partners, it is clear that protein-based studies will 
be required to further assess differential interactions between translated variants. 
However, recognition of wide availability of PDZ-binding sequences is an important 
first step and is further investigated in Chapter 6. 
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8.4 CHAPTER 6: GENE EXPRESSION PROFILES OF COLORECTAL 
CANCER  AND COLONIC SUB–EPITHELIAL MYOFIBROBLAST 
CELL  LINES ASSOCIATED WITH PROM-1/CD/AC133 SILENCING.  
 
8.4.1 Discussion 
 
As previously stated, the biological function of PROM-1/CD/AC133 remains elusive 
despite: (i) expression in various differentiated tissues (Weigmann et al., 1997; Florek 
et al., 2005; Karbanová et al., 2008); and, (ii) identification of several organ-specific 
somatic stem and CSCs based upon its expression (Singh et al., 2003; Collins et al., 
2005; Liu et al., 2006; Fargeas et al., 2007; Hermann et al., 2007; Monzani et al., 
2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Bauer et al., 2008; Eramo et al., 
2008; Ferrandina et al., 2008; Ferrandina et al., 2009; reviewed in Chapter 4). 
However, it has been established that CD/AC133 is retained in the microvillar 
epithelial cell membrane by direct interaction with plasma membrane cholesterol 
(Röper et al., 2000; Thiele et al., 2000; Giebel et al., 2004; Corbeil et al., 2010). 
Observations such as this have suggested a critical role for the assemblies containing   
CD/AC133 and specific membrane lipids in the maintenance of membrane-based 
polarity of epithelial cells in the absence of functional tight junctions (Marzesco et al., 
2005; Corbeil et al., 2010). This may explain why CD/AC133 maintains its polarized 
distribution in neuroepithelial cells at the neural tube stage, when tight junctions are 
down-regulated (Marzesco et al., 2005). Furthermore, CD/AC133 membrane micro-
domains have been suggested to play a role in signal transduction and a variety of 
membrane trafficking events (e.g. apical delivery, membrane budding and fission) 
(Simons et al., 2000; Huttner et al., 2001; Corbeil et al., 2010; Bauer et al., 2011). 
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This function is in addition to their hypothetical role in organising the molecular 
determinants essential to maintain the stem cell, its undifferentiated cell properties 
and their loss or disposal (Marzesco et al., 2005; Corbeil et al., 2010; Fargeas et al., 
2011). Therefore, the aim of the study reported in Chapter 6 was to investigate a role 
for CD/AC133 within established cellular signalling cascades, with specific reference 
to proteins containing PDZ-binding domains as outlined in Chapter 5.  
 
The expression profile of approximately 3000 putative target genes involved in cell 
signalling cascades was assessed using the Biotrove OpenArray system. Analyses 
performed to determine a possible role for PDZ domain binding proteins in   
CD/AC133 mediated signalling identified two targets regulated by siPROM-1. 
However, these mRNAs contain both a PDZ-1 and PDZ-2 binding domain, and 
therefore it remains unclear whether PROM-1 splicing acts as a mechanism to control 
intracellular signalling through differential PDZ binding domains. Consequently, 
further studies will be necessary utilising additional technologies to investigate this 
premise in future. 
 
siPROM-1 mediated regulation affected eleven putative target genes in all three of the 
assessed cell lines, with ten up-regulated (AKT3, BCL2, EGR1, GRB10, HMBS, 
HOXB13, IL16, ITGB6, MMP2, MYC), and one further transcript differentially 
regulated between cell lines (TP53). When bioinformatic assessments were performed 
including only these eleven targets, 4 statistically significant PROM-1 RNA 
interference mediated pathways were identified: central cancer pathway (p=0.002); 
colorectal cancer pathway (p=0.003); NF-kB (p=0.006); and, p53 (p=0.047). 
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PROM-1 RNA interference mediated regulation of the above pathways provides some 
intriguing hypotheses concerning the biological function of this marker. Evasion of 
apoptosis is one of the hallmarks of human cancers (Liu et al., 2011), with NF-kB 
signalling previously implicated in this process (Perkins, 2007; Hayden et al., 2008; 
Baud et al., 2009). Furthermore, NF-kB has also been shown to regulate many genes 
differently expressed and implicated in cell proliferation and invasion in cancer, 
including targets identified by Chapter 6: AKT3 (Salminen and Kaarniranta, 2010), 
BCL2 (Turco et al., 2004), EGR1 (Zheng et al., 2009), GRB10 (Chen et al., 2003), 
IL16 (Hidi et al., 2000), matrix metalloproteinases (Choo et al., 2008), MYC (Rattan 
et al., 2010) and TP53 (Tergaonkar and Perkins, 2009). 
 
Regulation of the differentiation and proliferation status of CD/AC133 subpopulations 
through the colorectal cancer signalling pathway (reviewed by Mizrak et al., 2008) 
fits with a central role for this marker in carcinogenesis also, since aberrant wnt 
signalling due to gain / loss of function mutations in its downstream targets such as 
APC or ß-catenin underpins the pathogenesis of CRC (Fodde and Brabletz, 2007; 
Mizrak et al., 2008). Many of the siPROM-1 mediated transcripts reported above have 
also previously been associated with this disease and are discussed at length in 
Chapter 6.4: AKT3 (De Roock et al., 2011), BCL2 (Liu et al., 2003), EGR1 (Ernst et 
al., 2011), GRB10 (Nowakowska-Zajdel et al., 2011), HOXB13 (Jung et al., 2005), 
IL16 (Gao et al., 2009), MMP2 (Dong et al., 2011), MYC (Telang and Katdare, 2011) 
and TP53 (Russo et al., 2005). 
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An additional 14 PROM-1 RNAi mediated pathways were identified when 
bioinformatic assessments were performed that included transcripts affected by 
siPROM-1 in at least one of the three assessed cell lines (Table 6.58): adherens 
junction (modified Fisher Exact P-Value: p<0.001); apoptosis (p=0.003); cell-cycle 
(p=0.013); ERBB (p<0.001); GnRH (p<0.001); hedgehog (p=0.001); Insulin 
(p<0.001); JAK-STAT (p=0.002); MAP kinase (p<0.001); mTOR (p=0.034); TGF-ß 
(p=0.010); toll-like receptor (p=0.046); VGEF (p=0.006); and, wnt (p<0.001) 
pathways. While these pathways complement previously discussed associations their 
identification in only one or more cell lines raises questions with regard to their 
validity. Therefore, it currently remains to be established if issues concerning the 
relative sensitivity of this PCR-array platform discussed in Chapter 6.4 may explain 
the failure of the advanced bioinfomatic techniques utilised in this study to 
corroborate these additional fourteen putative siPROM-1 mediated pathways in all 
three cell lines. 
 
The associations reported above, and those discussed in more detail within Chapter 6, 
clearly demonstrate that RNA interference ‘knock-down’ of PROM-1 mediates 
regulation of four key pathways linked with CRC development. However, criticisms 
of the presented data might include: (i) the use of PCR-array technology to acquire 
this data set; (ii) lack of corroboration with more reliable quantitative technologies; 
and, (iii) integration of this data set by bioinformatics tools which have not been 
subjected to assessment by peer review publications. 
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It is important to highlight that this study utilised PCR-array technology, not 
microarrays, although the latter technology also permits investigation of the 
expression of thousands of genes within a single sample and removes the practical 
limit on the number of candidate genes whose expression can be studied conveniently 
and in parallel. Numerous expression array-based studies analysing cell lines and 
CRC biopsies have identified many sets of transcripts potentially useful as 
postoperative markers of progression and prognosis. However, the studies use 
different technologies and protocols, and more worryingly all report different, 
sometimes contradictory, sets of markers (Bustin et al., 2006; Marko et al., 2011).  
 
To-date overlaps of microarray candidate gene lists associated with specific biological 
phenotypes remain disturbingly poor between studies. This may relate to assay 
specificity, as results are not comparable between seemingly identical experiments 
performed in different laboratories, or even on different days. This is exacerbated 
when data from different array platforms are compared. In addition, data over-fitting, 
where the number of parameters in a model is too large relative to the number of 
samples available, is another substantial problem. Consequently, models usually fit 
the original data but are poor predictors for independent data sets. Since most models 
use small numbers of samples, different data analysis methods for the same data 
generate different predictive results (Shih et al., 2005; Draghici et al., 2006; Konishi 
et al., 2008).  
 
Despite such limitations, it should be appreciated that microarray technology is not 
without use. Microarray gene expression patterns have been reported to be capable of 
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segregating CRCs according to their final metastatic status, rather than their clinical 
stages. Furthermore, gene expression profiles have allowed the classification of 
tumours clinically staged into two classes: localised, or metastasised; with disease-
free survival and overall survival significantly longer in the localised class than the 
metastasised class (Yamasaki et al., 2007; Jorissen et al., 2009).  
 
However, PCR-array technology offers a compromise solution in that these arrays 
permit the parallel analysis of large numbers of targets whilst retaining the rigour of 
qPCR-associated specificity. It is clear that the complexity of tumourigenesis / 
development of metastases demands the deregulation of multiple targets for these 
processes to occur, and given the paucity of identified downstream targets for PROM-
1/CD/AC133, PCR-array technology was utilised to initially investigate CD/AC133 
mediated signalling. Biotrove claim their assays are designed for comparable 
efficiency and thus perform relative quantification using a modified Pfaffl model 
(Pfaffl, 2001). However, these expression signatures obviously require corroboration 
to overcome the limitations associated with any large scale, parallel analysis of 
mRNA levels, be they microarray or PCR-array based. Individual PCR assays are 
well suited and widely used to translate microarray / PCR-array-derived profiles into 
accurate and quantitative biologically relevant data (Murphy et al., 2007). This 
process has been undertaken and is discussed in Chapter 7.  
 
The PCR-array data presented in Chapter 6 have been analysed using ‘DAVID: 
Database for Annotation, Visualization, and Integrated Discovery’ which was 
developed by the Clinical Services Program of the American National Cancer 
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Institute. This resource consists of an integrated online biological database offering 
analytic tools which aim to systematically extract biological / functional meaning 
from large gene / protein lists. The DAVID bioinformatics database is widely utilised 
and recognition of this has resulted in the publication of guidelines concerning its use 
by the journal Nature Protocols (Huang da et al., 2009). However, rather peculiarly, 
published studies assessing the pathway identification process used by the DAVID 
database (Dennis et al., 2003) and the statistical analyses of the resulting matches 
(Hosack et al., 2003) have been published without peer review. One accepts the 
presented associations are limited by this shortcoming, but one would reiterate that 
validation of PCR-array data is reported in Chapter 7. 
 
8.5 CHAPTER 7: VALIDATION OF PCR-ARRAY GENE EXPRESSION 
PROFILES ASSOCIATED WITH DIFFERENTIAL REGULATION OF 
CD/AC133 CELL SURFACE PHENOTYPE IN COLORECTAL CANCER 
AND SUB–EPITHELIAL MYOFIBROBLAST CELL LINES. 
 
8.5.1 Discussion 
 
Despite an immense volume of work being undertaken to identify surrogate 
biomarkers for CRC-CSCs, no definitive marker(s) have been established in human 
tissues that can reliably isolate this cell subtype. Nonetheless, CD/AC133 is reported 
by some authors to be the most promising candidate for further evaluation (O'Brien et 
al., 2007; Ricci-Vitiani et al., 2007). The biological role for this molecule remains 
unknown, although CD133 expression continues to be reported as a marker with high 
prognostic impact for CRC in isolation (Horst et al., 2008; Horst et al., 2009b,c; 
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Kojima et al., 2008; Li et al., 2009; Yasuda et al., 2009; Artells et al., 2010; Li et al., 
2012) and in combination with other makers (Horst et al., 2009a; Saigusa et al., 2009; 
Saigusa et al., 2011; Galizia et al. 2012). 
 
Regulation of the differentiation and proliferation status of PROM-1/CD/AC133high 
cells is influenced by the notch (Fan et al., 2006), hedgehog (Varnat et al., 2009), 
bone morphogenic protein (Piccirillo et al., 2006) and wnt / ß-catenin signalling 
pathways (Nikolova et al., 2007), which are well established in the proliferation and 
differentiation of all human cell types (Hansson et al., 2004). PCR-array data 
presented in Chapter 6 extend the findings of these reports by supporting a role for 
NF-kB signalling in PROM-1/CD/AC133high CRC and SEMF cell lines, which has 
previously been demonstrated for primitive hematopoietic stem cell subpopulations 
(Panepucci et al., 2010). Additionally, the PCR-array data presented in Chapter 6 
implicate three other cascades: the central cancer, colorectal cancer and p53 signalling 
pathways.  
 
Although array technology has been widely used for gene expression analyses, issues 
of sensitivity, accuracy, specificity and reproducibility of data generated by this 
technique have yet to be fully resolved (Carter et al., 2005; Kim et al., 2010; Chapter 
8.4.1). To overcome these limitations, qPCR technology is often utilised to translate 
microarray-derived profiles into accurate and quantitative, clinically relevant data 
(Murphy et al., 2009). PCR-arrays (Chapter 6) address some, but not all of the issues: 
for example the amplification efficiency of each individual assay is not determined 
during the course of every run. Hence, the aim of the study presented in Chapter 7 
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was to validate gene expression profiles associated with PROM-1 RNA interference 
technology for CRC and SEMF cell lines using a lower throughput RT-qPCR 
technique. This was performed using multiplex tandem PCR (MT-PCR), since this 
procedure allows the end user more control over the individual parameters of the RT-
qPCR assay, whilst retaining the ability to simultaneously evaluate multiple, albeit 
significantly fewer, targets at the mRNA level (Stanley and Szewczuk, 2005).  
 
Consequently, expression levels of 10 of the 11 major siPROM-1 mediated transcripts 
identified by the Biotrove platform were assessed in cell populations treated with 
RNA interference. An additional 41 genes (Table 2.4) with similar experimental 
conditions to those of the 10 major transcripts were selected for analysis on the basis 
of: (i) previous reports in the published literature indicating they were down-stream 
targets of PROM-1/CD/AC133; (ii) their association with CRC despite no previous 
reports indicating they were influenced by CD/AC133 status; and, (iii) a small 
random selection of targets demonstrated in Chapter 6 not to be differentially 
regulated by siPROM-1, in order to assess the validity of negative results generated by 
the Biotrove platform. Further clarification was provided by performing fluorescence-
activated cell sorting of untreated CRC and colonic SEMF cell lines to isolate 
AC133high cell subpopulations, and determine whether these samples inversely 
expressed the 51 target transcripts discussed above, when compared with siPROM-1 
treated cells. 
 
When MT-PCR assays were performed the expression levels of four major targets 
were found to be concordant with data generated by the Biotrove platform (AKT3, 
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BCL2, IL16, MYC). A further four assessed transcripts were demonstrated by both the 
Biotrove and MT-PCR platforms to be independent of siPROM-1. Concordance 
between these technologies was also demonstrated for TP53 when assessed by cell 
line, with apparent up-regulation in CaCo-2 and HT-29 cancer cell lines and down-
regulation in CCD18Co cells. Overall, data from these platforms demonstrate a 
concordance between the two technologies of 21% (9 concordant transcripts from a 
possible 43). The biological validity of these results was further investigated by 
quantitating copy numbers of the 5 concordant transcripts in PROM-1/CD/AC133high 
cell subpopulations, which demonstrated that four of the targets were inversely 
regulated in this subpopulation when compared with siPROM-1 treated cells (AKT3, 
BCL2, MYC, TP53).  
 
These data provide some interesting insights into possible CD/AC133 mediated 
signalling pathways. Activation of AKT signalling by both genetic and epigenetic 
alterations has been found to be important for both initiation and progression of 
multiple gastrointestinal malignancies, including CRC (Michl and Downward, 2005) 
(Figure 7.13). For example, the AKT pathway phosphorylates several downstream 
targets including NF-κB, identified by Chapter 6 as an siPROM-1 mediated pathway, 
through which it regulates cellular invasiveness, tumour associated angiogenesis and 
tumour cell resistance to apoptosis (Boye et al., 2008). AKT also has a role in the 
regulation of cell survival through the mitochondrial pathway, blocking the pro-
apoptotic protein BAD by phosphorylation to increase expression of the anti-apoptotic 
protein BCL2 (Pastorino et al., 1999), a further siPROM-1 regulated pathway 
identified by Chapter 6, which in turn increases cell survival. Consequently, affirming 
  PhD Thesis 2012 – Chapter 8 
 
 
_____________________________________________________________________ 
 
357 
 
 
 
that PROM-1 RNA interference treatment of CRC cell lines results in transcriptional 
regulation of the AKT pathway is critically important to substantiate a key role for 
CD/AC133 in colorectal tumourigenesis.  
 
Over-expression of the BCL2 oncogene has also been implicated in cancer 
progression (Figure 7.14), with ectopic expression of this anti-apoptotic protein 
resulting in increased metastatic capacity of epithelial cells by inhibiting anoikis and 
amorphosis, without directly affecting primary tumour growth, cell motility or 
invasiveness (Martin and Leder, 2001; Schmitt et al., 2002; Pinkas et al., 2004). 
While BCL2 expression can be demonstrated in normal colorectal mucosa (Sinicrope 
et al., 1995) it is hypothesised that abnormal activation of BCL2 is a frequent early 
step in CRC carcinogenesis, since its expression by dysplastic colorectal adenomas is 
greater than that of CRC specimens (Bronner et al., 1995; Huerta et al., 2006). In light 
of these and other published reports, the data presented in this chapter that reveal a 
link between siPROM-1 and BCL2 expression further reinforce a proposed function 
for CD/AC133 in CRC, a central concept which has been explored by this thesis. 
 
The role which BCL2 plays in tumourigenesis may be further facilitated by 
intercedent CD/AC133 deregulation of MYC mediated signalling, which is thought to 
regulate the motility of intravasating and extravasating cells (Sekhon et al., 2008; 
Wang et al., 2009; Cho et al., 2010), control initiation of angiogenesis (Ngo et al., 
2000), to be associated with chromosomal instability (Yin et al., 1999), enhance 
signalling interactions with the tumour microenvironment as well as a multitude of 
other functions (Meyer and Penn, 2008) (Figure 7.15). The significance of siPROM-1 
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mediated control of MYC mRNA copy numbers cannot be underestimated and is 
emphasised by genome-wide profiling studies demonstrating that expression of many 
thousands of transcripts may be directly regulated by the MYC proto-oncogene 
(Eilers and Eisenman, 2006). Furthermore, the potential role of MYC in CRC is 
highlighted by its activation by the wnt pathway, a pivotal signalling system in this 
disease, through two wnt / ß-catenin responsive enhancers in the MYC promoter 
region (He et al., 1998; Yochum et al., 2008). It is therefore unsurprising that the 
MYC gene is over-expressed in approximately 80% of CRCs (Nesbit et al., 1999; 
Prochownik, 2004). Consequently, the identification by this study of an association 
between the MYC transcription factor and siPROM-1 contributes significantly to the 
burden of evidence that proposes CD/AC133 may play a crucial part in colorectal 
carcinogenesis, and with the identification of additional siPROM-1 mediated 
transcripts discussed above, the presented data are beginning to unravel the complex 
interactions of CD/AC133 in CRC cells. 
 
Finally, CD/AC133 interaction with the p53 protein (TP53) may deregulate activation 
of dependent downstream targets, including documented regulators of cell cycling, 
apoptosis and DNA repair, which underpin the primary tumour suppressor function of 
TP53 (Figure 7.16). Mutation of the p53 gene is thought to be critically important in 
colorectal tumour progression, occurring in approximately 50-70% of cases 
(Iacopetta, 2003; Brosh and Rotter, 2009). Moreover, aberrant p53 function has been 
demonstrated to result in up-regulation of EGR1, which is a transcription factor 
implicated in growth control, carcinogenesis and importantly regulation of apoptosis 
(Weisz et al., 2004). A further signalling cascade thought to mediate the association 
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between p53 and apoptosis is the mitochondrial pathway, since p53 regulates 
expression of the BAX protein which in turn influences activity of the BCL2 pathway 
(Oltvai et al., 1993; Miyashita et al., 1994; Miyashita and Reed, 1995). Additional 
signalling cascades have been implicated in the regulation of this process; for 
example, feedback loops have been demonstrated to interlink apoptotic signalling 
between the AKT and p53 pathways (Gottlieb et al., 2002), with this association 
complemented by AKT mediated inhibition of p53, via activation of the MDM2 
oncogene (Trotman and Pandolfi, 2003). p53 is also thought to repress the MYC 
transcription factor, discussed previously, through a mechanism that involves histone 
deacetylation (Ho et al., 2005). Overall, therefore, the associations between the p53 
pathway and the siPROM-1 mediated transcripts mentioned above have strengthened 
the conceptual legitimacy of each of these markers, which previously have been 
discussed in isolation, while beginning to allow a rudimentary understanding of the 
complex web of interacting cascades that CD/AC133 orchestrates. Given these 
correlations, it might be hypothesised that aberrant p53 function, mediated by PROM-
1/CD/AC133, fails to regulate downstream targets resulting in tumourigenesis and / or 
tumour progression from AC133high cell subpopulations. However, on first review of 
the data, siPROM-1 up-regulation of TP53 in CRC cell lines and down-regulation in 
SEMF cells might appear to contradict this hypothesis. Nevertheless, when the 
presence of TP53 mutations in CaCo-2 / HT-29 cells (Mariadason et al., 2003) and 
their malignant phenotype is contrasted with that of the immortalised ‘normal’ 
CCD18Co cell line, which expresses wild-type p53, differing responses in TP53 
expression levels following RNAi might well be expected.  
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The main purpose of obtaining the data discussed above was to see whether it was 
possible to corroborate the results obtained in Chapter 6; nevertheless criticisms of 
Chapter 7 might include: (i) the use of MT-PCR rather than traditional RT-qPCR 
assays; (ii) investigating the biological validity of these results in PROM-
1/CD/AC133high cell subpopulations, rather than genetically modified cell lines that 
incorporate inducible promoter and target sequences; and, (iii) the absence of 
techniques confirming that alterations in transcript expression are detectable at the 
protein level. 
 
MT-PCR technology was chosen as it is a convenient format for analysing multiple 
targets from the same RNA sample, yet it retains some of the flexibility associated 
with individual RT-qPCR assays. Traditionally, polymerase chain reaction assays 
have been limited to ≤ 5 targets in a single tube, due to the availability of thermal 
cycler fluorescent channels and the competition that will occur between individual 
reactions occurring in the one tube (Stanley and Szewczuk, 2005). Furthermore, 
optimisation of each multiplex reaction is a laborious process (Henegariu et al., 1997). 
MT-PCR utilises a two-step approach, whereupon multiplex amplicons are first 
enriched using limited PCR, after which the product is used as a template for a large 
number of single-target reactions (Stanley and Szewczuk, 2005). In addition to the 
ease with which MT-PCR allowed investigation of 51 targets of interest, studies 
investigating the relationship between values measured by MT-PCR and traditional 
RT-qPCR have reported excellent correlations (Stanley and Szewczuk, 2005). 
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The decision to assess the biological validity of the previously reported expression 
profiles using PROM-1/CD/AC133high cell subpopulations, as opposed to genetically 
modified cell lines with inducible promoter and target sequences, was made for a 
number of reasons. However, the main rationale for selecting this experimental 
approach was that it requires relatively minor modifications of tissue culture 
conditions, when compared with the extensive alterations required to select for and 
maintain genetically modified cell populations. Unnecessary processing of the cell 
population may alter its differentiation / proliferation status, resulting in MT-PCR 
assay data that is neither representative nor functionally significant. This matter will 
not be discussed in further detail as it has previously been examined in Chapter 8.2.1. 
Finally, the use of fluorescence-activated cell sorting was associated with a number of 
benefits, since this is a quantitative, reliable, reproducible, fast and easy to use 
technology. 
 
Changes in relative expression levels demonstrated at the mRNA level for the 
discussed amplicons were not followed up with protein data in either Chapter 6 or 7. 
Clearly, concordance of RNA data obtained using several techniques and approaches 
simply means that the mRNA differences observed in different cell types are likely to 
be real. They do not imply that these differences will also be reflected at the protein 
level. Consequently, assessment of changes in protein concentration by techniques 
such as immunohistochemistry or western blot assays would be advantageous. 
However, these experiments were not performed due to time constraints. 
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8.6 SUMMARY 
 
In summary, the data reported in Chapter 3 demonstrate that PROM-1/CD/AC133 is 
widely transcribed / expressed in both CRC and adjacent normal colon samples and 
thus cannot be considered as a precise marker for a rare subpopulation of colon or 
rectal CSCs. Similarly, expression of this marker inversely correlated with the 
metastatic process and is thus unlikely to identify migrating tumour initiating cells. 
AC133high cell populations were studied in Chapter 4 but did not universally exhibit 
up / down-regulated translation for the majority of studied putative stem-cell markers, 
particularly BMI-1 and LGR5. Therefore, when data presented in both Chapters 3 & 
4 are interpreted together, it is clear that the colorectal AC133high subtype does not 
identify a rare population of colorectal tumour cells, is not associated with altered 
regulation of factors which control plasticity or influence the ability to self-renew, and 
thus by implication, PROM-1/CD/AC133 is an unlikely colorectal CSC marker. Data 
analyses reported in Chapter 4, however, did identify a clear and consistent 
association between AC133 status and ABCB1 expression in human CRC and 
myofibroblasts cell lines. This finding warrants further investigation to determine 
whether ABCB1 may play a role in the chemoresistance exhibited by AC133high 
colorectal cancer cell populations. 
While there is a lack of evidence to support the use of PROM-1/CD/AC133 for 
identification of the CRC-CSC subtype, a significant body of published data has 
proposed that this marker has prognostic significance for CRC patients. Therefore, 
Chapters 5, 6 & 7 focussed upon the possible role of PROM-1/CD/AC133 in CRC. 
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The biological function of this marker remains unclear and thus a systematic approach 
was taken to determine factors that may control its expression, in addition to 
identifying downstream targets that might mediate putative PROM-1/CD/AC133 
signalling. Consequently, the study presented in Chapter 5 assessed PROM-1 splice 
variant expression in CRC and colonic sub-epithelial myofibroblast cell lines as: (i) 
aberrant splicing mechanisms have been associated with tumourigenesis; and, (ii) the 
differential expression of established human PROM-1 mRNA isoforms remain un-
investigated in CRC. The results presented in Chapter 5 demonstrate transcription of 
multiple PROM-1 splice isoforms in the three assessed cell lines. While the analysis 
of these data was complex the results suggest a number of distinctive cytoplasmic C-
terminal tails may be present in each cell line that could mediate differential PROM-
1/CD/AC133 intracellular signalling. PDZ-domain-containing proteins were 
identified as potential distinct cytoplasmic partners for individual PROM-
1/CD/AC133 isoform subgroups. However, this hypothesis could not be confirmed 
and will require additional investigation in the future. 
Chapter 6 sought to further investigate a possible role for PROM-1/CD/AC133 
mediated signalling influencing pathways that control cellular proliferation and 
differentiation. The data reported in Chapter 6 have begun to build a framework for 
reconstructing a genetic regulatory network that affects four such pathways in all 
assessed cell lines using bioinformatic analyses of 11 major PROM–1 mediated 
targets. The discussion of these pathways above has established a clear rationale for 
the involvement of PROM-1/CD/AC133 in CRC tumourigenesis as well as for the 
apparent association with poor survival. Nevertheless, further studies were necessary 
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to corroborate these data. Consequently, Chapter 7 sought to substantiate the 
differential expression of five target genes implicated for the first time as being 
regulated by PROM-1/CD/AC133 in CRC. The reliability of this association, and the 
biological relevance of this finding, was further enhanced by the cell sorting 
experiments in Chapter 7, where AC133high and AC133low sub populations were 
demonstrated to express the expected levels of four of the five-target genes. 
Importantly, these targets specify transcripts reported to be involved with tumour cell 
plasticity, self-renewal, and cellular migration, suggesting that PROM-1/CD/AC133 
could possibly play a role in influencing the critical properties of CRC cells. 
Therefore, while Chapters 3 & 4 refute the use of PROM-1/CD/AC133 as a CRC-
CSC marker, the studies reported in Chapters 6 & 7 have identified a specific set of 
target genes and signalling pathways that provide a springboard for further 
investigations into the functional role of PROM-1/CD/AC133 in CRC, with the 
potential for better treatments for this disease in future. 
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9.1  FUTURE STUDIES 
 
The studies described in this thesis demonstrate emphatically that PROM-
1/CD/AC133 expression is unlikely to identify a rare population of colorectal cancer 
stem-cells (CRC-CSC). This is in keeping with recent published data showing that 
PROM-1/CD/AC133low tumour cells possess self-renewal and tumour-initiating 
potential even when injected at very low numbers (Shmelkov et al., 2008). In 
combination with the indeterminate biological role of PROM-1/CD/AC133, these 
conflicting data highlight the need for additional distinguishing markers that are 
directly involved in maintaining the functional properties of the putative CRC-CSC 
population. Indeed, the variability in PROM-1 expression in colorectal cancers 
(CRCs) observed in Chapter 3, combined with the inconsistent biological properties 
of PROM-1/CD/AC133high cells in vitro and mouse models suggests that this marker 
alone will be insufficient to isolate CRC-CSCs.  
 
However, it is also clear that expression of PROM-1/CD/AC133 is associated with 
significantly worse survival in patients treated by surgery alone or with 5-
fluorouracil-based chemotherapy and that in stage III patients PROM-1/CD/AC133low, 
but not PROM-1/CD/AC133high expression, reveals an apparent survival benefit from 
5-fluorouracil treatment (Ong et al, 2010). These data indicate that that PROM-
9 Future work 
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1/CD/AC133 expression may be a useful marker of increased chemoresistance and 
that the novel targets described in this study will help in understanding the biology of 
CRC cells in the laboratory. 
 
Furthermore, it is also evident from studies presented in this thesis that ‘knock-down’ 
of PROM-1 significantly affects the expression levels of transcripts commonly 
associated with tumour cell plasticity, self-renewal, and cellular migration. Moreover, 
bioinformatic analyses demonstrated a statistically significant link between PROM-1 
expression and regulation of the central cancer, colorectal cancer, NF-kB and p53 
pathways. Nevertheless, the exact function of this cell-surface protein continues to be 
obscure, and further studies will be necessary to determine fully the extent to which 
PROM-1/CD/AC133 expression influences the critical properties of CRC cells. 
 
The discovery that PROM-1/CD/AC133 regulates pathways associated with cell 
growth, differentiation and apoptosis suggests an important functional role in normal 
tissue; hence special attention must be paid to its expression pattern in normal colonic 
epithelium, as well as surrounding stromal tissue. Another issue concerns the 
regulation of the five PROM-1 promoter sequences (P1-P5). Although studies 
assessing samples from human gliomas have demonstrated that methylation patterns 
of PROM-1 promoter regions P1-P5 are altered when compared to non-malignant 
control samples (Tabu et al., 2008), and that the activity of promoter sequences is 
differentially regulated by methylation (Pleshkan et al., 2008), no work has been 
undertaken to analyse PROM-1 promoter methylation patterns in normal tissue. 
Furthermore, although post-translational modulation of PROM-1/CD/AC133 
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expression in CRC cells by sodium butyrate has been demonstrated (Sgambato et al, 
2010), no biological factors have been identified that either alter PROM-1 
methylation, or up-regulate PROM-1 transcription. However, our group has recently 
generated preliminary data suggesting that vitamin D can down-regulate PROM-1 
expression at the transcriptional level. This is thought to occur through a putative 
negative vitamin D response element within the PROM-1 promoter region P3. 
Expression levels of CD/AC133 in HT-29 cells were correspondingly found to be 
decreased following vitamin D treatment. Interestingly, in CaCo2 cells vitamin D had 
no effect on PROM-1 mRNA levels, but did down-regulate CD/AC133 levels (H. 
Tian, PhD 2010 University of London). These differential effects of vitamin D, and 
any involvement of methylation upon vitamin D-mediated down-regulation of 
PROM-1 will require investigation. Nevertheless, this finding is exciting and is 
specifically caused by vitamin D rather than as a consequence of processes 
responsible for cellular differentiation, since other agents that induce cellular 
differentiation do not affect PROM-1 copy numbers. This thesis proposes a functional 
role for PROM-1/CD/AC133 in the regulation of signal transduction networks in 
normal cell behaviour and concomitant dysregulation in CRC cells. Consequently, our 
finding of decreased expression of this marker after vitamin D treatment supports 
epidemiological data suggesting that vitamin D confers a protective benefit against 
CRC. This concept can be extended further by surmising that down-regulation of 
PROM-1 by vitamin D constitutes one of several possible pathways through which 
this agent helps inhibit colorectal tumourigenesis. As attractive as a simple and 
unsubstantiated hypothesis such as this is, the role of PROM-1/CD/AC133 in CRC 
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will need to be established before the inhibitory effect of any one given agent can be 
explained through it. 
 
Future studies will also have to address the contribution of differential PROM-1 
splicing in both normal and malignant colorectal tissues. It would seem that the 
different PROM-1 variants are biologically relevant given their highly conserved 
sequences between different species; however, their importance in disease is yet to be 
established. This thesis has demonstrated widespread expression of the majority of the 
studied PROM-1 splice variants within the colonic immortalised / CRC cell lines 
utilised by this study. While some evidence was found supporting the possibility that 
differential splicing may facilitate interaction of PROM-1/CD/AC133 with different 
PDZ domain expressing intra-cellular partners, it was not possible to further elucidate 
the nature of this relationship due to the format of these studies. Therefore, it will be 
necessary to conduct more sophisticated protein based assays to determine binding 
partners for PROM-1/CD/AC133 isoforms with different C-termini. Experiments to 
achieve this aim are currently being designed. 
 
The regulatory mechanisms governing translation of PROM-1 and its downstream 
targets also remain relatively unexamined. In order to address this, our group, in 
conjunction with the European Molecular Biology Laboratories in Heidelberg, have 
recently begun a study assessing the effect of siPROM-1 upon the micro-
transcriptome utilising microRNA array technology. The preliminary results of this 
study are extremely striking, with the expression of three specific microRNA 
amplicons consistently up-regulated by siPROM-1 in normal fibroblasts as well as in 
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two separate CRC cell lines. Altered expression of these microRNA transcripts has 
previously been associated with tumourigenesis. Therefore, we are currently 
establishing if any of the mRNA down-stream targets regulated by these microRNA 
sequences are involved in pathways identified by this thesis to be susceptible to 
PROM-1/CD/AC133 mediated regulation. Clearly, any such association would lend 
considerable support to the findings of the studies presented by this thesis. 
Additionally, significant PROM-1/CD/AC133 mediated signal transduction via the 
micro-transcriptome may explain the difficulties encountered by investigators in 
attributing a biological significance to this marker. 
 
Finally, investigation of the intricacies of PROM-1/CD/AC133 mediated signalling 
may best examined in more biologically relevant conditions. Isolated cell-culture 
experiments do not allow examination of the role of this cell surface marker in 
receiving cues from the extracellular environment, or in cell-cell interaction. 
However, human in vivo studies have considerable limitations when assessing 
molecular function, while animal models may not accurately reflect human disease 
processes. To this end, our group has begun to develop complex co-culture models 
where collagen, colonic myofibroblasts and endothelial cells are used as a primitive 
‘stroma’ on which CRC cells develop multilayered organised ‘epithelial-like’ 
structures. Depending upon the composition of these co-culture models, the constructs 
can be seen to spontaneously demonstrate signs of epithelial-mesenchymal transition 
and invasion into the putative stroma. Furthermore, areas within the multilayered 
epithelial component are highly suspicious as foci of spontaneous malignant 
degeneration, although the significance of these areas is still under investigation. 
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Work is now beginning utilising this model as a vehicle for assessing the role for 
PROM-1/CD/AC133 in colorectal tumourigenesis. In particular, these experiments 
will facilitate investigation of the relationship between this marker and: (i.) the extra-
cellular matrix; (ii.) colonic myofibroblasts (which are central to colonic epithelial 
differentiation and proliferation); and, (iii.) CRC cell-cell interaction. 
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11.1  APPENDIX ONE 
 
 
 
 
Figure A.1 – CD/AC133 glycotype expression in normal tissue samples obtained from four patients 
who underwent colorectal resection for diverticular disease. 
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